-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KYSl2Xcp0Jl3+tjwMbWjMLyGOf4wgzDl8zMhKpE+Ewd4ACy26UYD8z4L/84UmVC9
 KQoiDGvX4lo1HmkdNRIXrw==

<SEC-DOCUMENT>0000950123-07-005707.txt : 20070420
<SEC-HEADER>0000950123-07-005707.hdr.sgml : 20070420
<ACCEPTANCE-DATETIME>20070420105950
ACCESSION NUMBER:		0000950123-07-005707
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20070521
FILED AS OF DATE:		20070420
DATE AS OF CHANGE:		20070420
EFFECTIVENESS DATE:		20070420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELECTRO OPTICAL SCIENCES INC /NY
		CENTRAL INDEX KEY:			0001051514
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133986004

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51481
		FILM NUMBER:		07777771

	BUSINESS ADDRESS:	
		STREET 1:		3 WEST MAIN STREET, SUITE 201
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
		BUSINESS PHONE:		914-591-3783

	MAIL ADDRESS:	
		STREET 1:		3 WEST MAIN STREET, SUITE 201
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>y33491def14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>UNITED STATES</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Washington,&#160;D.C. 20549</B>
</DIV>

<DIV style="margin-top: 5pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>SCHEDULE&#160;14A</B>
</DIV>

<DIV style="margin-top: 5pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>PROXY STATEMENT PURSUANT TO SECTION&#160;14(a) OF THE
    SECURITIES</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXCHANGE ACT OF 1934</B>
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Filed by the Registrant&#160;<FONT face="wingdings">&#254;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Filed by a Party other than the
    Registrant&#160;<FONT face="wingdings">o
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Check the appropriate box:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT face="wingdings">o</FONT>&#160;&#160;Preliminary Proxy
    Statement
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT face="wingdings">o</FONT>&#160;&#160;Confidential, for Use
    of the Commission Only (as permitted by
    <FONT style="white-space: nowrap">Rule&#160;14a-6(e)</FONT>
    (2))
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT face="wingdings">&#254;</FONT>&#160;&#160;Definitive Proxy
    Statement
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT face="wingdings">o</FONT>&#160;&#160;Definitive Additional
    Materials
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT face="wingdings">o</FONT>&#160;&#160;Soliciting Material
    Pursuant to
    <FONT style="white-space: nowrap">&#167;240.14a-12</FONT>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#160;&#160;Electro-Optical Sciences, Inc.
</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">(Name of Registrant as Specified In
    Its Charter)
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">(Name of Person(s) Filing Proxy
    Statement if Other Than the Registrant)
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Payment of Filing Fee (Check the appropriate box)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT face="wingdings">&#254;</FONT>&#160;&#160;
</TD>
    <TD align="left">    No fee required.
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT face="wingdings">o</FONT>&#160;&#160;
</TD>
    <TD align="left">    Fee computed on table below per Exchange Act
    <FONT style="white-space: nowrap">Rules&#160;14a-6(i)&#160;(1)</FONT>
    and 0-11.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;&#160;
</TD>
    <TD align="left">
    Title of each class of securities to which transaction applies:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;&#160;
</TD>
    <TD align="left">
    Aggregate number of securities to which transaction applies:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;&#160;
</TD>
    <TD align="left">
    Per unit price or other underlying value of transaction computed
    pursuant to Exchange Act
    <FONT style="white-space: nowrap">Rule&#160;0-11</FONT>
    (Set forth the amount on which the filing fee is calculated and
    state how it was determined):
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (4)&#160;
</TD>
    <TD align="left">
    Proposed maximum aggregate value of transaction:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 7%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (5)&#160;
</TD>
    <TD align="left">
    Total fee paid:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 7%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT face="wingdings">o</FONT>&#160;&#160;
</TD>
    <TD align="left">    Fee paid previously with preliminary materials.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT face="wingdings">o</FONT>&#160;&#160;
</TD>
    <TD align="left">    Check box if any part of the fee is offset as provided by
    Exchange Act
    <FONT style="white-space: nowrap">Rule&#160;0-11(a)&#160;(2)</FONT>
    and identify the filing for which the offsetting fee was paid
    previously. Identify the previous filing by registration
    statement number, or the Form or Schedule and the date of its
    filing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;&#160;
</TD>
    <TD align="left">
    Amount Previously Paid:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;&#160;
</TD>
    <TD align="left">
    Form, Schedule or Registration Statement No.:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;&#160;
</TD>
    <TD align="left">
    Filing Party:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="5%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (4)&#160;&#160;
</TD>
    <TD align="left">
    Date Filed:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 8%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTRO-OPTICAL
    SCIENCES, INC.<BR>
    <FONT style="font-size: 10pt">3&#160;West Main Street,
    Suite&#160;201<BR>
    Irvington, New York 10533<BR>
    <BR>
    </FONT></FONT><FONT style="font-size: 12pt; font-family: 'Times New Roman', Times">NOTICE
    OF ANNUAL MEETING OF STOCKHOLDERS<BR>
    To Be Held on May&#160;21, 2007</FONT></B>
</DIV>

<DIV style="margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dear Stockholder:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You are cordially invited to attend the Annual Meeting of
    Stockholders of Electro-Optical Sciences, Inc., a Delaware
    corporation. The meeting will be held at the Westchester
    Marriott Hotel, 670 White Plains Road, Tarrytown, New York
    10591, on Monday, May&#160;21, 2007 at 9:00&#160;a.m. local
    time, for the following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;To elect directors to serve for the ensuing year and
    until their successors are elected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;To ratify the selection by the audit committee of the
    Board of Directors of Eisner LLP as
    <FONT style="white-space: nowrap">Electro-Optical</FONT>
    Sciences&#146; independent registered public accounting firm for
    the fiscal year ending December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;To approve an amendment to our 2003 Stock Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;To ratify an amendment to our 2005 Stock Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;To conduct any other business properly brought before
    the meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These items of business are more fully described in the Proxy
    Statement accompanying this Notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The record date for the Annual Meeting is April&#160;12, 2007.
    Only stockholders of record at the close of business on that
    date may vote at the meeting or any adjournment thereof.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By Order of the Board of Directors
</DIV>

<DIV style="margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="y33491y3349101.gif" alt="-s- Joseph V. Gulfo, M.D., Ph.D" >
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Joseph V. Gulfo,&#160;M.D., M.B.A.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    President and Chief Executive Officer
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Irvington, New York
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April&#160;20, 2007
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


</DIV>
<DIV style="width: 100%; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>YOUR VOTE IS IMPORTANT</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>THIS PROXY STATEMENT IS FURNISHED IN CONNECTION WITH THE
    SOLICITATION OF PROXIES BY THE COMPANY, ON BEHALF OF THE BOARD
    DIRECTORS, FOR THE 2007 ANNUAL MEETING OF STOCKHOLDERS. THE
    PROXY STATEMENT AND THE RELATED PROXY FORM&#160;ARE BEING
    DISTRIBUTED ON OR ABOUT APRIL&#160;20, 2007. YOU CAN VOTE YOUR
    SHARES&#160;USING ONE OF THE FOLLOWING METHODS:</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <B>&#149;&#160;</B>
</TD>
    <TD align="left">    <B>COMPLETE AND RETURN A WRITTEN PROXY CARD;</B>
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <B>&#149;&#160;</B>
</TD>
    <TD align="left">    <B>BY INTERNET OR TELEPHONE; OR</B>
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <B>&#149;&#160;</B>
</TD>
    <TD align="left">    <B>ATTEND THE COMPANY&#146;S 2007 ANNUAL MEETING OF STOCKHOLDERS
    AND VOTE.</B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>ALL STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE MEETING.
    HOWEVER, TO ENSURE YOUR REPRESENTATION AT THE MEETING, YOU ARE
    URGED TO MARK, SIGN, DATE AND RETURN THE ENCLOSED PROXY CARD AS
    PROMPTLY AS POSSIBLE IN THE POSTAGE-PREPAID ENVELOPE ENCLOSED
    FOR THAT PURPOSE OR VOTE YOUR SHARES&#160;BY INTERNET OR
    TELEPHONE. ANY STOCKHOLDER ATTENDING THE MEETING MAY VOTE IN
    PERSON EVEN IF HE OR SHE HAS RETURNED A PROXY CARD OR VOTED BY
    INTERNET OR TELEPHONE.</B>
</DIV>
</DIV><!-- End box 1 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">TABLE
    OF CONTENTS</FONT></U></B>
</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="97%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'><FONT style="font-size: 10pt">QUESTIONS AND
    ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">1
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'><FONT style="font-size: 10pt">PROPOSAL&#160;1
    ELECTION OF DIRECTORS</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">5
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'><FONT style="font-size: 10pt">REPORT OF THE AUDIT
    COMMITTEE OF THE BOARD OF DIRECTORS</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">10
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'><FONT style="font-size: 10pt">PROPOSAL&#160;2
    RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC
    ACCOUNTING FIRM</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">11
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'><FONT style="font-size: 10pt">PROPOSAL&#160;3
    AMENDMENT TO 2003 STOCK INCENTIVE PLAN</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">12
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'><FONT style="font-size: 10pt">PROPOSAL&#160;4
    AMENDMENT TO 2005 STOCK INCENTIVE PLAN</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">17
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'><FONT style="font-size: 10pt">SECURITY OWNERSHIP
    OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">21
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'><FONT style="font-size: 10pt">SECTION&#160;16(a)
    BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">23
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'><FONT style="font-size: 10pt">EXECUTIVE OFFICERS
    OF THE COMPANY</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">23
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'><FONT style="font-size: 10pt">COMPENSATION
    DISCUSSION AND ANALYSIS</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">24
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'><FONT style="font-size: 10pt">SUMMARY
    COMPENSATION TABLE</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">25
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'><FONT style="font-size: 10pt">REPORT OF THE
    COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ON EXECUTIVE
    COMPENSATION</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">35
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'><FONT style="font-size: 10pt">CERTAIN
    TRANSACTIONS</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">36
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'><FONT style="font-size: 10pt">PERFORMANCE
    MEASUREMENT COMPARISON</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">36
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'><FONT style="font-size: 10pt">HOUSEHOLDING OF
    PROXY MATERIALS</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">36
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'><FONT style="font-size: 10pt">OTHER
    MATTERS</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">37
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'><FONT style="font-size: 10pt">ANNEX A&#160;&#151;
    AUDIT COMMITTEE CHARTER</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">A-1
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'><FONT style="font-size: 10pt">ANNEX B&#160;&#151;
    COMPENSATION COMMITTEE CHARTER</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">B-1
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'><FONT style="font-size: 10pt">ANNEX C&#160;&#151;
    NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">C-1
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#122'><FONT style="font-size: 10pt">ANNEX D&#160;&#151;
    AMENDMENT TO 2003 STOCK INCENTIVE PLAN</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">D-1
    </FONT>
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#123'><FONT style="font-size: 10pt">ANNEX E&#160;&#151;
    AMENDMENT TO 2005 STOCK INCENTIVE PLAN</FONT></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-size: 10pt">E-1
    </FONT>
</TD>
<TD>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTRO-OPTICAL
    SCIENCES, INC.<BR>
    <FONT style="font-size: 10pt">3&#160;West Main Street,
    Suite&#160;201<BR>
    Irvington, New York 10533</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROXY
    STATEMENT<BR>
    FOR THE 2007 ANNUAL MEETING OF STOCKHOLDERS<BR>
    MAY&#160;21, 2007</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='101'><B><FONT style="font-size: 12pt">QUESTIONS AND
    ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Why am I
    receiving these materials?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We sent you this proxy statement and the enclosed proxy card
    because the Board of Directors of
    <FONT style="white-space: nowrap">Electro-Optical</FONT>
    Sciences, Inc. (which we will refer to as the
    &#147;Company&#148; throughout this proxy statement) is
    soliciting your proxy to vote at the Company&#146;s 2007 Annual
    Meeting of Stockholders. You are invited to attend the Annual
    Meeting, and we request that you vote on the proposals described
    in this proxy statement. You do not need to attend the meeting
    to vote your shares, however. Instead, you may simply complete,
    sign and return the enclosed proxy card, or you may grant a
    proxy to vote your shares by means of the telephone or on the
    Internet.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company intends to mail this proxy statement and the
    accompanying proxy card together with the Company&#146;s Annual
    Report to stockholders on or about April&#160;20, 2007, to all
    stockholders of record entitled to vote at the Annual Meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Who can
    vote at the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Only stockholders of record at the close of business on
    April&#160;12, 2007 will be entitled to vote at the Annual
    Meeting. On this record date, there were 13,372,483&#160;shares
    of common stock outstanding and entitled to vote.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stockholder
    of Record: Shares&#160;Registered in Your Name</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If on April&#160;12, 2007, your shares were registered directly
    in your name with the Company&#146;s transfer agent, American
    Stock Transfer and Trust Company, then you are a stockholder of
    record. As a stockholder of record, you may vote in person at
    the meeting or vote by proxy.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Beneficial
    Owner: Shares&#160;Registered in the Name of a Broker or
    Bank</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If on April&#160;12, 2007, your shares were held not in your
    name, but rather, in an account at a brokerage firm, bank,
    dealer, or other similar organization, then you are the
    beneficial owner of shares held in &#147;street name&#148; and
    these proxy materials are being forwarded to you by that
    organization. The organization holding your account is
    considered to be the stockholder of record for purposes of
    voting at the Annual Meeting. As a beneficial owner, you have
    the right to direct your broker or other agent on how to vote
    the shares in your account. You are also invited to attend the
    Annual Meeting. Since you are not the stockholder of record,
    however, you may not vote your shares in person at the meeting
    unless you request and obtain a valid proxy from your broker or
    other agent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What am I
    voting on?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are four matters scheduled for a vote:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Election of seven directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The ratification of Eisner LLP as the Company &#146;s
    independent registered public accounting firm for the fiscal
    year ending December&#160;31, 2007;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The approval of an amendment to our 2003 Stock Incentive
    Plan;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The ratification of an amendment to our 2005 Stock Incentive
    Plan.
</TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How do I
    vote?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may either vote &#147;For&#148; all the nominees to the
    Board of Directors or you may &#147;Withhold&#148; your vote for
    any nominee you specify. For each of the other matters to be
    voted on, you may vote &#147;For&#148; or &#147;Against&#148; or
    abstain from voting. The procedures for voting are fairly simple:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stockholder
    of Record: Shares&#160;Registered in Your Name</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are a stockholder of record, you may vote in person at
    the Annual Meeting, or vote by proxy using the enclosed proxy
    card or via the Internet or telephone (see &#147;Voting Via
    Internet or By Telephone&#148; below). If you vote by proxy,
    your shares will be voted as you specify on the proxy card.
    Whether or not you plan to attend the meeting, we urge you to
    vote by proxy to ensure your vote is counted. You may still
    attend the Annual Meeting and vote in person if you have already
    voted by proxy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To vote in person, come to the Annual Meeting and we will give
    you a ballot when you arrive.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To vote using the enclosed proxy card, simply complete, sign and
    date the enclosed proxy card and return it promptly in the
    envelope provided. If you return your signed proxy card to us
    before the Annual Meeting, we will vote your shares as you
    direct.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Beneficial
    Owner: Shares&#160;Registered in the Name of Broker or
    Bank</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are a beneficial owner of shares registered in the name
    of your broker, bank, or other agent, you should have received a
    proxy card and voting instructions with these proxy materials
    from that organization rather than from the Company. Simply
    complete and mail the proxy card to ensure that your vote is
    counted. To vote in person at the Annual Meeting, you must
    obtain a valid proxy from your broker, bank, or other agent.
    Follow the instructions from your broker or bank included with
    these proxy materials, or contact your broker or bank to request
    a proxy form.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Via the Internet or by Telephone</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stockholders may grant a proxy to vote their shares by means of
    the telephone or on the Internet. The laws of the State of
    Delaware, under which the Company is incorporated, specifically
    permit electronically transmitted proxies, provided that each
    such proxy contains or is submitted with information from which
    the Inspector of Elections can determine that such proxy was
    authorized by the stockholder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The telephone and Internet voting procedures below are designed
    to authenticate stockholders&#146; identities, to allow
    stockholders to grant a proxy to vote their shares and to
    confirm that stockholders&#146; instructions have been recorded
    properly. Stockholders granting a proxy to vote via the Internet
    should understand that there may be costs associated with
    electronic access, such as usage charges from Internet access
    providers and telephone companies, which must be borne by the
    stockholder.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">For
    Shares&#160;Registered in Your Name</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stockholders of record may go to
    <U>http://proxy.georgeson.com</U> to grant a proxy to vote their
    shares by means of the Internet. They will be required to
    provide the Company&#146;s number and control number contained
    on their proxy cards. Any stockholder using a touch-tone
    telephone may also grant a proxy to vote shares by calling
    1-877-450-9556 and following the operator&#146;s instructions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">For
    Shares&#160;Registered in the Name of a Broker or
    Bank</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most beneficial owners whose stock is held in street name
    receive instruction for granting proxies from their banks,
    brokers or other agents, rather than the Company&#146;s proxy
    card.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">General
    Information for All Shares&#160;Voted Via the Internet or By
    Telephone</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Votes submitted via the Internet or by telephone must be
    received by 11:59&#160;p.m., Eastern Time on May&#160;20, 2007.
    Submitting your proxy via the Internet or by telephone will not
    affect your right to vote in person should you decide to attend
    the Annual Meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How many
    votes do I have?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On each matter to be voted upon, you have one vote for each
    share of common stock you own as of April&#160;12, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What if I
    return a proxy card but do not make specific choices?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you return a signed and dated proxy card without marking any
    voting selections, your shares will be voted &#147;For&#148; all
    the nominees to the Board of Directors and &#147;For&#148;
    proposals&#160;2, 3 and 4. If any other matter is properly
    presented at the meeting, your proxy (i.e., one of the
    individuals named on your proxy card) will vote your shares
    using his best judgment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Who is
    paying for this proxy solicitation?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will pay for the entire cost of soliciting proxies. In
    addition to these mailed proxy materials, we will bear the cost
    of soliciting proxies by the Board. In addition to the
    solicitation of proxies by mail, solicitation may be made
    personally or by telephone or electronic communication by our
    directors, officers and employees, none of whom will receive
    additional compensation for these services, and by Georgeson
    Inc., who we have retained to aid in the solicitation of
    proxies. We will pay Georgeson Inc. a fee of $6,500 plus
    expenses for these services. We will also reimburse brokers and
    other nominees for their reasonable
    <FONT style="white-space: nowrap">out-of-pocket</FONT>
    expenses incurred in connection with distributing forms of
    proxies and proxy materials to the beneficial owners of common
    stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What does
    it mean if I receive more than one proxy card?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you receive more than one proxy card, your shares are
    registered in more than one name or are registered in different
    accounts. Please complete, sign and return each proxy card to
    ensure that all of your shares are voted.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Can I
    change my vote after submitting my proxy?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Yes. You may revoke your proxy at any time before the final vote
    at the meeting. If you are the record holder of your shares, you
    may revoke your proxy in any one of four ways:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may issue a proxy with a later date.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may send a written notice that you are revoking your proxy
    to the Company&#146;s Secretary at 3&#160;West&#160;Main Street,
    Suite&#160;201, Irvington, New York 10533.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may vote by telephone or the Internet.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may attend the Annual Meeting and vote in person. Simply
    attending the meeting will not, by itself, revoke your proxy.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If your shares are held by your broker or bank as a nominee or
    agent, you should follow the instructions provided by your
    broker or bank.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">When are
    stockholder proposals due for next year&#146;s Annual
    Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under
    <FONT style="white-space: nowrap">Rule&#160;14a-8</FONT>
    promulgated under the Securities Exchange Act of 1934, as
    amended, stockholders of the Company may present proper
    proposals for inclusion in the Company&#146;s proxy statement
    and for consideration at the next Annual Meeting of Stockholders
    by submitting their proposals to the Company in a timely manner.
    In order to be considered for inclusion in the proxy statement
    distributed to stockholders prior
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    to the Annual Meeting of Stockholders in the year 2008, a
    stockholder proposal must be received by the Company no later
    than December&#160;22, 2007 and must otherwise comply with the
    requirements of
    <FONT style="white-space: nowrap">Rule&#160;14a-8.</FONT>
    In order to be considered for presentation at the Annual Meeting
    of Stockholders in the year 2008, although not included in the
    proxy statement, a stockholder proposal or nomination(s) must
    comply with the requirements of the Company&#146;s Bylaws and be
    received by the Company no later than the close of business on
    February&#160;21, 2008 and no earlier than the close on business
    on January&#160;22, 2008; provided, however, that in the event
    that the date of the 2008 Annual Meeting is more than thirty
    (30)&#160;days before or more than sixty (60)&#160;days after
    May&#160;21, 2008, notice by the stockholder to be timely must
    be so delivered not earlier than the close of business on the
    one hundred and twentieth
    (120<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>)
    day prior to such Annual Meeting and not later than the close of
    business on the later of the ninetieth
    (90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>)
    day prior to such Annual Meeting or the close of business on the
    tenth
    (10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>)
    day following the day on which public announcement of the date
    of such meeting is first made by the Company. Stockholder
    proposals should be delivered in writing to Electro-Optical
    Sciences, Inc., 3&#160;West Main Street, Suite&#160;201,
    Irvington, New York 10533, Attention: Secretary. A copy of the
    Company&#146;s Bylaws may be obtained from the Company upon
    written request to the Secretary.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How are
    votes counted?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Votes will be counted by the inspector of election appointed for
    the meeting, who will separately count &#147;For&#148; and, with
    respect to proposals other than the election of directors,
    &#147;Against&#148; votes, abstentions and broker non-votes. In
    addition, with respect to the election of directors, the
    inspector of election will count the number of
    &#147;Withhold&#148; votes received by each nominee. A
    &#147;broker non-vote&#148; occurs when a nominee holding shares
    for a beneficial owner does not vote on a particular proposal
    because the nominee does not have discretionary voting power
    with respect to that proposal and has not received instructions
    with respect to that proposal from the beneficial owner (despite
    voting on at least one other proposal for which it does have
    discretionary authority or for which it has received
    instructions). Abstentions will be counted towards the vote
    total for each proposal, and will have the same effect as
    &#147;Against&#148; votes. Broker non-votes have no effect and
    will not be counted towards the vote total for any proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If your shares are held by your broker as your nominee (that is,
    in &#147;street name&#148;), you will need to obtain a proxy
    form from the institution that holds your shares and follow the
    instructions included on that form regarding how to instruct
    your broker to vote your shares. If you do not give instructions
    to your broker, your broker can vote your shares with respect to
    &#147;discretionary&#148; items, but not with respect to
    &#147;non-discretionary&#148; items. Discretionary items are
    proposals considered routine under the rules of the NASDAQ
    Capital Market (&#147;NASDAQ&#148;) on which your broker may
    vote shares held in street name in the absence of your voting
    instructions. On non-discretionary items for which you do not
    give your broker instructions, the shares will be treated as
    broker non-votes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How many
    votes are needed to approve each proposal?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    For Proposal&#160;No.&#160;1, the election of directors, the
    seven nominees receiving the most &#147;For&#148; votes (among
    votes properly cast in person or by proxy) will be elected.
    Broker non-votes will count towards the quorum but will have no
    effect. Stockholders do not have the right to cumulate their
    votes for directors.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Proposal&#160;No.&#160;2, the ratification of Eisner LLP as the
    Company&#146;s independent registered public accounting firm for
    the fiscal year ending December&#160;31, 2007, must receive a
    &#147;For&#148; vote from the majority of shares present and
    entitled to vote either in person or by proxy to be approved. If
    you &#147;Abstain&#148; from voting, it will have the same
    effect as an &#147;Against&#148; vote. Broker non-votes will
    have no effect.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    For Proposal&#160;No.&#160;3, the approval of an amendment to
    our 2003 Stock Incentive Plan, a &#147;For&#148; vote must be
    received by a majority of shares present and entitled to vote
    either in person or by proxy to be approved. If you
    &#147;Abstain&#148; from voting, it will have the same effect as
    an &#147;Against&#148; vote. Broker non-votes will have no
    effect.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    For Proposal&#160;No.&#160;4, the ratification of an amendment
    to our 2005 Stock Incentive Plan, a &#147;For&#148; vote must be
    received by a majority of shares present and entitled to vote
    either in person or by proxy to be ratified. If you
    &#147;Abstain&#148; from voting, it will have the same effect as
    an &#147;Against&#148; vote. Broker
    <FONT style="white-space: nowrap">non-votes</FONT>
    will have no effect.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What is
    the quorum requirement?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A quorum of stockholders is necessary to hold a valid meeting. A
    quorum will be present if at least a majority of the outstanding
    shares entitled to vote are represented by votes at the meeting
    or by proxy. On the record date, there were
    13,372,483&#160;shares outstanding and entitled to vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your shares will be counted towards the quorum only if you
    submit a valid proxy (or one is submitted on your behalf by your
    broker, bank or other nominee) or if you vote in person at the
    meeting or by telephone or the Internet. Abstentions and broker
    non-votes will be counted towards the quorum requirement. If
    there is no quorum, the chairman of the meeting or a majority of
    the votes present at the meeting may adjourn the meeting to
    another date.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How can I
    find out the results of the voting at the Annual
    Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Preliminary voting results will be announced at the Annual
    Meeting. Final voting results will be published in the
    Company&#146;s quarterly report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the second quarter of 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How can I
    obtain additional copies?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For additional copies of this proxy statement and the enclosed
    proxy card and Annual Report to Stockholders, you should contact
    our corporate office at 3 West Main Street, Suite&#160;201,
    Irvington, New&#160;York&#160;10533, Attention: Secretary,
    telephone
    <FONT style="white-space: nowrap">(914)&#160;591-3783.</FONT>
</DIV>
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;1<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTION
    OF DIRECTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are seven nominees for the nine director positions
    presently authorized by the Company&#146;s Board of Directors
    and the Company&#146;s Bylaws. The two vacant directorships may
    be filled in the future at the discretion of the Company&#146;s
    Board of Directors. This discretionary power gives us the
    flexibility of appointing new directors in periods between our
    Annual Meetings should suitable candidates come to our
    attention. The names of the persons who are nominees for
    director and their positions and offices with the Company are
    set forth in the table below. Each director to be elected will
    hold office until the 2008 Annual Meeting of Stockholders and
    until his successor is elected and has qualified, or until such
    director&#146;s earlier death, resignation or removal. Each
    nominee listed below is currently a director of the Company,
    having been previously elected by the stockholders. Although
    there is no formal policy, the Company encourages its directors
    to attend the Company&#146;s annual meetings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Directors are elected by a plurality of the votes present in
    person or represented by proxy and entitled to vote at the
    Annual Meeting. Shares represented by executed proxies will be
    voted, if authority to do so is not withheld, for the election
    of the seven nominees named below. In the event that any nominee
    should be unavailable for election as a result of an unexpected
    occurrence, your shares will be voted for the election of such
    substitute nominee as management may propose. Proxies may not be
    voted for more than seven directors, however. Each of the
    current directors has been nominated for and has agreed to stand
    for election and management has no reason to believe that any
    nominee will be unable to serve.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a brief biography of each nominee for director,
    including their respective ages as of February&#160;28, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D.,
    M.B.A.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">43
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Director, President and Chief
    Executive Officer
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Breaux Castleman
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">66
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <FONT style="font-size: 10pt">Director, Chairman of the Board of
    Directors
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Sidney Braginsky
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">69
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">George C. Chryssis
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">59
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Martin D. Cleary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">61
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dan W. Lufkin
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">75
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gerald Wagner,&#160;Ph.D.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">63
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <FONT style="font-size: 10pt">Director
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Joseph V. Gulfo,&#160;M.D., M.B.A.</I> has served as our
    President and Chief Executive Officer and a member of our Board
    of Directors since January 2004. From May 1999 to November 2003,
    he served as Chairman, Chief&#160;Executive Officer and
    President of Antigen Express, Inc., a development-stage company
    developing immunodiagnostics and therapeutics for cancer.
    Dr.&#160;Gulfo serves as a director of ProCertus BioPharm, Inc.,
    a privately-held company. Dr.&#160;Gulfo received a B.S. in
    biology from Seton Hall University, an M.D. from the University
    of Medicine and Dentistry of New Jersey and an M.B.A. in finance
    from Seton Hall University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Breaux Castleman </I>has served as a member of our Board of
    Directors and Chairman of our Board since July 2003. Since
    August 2001, he has served as President, Chief Executive Officer
    and Chairman of Syntiro Healthcare Services, Inc.
    Mr.&#160;Castleman also serves as a director of FemPartners,
    Inc. which is a privately-held company. From December 1999 to
    July 2001, he served as Chief Executive Officer of Physia Corp.
    He served as President of Scripps Clinic from July 1996 to
    November 1998. He holds a B.A. in economics from Yale University
    and attended New York University Graduate School of Business
    Administration.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Sidney Braginsky </I>has served as a member of our Board of
    Directors since 2001. He also currently serves as the Chairman
    and Chief Executive Officer of Digilab, LLC (a spectroscopy
    instruments manufacturer), Chairman of Atropos Technologies,
    LLC, a director of Diomed Inc., Double D Venture Fund, LLC,
    Noven Pharmaceuticals, Inc., Sword Diagnostics, Inc. and
    Micronix Pty Ltd. (an Australian medical device company),
    Chairman of the International Standards Organization
    U.S.&#160;Technical Advisory Group TC 172 on Optics and
    Photonics, Chairman of the Board of the City University of New
    York Robert Chambers Laboratory and Trustee on the Boards of
    Long Island High Tech Incubator and the Long Island Museum of
    Science and Technology. He formerly served as President of
    Olympus America and Mediscience Corp. and Chairman of Double D
    Venture Fund, LLC. Mr.&#160;Braginsky received his B.S. in
    biology from Queens College.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>George C. Chryssis </I>has served as a member of our Board of
    Directors since 2001. Since August 2003, he has served as
    President, Chief Executive Officer and Chairman of the board of
    directors of MISTsoft Corp., a privately-held software company
    which he founded. From June 1999 until their dissolution on
    December&#160;31, 2005, he served as the Managing Member of
    Arcadian Capital Management, LLC and General Partner of Arcadian
    Venture Partners, LP, a venture capital firm with investments in
    early stage technology companies, including the Company. Since
    2003, he has also served as Chairman of the board of directors
    of DelCom Corp., a privately-held telecommunications software
    company. Mr.&#160;Chryssis received a B.S. and M.S. in
    electrical engineering from Northeastern University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Martin D. Cleary </I>was appointed as a member of our Board
    of Directors in October 2005. Since February&#160;2003, he has
    served as the President and Chief Executive Officer of Juvaris
    Biotherapeutics, Inc., a company engaged in the development of
    therapeutic vaccines for cancer and infectious diseases. From
    September 1999 to May 2002, he served as the President and Chief
    Executive Officer of Genteric, Inc., a company engaged in
    non-viral gene delivery. Mr.&#160;Cleary received a B.S. in
    accounting from Rutgers University in 1971, and a certificate in
    international studies from Columbia University in 1973.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dan W. Lufkin </I>has served as a member of our Board of
    Directors since July 2003. He is also a co-founder and former
    Chairman of the investment banking firm, Donaldson,
    Lufkin&#160;&#38; Jenrette, Inc. Mr.&#160;Lufkin currently
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    serves as a consultant to
    <FONT style="white-space: nowrap">and/or</FONT> board
    member of a number of private companies and non-profit
    endeavors. Mr.&#160;Lufkin received a B.A. degree from Yale
    University and an M.B.A. from Harvard Business School.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gerald Wagner,&#160;Ph.D.</I> was appointed as a member of
    our Board of Directors in May 2005 and was our acting Chief
    Operating Officer from January 2006 until January 2007. He
    currently serves as a consultant to the Company. Since 2002, he
    has owned and operated Gerald Wagner Consulting LLC, an
    international consulting company specializing in international
    project management, technology and application consulting, and
    company assessments. Dr.&#160;Wagner serves as a board member
    for IntegraGen S.A, Evry, France. From March 1992 to September
    2003, he was a Senior Vice President, Lab Testing Systems, at
    Bayer, Inc. Dr.&#160;Wagner received a Masters and Ph.D. in
    electro-mechanical design from Technical University, Darmstadt,
    Germany.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Independence
    of the Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As required under the Nasdaq listing standards, a majority of
    the members of a listed company&#146;s Board of Directors must
    qualify as &#147;independent,&#148; as affirmatively determined
    by the Board of Directors. The Company&#146;s Board of Directors
    consults with the Company&#146;s counsel to ensure that the
    Board&#146;s determinations are consistent with all relevant
    securities and other laws and regulations regarding the
    definition of &#147;independent,&#148; including those set forth
    in pertinent listing standards of Nasdaq, as are in effect from
    time to time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Consistent with these considerations, after review of all
    relevant transactions or relationships between each director, or
    any of his or her family members, and the Company, its senior
    management and its independent registered public accounting
    firm, the Board has affirmatively determined that all of the
    Company&#146;s directors are independent directors within the
    meaning of the applicable Nasdaq listing standards, except
    Dr.&#160;Gulfo, the President and Chief Executive Officer of the
    Company and Gerald Wagner,&#160;Ph.D., the former acting Chief
    Operating Officer of the Company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Information
    Regarding the Board of Directors and its Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s Board of Directors has an audit committee, a
    compensation committee and a nominating and governance
    committee. The following table provides membership information
    for 2006 for each of these committees:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Audit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Compensation</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nominating</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D.,
    M.B.A.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Breaux Castleman
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Sidney Braginsky
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">George C. Chryssis
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Martin D. Cleary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dan W. Lufkin
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gerald Wagner,&#160;Ph.D.
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Below is a description of each committee of the Board of
    Directors. Each of the committees has authority to engage legal
    counsel or other experts or consultants, as it deems appropriate
    to carry out its responsibilities. The Board of Directors has
    determined that each member of each committee meets the
    applicable rules and regulations regarding
    &#147;independence&#148; and that each member is free of any
    relationship that would interfere with his individual exercise
    of independent judgment with regard to the Company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Audit
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The current members of our audit committee are
    Messrs.&#160;Braginsky, Lufkin and Cleary, each of whom we
    believe satisfies the independence requirements of Nasdaq and
    the Securities and Exchange Commission (the &#147;SEC&#148;).
    Mr.&#160;Cleary chairs this committee. We believe
    Mr.&#160;Cleary is qualified as an audit committee
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    financial expert under the regulations of the SEC and has the
    accounting and related financial management expertise required
    by Nasdaq. Our audit committee assists our Board in its
    oversight of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the integrity of our financial statements;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our independent registered public accounting firm&#146;s
    qualifications and independence;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the performance of our independent auditors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit committee has the sole and direct responsibility for
    appointing, evaluating and retaining our independent registered
    public accounting firm and overseeing their work. All audit
    services to be provided to us and all non-audit services, other
    than de minimis non-audit services, to be provided to us by our
    independent auditors must be approved in advance by our audit
    committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The charter of our audit committee is attached hereto as
    <U>Annex&#160;A</U>.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our compensation committee are
    Messrs.&#160;Castleman, Braginsky and Chryssis, each of whom we
    believe satisfies the independence requirements of Nasdaq and
    the SEC. Mr.&#160;Castleman chairs this committee. The purpose
    of our compensation committee is to discharge the
    responsibilities of our Board of Directors relating to
    compensation of our executive officers. Specific
    responsibilities of our compensation committee include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and recommending compensation of our executive
    officers;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    administering our stock incentive plans;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and recommending incentive compensation and equity
    plans.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A narrative description of our compensation committee&#146;s
    processes and procedures for the consideration and determination
    of executive and director compensation is included in the
    compensation discussion and Analysis in this proxy statement.
    The charter of our compensation committee is attached hereto as
    <U>Annex&#160;B</U>.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Nominating
    and Governance Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our nominating and governance committee are
    Messrs.&#160;Lufkin, Castleman and Cleary, each of whom we
    believe satisfies the independence requirements of Nasdaq and
    the SEC. Mr.&#160;Lufkin chairs this committee. Our nominating
    and governance committee:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    identifies and recommends nominees for election to our Board of
    Directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    develops and recommends our corporate governance
    principles;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversees the evaluation of our Board of Directors and management.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The nominating and governance committee has not adopted specific
    minimum criteria for director nominees. The committee identifies
    nominees by first evaluating the current members of the Board of
    Directors willing to continue in service. Current members of the
    Board with skills and experience that are relevant to the
    Company&#146;s business and who are willing to continue in
    service are considered for re-nomination. If any member of the
    Board does not wish to continue in service, or if the nominating
    and governance committee decides not to nominate a member for
    re-election, the nominating and governance committee first
    considers the appropriateness of the size of the Board. If the
    nominating and governance committee determines that the Board
    seat should be retained and a vacancy exists, the committee
    considers factors that it deems are in the best interests of the
    Company and its stockholders in identifying and evaluating a new
    nominee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In identifying suitable candidates for nomination as a director,
    the nominating and governance committee will consider the needs
    of the Board and the range of skills and characteristics
    required for effective functioning of the Board. In evaluating
    such skills and characteristics, the nominating and governance
    committee may take into consideration such factors as it deems
    appropriate, such as a nominee&#146;s business and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    professional expertise and experiences, including particular
    experience in areas relevant to the Company&#146;s business
    activities, concern for long-term interests of the stockholders,
    and personal integrity and judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The nominating and governance committee will consider all bona
    fide candidates for election of the Board and will consider any
    stockholder nominations pursuant to the same criteria, provided
    those nominated are submitted pursuant to the process described
    in the Company&#146;s Bylaws and applicable law and within the
    time periods set forth herein for receipt of stockholder
    proposals for the 2008 Annual Meeting of Stockholders. To date,
    the Company has not received any recommendations from
    stockholders for candidates for inclusion on the
    committee&#146;s slate of nominees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The charter of our nominating and governance committee is
    attached hereto as <U>Annex&#160;C</U>.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Meetings
    of the Board of Directors and Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors met five times during the last fiscal
    year, including once by conference call, and acted three times
    by unanimous written consent. All directors attended at least
    75% of the meetings of the Board held during the period for
    which they were a director.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit committee met four times and acted once by unanimous
    written consent during the fiscal year, and the compensation
    committee met twice and acted twice by unanimous written consent
    during the fiscal year. The nominating and governance committee
    acted once by unanimous written consent during the fiscal year.
    All directors attended at least 75% of the meetings of the Board
    committees on which they served held during the period for which
    they were a committee member.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not maintain a policy regarding director attendance at the
    Annual Meeting of Stockholders. At the 2006 Annual Meeting of
    Stockholders, all of the directors were present.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Communications with the Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have a formal policy regarding stockholder
    communication with the Board of Directors. However, stockholders
    of the Company may communicate directly with the Board of
    Directors in writing, addressed to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Board of Directors
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    c/o&#160;Secretary
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Electro-Optical Sciences, Inc.
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3&#160;West Main Street, Suite&#160;201
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Irvington, New York 10533
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Secretary will review each stockholder communication. The
    Secretary will forward to the entire Board of Directors (or to
    members of a Board of Directors&#146; committee, if the
    communication relates to a subject matter clearly within that
    committee&#146;s area of responsibility) each communication that
    (a)&#160;relates to the Company&#146;s business or governance,
    (b)&#160;is not offensive and is legible in form and reasonably
    understandable in content, and (c)&#160;does not relate to a
    personal grievance against the Company or an employee or to
    further a personal interest not shared by the other stockholders
    generally. Stockholders who would like their submissions
    directed to an individual member of the Board of Directors may
    so specify, and the communication will be forwarded, as
    appropriate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has adopted Electro-Optical Sciences, Inc. Code of
    Business Conduct and Ethics that applies to all officers,
    directors and employees. The Code of Business Conduct and Ethics
    is available in the Corporate Governance section of the Investor
    Relations section of the Company&#146;s website at
    www.eosciences.com. If the Company makes any substantive
    amendments to the Code of Business Conduct and Ethics or grants
    any waiver from a provision of the Code to any executive officer
    or director, the Company will promptly disclose the nature of
    the amendment or waiver on its website at the location and
    address specified above.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    THE AUDIT COMMITTEE OF THE BOARD OF
    DIRECTORS</A><SUP style="font-size: 85%; vertical-align: text-top">1</SUP></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit committee oversees the Company&#146;s financial
    reporting process on behalf of the Board of Directors.
    Management has the primary responsibility for the financial
    statements and the reporting process, including the systems of
    internal control over financial reporting and disclosure
    controls and procedures. In fulfilling its oversight
    responsibilities, the audit committee reviewed the audited
    financial statements included in the Company&#146;s Annual
    Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2006 with management,
    including a discussion of the quality, not just the
    acceptability, of the accounting principles, the reasonableness
    of significant judgments, and the clarity of disclosures in the
    financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit committee is responsible for reviewing, approving and
    managing the engagement of the Company&#146;s independent
    registered public accounting firm, including the scope, extent
    and procedures of the annual audit and compensation to be paid
    therefor, and all other matters the audit committee deems
    appropriate, including the Company&#146;s independent registered
    public accounting firm&#146;s accountability to the Board and
    the audit committee. The audit committee reviewed with the
    Company&#146;s independent registered public accounting firm,
    which is responsible for expressing an opinion on the conformity
    of audited financial statements with generally accepted
    accounting principles, its judgment as to the quality, not just
    the acceptability, of the Company&#146;s accounting principles
    and such other matters as are required to be discussed with the
    audit committee under auditing standards generally accepted in
    the United States, including those described in Statement on
    Auditing Standards No.&#160;61, as amended, &#147;Communication
    with Audit Committees,&#148; and discussed and reviewed the
    results of the Company&#146;s independent registered public
    accounting firm&#146;s examination of the financial statements.
    In addition, the audit committee discussed with the
    Company&#146;s independent registered public accounting firm the
    independent registered public accounting firm&#146;s
    independence from management and the Company, including the
    matters in the written disclosures and the letter regarding its
    independence as required by the Independence Standards Board
    Standard No.&#160;1, &#147;Independence Discussions with Audit
    Committees.&#148; The audit committee also considered whether
    the provision of non-audit services was compatible with
    maintaining the independent registered public accounting
    firm&#146;s independence.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit committee discussed with the Company&#146;s
    independent registered public accounting firm the overall scope
    and plans for its audits. The audit committee meets with the
    Company&#146;s independent registered public accounting firm,
    with and without management present, to discuss the results of
    its examinations, its evaluations of the Company&#146;s internal
    control over financial reporting and the overall quality of the
    Company&#146;s financial reporting. The audit committee held
    four meetings during the fiscal year ended December&#160;31,
    2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In reliance on the reviews and discussions referred to above,
    the audit committee recommended to the Board of Directors (and
    the Board has approved) that the audited financial statements be
    included in the Company&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2006 for filing with the
    Securities and Exchange Commission. The audit committee has also
    retained Eisner LLP as the Company&#146;s independent registered
    public accounting firm for the fiscal year ending
    December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>AUDIT COMMITTEE</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sidney Braginsky<BR>
    Dan W. Lufkin<BR>
    Martin D. Cleary
</DIV>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="text-align:justify; margin-left: 6%; margin-right: 0%; text-indent: -2%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <SUP style="font-size: 85%; vertical-align: text-top">1</SUP>&#160;The
    material in this report is not &#147;soliciting material,&#148;
    is not deemed &#147;filed&#148; with the SEC and is not to be
    incorporated by reference into any filing of the Company under
    the Securities Act of 1933, as amended, or the Securities
    Exchange Act of 1934, as amended, whether made before or after
    the date hereof and irrespective of any general incorporation
    language in any such filing.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;2<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RATIFICATION
    OF SELECTION OF INDEPENDENT<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REGISTERED
    PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit committee of the Board of Directors has selected
    Eisner LLP as the Company&#146;s independent registered public
    accounting firm for the fiscal year ending December&#160;31,
    2007 and has further directed that management submit the
    selection of Eisner LLP as the Company&#146;s independent
    registered public accounting firm for ratification by the
    stockholders at the Annual Meeting. Eisner LLP audited the
    Company&#146;s financial statements in 2005 and 2006.
    Representatives of Eisner LLP are expected to be present at the
    Annual Meeting, will have an opportunity to make a statement if
    they so desire and will be available to respond to appropriate
    questions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stockholder ratification of the selection of Eisner LLP as the
    Company&#146;s independent registered public accounting firm is
    not required by the Company&#146;s Bylaws or otherwise. However,
    the Board of Directors, on behalf of the audit committee, is
    submitting the selection of Eisner LLP to the stockholders for
    ratification as a matter of good corporate practice. If the
    stockholders fail to ratify the selection, the audit committee
    will reconsider whether or not to retain that firm. Even if the
    selection is ratified, the audit committee in its discretion may
    direct the appointment of different independent registered
    public accounting firm at any time during the year if they
    determine that such a change would be in the best interests of
    the Company and its stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The affirmative vote of the holders of a majority of the shares
    present in person or represented by proxy and entitled to vote
    will be required to ratify the selection of Eisner LLP.
    Abstentions will be counted toward the tabulation of votes cast
    on proposals presented to the stockholders and will have the
    same effect as negative votes. Broker non-votes are counted
    towards a quorum, but are not counted for any purpose in
    determining whether this matter has been approved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>THE BOARD OF DIRECTORS RECOMMENDS</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>A VOTE IN FAVOR OF PROPOSAL&#160;2.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Principal
    Accountant Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the aggregate fees billed to the
    Company by Eisner LLP for professional services rendered during
    the fiscal years ended December&#160;31, 2006 and
    December&#160;31, 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fiscal Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Audit Fees
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    402,156.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    90,865.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Audit-Related Fees
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Tax Fees
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64,500.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">All Other Fees
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,025.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <FONT style="font-size: 10pt">Total Fees
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    402,156.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,390.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Audit Fees.</I>&#160;&#160;In 2005 Audit Fees consisted of
    fees for professional services rendered for the audit of the
    Company&#146;s financial statements as of December&#160;31,
    2004, 2003 and 2002, review of interim financial statements and
    services normally provided by the independent auditor in
    connection with regulatory filings, including the Company&#146;s
    Registration Statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    as filed with the SEC in 2005. In 2006 Audit Fees consisted of
    fees for the 2005 audit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Audit-Related Fees.</I>&#160;&#160;During the years ended
    December&#160;31, 2005 and December&#160;31, 2006, Eisner LLP
    did not provide audit-related services to the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Tax Fees.</I>&#160;&#160;During the year ended
    December&#160;31, 2005, Eisner LLP did not provide tax services
    to the Company. The 2006 Tax Fees related to the preparation of
    the Company&#146;s 2005 Federal and State income tax returns and
    associated estimated payments and applications for filing
    extensions and the undertaking of a study to analyze the amount
    and timing of the tax loss carryforwards.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>All Other Fees.</I>&#160;&#160;During the fiscal year ended
    December&#160;31, 2005, no fees were billed by Eisner LLP other
    than as set forth under &#147;Audit Fees,&#148;
    &#147;Audit-Related Fees&#148; and &#147;Tax Fees&#148; above.
    In 2006 all Other Fees related to work on Sarbanes-Oxley matters
    and the filing of an
    <FONT style="white-space: nowrap">S-8</FONT> in July
    2006 and an
    <FONT style="white-space: nowrap">S-3</FONT> in
    December 2006 with the SEC.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pre-Approval
    of Audit and Non-Audit Services</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The services performed by Eisner LLP in 2006 were pre-approved
    by the audit committee. The audit committee pre-approves all
    audit services and permitted non-audit services performed or
    proposed to be undertaken by the independent registered public
    accounting firm, except where such services are determined to be
    de minimis under the Securities Exchange Act of 1934, as
    amended, giving particular attention to the relationship between
    the types of services provided and the independent registered
    public accounting firm&#146;s independence. The audit committee
    may delegate pre-approval authority to one or more of its
    members. The member to whom such authority is delegated must
    report, for informational purposes only, any pre-approval
    decisions to the audit committee at its next scheduled meeting.
</DIV>
<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;3<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">AMENDMENT
    TO 2003 STOCK INCENTIVE PLAN</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors is proposing for stockholder approval an
    amendment to the Company&#146;s 2003 Stock Incentive Plan (the
    2003 Plan), which we refer to as the 2003 Plan Amendment and
    which is included as <U>Annex&#160;D</U> to this proxy
    statement. We have previously used the 2003 Plan as a means of
    attracting, retaining, motivating and rewarding directors,
    officers, other employees, scientific collaborators and
    consultants and further aligning their interests with those of
    our stockholders. Although no new options or other equity-based
    awards are currently issuable under the 2003 Plan, an increase
    in the number of shares authorized under the 2003 Plan is
    required in order to satisfy our contractual obligation in
    connection with an option granted on February&#160;2, 2004 to
    our President and Chief Executive Officer, Dr.&#160;Gulfo.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The 2003 Plan Amendment would increase by 500,000 the aggregate
    number of shares of common stock that are available under the
    2003 Plan to a total of 1,250,000&#160;shares of common stock.
    On April&#160;17, 2007, the compensation committee approved and
    adopted the 2003 Plan Amendment, subject to approval by the
    stockholders at the 2007 Annual Meeting. On April&#160;17, 2007,
    the Board of Directors ratified the actions of the compensation
    committee and recommended that the stockholders approve the 2003
    Plan Amendment. No options or other awards have been or are
    permitted to be granted under the 2003 Plan since the adoption
    of the 2005 Plan on May&#160;24, 2005. The shares available
    under the 2003 Plan are, and will continue to be, available for
    issuance only pursuant to grants previously made under the 2003
    Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vote Required.</I>&#160;&#160;The affirmative vote of the
    holders of a majority of our outstanding shares of common stock,
    present in person or represented by proxy at the annual meeting
    and entitled to vote, is required to approve the 2003 Plan
    Amendment. Unless otherwise indicated, properly executed proxies
    will be voted in favor of the Proposal&#160;3 to approve the
    2003 Plan Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>THE BOARD OF DIRECTORS RECOMMENDS</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>A VOTE IN FAVOR OF PROPOSAL&#160;3.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors believes that our growth depends
    significantly upon the efforts of our officers and key employees
    and that such individuals are best motivated to put forth
    maximum effort on our behalf if they own an equity interest in
    the Company. The Board of Directors is committed to creating and
    maintaining a compensation system based to a significant extent
    on grants of equity-based awards. The Board of Directors
    considers equity-based incentives an important component of its
    efforts to attract and retain talented individuals. In addition,
    the Board of Directors believes that option grants help us to
    attain our long-term goals by linking the compensation of key
    employees to stockholder returns.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with this philosophy, when we retained our
    President and Chief Executive Officer, Dr.&#160;Gulfo, we
    granted him three separate stock options. The first two stock
    option grants for the purchase of a total of 81,753&#160;shares
    of our common stock at an exercise price of $0.46&#160;per share
    have fully vested. The number of shares of our common stock
    subject to the third stock option can only be calculated at the
    time of FDA Pre-Market Approval (PMA) of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    The number of shares purchasable under this option at an
    exercise price of $0.46&#160;per share is equal to that number
    of shares of common stock equal to four percent of our
    fully-diluted capital stock at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    minus the number of shares of common stock underlying the other
    stock options granted to Dr.&#160;Gulfo, which is 81,573. This
    third stock option vests 50% at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    and the remaining 50% vests in four equal installments over the
    one-year period following such PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    Based on 15,612,705&#160;shares outstanding (on a fully-diluted
    basis) as of December&#160;31, 2006 and assuming such shares
    remain the total number of shares outstanding on the date we
    receive PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    the number of shares subject to this option would be 542,755. In
    the event we issue additional equity securities prior to the
    date of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    the number of shares issuable pursuant to Dr.&#160;Gulfo&#146;s
    third option would increase proportionately.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With 750,000&#160;shares authorized under the 2003 Plan, and
    excluding Dr.&#160;Gulfo&#146;s third option, awards have been
    granted with respect to 405,441 of such shares. Therefore there
    will not be enough shares authorized under the 2003 Plan upon
    Dr.&#160;Gulfo&#146;s exercise of this option and it is
    necessary to increase the number of authorized shares under the
    2003 Plan for this purpose. Accordingly, the compensation
    committee and our Board of Directors has determined that it is
    in the best interest of the Company to increase the total number
    of authorized shares under the 2003 Plan to 1,250,000, which the
    compensation committee believes is a sufficient number of shares
    based on management&#146;s estimate of the timing of PMA
    approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    Upon the vesting in full of Dr.&#160;Gulfo&#146;s third option
    and the determination of the number of shares subject to such
    option, the number of shares available for issuance under the
    2003 Plan shall automatically be reduced to the number of shares
    subject to all outstanding options granted under the 2003 Plan,
    including Dr.&#160;Gulfo&#146;s options.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">New Plan
    Benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No new options or other equity-based awards are or will be
    issuable under the 2003 Plan. See &#147;Executive
    Compensation&#160;&#151; Outstanding Equity Awards At
    2006&#160;Year-End and Grants of Plan-Based Awards for Fiscal
    Year 2006&#148; for information regarding equity grants made to
    the executive officers and &#147;Compensation of
    Directors&#160;&#151; Director Compensation Table for 2006&#148;
    for information regarding equity grants made to members of our
    Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Description
    of the Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summary of the 2003 Plan is qualified in its
    entirety by reference to the full text of the 2003 Plan, as
    proposed to be amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Administration.</I>&#160;&#160;The 2003 Plan is administered
    by the compensation committee of the Board of Directors. Subject
    to the terms of the plan, the compensation committee selected
    participants to receive awards, determined the types of awards
    and terms and conditions of awards, and interprets provisions of
    the plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Common Stock Reserved for Issuance under the
    Plan.</I>&#160;&#160;Seven hundred fifty-thousand (750,000)
    shares of the Company&#146;s common stock have been authorized
    and reserved for issuance under the 2003 Plan prior to the
    adoption of the 2003 Plan Amendment. The common stock issued or
    to be issued under the 2003 Plan consists of authorized but
    unissued shares. If any shares covered by an award are not
    purchased or are forfeited, or if an award otherwise terminates
    without delivery of any common stock, then the number of shares
    of common stock counted against the aggregate number of shares
    available under the plan with respect to the award will, to the
    extent of any such forfeiture or termination, again be available
    for issuance under the 2003 Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Eligibility.</I>&#160;&#160;Awards were made under the 2003
    Plan to employees, officers, directors and scientific
    collaborators of or consultants to the Company whose
    participation in the plan was determined to be in the best
    interests of the Company by the Board of Directors.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amendment or Termination of the Plan.</I>&#160;&#160;The
    Board of Directors may terminate or amend the plan at any time
    and for any reason; provided, however, that no such action may
    adversely affect the rights of the holder of any outstanding
    award in a material way without the consent of the holder. The
    2003 Plan shall terminate in any event ten years after its
    effective date. Any amendment which would increase the number of
    shares of common stock which may be issued under the plan or
    modify the class of persons eligible to receive awards under the
    plan are subject to the approval of the Company&#146;s
    stockholders if and to the extent such approval is necessary or
    desirable to comply with applicable law or exchange or listing
    requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Options.</I>&#160;&#160;The 2003 Plan permitted the granting
    of options to purchase shares of common stock intended to
    qualify as incentive stock options under the Internal Revenue
    Code and stock options that do not qualify as incentive stock
    options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of each stock option may not be less than the
    par value of the common stock, provided that the exercise price
    of an incentive stock option may not be less than fair market
    value on the date of grant. The fair market value is generally
    determined as the closing price of the common stock on The
    Nasdaq Stock Market, Inc. on the grant date. In the case of
    certain 10% stockholders who receive incentive stock options,
    the exercise price may not be less than 110% of the fair market
    value of the common stock on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The term of each stock option is fixed by the compensation
    committee and may not exceed 10&#160;years from the date of
    grant. The compensation committee determined at what time or
    times each option may be exercised and the period of time, if
    any, after retirement, death, disability or termination of
    employment during which options may be exercised. Options may be
    made exercisable in installments. The exercisability of options
    may be accelerated by the compensation committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, an optionee may pay the exercise price of an option
    by cash, check, by tendering shares of common stock, or by means
    of a broker-assisted cashless exercise. However, executive
    officers and directors may not use the cashless exercise method
    unless they have obtained the express prior approval of the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon termination of an option holder&#146;s employment or
    service with the Company due to death or disability, any portion
    of an option held by the option holder which is not then
    exercisable shall thereupon terminate, and any portion of an
    option held by the option holder which is then exercisable shall
    remain exercisable for the lesser of one year following such
    termination of employment or service or until the expiration of
    the term of the option. Upon termination of an option
    holder&#146;s employment or service with the Company for cause,
    any option held by the option holder shall immediately terminate
    and shall cease to be exercisable. If an option holder&#146;s
    employment or service with the Company terminates for any other
    reason other than death, disability or cause, then any portion
    of an option which is not then exercisable shall thereupon
    terminate, and any portion of an option which is then
    exercisable shall remain exercisable for the lesser of
    90&#160;days following such termination or until the expiration
    of the term of the option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock options granted under the 2003 Plan may not be sold,
    transferred, pledged or assigned other than by will or under
    applicable laws of descent and distribution. However, we may
    permit limited transfers of non-qualified options for the
    benefit of immediate family members of grantees to help with
    estate planning concerns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stock Awards.</I>&#160;&#160;The compensation committee may
    have also made stock awards to eligible personnel upon such
    terms and conditions as the committee deemed appropriate. A
    stock award may take the form of the issuance and transfer to
    the recipient of shares of common stock or a grant of stock
    units representing a right to receive shares of common stock in
    the future and, in either case, may be subject to designated
    vesting conditions and transfer restrictions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purchase price payable for shares of common stock
    transferred pursuant to a stock award must be at least equal to
    their par value, unless other lawful consideration is received
    by the Company for the issuance of the shares or treasury shares
    are delivered in connection with the award.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise determined by the compensation committee,
    (i)&#160;the recipient of a stock award will be entitled to
    receive dividend payments, if any (or, in the case of an award
    of stock units, dividend equivalent payments), on or with
    respect to the shares that remain covered by the award (which
    the committee may specify are payable on a deferred basis and
    are forfeitable to the same extent as the underlying award),
    (ii)&#160;the recipient of a non-vested stock award may exercise
    voting rights if and to the extent that shares of common stock
    have been issued to him pursuant to the award, and
    (iii)&#160;the recipient will have no other rights as a
    stockholder with respect to such shares unless and until the
    shares are issued to him free of all conditions and restrictions
    under the plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the compensation committee determined otherwise, a
    non-vested stock award will be forfeited upon the termination of
    the recipient&#146;s employment or other service with the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless and until all applicable vesting conditions are satisfied
    and vested shares are issued, neither the stock award nor any
    shares of common stock issued pursuant to the award may be sold,
    transferred, pledged or assigned other than to the Company in
    accordance with the terms of the award or the plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Effect of Certain Corporate
    Transactions.</I>&#160;&#160;Certain change of control
    transactions involving us, such as a sale of the Company, may
    cause awards granted under the 2003 Plan to vest, unless the
    awards are continued or substituted for in connection with the
    change of control transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Adjustments for Stock Dividends and Similar
    Events.</I>&#160;&#160;Proportionate adjustments in outstanding
    awards and the number of shares available for issuance under the
    2003 Plan, including the individual limitations on awards, will
    be made to reflect common stock dividends, stock splits and
    other similar events.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Federal
    Income Tax Consequences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following discussion is a general summary of the principal
    federal income tax consequences under current law relating to
    award granted under the 2003 Plan. The summary is not intended
    to be exhaustive and, among other things, does not describe
    state, local or foreign income and other tax consequences.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Incentive Stock Options.</I>&#160;&#160;The grant of an
    option will not be a taxable event for the grantee or for the
    Company. A grantee will not recognize taxable income upon
    exercise of an incentive stock option (except that the
    alternative minimum tax may apply), and any gain realized upon a
    disposition of our common stock received pursuant to the
    exercise of an incentive stock option will be taxed as long-term
    capital gain if the grantee does not dispose of the shares of
    common stock within least two years after the date of grant nor
    within one year after the date of exercise (holding period
    requirement). We will not be entitled to any business expense
    deduction with respect to the exercise of an incentive stock
    option, except as discussed below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the exercise of an option to qualify for the foregoing tax
    treatment, the grantee generally must be an employee of the
    Company from the date the option is granted through a date
    within three months before the date of exercise of the option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If all of the foregoing requirements are met except the holding
    period requirement mentioned above, the grantee will recognize
    ordinary income upon the disposition of the common stock in an
    amount generally equal to the excess of the fair market value of
    the common stock at the time the option was exercised over the
    option exercise price (but not in excess of the gain realized on
    the sale). The balance of the realized gain, if any, will be
    capital gain. We will be allowed a business expense deduction to
    the extent the grantee recognizes ordinary income, subject to
    our compliance with Section&#160;162(m) of the Internal Revenue
    Code and to certain reporting requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Non-Qualified Options.</I>&#160;&#160;The grant of an option
    will not be a taxable event for the grantee or the Company. Upon
    exercising a non-qualified option, a grantee will recognize
    ordinary income in an amount equal to the difference between the
    exercise price and the fair market value of the common stock on
    the date of exercise. Upon a subsequent sale or exchange of
    shares acquired pursuant to the exercise of a non-qualified
    option, the grantee will have taxable capital gain or loss,
    measured by the difference between the amount realized on the
    disposition and the tax basis of the shares of common stock
    (generally, the amount paid for the shares plus the amount
    treated as ordinary income at the time the option was exercised).
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we comply with applicable reporting requirements and with the
    restrictions of Section&#160;162(m) of the Internal Revenue
    Code, we will be entitled to a business expense deduction in the
    same amount and generally at the same time as the grantee
    recognizes ordinary income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A grantee who has transferred a non-qualified stock option to a
    family member by gift will realize taxable income at the time
    the non-qualified stock option is exercised by the family
    member. The grantee will be subject to withholding of income and
    employment taxes at that time. The family member&#146;s tax
    basis in the shares of common stock will be the fair market
    value of the shares of common stock on the date the option is
    exercised. The transfer of vested non-qualified stock options
    will be treated as a completed gift for gift and estate tax
    purposes. Once the gift is completed, neither the transferred
    options nor the shares acquired on exercise of the transferred
    options will be includable in the grantee&#146;s estate for
    estate tax purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event a grantee transfers a non-qualified stock option to
    his or her ex-spouse incident to the grantee&#146;s divorce,
    neither the grantee nor the ex-spouse will recognize any taxable
    income at the time of the transfer. In general, a transfer is
    made &#147;incident to divorce&#148; if the transfer occurs
    within one year after the marriage ends or if it is related to
    the end of the marriage (for example, if the transfer is made
    pursuant to a divorce order or settlement agreement). Upon the
    subsequent exercise of such option by the ex-spouse, the
    ex-spouse will recognize taxable income in an amount equal to
    the difference between the exercise price and the fair market
    value of the shares of common stock at the time of exercise. The
    ex-spouse will be subject to employment and income tax
    withholding at this time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Restricted Stock.</I>&#160;&#160;A grantee who is awarded
    restricted stock will not recognize any taxable income for
    federal income tax purposes in the year of the award, provided
    that the shares of common stock are subject to restrictions
    (that is, the restricted stock is nontransferable and subject to
    a substantial risk of forfeiture). However, the grantee may
    elect under Section&#160;83(b) of the Internal Revenue Code to
    recognize compensation income in the year of the award in an
    amount equal to the fair market value of the common stock on the
    date of the award (less the purchase price, if any), determined
    without regard to the restrictions. If the grantee does not make
    such a Section&#160;83(b) election, the fair market value of the
    common stock on the date the restrictions lapse (less the
    purchase price, if any) will be treated as compensation income
    to the grantee and will be taxable in the year the restrictions
    lapse. If we comply with applicable reporting requirements and
    with the restrictions of Section&#160;162(m) of the Internal
    Revenue Code, we will be entitled to a business expense
    deduction in the same amount and generally at the same time as
    the grantee recognizes ordinary income. Dividend payments on
    restricted stock are treated as compensation income unless the
    grantee has made a Section&#160;83(b) election.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Unrestricted Stock.</I>&#160;&#160;A grantee who is awarded
    unrestricted shares will recognize ordinary income in an amount
    equal to the fair market value of the shares of common stock on
    the date of the award, reduced by the amount, if any, paid for
    such shares of common stock. The Company will generally be
    allowed a business expense deduction in the same amount and at
    the same time as the grantee recognizes ordinary income, subject
    to our compliance with Section&#160;162(m) of the Internal
    Revenue Code.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Internal
    Revenue Code Sections&#160;409A and 280G</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;409A of the Internal Revenue Code provides that
    deferred compensation that is not structured to satisfy
    Section&#160;409A and that is not subject to a substantial risk
    of forfeiture may result in current federal income taxation, an
    additional tax of 20% of the compensation required to be
    included in income and interest for any underpayment of tax at
    the ordinary underpayment rate plus one percentage point for any
    period during which taxation of the compensation has been
    deferred. Stock options granted with an exercise price equal to
    the fair market value of the underlying common stock on the date
    of grant are generally exempt from the application of
    Section&#160;409A. In addition, Section&#160;280G of the
    Internal Revenue Code provides that to the extent that payments
    which are contingent on a change in control are determined to
    exceed certain Internal Revenue Code limitations, they may be
    subject to a 20% nondeductible excise tax on the employee and
    the Company&#146;s deduction with respect to the associated
    compensation expense may be disallowed in whole or in part.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;4<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">AMENDMENT
    TO 2005 STOCK INCENTIVE PLAN</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors is proposing for stockholder ratification
    an amendment to the Company&#146;s 2005 Stock Incentive Plan
    (the 2005 Plan), which we refer to as the 2005 Plan Amendment
    and which is included as <U>Annex&#160;E</U> to this proxy
    statement. We use the 2005 Plan as a means of attracting,
    retaining, motivating and rewarding directors, officers, other
    employees, scientific collaborators and consultants and further
    aligning their interests with those of our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee of our Board of Directors determined
    that, for administrative efficiency and clarity, the 2005 Plan
    should be amended to replace the formulaic provision for
    calculating the aggregate number of shares authorized under the
    2005 Plan with 1,724,028, the actual number of shares issuable
    under such plan derived from the original formula. On
    April&#160;17, 2007, the compensation committee adopted the 2005
    Plan Amendment, subject to approval by the stockholders at the
    2007 Annual Meeting. On April&#160;17, 2007, the Board of
    Directors ratified the actions of the compensation committee and
    recommended that the stockholders ratify the 2005 Plan
    Amendment. The 2005 Plan Amendment does not change the maximum
    number of shares issuable under the 2005 Plan as currently in
    effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vote Required.</I>&#160;&#160;Neither the 2005 Plan nor the
    Company&#146;s Bylaws require the affirmative vote of the
    holders of a majority of votes represented by our outstanding
    shares of common stock, present in person or represented by
    proxy at the annual meeting and entitled to vote, to approve the
    2005 Plan Amendment. However, the Board of Directors, on behalf
    of the compensation committee, is submitting the 2005 Plan
    Amendment to the stockholders for ratification as a matter of
    good corporate practice. If the stockholders fail to ratify the
    amendment, the compensation committee will reconsider whether or
    not to adopt the 2005 Plan Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The affirmative vote of the holders of a majority of the shares
    present in person or represented by proxy and entitled to vote
    will be required to ratify 2005 Plan Amendment. Unless otherwise
    indicated, properly executed proxies will be voted in favor of
    the Proposal&#160;4 to ratify the 2005 Plan Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>THE BOARD OF DIRECTORS RECOMMENDS</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>A VOTE IN FAVOR OF PROPOSAL&#160;4.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors believes that our growth depends
    significantly upon the efforts of our officers and key employees
    and that such individuals are best motivated to put forth
    maximum effort on our behalf if they own an equity interest in
    the Company. The Board of Directors is committed to creating and
    maintaining a compensation system based to a significant extent
    on grants of equity-based awards. The Board of Directors
    considers equity-based incentives an important component of its
    efforts to attract and retain talented individuals. In addition,
    the Board of Directors believes that option grants help us to
    attain our long-term goals by linking the compensation of key
    employees to stockholder returns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors determined that, for administrative
    efficiency and clarity, the 2005 Plan should be amended to
    replace the formulaic provision for calculating the aggregate
    number of shares authorized under the 2005 Plan with 1,724,028,
    the actual number of shares issuable under such plan derived
    from the original formula. The 2005 Plan Amendment does not
    change the maximum number of shares issuable under the 2005 Plan
    as currently in effect.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">New Plan
    Benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the 2005 Plan is being amended only to specify numerically
    rather than by formula the total number of authorized shares,
    there are no new plan benefits to be disclosed.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Description
    of the Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summary of the 2005 Plan is qualified in its
    entirety by reference to the full text of the 2005 Plan, as
    proposed to be amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Administration.</I>&#160;&#160;The 2005 Plan is administered
    by the compensation committee of the Board of Directors. Subject
    to the terms of the plan, the compensation committee may select
    participants to receive awards, determine the types of awards
    and terms and conditions of awards, and interpret provisions of
    the plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Common Stock Reserved for Issuance under the
    Plan.</I>&#160;&#160;One million seven hundred twenty-four
    thousand twenty-eight (1,724,028) shares of the Company&#146;s
    common stock have been authorized and reserved for issuance
    under the 2005 Plan. Pursuant to the 2005 Plan as originally
    adopted, the number of shares of common stock authorized and
    reserved for issuance was 1,000,000. The number of shares of
    common stock authorized and reserved for issuance under the 2005
    Plan increased to 1,724,028 in accordance with the formula set
    forth therein. The common stock issued or to be issued under the
    2005 Plan consists of authorized but unissued shares. If any
    shares covered by an award are not purchased or are forfeited,
    or if an award otherwise terminates without delivery of any
    common stock, then the number of shares of common stock counted
    against the aggregate number of shares available under the plan
    with respect to the award will, to the extent of any such
    forfeiture or termination, again be available for making awards
    under the 2005 Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Eligibility.</I>&#160;&#160;Awards may be made under the 2005
    Plan to employees, officers, directors and scientific
    collaborators of or consultants to the Company whose
    participation in the plan is determined to be in the best
    interests of the Company by the Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amendment or Termination of the Plan.</I>&#160;&#160;The
    Board of Directors may terminate or amend the plan at any time
    and for any reason; provided, however, that no such action may
    adversely affect the rights of the holder of any outstanding
    award in a material way without the consent of the holder. The
    2005 Plan shall terminate in any event ten years after its
    effective date. Any amendment which would increase the number of
    shares of common stock which may be issued under the plan or
    modify the class of persons eligible to receive awards under the
    plan are subject to the approval of the Company&#146;s
    stockholders if and to the extent such approval is necessary or
    desirable to comply with applicable law or exchange or listing
    requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Options.</I>&#160;&#160;The 2005 Plan permits the granting of
    options to purchase shares of common stock intended to qualify
    as incentive stock options under the Internal Revenue Code and
    stock options that do not qualify as incentive stock options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of each stock option is granted at fair
    market value of our common stock on the date of grant. The fair
    market value is generally determined as the closing price of the
    common stock on The Nasdaq Stock Market, Inc. on the grant date.
    In the case of certain 10% stockholders who receive incentive
    stock options, the exercise price may not be less than 110% of
    the fair market value of the common stock on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The term of each stock option is fixed by the compensation
    committee and may not exceed 10&#160;years from the date of
    grant. The compensation committee determines at what time or
    times each option may be exercised and the period of time, if
    any, after retirement, death, disability or termination of
    employment during which options may be exercised. Options may be
    made exercisable in installments. The exercisability of options
    may be accelerated by the compensation committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, an optionee may pay the exercise price of an option
    by cash, check, by tendering shares of common stock, or by means
    of a broker-assisted cashless exercise. However, executive
    officers and directors may not use the cashless exercise method
    unless they have obtained the express prior approval of the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon termination of an option holder&#146;s employment or
    service with the Company due to death or disability, any portion
    of an option held by the option holder which not then
    exercisable shall thereupon terminate, and any portion of an
    option held by the option holder which is then exercisable shall
    remain exercisable for the lesser of one year following such
    termination of employment or service or until the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    expiration of the term of the option. Upon termination of an
    option holder&#146;s employment or service with the Company for
    cause, any option held by the option holder shall immediately
    terminate and shall cease to be exercisable. If an option
    holder&#146;s employment or service with the Company terminates
    for any other reason other than death, disability or cause, then
    any portion of an option which is not then exercisable shall
    thereupon terminate, and any portion of an option which is then
    exercisable shall remain exercisable for the lesser of
    90&#160;days following such termination or until the expiration
    of the term of the option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock options granted under the 2005 Plan may not be sold,
    transferred, pledged or assigned other than by will or under
    applicable laws of descent and distribution. However, we may
    permit limited transfers of non-qualified options for the
    benefit of immediate family members of grantees to help with
    estate planning concerns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stock Awards.</I>&#160;&#160;The compensation committee may
    also award stock awards to eligible personnel upon such terms
    and conditions as the committee deems appropriate. A stock award
    may take the form of the issuance and transfer to the recipient
    of shares of common stock or a grant of stock units representing
    a right to receive shares of common stock in the future and, in
    either case, may be subject to designated vesting conditions and
    transfer restrictions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purchase price payable for shares of common stock
    transferred pursuant to a stock award must be at least equal to
    their fair market value on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise determined by the compensation committee,
    (i)&#160;the recipient of a stock award will be entitled to
    receive dividend payments, if any (or, in the case of an award
    of stock units, dividend equivalent payments), on or with
    respect to the shares that remain covered by the award (which
    the committee may specify are payable on a deferred basis and
    are forfeitable to the same extent as the underlying award),
    (ii)&#160;the recipient of a non-vested stock award may exercise
    voting rights if and to the extent that shares of common stock
    have been issued to him pursuant to the award, and
    (iii)&#160;the recipient will have no other rights as a
    stockholder with respect to such shares unless and until the
    shares are issued to him free of all conditions and restrictions
    under the plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the compensation committee determines otherwise, a
    non-vested stock award will be forfeited upon the termination of
    the recipient&#146;s employment or other service with the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless and until all applicable vesting conditions are satisfied
    and vested shares are issued, neither the stock award nor any
    shares of common stock issued pursuant to the award may be sold,
    transferred, pledged or assigned other than to the Company in
    accordance with the terms of the award or the plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Effect of Certain Corporate
    Transactions.</I>&#160;&#160;Certain change of control
    transactions involving us, such as a sale of the Company, may
    cause awards granted under the 2005 Plan to vest, unless the
    awards are continued or substituted for in connection with the
    change of control transaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Adjustments for Stock Dividends and Similar
    Events.</I>&#160;&#160;Proportionate adjustments in outstanding
    awards and the number of shares available for issuance under the
    2005 Plan, including the individual limitations on awards, will
    be made to reflect common stock dividends, stock splits and
    other similar events.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Federal
    Income Tax Consequences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following discussion is a general summary of the principal
    federal income tax consequences under current law relating to
    award granted under the 2003 Plan. The summary is not intended
    to be exhaustive and, among other things, does not describe
    state, local or foreign income and other tax consequences.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Incentive Stock Options.</I>&#160;&#160;The grant of an
    option will not be a taxable event for the grantee or for the
    Company. A grantee will not recognize taxable income upon
    exercise of an incentive stock option (except that the
    alternative minimum tax may apply), and any gain realized upon a
    disposition of our common stock received pursuant to the
    exercise of an incentive stock option will be taxed as long-term
    capital gain if the grantee does not dispose of the shares of
    common stock within least two years after the date of grant nor
    within one year after the date of exercise (holding period
    requirement). We will not be entitled to any business expense
    deduction with respect to the exercise of an incentive stock
    option, except as discussed below.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the exercise of an option to qualify for the foregoing tax
    treatment, the grantee generally must be an employee of the
    Company from the date the option is granted through a date
    within three months before the date of exercise of the option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If all of the foregoing requirements are met except the holding
    period requirement mentioned above, the grantee will recognize
    ordinary income upon the disposition of the common stock in an
    amount generally equal to the excess of the fair market value of
    the common stock at the time the option was exercised over the
    option exercise price (but not in excess of the gain realized on
    the sale). The balance of the realized gain, if any, will be
    capital gain. We will be allowed a business expense deduction to
    the extent the grantee recognizes ordinary income, subject to
    our compliance with Section&#160;162(m) of the Internal Revenue
    Code and to certain reporting requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Non-Qualified Options.</I>&#160;&#160;The grant of an option
    will not be a taxable event for the grantee or the Company. Upon
    exercising a non-qualified option, a grantee will recognize
    ordinary income in an amount equal to the difference between the
    exercise price and the fair market value of the common stock on
    the date of exercise. Upon a subsequent sale or exchange of
    shares acquired pursuant to the exercise of a non-qualified
    option, the grantee will have taxable capital gain or loss,
    measured by the difference between the amount realized on the
    disposition and the tax basis of the shares of common stock
    (generally, the amount paid for the shares plus the amount
    treated as ordinary income at the time the option was exercised).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we comply with applicable reporting requirements and with the
    restrictions of Section&#160;162(m) of the Internal Revenue
    Code, we will be entitled to a business expense deduction in the
    same amount and generally at the same time as the grantee
    recognizes ordinary income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A grantee who has transferred a non-qualified stock option to a
    family member by gift will realize taxable income at the time
    the non-qualified stock option is exercised by the family
    member. The grantee will be subject to withholding of income and
    employment taxes at that time. The family member&#146;s tax
    basis in the shares of common stock will be the fair market
    value of the shares of common stock on the date the option is
    exercised. The transfer of vested non-qualified stock options
    will be treated as a completed gift for gift and estate tax
    purposes. Once the gift is completed, neither the transferred
    options nor the shares acquired on exercise of the transferred
    options will be includable in the grantee&#146;s estate for
    estate tax purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event a grantee transfers a non-qualified stock option to
    his or her ex-spouse incident to the grantee&#146;s divorce,
    neither the grantee nor the ex-spouse will recognize any taxable
    income at the time of the transfer. In general, a transfer is
    made &#147;incident to divorce&#148; if the transfer occurs
    within one year after the marriage ends or if it is related to
    the end of the marriage (for example, if the transfer is made
    pursuant to a divorce order or settlement agreement). Upon the
    subsequent exercise of such option by the ex-spouse, the
    ex-spouse will recognize taxable income in an amount equal to
    the difference between the exercise price and the fair market
    value of the shares of common stock at the time of exercise. The
    ex-spouse will be subject to employment and income tax
    withholding at this time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Restricted Stock.</I>&#160;&#160;A grantee who is awarded
    restricted stock will not recognize any taxable income for
    federal income tax purposes in the year of the award, provided
    that the shares of common stock are subject to restrictions
    (that is, the restricted stock is nontransferable and subject to
    a substantial risk of forfeiture). However, the grantee may
    elect under Section&#160;83(b) of the Internal Revenue Code to
    recognize compensation income in the year of the award in an
    amount equal to the fair market value of the common stock on the
    date of the award (less the purchase price, if any), determined
    without regard to the restrictions. If the grantee does not make
    such a Section&#160;83(b) election, the fair market value of the
    common stock on the date the restrictions lapse (less the
    purchase price, if any) will be treated as compensation income
    to the grantee and will be taxable in the year the restrictions
    lapse. If we comply with applicable reporting requirements and
    with the restrictions of Section&#160;162(m) of the Internal
    Revenue Code, we will be entitled to a business expense
    deduction in the same amount and generally at the same time as
    the grantee recognizes ordinary income. Dividend payments on
    restricted stock are treated as compensation income unless the
    grantee has made a Section&#160;83(b) election.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Unrestricted Stock.</I>&#160;&#160;A grantee who is awarded
    unrestricted shares will recognize ordinary income in an amount
    equal to the fair market value of the shares of common stock on
    the date of the award, reduced by the amount, if any, paid for
    such shares of common stock. The Company will generally be
    allowed a business expense deduction in the same amount and at
    the same time as the grantee recognizes ordinary income, subject
    to our compliance with Section&#160;162(m) of the Internal
    Revenue Code.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Internal
    Revenue Code Sections&#160;409A and 280G</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;409A of the Internal Revenue Code provides that
    deferred compensation that is not structured to satisfy
    Section&#160;409A and that is not subject to a substantial risk
    of forfeiture may result in current federal income taxation, an
    additional tax of 20% of the compensation required to be
    included in income and interest for any underpayment of tax at
    the ordinary underpayment rate plus one percentage point for any
    period during which taxation of the compensation has been
    deferred. Stock options granted with an exercise price equal to
    the fair market value of the underlying common stock on the date
    of grant are generally exempt from the application of
    Section&#160;409A. In addition, Section&#160;280G of the
    Internal Revenue Code provides that to the extent that payments
    which are contingent on a change in control are determined to
    exceed certain Internal Revenue Code limitations, they may be
    subject to a 20% nondeductible excise tax on the employee and
    the Company&#146;s deduction with respect to the associated
    compensation expense may be disallowed in whole or in part.
</DIV>
<A name='108'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECURITY
    OWNERSHIP OF<BR>
    CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth certain information regarding the
    ownership of the Company&#146;s common stock as of
    February&#160;28, 2007 (except as noted) by: (i)&#160;each
    nominee for director; (ii)&#160;each of the executive officers
    named in the Summary Compensation Table presented later in this
    proxy statement; (iii)&#160;all executive officers and directors
    of the Company as a group; and (iv)&#160;all those known by the
    Company to be beneficial owners of more than five percent of its
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Beneficial Ownership(1)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Common Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Percentage of Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Beneficially Owned</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Beneficially Owned</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Named Executive
    Officers</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Richard I. Steinhart
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jon I. Klippel
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Christiano Butler
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Karen Krumeich(2)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">William Bronner(3)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Directors</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Breaux Castleman
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Sidney Braginsky(4)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">George C. Chryssis
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Martin Cleary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dan W. Lufkin(5)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    571,119
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.91
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gerald Wagner,&#160;Ph.D.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.17
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">All directors and named executive
    officers as a group (all 12&#160;persons)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,275,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.74
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B><FONT style="font-size: 10pt">Holders of more than
    5%</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">FMR Corp.(6)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,210,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.29
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Manulife Financial Corporation(7)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,249,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.56
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Phronesis Partners, LLC(8)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    790,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.41
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Caremi Partners, Ltd.(9)
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    929,460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.37
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="center" valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Less than one percent.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    This table is based upon information supplied by officers,
    directors and principal stockholders and Schedules 13G filed
    with the SEC. Unless otherwise indicated in the footnotes to
    this table and subject to community property laws where
    applicable, the Company believes that each of the stockholders
    named in this table has sole voting and investment power with
    respect to the shares indicated as beneficially owned.
    Applicable percentages are based on 14,593,451&#160;shares
    outstanding on February&#160;28, 2007, adjusted as required by
    rules promulgated by the SEC. Unless otherwise indicated, the
    address of each of the individuals and entities listed in this
    table is c/o&#160;Electro-Optical Sciences, at the address on
    the first page of this proxy statement.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Ms.&#160;Krumeich resigned as Vice President and Chief Financial
    Officer effective April&#160;24, 2006.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an option for 7,500&#160;shares which expired on
    March&#160;1, 2007. Mr.&#160;Bronner resigned as Vice President,
    Legal Counsel and Compliance, and Secretary effective
    November&#160;30, 2006.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 51,500&#160;shares of common stock held by Double D
    Venture Fund, LLC, an investment fund with which
    Mr.&#160;Braginsky is affiliated. Mr.&#160;Braginsky expressly
    disclaims ownership of these shares except to the extent of his
    pecuniary interest in Double D Venture Fund, LLC.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 252,257&#160;shares of common stock held by trusts the
    beneficiaries of which are family members of Mr.&#160;Lufkin.
    Mr.&#160;Lufkin expressly disclaims ownership of the shares held
    by these trusts.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based solely on information contained in a Schedule&#160;13G
    jointly filed by FMR Corp. (&#147;FMR&#148;) and its indirect,
    wholly-owned subsidiary, Fidelity Management and Research
    (&#147;Fidelity&#148;) on February&#160;14, 2007, Edward C.
    Johnson 3d and FMR, through its control of Fidelity, and the
    funds each has sole power to dispose of the
    1,210,526&#160;shares of common stock owned by the funds.
    Neither FMR Corp. nor Edward C. Johnson 3d, has the sole power
    to vote or direct the voting of the shares owned directly by the
    Fidelity funds, which power resides with the funds&#146; Board
    of Trustees. Fidelity carries out the voting of the shares under
    written guidelines established by the funds&#146; Board of
    Trustees. Fidelity is an investment adviser registered under the
    Investment Advisers Act of 1940, as amended (the
    &#147;Investment Advisers Act&#148;).</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based solely on information contained in a Schedule&#160;13G
    jointly filed by Manulife Financial Corporation
    (&#147;MFC&#148;) and MFC&#146;s indirect, wholly-owned
    subsidiaries, John Hancock Advisers LLC (&#147;JHA&#148;) and
    MFC Global Investment Management (U.S.), LLC (&#147;MFC
    Global&#148;) on February&#160;8, 2007. MFC Global has sole
    voting and sole dispositive power over 47,964&#160;shares of
    common stock. MFC Global has shared voting and shared
    dispositive power over 1,201,868&#160;shares of common stock.
    JHA has shared voting and shared dispositive power over the
    shares of common stock it owns. JHA and MFC Global are
    investment advisers registered under the Investment Advisers Act.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based solely on information contained in a Schedule&#160;13G
    jointly filed by Phronesis Partners, LLC (&#147;Phronesis&#148;)
    and James Wiggins on November&#160;9, 2006. Phronesis and James
    Wiggins each has sole voting power over 790,000&#160;shares of
    common stock and shared dispositive power over
    790,000&#160;shares of common stock. James Wiggins disclaims
    beneficial ownership except to the extent of his pecuniary
    interest in the 790,000&#160;shares of common stock.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based solely on information contained in a Schedule&#160;13G
    filed jointly by Caremi Partners, Ltd. (&#147;Caremi&#148;) and
    S. Donald Sussman, the controlling person of Caremi, on
    February&#160;15, 2006. Caremi and Mr.&#160;Sussman have shared
    voting power over 929,460&#160;shares of common stock owned by
    Caremi and shared dispositive power over 929,460&#160;shares of
    common stock owned by Caremi.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECTION&#160;16(a)
    BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;16(a) of the Securities Exchange Act of 1934, as
    amended, requires the Company&#146;s directors and executive
    officers, and persons who own more than ten percent of a
    registered class of the Company&#146;s equity securities, to
    file with the Securities and Exchange Commission initial reports
    of ownership and reports of changes in ownership of common stock
    and other equity securities of the Company. Officers, directors
    and greater than ten percent stockholders are required by SEC
    regulation to furnish the Company with copies of all
    Section&#160;16(a) forms they file.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the Company&#146;s knowledge, based solely on a review of the
    copies of such reports furnished to the Company and written
    representations that no other reports were required, during the
    fiscal year ended December&#160;31, 2006, all Section&#160;16(a)
    filing requirements applicable to its officers, directors and
    greater than ten percent beneficial owners were complied with.
</DIV>
<A name='110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXECUTIVE
    OFFICERS OF THE COMPANY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s executive officers, their ages and their
    positions as of February&#160;28, 2007, are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D.,
    M.B.A.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">43
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Director, President and Chief
    Executive Officer
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Richard I. Steinhart
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">49
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Vice President, Finance, Chief
    Financial Officer, Treasurer, and Secretary
    </FONT>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jon I. Klippel
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">52
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Vice President, Marketing and Sales
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Christiano Butler
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD nowrap align="right" valign="top">
    <FONT style="font-size: 10pt">49
    </FONT>
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <FONT style="font-size: 10pt">Vice President, Technical Support
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Joseph V. Gulfo,&#160;M.D., M.B.A.</I> has served as our
    President and Chief Executive Officer and a member of our Board
    of Directors since January 2004. From May 1999 to November 2003,
    he served as Chairman, Chief Executive Officer and President of
    Antigen Express, Inc., a development-stage company developing
    immunodiagnostics and therapeutics for cancer. Dr.&#160;Gulfo
    serves as a director of ProCertus BioPharm, Inc., a
    privately-held company. Dr.&#160;Gulfo received a B.S. in
    biology from Seton Hall University, an M.D. from the University
    of Medicine and Dentistry of New Jersey and an M.B.A. in finance
    from Seton Hall University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard I. Steinhart </I>has served as our Vice President,
    Finance and Chief Financial Officer and Treasurer since April
    2006 and as our Secretary since November 2006. From May 1992
    until joining the Company Mr.&#160;Steinhart was a Managing
    Director of Forest Street Capital/SAE Ventures, a boutique
    investment banking, venture capital, and management consulting
    firm focused on healthcare and technology companies. Prior to
    Forest Street Capital/SAE Ventures, he was Vice President and
    Chief Financial Officer of Emisphere Technologies, Inc.
    Mr.&#160;Steinhart&#146;s other experience includes seven years
    at CW Group, Inc., a venture capital firm focused on medical
    technology and biopharmaceutical companies, where he was a
    General Partner and Chief Financial Officer. Mr.&#160;Steinhart
    serves on the Board of Manhattan Pharmaceuticals, Inc., an
    AMEX-listed biopharmaceutical company and is Chairman of its
    Audit Committee. Mr.&#160;Steinhart began his career at Price
    Waterhouse, now known as PricewaterhouseCoopers. He holds B.B.A.
    and M.B.A degrees from Pace University and is a Certified Public
    Accountant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Jon I. Klippel </I>has served as our Vice President,
    Marketing and Sales since December 2004. From April 2004 to
    November 2004, he was a marketing and sales consultant. From
    January 2003 to March 2004, he served as Senior Marketing
    Manager of PDI, Inc., a publicly-traded company offering
    outsourced marketing, sales and sale support services to
    biopharmaceutical and medical device companies. From February
    2002 to December 2002, he was a marketing and sales consultant.
    From July 2000 to February 2002, he served as Director of
    Marketing and Business Development at National Imaging
    Associates, Inc., a privately-held diagnostic imaging management
    company. Mr.&#160;Klippel received a B.A. in political science
    from Albright College and an M.B.A. from Rutgers University
    Graduate School of Business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Christiano Butler </I>began serving as Vice President of
    Technical Support in June 2006. Mr.&#160;Butler brings more than
    20&#160;years of experience in the medical device industry in
    areas of product support and operations management engineering.
    From August 1985 until joining the company, Mr.&#160;Butler
    worked at Bayer
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    HealthCare in a series of positions with increasing
    responsibility. Most recently he served as Manager for Global
    Service and Support. Mr.&#160;Butler received a B.S. from the
    S.U.N.Y Regents College Program.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers are elected by, and serve at the
    discretion of, our Board of Directors. There are no family
    relationships between our directors and executive officers.
</DIV>
<A name='111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPENSATION
    DISCUSSION AND ANALYSIS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The principal goals of our compensation philosophy are: one, to
    attract, motivate and retain highly talented individuals at all
    levels of our organization, and, two, to align our
    employees&#146; incentives with the long-term interests of our
    stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At this stage in our growth, our principal business objective is
    to obtain PMA approval of our flagship product,
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    Achievement of this objective requires that we closely monitor
    our expenses, including compensation expenses. Accordingly, we
    seek to target our cash compensation levels at or below market
    and pay a significant portion of total compensation in the form
    of stock options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our pivotal trials and FDA approval process proceeds as
    expected we currently anticipate receiving FDA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    in mid-2008. As we move towards achievement of this critical
    milestone, we expect to re-evaluate our compensation philosophy
    and establish additional performance milestones appropriate for
    our overall business strategy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At the senior levels, we have developed a compensation package
    that includes both cash, in the form of base pay with
    discretionary bonus, and long-term incentive compensation in the
    form of stock options. Because of our need to conserve cash, we
    target the cash portion of our compensation package below market
    levels. However, we seek to set our level of stock option awards
    in line with industry comparables. All of our stock option
    grants are tied to either length of service or to the
    achievement of certain performance-based milestones, the most
    significant goal of which is approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    by the FDA. At lower levels, our compensation plan design is
    similar with employees paid a base salary and long-term
    incentive compensation in the form of stock options. However,
    lower level employees have a much smaller percentage of their
    overall compensation tied directly to long-term incentive
    compensation. As is the case with our senior executives, all
    employees are awarded stock options that vest with either length
    of service or the attainment of specific performance-based
    milestones.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To assist us in evaluating overall compensation during 2006 and
    for future compensation planning, we engaged A.G.
    Ferguson&#160;&#38; Associates, Inc. (AGF), a consulting firm
    with more that 25&#160;years of experience in executive
    compensation consulting, to review our senior level compensation
    policies. In performing their study, AGF analyzed a peer group
    of twenty-three publicly-held companies, as well as industry
    specific data from the 2006 Compensation and Entrepreneurship
    Report in Life Sciences (a survey of 170 private companies in
    the life sciences, including approximately 80 medical device
    companies) and general compensation data from the Economic
    Research Institute.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our view, the overall results of AGF&#146;s review validated
    our existing policy. The peer group analysis indicated that
    average total cash compensation paid to our top five named
    executives was significantly below market cash pay ranges and
    that the stock option grants used for long term incentive
    compensation were in line with market ranges for our peer group.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    AGF also indicated to us that we should consider adopting a more
    formal management incentive program for our named executives.
    They suggested that this program should include yearly cash
    bonus targets based on attaining specific milestones, and they
    also suggested that we consider the use of restricted stock
    awards, which would reduce the overall stock dilution caused by
    our stock option program. We will consider these recommendations
    as we plan future compensation packages.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    COMPENSATION TABLE FOR YEAR ENDED DECEMBER&#160;31,
    2006</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="38%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo, M.D., M.B.A.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,115
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,800(1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    296,715
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">President and Chief<BR>
    Executive Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Richard I. Steinhart
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    325,000
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    463,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Finance,<BR>
    Chief Financial Officer,<BR>
    Secretary and Treasurer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Karen Krumeich
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,058
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,058
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President Finance,<BR>
    Chief Financial Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jon. I. Klippel
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,373
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,900
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    169,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Marketing<BR>
    and Sales
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">William Bronner
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,850
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,355
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    195,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President, <BR>
    Legal Counsel and Compliance<BR>
    and Secretary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Christiano Butler
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170,000
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Technical Support
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">(1) Travel Allowance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">401(K) Contribution
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Total
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    This amount consists of company matching contributions made
    under our 401(k) plan of $6,600 and reimbursement of travel and
    lodging expense of $37,200.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    For Black-Scholes valuation model see Note&#160;8 to Financial
    Statements in our 2006 Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overall
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">President
    and Chief Executive Officer, Joseph V. Gulfo,&#160;M.D.,
    M.B.A.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;5, 2004, we entered into an employment agreement
    with Dr.&#160;Joseph V. Gulfo, our President and Chief Executive
    Officer. The employment agreement provides Dr.&#160;Gulfo with
    an annual base salary of $175,000, subject to periodic review by
    our Board of Directors, and yearly bonuses at the discretion of
    our Board of Directors. In 2005, our Board of Directors deferred
    any decision regarding Dr.&#160;Gulfo&#146;s base salary and
    bonus awards until after completion of our initial public
    offering. In 2006, based upon the completion of our initial
    public offering, significant technical progress in the
    development of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and a number of subjective factors, our Board of Directors
    decided to increase Dr.&#160;Gulfo&#146;s base salary to
    $235,000 and award him a bonus of $50,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Gulfo&#146;s employment agreement also provides for
    three separate grants of stock options. The first two stock
    option grants for the purchase of a total of 81,753&#160;shares
    of our common stock at an exercise price of $0.46&#160;per share
    have fully vested. The number of shares of our common stock
    subject to the third stock option can only be calculated at the
    time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    The number of shares purchasable under this option at an
    exercise price of $0.46&#160;per share is equal to that number
    of shares of common stock equal to four percent of our
    fully-diluted capital stock at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    minus the number of shares of common stock underlying the other
    stock options granted to Dr.&#160;Gulfo under the employment
    agreement, which is 81,573. Based on 15,612,705&#160;shares
    outstanding (on a fully-diluted basis) as of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    December&#160;31, 2006 and assuming such shares remain the total
    number of shares outstanding on the date we receive PMA approval
    of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    the number of shares subject to this option is 542,755. This
    third stock option vests 50% at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    and the remaining 50% vests in four equal installments over the
    one year period following such PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on its review of the AGF report and its own internal
    analysis, the Compensation Committee of our Board of Directors
    has concluded that Dr.&#160;Gulfo&#146;s total compensation was
    appropriate for 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Vice
    President Finance, and Chief Financial Officer, Secretary and
    Treasurer Richard Steinhart</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Vice President and Chief Financial Officer, Secretary and
    Treasurer Richard Steinhart, joined us in April of 2006.
    Mr.&#160;Steinhart earned a salary of $138,125 in 2006.
    Mr.&#160;Steinhart&#146;s compensation, including base salary
    and stock option package, was detailed in a letter agreement
    with Mr.&#160;Steinhart dated April&#160;24, 2006. Pursuant to
    that letter, Mr.&#160;Steinhart received a base salary of
    $195,000 and a stock option grant for the purchase of
    100,000&#160;shares of common stock at an exercise price of
    $5.82. In accordance with our policy, these options were priced
    on the date of grant as determined by the Compensation Committee
    of our Board of Directors. As is consistent throughout our
    executive ranks, Mr.&#160;Steinhart&#146;s options vest both
    over time and with the attainment of several corporate-wide
    milestones. In our letter agreement with Mr.&#160;Steinhart, we
    agreed that if we completed a corporate fundraising with gross
    proceeds of more than $10&#160;million, 40,000 options would
    vest and Mr.&#160;Steinhart would be entitled to a salary
    review. This milestone was met when we completed our
    November&#160;3, 2006 financing and raised approximately
    $13.2&#160;million in gross proceeds. Mr.&#160;Steinhart
    received no cash bonus and his salary was not reviewed in 2006.
    However, 40,000 of Mr.&#160;Steinhart&#146;s options were vested
    in 2006 along with 8,000 that were vested in accordance with
    time-based criteria.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also considered a number of subjective factors in considering
    Mr.&#160;Steinhart&#146;s overall compensation, including his
    prior business experience and overall company performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on review of the AGF report and its own internal analysis,
    the Compensation Committee of our Board of Directors concluded
    that Mr.&#160;Steinhart&#146;s pay package was appropriate for
    2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Former
    Vice President and Chief Financial Officer, Karen
    Krumeich</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ms.&#160;Krumeich resigned as our Vice President and Chief
    Financial Officer effective April&#160;24, 2006.
    Ms.&#160;Krumeich was being paid a base annual salary of
    $165,000 and was given six months severance following her
    resignation. Her total cash earnings in 2006 were $139,058.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ms.&#160;Karen Krumeich had received a
    <FONT style="white-space: nowrap">5-year</FONT>
    60,000&#160;share option grant when she joined the Company in
    December 2004. These $0.46 options vested at the time of our
    initial public offering, and Ms.&#160;Krumeich exercised these
    options following her departure from the Company, but within the
    <FONT style="white-space: nowrap">90-day</FONT> limit
    following employment imposed by our 2003 Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Because of Ms.&#160;Krumeich&#146;s resignation, our
    compensation consultant did not review her compensation
    arrangements. However, based on many factors the Compensation
    Committee of the Board of Directors concluded that
    Ms.&#160;Krumeich&#146;s pay package was appropriate for 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Former,
    Vice President, Legal Counsel and Compliance, and Secretary
    Mr.&#160;William Bronner</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Mr.&#160;Bronner resigned as our Vice President, Legal Counsel
    and Compliance, and Secretary effective November&#160;30, 2006.
    Mr.&#160;Bronner earned a salary of $111,846 in 2006, and as
    payment for all unused vacation and other personal time he
    earned while working for the Company we paid him $50,000 in
    January 2007. As a result, Mr.&#160;Bronner had total earnings
    in 2006 of $161,846. In addition, we agreed to a
    <FONT style="white-space: nowrap">13-month</FONT>
    consulting contract with Mr.&#160;Bronner beginning December
    2006 and continuing through December 2007 for $4,166.67&#160;per
    month.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2006 Mr.&#160;Bronner was granted 7,500 stock options at
    $7.08&#160;per share. Pursuant to his resignation agreement, all
    of Mr.&#160;Bronner&#146;s options vested in full. In addition
    to his 2006 grant, Mr.&#160;Bronner had the following option
    grants:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="margin-left: 4%; margin-right: 0%">
<TABLE border="0" width="96%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="77%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">February&#160;19, 2002
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,875&#160;shares at $1.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">January&#160;15, 2003
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,160&#160;shares at $1.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">February&#160;2, 2004
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000&#160;shares at $0.46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">December&#160;17, 2004
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000&#160;shares at $0.46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Mr.&#160;Bronner exercised all of his 2002, 2003, and 2004
    options, totaling 71,035&#160;shares in January 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Because of Mr.&#160;Bronner&#146;s resignation, our compensation
    consultant did not review his compensation arrangements.
    However, based on many factors the Compensation Committee of the
    Board of Directors concluded that Mr.&#160;Bronner&#146;s pay
    package was appropriate for 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Vice
    President of Technical Support, Mr.&#160;Christiano
    Butler</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Vice President of Technical Support, Mr.&#160;Christiano
    Butler&#146;s cash compensation in 2006 was $83,123.
    Mr.&#160;Butler&#146;s compensation, including base salary and
    stock option package, was detailed in a letter agreement with
    the Company dated May&#160;30, 2006. In that letter
    Mr.&#160;Butler received a base salary of $140,000 and a stock
    option grant consisting of 40,000&#160;shares of common stock at
    an exercise price of $7.60&#160;per share. In accordance with
    our policy, these options were priced on the date of grant as
    determined by the Compensation Committee. As is consistent
    throughout our executive ranks, Mr.&#160;Butler&#146;s options
    vest both over time and with the attainment of several
    corporate-wide milestones. Two-thousand of
    Mr.&#160;Butler&#146;s time-based options vested during 2006.
    Mr.&#160;Butler&#146;s compensation arrangements follow the
    pattern of our other executives, his cash compensation is below
    our peer group of companies, but his long-term incentive
    compensation is consistent with comparable jobs at our peer
    group of companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also considered a number of subjective factors in considering
    Butler&#146;s overall compensation including his prior business
    experience and the overall performance of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on its own internal analysis, the Compensation Committee
    of the Board of Directors concluded that Mr.&#160;Butler&#146;s
    pay package was appropriate for 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Vice
    President of Marketing and Sales, Jon Klippel</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Vice President of Marketing and Sales, Jon Klippel, was paid
    $149,373 in 2006. His base salary at the end of 2006 was
    $140,000, and during the year he received a $5,000 raise and a
    $10,000 discretionary bonus. In addition, Mr.&#160;Klippel
    received 5,000&#160;milestone-based options during 2006. AGF
    reported to us that Mr.&#160;Klippel&#146;s salary also followed
    the Company&#146;s executive compensation pattern of cash
    remuneration that ranked below our industry peer group but
    included adequate long-term compensation in the form of stock
    options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Mr.&#160;Klippel has been awarded two separate stock option
    grants. In December of 2004, he received a
    <FONT style="white-space: nowrap">5-year</FONT> stock
    option grant totaling 45,000&#160;shares. These options priced
    at $0.46&#160;per share were all vested at the Company&#146;s
    initial public offering. In addition Mr.&#160;Klippel was
    awarded an additional
    <FONT style="white-space: nowrap">5-year</FONT>
    5,000&#160;share grant in May of 2006, exercisable at
    $7.08&#160;per share. AGF reported that these two grants put
    Mr.&#160;Klippel&#146;s long-term compensation on par with other
    marketing and sales executives in our peer group.
    Mr.&#160;Klippel did not exercise any stock options in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We considered the quality of Mr.&#160;Klippel&#146;s work over
    the last year in connection with our pre-marketing plans and our
    reimbursement strategy and his prior business experience to
    evaluate his 2006 compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on own internal analysis, the Compensation Committee of
    our Board of Directors concluded that Mr.&#160;Klippel&#146;s
    pay package was appropriate for 2006.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Components
    of Executive Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically applied a structure where a significant
    portion of our executive compensation comes in the form of
    long-term incentive compensation. While the allocation varies,
    in general our executive officers have a far greater percentage
    of their compensation in the form of long-term compensation than
    our lower level employees. However, we firmly believe that all
    employees should have an equity ownership position. We believe
    this is a strong motivator and an important component of our
    overall compensation strategy. In our view, the approach we have
    taken was confirmed by the work AGF did for the Compensation
    Committee of our Board of Directors.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Base
    Salaries</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The base salary is the guaranteed portion of our employee&#146;s
    annual cash compensation. The base salary reflects our
    employees&#146; experience, skill set, and the market value of
    that experience and skill set. When setting an employee&#146;s
    base salary we also consider such employee&#146;s prior
    year&#146;s accomplishments.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Bonuses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have a formalized bonus program and as such have only
    paid limited discretionary bonuses. Our compensation consultant,
    AGF, has recommended that we initiate a more formal management
    incentive program, and our Board of Directors and Compensation
    Committee are currently evaluating the establishment of an
    appropriate program; however, no decision has been reached.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Equity
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The only form of equity compensation we currently award
    employees consists of stock options, both qualified and
    non-qualified. All of the options have been granted out of our
    three stock option plans: our 1996 Plan, 2003 Stock Plan, and
    2005 Plan. Since January&#160;1, 2005, our 2005 Plan is the only
    plan under which we are granting awards. These plans allow our
    Board of Directors to grant incentives to employees, directors,
    consultants and collaborating scientists in the form of
    qualified and non-qualified stock options and restricted stock
    awards. We have used this form of compensation because of the
    expectations of our employees that in a company such as ours
    they would be given the opportunity to own equity. In our
    industry, option grants have been traditionally the most
    widely-used form to convey equity ownership.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock awards under our 2005 Plan are granted at prices which are
    no less than the market value of the stock on the date of the
    grant as determined by the Compensation Committee of the Board
    of Directors. New employees who get options as part of their
    employment agreement have those options priced at the closing
    price of our stock on the date of grant, also as determined by
    the Compensation Committee of the Board of Directors. Options
    granted under the 2005 Plan historically have been time-based or
    performance-based options, and vesting varies accordingly.
    Options under this plan expire five years from the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company began recording
    compensation expense associated with stock options and other
    forms of equity compensation in accordance with Statement of
    Financial Accounting Standards No.&#160;123 (revised 2004).
    Under this method, the Company must recognize a compensation
    charge related to all stock option awards granted on or
    subsequent to January&#160;1, 2006. This charge is based on the
    grant date fair value estimated in accordance with the
    provisions of SFAS&#160;123R. A compensation charge is recorded
    when it is probable that performance or service conditions will
    be satisfied. The probability of vesting is updated at each
    reporting period and compensation is adjusted via a cumulative
    <FONT style="white-space: nowrap">catch-up</FONT>
    adjustment or prospectively depending upon the nature of the
    change. Despite the fact that this new accounting provision
    makes accounting for stock options less attractive to the
    Company, we have continued to use this approach because we
    believe it is the most cash-efficient way for the Company to
    convey equity ownership to our employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation consultant, AGF, has recommended that
    we consider the use of restricted stock awards for our senior
    executives. While the use of restricted stock would reduce the
    total number of shares we issue and lower potential dilution to
    our shareholders, this method may not be attractive because of
    potential tax consequences to our employees. Our Board of
    Directors and its Compensation Committee are in the process of
    evaluating the use of restricted stock awards for future years.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">GRANTS OF
    PLAN BASED AWARDS FOR YEAR ENDED DECEMBER&#160;31,
    2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise or Base<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Price of Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D., M.B.A.
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">President and Chief Executive
    Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Richard I. Steinhart
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">4/22/06</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Finance, Chief<BR>
    Financial Officer,<BR>
    Secretary and Treasurer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Karen Krumeich
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President Finance,<BR>
    Chief Financial Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jon. I. Klippel
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">5/22/06</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Marketing and Sales
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">William Bronner
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">5/22/06</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President, Legal
    Counsel<BR>
    and Compliance<BR>
    and Secretary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Christiano Butler
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">5/30/06</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President,  Technical Support
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OUTSTANDING
    EQUITY AWARDS AT 2006 YEAR-END</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised /<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options that are<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options that are<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D.,
    M.B.A.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,753
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">2/22/09</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">President and Chief
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    542,755
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">2/22/09</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Executive Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Richard I. Steinhart
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,000
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">4/24/11</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President<BR>
    Finance, Chief<BR>
    Financial Officer,<BR>
    Secretary and Treasurer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Karen Krumeich
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President<BR>
    Finance Chief Financial Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jon. I. Klippel
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">12/17/09</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">5/22/11</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Marketing and Sales
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">William Bronner
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,500
</TD>
<TD nowrap align="left" valign="bottom">
    (4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">5/22/11</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President,
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">2/19/12</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Legal Counsel and
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">2/2/09</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Compliance
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    .46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">12/17/09</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">and Secretary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,160
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">1/15/13</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Christiano Butler
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,000
</TD>
<TD nowrap align="left" valign="bottom">
    (5)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="white-space: nowrap">5/30/11</FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President<BR>
    Technical Support
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Gulfo&#146;s employment agreement provides for three
    separate grants of stock options. The first two stock option
    grants for the purchase of a total of 81,753&#160;shares of our
    common stock at an exercise price of $0.46&#160;per share have
    fully vested. The number of shares of our common stock subject
    to the third stock option can only be calculated at the time of
    PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    The number of shares purchasable under this option at an
    exercise price of $0.46&#160;per share is equal to that number
    of shares of common stock equal to four percent of our
    fully-diluted capital stock at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    minus the number of shares of common stock underlying the other
    stock options granted to Dr.&#160;Gulfo under the employment
    agreement, which is 81,573. Based on 15,612,705&#160;shares
    outstanding (on a fully-diluted basis) as of December&#160;31,
    2006 and assuming such shares remain the total number of shares
    outstanding on the date we receive PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    the number of shares subject to this option is 542,755. This
    third stock option grant vests 50% at the time of PMA approval
    of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    and the remaining 50% vests in four equal installments over the
    one year period following such PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Steinhart&#146;s option vests on service
    (8,000&#160;shares vest yearly on April&#160;24, 2007,
    April&#160;24, 2008, April&#160;24, 2009, and April&#160;24,
    2010)&#160;and at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    (20,000&#160;shares).</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Klippel&#146;s 5,000&#160;share option vests 50% at the
    time of first commercial sale of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and 50% upon achievement of profitability by the Company.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    This option grant of Mr.&#160;Bronner was unexercised and
    expired March&#160;1, 2007.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Butler&#146;s option vests on service
    (2,000&#160;shares vest yearly on May&#160;29, 2007,
    May&#160;29, 2008, May&#160;29, 2009 and May&#160;29, 2010),
    15,000&#160;shares vest at the time of completion of the pivotal
    trial of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    and 15,000&#160;shares vest at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OPTION
    EXERCISE AND VESTED STOCK OPTION AWARDS FOR 2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acquired on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Realized on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Joseph V. Gulfo,&#160;M.D., M.B.A.
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">President and Chief Executive
    Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Richard I. Steinhart
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Finance, Chief
    Financial Officer,<BR>
    Secretary and Treasurer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Karen Krumeich
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,000(1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President Finance,<BR>
    Chief Financial Officer
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Jon. I. Klippel
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President Marketing and Sales
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">William Bronner
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Former Vice President, Legal
    Counsel and<BR>
    Compliance and Secretary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Christiano Butler
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Vice President, Technical Support
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Ms.&#160;Krumeich exercised these $0.46 options following her
    departure from the Company, but within the 90&#160;day limit
    following employment imposed by the 2003 Plan.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    In January 2007, Mr.&#160;Bronner acquired 71,035&#160;shares on
    exercise of options that were priced at both $0.46 and
    $1.00&#160;per share. The value realized upon exercise of these
    options was $441,217. Mr.&#160;Bronner exercised these options
    following his departure from the Company, but within the
    90&#160;day limit following employment imposed by the 1996 and
    2003 Plans.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Severance
    Benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Gulfo and Mr.&#160;Steinhart are the two current senior
    executives whose employment agreements include provisions for
    severance benefits payable by the Company. In
    Dr.&#160;Gulfo&#146;s case, if he is terminated without cause he
    is entitled to his then current monthly salary for a period of
    15&#160;months and, if Dr.&#160;Gulfo is then covered by health
    insurance provided by us, the cost to Dr.&#160;Gulfo of COBRA
    coverage for 15&#160;months. If we elect not to renew
    Dr.&#160;Gulfo&#146;s employment agreement, Dr.&#160;Gulfo is
    entitled to an amount equal to his then current base salary for
    nine months and, if Dr.&#160;Gulfo is covered by our health
    insurance policy at such time, the cost of COBRA for nine months
    (subject to reduction to the extent Dr.&#160;Gulfo received
    comparable benefits from a subsequent employer during such
    nine-month period). Dr.&#160;Gulfo&#146;s severance period may
    be extended for an additional 12&#160;months in the event we
    elect to extend the length of his non-compete covenant to two
    years, in which case we would have to pay him additional
    severance equal to twelve months of his base salary at the time
    of termination and his most recent bonus. In
    Mr.&#160;Steinhart&#146;s case, if he is terminated without
    cause he is entitled to 6&#160;months of his base salary and
    acceleration of his milestone-based options if the milestones
    are achieved within six months of his termination.
    Ms.&#160;Krumeich resigned as our Vice President and Chief
    Financial Officer effective April&#160;24, 2006.
    Ms.&#160;Krumeich was given six months severance, and the cost
    of COBRA benefits was paid for six months. Total severance
    benefits paid to Ms.&#160;Krumeich amounted to $87,429. We do
    not have a standard policy with regard to severance pay, and the
    Compensation Committee is currently considering developing and
    adopting a consistent policy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assuming a termination date of December&#160;29, 2006:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;If Dr.&#160;Gulfo was terminated by us for cause, upon
    death or disability, then he would not have received severance
    under his employment agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;If Dr.&#160;Gulfo terminated his contract for good
    reason or was terminated by us without cause, he would have
    received $306,935, of which $293,750 represents 15&#160;months
    of his monthly salary and $13,185 represents 15&#160;months of
    COBRA coverage (estimated based on the Company&#146;s 2006 cost
    of COBRA premiums).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;If Dr.&#160;Gulfo was terminated by us without cause
    within 30&#160;days of our operations being discontinued, then
    he would not have received severance under his employment
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;If Dr.&#160;Gulfo&#146;s employment agreement is not
    renewed by us, then he would have received $242,911, of which
    $176,250 represents 9&#160;months of his monthly salary and
    $7,911 represents 9&#160;months of COBRA coverage (estimated
    based on the Company&#146;s 2006 cost of COBRA premiums).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;If Dr.&#160;Gulfo&#146;s employment agreement is not
    renewed by us and we extended the length of his non-compete
    covenant to two years, then he would have received $594,572, of
    which $528,750 represents 27&#160;months of his monthly salary,
    $15,822 represents 18&#160;months of COBRA coverage (estimated
    based on the Company&#146;s 2006 cost of COBRA premiums) and
    $50,000 represents the amount of his last bonus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vi)&#160;If Mr.&#160;Steinhart was terminated by us for cause,
    then he would not have received severance under his employment
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (vii)&#160;If Mr.&#160;Steinhart was terminated by us without
    cause, then he would have received $169,260, of which $97,500
    represents 6&#160;months of his monthly salary and $71,760
    represents income from the acceleration of the vesting of his
    unvested stock options assuming that PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>was
    received within 6&#160;months of his termination. The value of
    vesting acceleration is based on the closing price of the
    Company&#146;s common stock on December&#160;29, 2006 ($7.20)
    with respect to
    <FONT style="white-space: nowrap">in-the-money</FONT>
    unvested option shares minus the exercise price of the unvested
    option shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Retirement
    Plans</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not maintain a traditional defined benefit plan. We do,
    however, maintain a 401(k) plan covering all qualified
    employees. We match
    <FONT style="white-space: nowrap">dollar-for-dollar</FONT>
    the employee&#146;s contribution up to 3% of each
    participant&#146;s salary to a maximum of $220,000. We do not
    consider the 401(k) matching contribution to be a significant
    portion of any of our executives&#146; compensation package.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Change of
    Control</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2003 Plan and 2005 Plan contain provisions providing that if
    there is a change of control involving a merger, consolidation,
    mandatory share exchange or other similar business combination
    of the Company with or into any other entity or any transaction
    in which a successor entity acquires all the issued and
    outstanding capital stock of the Company, or all or
    substantially all the assets of the Company, then if and to the
    extent that outstanding options are not assumed or replaced with
    substantially equivalent options in connection with the
    acquisition event, then each optionee shall have the right to
    exercise in full all of his or her outstanding options, whether
    or not such options are otherwise vested or exercisable, and any
    outstanding options which are not exercised prior to the
    consummation of the change of control event shall thereupon
    terminate. The 1996 Plan does not contain a similar provision.
    However, all outstanding options issued under the 1996 Plan are
    fully vested as of February&#160;28, 2007, and the 1996 Plan
    expired on November&#160;30, 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Perquisites
    and Other Benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a company without any substantial revenue, we are not in a
    position to provide any significant perquisites or other
    benefits. Currently, the only perquisites are provided to
    Dr.&#160;Gulfo pursuant to his employment
    agreement:(i)reimbursement of economical travel expenses
    incidental to Dr.&#160;Gulfo&#146;s commute to our principal
    office in Irvington, New York from Wilmington, Delaware in an
    aggregate amount not to exceed $1,100&#160;per month, consisting
    of an unlimited Amtrak unreserved pass, a MetroNorth RailPass,
    NYC Subway transportation, and monthly car parking;
    (ii)&#160;economical lodging allowance consisting of
    $2,000&#160;per month, and (iii)&#160;reimbursement of
    economical communication expenses consisting of expenses for one
    cellular phone line, one phone line at Dr.&#160;Gulfo&#146;s
    home office and cable broadband internet service at
    Dr.&#160;Gulfo&#146;s home office. We have no plans for any
    additional perquisites.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to reimbursement of expenses incurred in attending
    meetings of our Board of Directors and committees of our Board,
    our non-employee directors will receive an annual fee of $10,000
    for serving as directors and an additional $500&#160;per meeting
    for each meeting attended, whether in person or by telephone. In
    addition, the chairman of our Board of Directors, the chairman
    of our audit committee and the chairman of our nominating and
    governance committee will each receive an annual fee of $10,000.
    Each member of our Board who is not a company employee will
    receive an annual stock option grant to purchase up to
    5,000&#160;shares of common stock. Such stock options will vest
    in full upon the first anniversary of issuance and have an
    exercise price equal to the fair market value of our common
    stock on the date of the grant. In addition, we reimburse each
    member of our Board who is not a company employee for reasonable
    travel and other expenses in connection with attending meetings
    of the Board.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIRECTOR
    COMPENSATION TABLE FOR 2006</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B># Option Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid in Cash<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Sidney Braginsky
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,650
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Breaux Castleman
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,650
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">George Chryssis
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,650
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Martin Cleary
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,650
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Dan W. Lufkin
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,650
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="font-size: 10pt">Gerald Wagner, Ph.D.&#160;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    402,489
</TD>
<TD nowrap align="left" valign="bottom">
    (1)(2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    180,000
</TD>
<TD nowrap align="left" valign="bottom">
    (4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    594,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents $21,650 in option awards with one-year vesting to all
    non-employee directors of the Company.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Wagner received $380,839 in awards based on his work as
    our Acting Chief Operating Officer in 2006. All of these options
    were vested by February&#160;1, 2007.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="1%"></TD>
    <TD width="95%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents Mr.&#160;Castleman&#146;s 2006 consulting fees
    related to obtaining FDA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents Dr.&#160;Wagner&#146;s 2006 consulting fee as our
    Acting Chief Operating Officer during 2006.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreement with Joseph V. Gulfo,&#160;M.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;5, 2004, we entered into an employment agreement
    with Dr.&#160;Joseph V. Gulfo, our President and Chief Executive
    Officer. Pursuant to the agreement, Dr.&#160;Gulfo is required
    to devote substantially all of his business time, attention and
    efforts to the performance of his duties under the agreement.
    The initial term of the employment agreement extended until
    December&#160;31, 2005 and was again extended until
    December&#160;31, 2006. The contract automatically renews for
    successive twelve-month terms unless either party sends a
    written notice of termination within 90&#160;days of the
    expiration of the renewal term. The employment agreement
    automatically extended until December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment agreement provides Dr.&#160;Gulfo with an annual
    base salary of $175,000 subject to periodic review by our Board
    of Directors, stock options, and performance bonuses. The target
    for such bonuses is 50% of Dr.&#160;Gulfo&#146;s then current
    base salary. In May 2006, Dr.&#160;Gulfo received a $50,000
    bonus and his base salary was raised to $235,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, Dr.&#160;Gulfo is entitled to be reimbursed for
    certain travel expenses up to $1,100&#160;per month,
    $2,000&#160;per month for lodging expenses and for certain
    communication expenses, including cellular phone service and
    broadband internet service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If Dr.&#160;Gulfo&#146;s employment is terminated by us without
    cause or Dr.&#160;Gulfo resigns for good reason, then
    Dr.&#160;Gulfo would be entitled to receive severance pay equal
    to 15&#160;months of his then current base salary and, if
    Dr.&#160;Gulfo is then covered by health insurance provided by
    us, the cost to Dr.&#160;Gulfo of COBRA coverage for
    15&#160;months. If we elect not to renew Dr.&#160;Gulfo&#146;s
    employment agreement, Dr.&#160;Gulfo is entitled to an amount
    equal to his then current base salary for nine months and, if
    Dr.&#160;Gulfo is covered by our health insurance policy at such
    time, the cost of COBRA for nine months (subject to reduction to
    the extent Dr.&#160;Gulfo received comparable benefits from a
    subsequent employer during such nine-month period).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Gulfo is subject to a non-compete covenant upon
    termination of his employment by us or him. The term of
    Dr.&#160;Gulfo&#146;s non-compete covenant is one year, which
    can be extended to two years in the event we elect to pay him
    additional severance equal to twelve months of his base salary
    at the time of termination and his most recent bonus (if any).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment agreement provides for three separate grants of
    stock options. The first two stock option grants for the
    purchase of a total of 81,753&#160;shares of our common stock at
    an exercise price of $0.46&#160;per share have fully vested. The
    number of shares of our common stock subject to the third stock
    option can only be calculated at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    The number of shares purchasable under this option at an
    exercise price of $0.46&#160;per share is equal to that number
    of shares of our common stock equal to four percent of our
    fully-diluted capital stock at the time of PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    minus the number of shares of common stock underlying the other
    options granted to Dr.&#160;Gulfo under the employment
    agreement, which is 81,753. Based on 15,612,705&#160;shares
    outstanding (on a fully-diluted basis) as of December&#160;31,
    2006 and assuming such shares remain the total number of shares
    outstanding on the date we receive PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    (assuming in both cases the exercise of all outstanding options
    and warrants), the number of shares subject to this option is
    542,755. This third stock option grant vests 50% at the time of
    PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    and the remaining 50% vests in four equal installments over the
    one year period following such PMA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Breaux Castleman</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2003, we entered into a consulting agreement with Breaux
    Castleman for consulting services related to FDA approval of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,
    administrative matters, financial reporting, and our business
    and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    financial strategy. Under this agreement, Mr.&#160;Castleman
    receives compensation for each month of services rendered.
    During 2003 Mr.&#160;Castleman was paid at the rate of $8,000
    for each month of services rendered and thereafter from 2004
    onward he has been paid at the rate of $2,000 for each month of
    services rendered. We made payments pursuant to this consulting
    agreement of $22,000 in 2004, and $26,000 in 2005 and $29,000 in
    2006. These payments did not exceed $100,000 in any twelve-month
    period since June 2003. In connection with our consulting
    agreement with Mr.&#160;Castleman, we granted Mr.&#160;Castleman
    a restricted stock award of 75,000&#160;shares of our common
    stock under our 2003 Plan for an aggregate purchase price of
    $34,500. Mr.&#160;Castleman issued an interest-bearing
    promissory note in the principal amount of $34,500 as payment
    for these shares. During the second quarter of 2005, this note
    was repaid in full. Our consulting agreement with
    Mr.&#160;Castleman is terminable by either party on
    30&#160;days&#146; written notice.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Marek Elbaum,&#160;Ph.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to a consulting agreement effective as of May&#160;31,
    2005, we retained Marek Elbaum,&#160;Ph.D., our founder and
    former Chief Science and Technology Officer, as our Chief
    Scientist to provide services relating to the integration of our
    product development, mentoring and advising our staff
    scientists, providing new product vision, supporting our
    research and development and providing such other services as
    assigned to him by our Chief Executive Officer. Pursuant to the
    consulting agreement, Dr.&#160;Elbaum will provide us with a
    majority of his business time in consideration of a monthly fee
    of approximately $14,500. The term of such agreement extends for
    a period of two years and is automatically renewable for an
    additional one year period unless either Dr.&#160;Elbaum or we
    decide to not so renew. In the event of a non-renewal, and in
    the event that Dr.&#160;Elbaum&#146;s services terminate as a
    result of his death or disability, we will pay to
    Dr.&#160;Elbaum a termination fee of $100,000. In addition, upon
    termination of the consulting agreement for any reason other
    than a termination by us for cause, we will pay to
    Dr.&#160;Elbaum for 18&#160;months an amount equal to what
    Dr.&#160;Elbaum would have had to pay to extend his insurance
    coverage under COBRA. Dr.&#160;Elbaum is subject to a
    non-compete covenant during the term of the consulting agreement
    and for a period of two years after the term of the consulting
    agreement. We have also agreed that all stock options previously
    granted to Dr.&#160;Elbaum will continue to vest in accordance
    with their original terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Robert Friedman,&#160;M.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to a consulting agreement effective as of June&#160;1,
    2005, we have retained the services of Robert
    Friedman,&#160;M.D. for an initial term of one year as a
    consultant, medical advisor to our Board of Directors, and as a
    liaison between our Board of Directors and our scientific and
    medical advisory committee, and in connection with the clinical
    testing of
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    In consideration of rendering of these services,
    Dr.&#160;Friedman will be paid at a rate of $5,000&#160;per day
    (assuming an
    <FONT style="white-space: nowrap">eight-hour</FONT>
    day) for up to 30&#160;days of service. The consulting agreement
    is automatically renewed for successive one-year terms unless
    either party terminates the agreement at least 30&#160;days
    prior to the expiration of the agreement. We paid
    Dr.&#160;Friedman $30,000 in 2005 and $42,000 in 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Gerald Wagner,&#160;Ph.D.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to a consulting agreement dated as of June&#160;1, 2005
    with Gerald Wagner Consulting LLC (GWC), a company owned and
    operated by Dr.&#160;Gerald Wagner, GWC agreed to direct our
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
    product development efforts and oversee the manufacturing
    process for
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    On March&#160;24, 2006, we entered into an amended and restated
    consulting agreement with GWC, which became effective on
    April&#160;1, 2006. Under this amended and restated consulting
    agreement, the Company agreed to pay GWC the annual amount of
    $180,000 payable monthly over the term of the agreement. The
    agreement provided for termination at the option of GWC or the
    Company, at any time by providing thirty (30)&#160;days prior
    written notice or immediately upon the mutual agreement of the
    Company and GWC. In connection with GWC&#146;s ongoing
    engagement as a consultant, Dr.&#160;Wagner received a stock
    option grant of 50,000&#160;shares of the Company&#146;s common
    stock which vests in full immediately upon commencement of the
    pivotal trial for
    MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.
    In addition, on March&#160;24, 2006, Dr.&#160;Wagner received
    another stock option grant of 49,500&#160;shares of the
    Company&#146;s common stock which vested immediately upon grant.
    The exercise price for these two stock option grants is the
    closing price per
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    share of the Company&#146;s common stock on the option grant
    date. Concomitant with the start of the Company&#146;s clinical
    trials in January 2007, Dr.&#160;Wagner&#146;s 50,000&#160;share
    option grant vested. In addition, Dr.&#160;Wagner transitioned
    out of his role as our Acting Chief Operating Officer, and
    signed an amended consulting contract with the Company. Under
    the terms of the amended contract, Dr.&#160;Wagner will be paid
    a monthly retainer of $2,500 and will be paid $2,500 for each
    additional day of consulting. This amended agreement will end at
    the option of Dr.&#160;Wagner or the Company at any time, by
    providing fifteen days prior written notice, or immediately upon
    the mutual agreement of the Company and Dr.&#160;Wagner.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitation
    of Liability and Indemnification of Directors and
    Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our fourth amended and restated certificate of incorporation and
    third amended and restated bylaws provide that we will indemnify
    our directors and executive officers and may indemnify our other
    officers and employees and other agents to the fullest extent
    permitted by law. Our fourth amended and restated certificate of
    incorporation and third amended and restated bylaws also permit
    us to secure insurance on behalf of any officer, director,
    employee or other agent for any liability arising out of his or
    her actions in such capacity, regardless of whether the bylaws
    would permit indemnification. We maintain directors&#146; and
    officers&#146; liability insurance. We believe that these
    provisions and agreements are necessary to attract and retain
    qualified persons as directors and executive officers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee is composed of three non-employee
    directors: Messrs.&#160;Castleman, Braginsky and Chryssis. No
    member of the compensation committee is or was formerly a
    permanent officer or employee of the Company. No interlocking
    relationship exists between the Company&#146;s Board of
    Directors or compensation committee and the Board of Directors
    or compensation committee of any other company, nor has such
    interlocking relationship existed in the past. Dr.&#160;Gulfo,
    our Chief Executive Officer, previously participated in the
    deliberations regarding executive compensation. None of our
    executive officers has served as a member of the compensation
    committee, or other committee serving an equivalent function, of
    any other entity, one of whose executive officers served as a
    member of our compensation committee.
</DIV>
<A name='113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ON<BR>
     EXECUTIVE
    COMPENSATION</A><SUP style="font-size: 85%; vertical-align: text-top">2</SUP></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee of the Board of Directors has
    reviewed and discussed the Compensation Discussion and Analysis
    with the Company&#146;s management, and based on such review and
    discussions, the compensation committee recommended to the Board
    of Directors that the Compensation Discussion and Analysis be
    included in this proxy statement.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>COMPENSATION COMMITTEE</B>
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Breaux Castleman
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sidney Braginsky
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    George C. Chryssis
</DIV>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="text-align:justify; margin-left: 6%; margin-right: 0%; text-indent: -2%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <SUP style="font-size: 85%; vertical-align: text-top">2</SUP>&#160;The
    material in this report is not &#147;soliciting material,&#148;
    is not deemed &#147;filed&#148; with the SEC and is not to be
    incorporated by reference into any filing of the Company under
    the Securities Act of 1933, as amended, or the Securities
    Exchange Act of 1934, as amended, whether made before or after
    the date hereof and irrespective of any general incorporation
    language in any such filing.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='115'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    TRANSACTIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into employment agreements and other
    agreements with certain of its executive officers. See
    &#147;Compensation Discussion and Analysis.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board has authorized the Company to enter into indemnity
    agreements with certain officers and directors which provide,
    among other things, that the Company will indemnify such officer
    or director, under the circumstances and to the extent provided
    for therein, for expenses, damages, judgments, fines and
    settlements he or she may be required to pay in actions or
    proceedings to which he or she is or may be made a party by
    reason of his or her position as a director, officer or other
    agent of the Company, and otherwise to the fullest extent
    permitted under Delaware law and the Company&#146;s bylaws.
</DIV>
<A name='116'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PERFORMANCE
    MEASUREMENT
    COMPARISON</A><SUP style="font-size: 85%; vertical-align: text-top">3</SUP></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following graph shows the total stockholder return of an
    investment of $100 in cash on October&#160;28, 2005 (the date of
    the Company&#146;s initial public offering) for (i)&#160;the
    Company&#146;s common stock, (ii)&#160;the Nasdaq Stock Market
    (U.S.) Index and (iii)&#160;a peer group index comprised of all
    public companies using SIC Code 3826 (Laboratory Analytical
    Instruments) (the &#147;Peer Group&#148;). All values assume
    reinvestment of the full amount of all dividends and are
    calculated as of December&#160;31 of each year:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPARISON
    OF CUMULATIVE TOTAL RETURN</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    AMONG ELECTRO-OPTICAL SCIENCES, INC.,
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    THE NASDAQ STOCK MARKET (U.S.) INDEX AND A PEER GROUP
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="y33491y3349102.gif" alt="" >
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<A name='117'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">HOUSEHOLDING
    OF PROXY MATERIALS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The SEC has adopted rules that permit companies and
    intermediaries (e.g., brokers) to satisfy the delivery
    requirements for proxy statements and annual reports with
    respect to two or more stockholders sharing the same address by
    delivering a single proxy statement addressed to those
    stockholders. This process, which is commonly referred to as
    &#147;householding,&#148; potentially means extra convenience
    for stockholders and cost savings for companies.
</DIV>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="text-align:justify; margin-left: 6%; margin-right: 0%; text-indent: -2%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <SUP style="font-size: 85%; vertical-align: text-top">3</SUP>&#160;This
    Section is not &#147;soliciting material,&#148; is not deemed
    &#147;filed&#148; with the SEC and is not to be incorporated by
    reference into any filing of the Company under the Securities
    Act of 1933, as amended, or the Securities Exchange Act of 1934,
    as amended, whether made before or after the date hereof and
    irrespective of any general incorporation language in any such
    filing.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This year, a number of brokers with account holders who are
    Company stockholders will be &#147;householding&#148; our proxy
    materials. A single proxy statement may be delivered to multiple
    stockholders sharing an address unless contrary instructions
    have been received from the affected stockholders. Once you have
    received notice from your broker that it will be
    &#147;householding&#148; communications to your address,
    &#147;householding&#148; will continue until you are notified
    otherwise or until you notify your broker or the Company that
    you no longer wish to participate in &#147;householding.&#148;
    If, at any time, you no longer wish to participate in
    &#147;householding&#148; and would prefer to receive a separate
    proxy statement and annual report in the future you may
    (1)&#160;notify your broker, (2)&#160;direct your written
    request to: Electro-Optical Sciences, Inc., 3&#160;West Main
    Street, Suite&#160;201, Irvington, New York 10533, Attention:
    Secretary, telephone
    <FONT style="white-space: nowrap">(914)&#160;591-3783</FONT>
    or (3)&#160;contact our Investor Relations representatives at
    Lazar Partners, Ltd., 420 Lexington Avenue, Suite&#160;442, New
    York, New York 10170. Stockholders who currently receive
    multiple copies of the proxy statement at their address and
    would like to request &#147;householding&#148; of their
    communications should contact their broker. In addition, the
    Company will promptly deliver, upon written or oral request to
    the address or telephone number above, a separate copy of the
    annual report and proxy statement to a stockholder at a shared
    address to which a single copy of the documents was delivered.
</DIV>
<A name='118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors knows of no other matters that will be
    presented for consideration at the Annual Meeting. If any other
    matters are properly brought before the meeting, it is the
    intention of the persons named in the accompanying proxy to vote
    on such matters in accordance with their best judgment.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By Order of the Board of Directors
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="y33491y3349101.gif" alt="-s- Joseph V. Gulfo, M.D., Ph.D" >
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Joseph V. Gulfo,&#160;M.D., M.B.A.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    President and Chief Executive Officer
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April&#160;20, 2007
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>A copy of the Company&#146;s Annual Report to the Securities
    and Exchange Commission on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2006 is available without
    charge upon written request to: Electro-Optical Sciences, Inc.,
    3&#160;West Main Street, Suite&#160;201, Irvington, New York
    10533, Attention: Secretary.</B>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='119'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">ANNEX&#160;A</FONT></U></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTRO-OPTICAL
    SCIENCES, INC.<BR>
    <BR>
    <U>AUDIT COMMITTEE CHARTER</U></FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">A.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Purpose</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purpose of the Audit Committee is to assist oversight by the
    Board of Directors (the &#147;Board&#148;) of Electro-Optical
    Sciences, Inc. (the &#147;Company&#148;) of the Company&#146;s
    accounting and financial reporting processes and the audits of
    the Company&#146;s financial statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">B.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Structure
    and Membership</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Number</U>.</I>&#160;&#160;Except as otherwise
    permitted by the applicable NASDAQ rules, the Audit Committee
    shall consist of at least three members of the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Independence</U>.</I>&#160;&#160;Except as
    otherwise permitted by the applicable NASDAQ rules, each member
    of the Audit Committee shall be independent as defined by NASDAQ
    rules, meet the criteria for independence set forth in
    <FONT style="white-space: nowrap">Rule&#160;10A-3(b)(1)</FONT>
    under the Exchange Act (subject to the exemptions provided in
    <FONT style="white-space: nowrap">Rule&#160;10A-3(c)),</FONT>
    and not have participated in the preparation of the financial
    statements of the Company or any current subsidiary of the
    Company at any time during the past three years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Financial Literacy</U>.</I>&#160;&#160;Each member
    of the Audit Committee must be able to read and understand
    fundamental financial statements, including the Company&#146;s
    balance sheet, income statement, and cash flow statement, at the
    time of his or her appointment to the Audit Committee. In
    addition, at least one member must have past employment
    experience in finance or accounting, requisite professional
    certification in accounting, or any other comparable experience
    or background which results in the individual&#146;s financial
    sophistication, including being or having been a chief executive
    officer, chief financial officer or other senior officer with
    financial oversight responsibilities. Unless otherwise
    determined by the Board (in which case disclosure of such
    determination shall be made in the Company&#146;s annual report
    filed with the Securities and Exchange Commission (the
    &#147;SEC&#148;)), at least one member of the Audit Committee
    shall be an &#147;audit committee financial expert&#148; (as
    defined by applicable SEC rules).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Chair</U>.</I>&#160;&#160;Unless the Board elects
    a Chair of the Audit Committee, the Audit Committee shall elect
    a Chair by majority vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Compensation</U>.</I>&#160;&#160;The compensation
    of Audit Committee members shall be as determined by the Board.
    No member of the Audit Committee may receive, directly or
    indirectly, any consulting, advisory or other compensatory fee
    from the Company or any of its subsidiaries, other than fees
    paid in his or her capacity as a member of the Board or a
    committee of the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Selection and Removal</U>.</I>&#160;&#160;Members
    of the Audit Committee shall be appointed by the Board, upon the
    recommendation of the Nominating and Corporate Governance
    Committee. The Board may remove members of the Audit Committee
    from such committee, with or without cause.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">C.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Authority
    and Responsibilities</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">General</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee shall discharge its responsibilities, and
    shall assess the information provided by the Company&#146;s
    management and the independent auditor, in accordance with its
    business judgment. Management is responsible for the
    preparation, presentation, and integrity of the Company&#146;s
    financial statements, for the appropriateness of the accounting
    principles and reporting policies that are used by the Company
    and for establishing and maintaining adequate internal control
    over financial reporting. The independent auditors are
    responsible for auditing the Company&#146;s financial statements
    and the Company&#146;s internal control over financial reporting
    and for reviewing the Company&#146;s unaudited interim financial
    statements. The authority and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-1
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    responsibilities set forth in this Charter do not reflect or
    create any duty or obligation of the Audit Committee to plan or
    conduct any audit, to determine or certify that the
    Company&#146;s financial statements are complete, accurate,
    fairly presented, or in accordance with generally accepted
    accounting principles or applicable law, or to guarantee the
    independent auditor&#146;s reports.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Oversight
    of Independent Auditors</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Selection</U>.</I>&#160;&#160;The Audit Committee
    shall be solely and directly responsible for appointing,
    evaluating, retaining and, when necessary, terminating the
    engagement of the independent auditor. The Audit Committee may,
    in its discretion, seek stockholder ratification of the
    independent auditor it appoints.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Independence</U>.</I>&#160;&#160;The Audit
    Committee shall take, or recommend that the full Board take,
    appropriate action to oversee the independence of the
    independent auditor. In connection with this responsibility, the
    Audit Committee shall obtain and review a formal written
    statement from the independent auditor describing all
    relationships between the auditor and the Company, including the
    disclosures required by Independence Standards Board Standard
    No.&#160;1. The Audit Committee shall actively engage in
    dialogue with the auditor concerning any disclosed relationships
    or services that might impact the objectivity and independence
    of the auditor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Compensation</U>.</I>&#160;&#160;The Audit
    Committee shall have sole and direct responsibility for setting
    the compensation of the independent auditor. The Audit Committee
    is empowered, without further action by the Board, to cause the
    Company to pay the compensation of the independent auditor
    established by the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Preapproval of Services</U>.</I>&#160;&#160;The
    Audit Committee shall preapprove all audit services to be
    provided to the Company, whether provided by the principal
    auditor or other firms, and all other services (review, attest
    and non-audit) to be provided to the Company by the independent
    auditor; provided, however, that de minimis non-audit services
    may instead be approved in accordance with applicable SEC rules.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Oversight</U>.</I>&#160;&#160;The independent
    auditor shall report directly to the Audit Committee, and the
    Audit Committee shall have sole and direct responsibility for
    overseeing the work of the independent auditor, including
    resolution of disagreements between Company management and the
    independent auditor regarding financial reporting. In connection
    with its oversight role, the Audit Committee shall, from time to
    time as appropriate, receive and consider the reports required
    to be made by the independent auditor regarding:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    critical accounting policies and practices;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    alternative treatments within generally accepted accounting
    principles for policies and practices related to material items
    that have been discussed with Company management, including
    ramifications of the use of such alternative disclosures and
    treatments, and the treatment preferred by the independent
    auditor;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other material written communications between the independent
    auditor and Company management.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Audited
    Financial Statements</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Review and Discussion</U>.</I>&#160;&#160;The
    Audit Committee shall review and discuss with the Company&#146;s
    management and independent auditor the Company&#146;s audited
    financial statements, including the matters about which
    Statement on Auditing Standards No.&#160;61 (Codification of
    Statements on Auditing Standards, AU &#167;380) requires
    discussion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;<I><U>Recommendation to Board Regarding Financial
    Statements</U>.</I>&#160;&#160;The Audit Committee shall
    consider whether it will recommend to the Board that the
    Company&#146;s audited financial statements be included in the
    Company&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-2
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;<I><U>Audit Committee Report</U>.</I>&#160;&#160;The
    Audit Committee shall prepare an annual committee report for
    inclusion where necessary in the proxy statement of the Company
    relating to its annual meeting of security holders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Review
    of Other Financial Disclosures</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    9.&#160;<I><U>Oversight</U>.</I>&#160;&#160;The Audit Committee
    shall coordinate the Board&#146;s oversight of the
    Company&#146;s internal control over financial reporting,
    disclosure controls and procedures and code of conduct. The
    Audit Committee shall receive and review the reports of the CEO
    and CFO required by
    <FONT style="white-space: nowrap">Rule&#160;13a-14</FONT>
    of the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    10.&#160;<I><U>Procedures for Complaints</U>.</I>&#160;&#160;The
    Audit Committee shall establish procedures for (i)&#160;the
    receipt, retention and treatment of complaints received by the
    Company regarding accounting, internal accounting controls or
    auditing matters; and (ii)&#160;the confidential, anonymous
    submission by employees of the Company of concerns regarding
    questionable accounting or auditing matters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    11.&#160;<I><U>Related-Party
    Transactions</U>.</I>&#160;&#160;The Audit Committee shall
    review all &#147;related party transactions&#148; (defined as
    transactions required to be disclosed pursuant to Item&#160;404
    of
    <FONT style="white-space: nowrap">Regulation&#160;S-K)</FONT>
    on an ongoing basis, and all such transactions must be approved
    by the Audit Committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Controls
    and Procedures</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    12.&#160;<I><U>Oversight</U>.</I>&#160;&#160;The Audit Committee
    shall coordinate the Board&#146;s oversight of the
    Company&#146;s internal control over financial reporting,
    disclosure controls and procedures and code of conduct. The
    Audit Committee shall receive and review the reports of the CEO
    and CFO required by
    <FONT style="white-space: nowrap">Rule&#160;13a-14</FONT>
    of the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    13.&#160;<I><U>Procedures for Complaints</U>.</I>&#160;&#160;The
    Audit Committee shall establish procedures for (i)&#160;the
    receipt, retention and treatment of complaints received by the
    Company regarding accounting, internal accounting controls or
    auditing matters; and (ii)&#160;the confidential, anonymous
    submission by employees of the Company of concerns regarding
    questionable accounting or auditing matters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    14.&#160;<I><U>Related-Party
    Transactions</U>.</I>&#160;&#160;The Audit Committee shall
    review all &#147;related party transactions&#148; (defined as
    transactions required to be disclosed pursuant to Item&#160;404
    of
    <FONT style="white-space: nowrap">Regulation&#160;S-K)</FONT>
    on an ongoing basis, and all such transactions must be approved
    by the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    15.&#160;<I><U>Additional Powers</U>.</I>&#160;&#160;The Audit
    Committee shall have such other duties as may be delegated from
    time to time by the Board.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">&#160;&#160;D.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Procedures
    and Administration</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Meetings</U>.</I>&#160;&#160;The Audit Committee
    shall meet as often as it deems necessary in order to perform
    its responsibilities. The Audit Committee may also act by
    unanimous written consent in lieu of a meeting. The Audit
    Committee shall periodically meet separately with: (i)&#160;the
    independent auditor; (ii)&#160;Company management and
    (iii)&#160;the Company&#146;s internal auditors. The Audit
    Committee shall keep such records of its meetings as it shall
    deem appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Subcommittees</U>.</I>&#160;&#160;The Audit
    Committee may form and delegate authority to one or more
    subcommittees (including a subcommittee consisting of a single
    member), as it deems appropriate from time to time under the
    circumstances. Any decision of a subcommittee to preapprove
    audit, review, attest or non-audit services shall be presented
    to the full Audit Committee at its next scheduled meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Reports to Board</U>.</I>&#160;&#160;The Audit
    Committee shall report regularly to the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Charter</U>.</I>&#160;&#160;At least annually, the
    Audit Committee shall review and reassess the adequacy of this
    Charter and recommend any proposed changes to the Board for
    approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Independent Advisors</U>.</I>&#160;&#160;The Audit
    Committee is authorized, without further action by the Board, to
    engage such independent legal, accounting and other advisors as
    it deems necessary or appropriate to carry out its
    responsibilities. Such independent advisors may be the regular
    advisors to the Company. The Audit
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-3
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Committee is empowered, without further action by the Board, to
    cause the Company to pay the compensation of such advisors as
    established by the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Investigations</U>.</I>&#160;&#160;The Audit
    Committee shall have the authority to conduct or authorize
    investigations into any matters within the scope of its
    responsibilities as it shall deem appropriate, including the
    authority to request any officer, employee or advisor of the
    Company to meet with the Audit Committee or any advisors engaged
    by the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;<I><U>Funding</U>.</I>&#160;&#160;The Audit Committee is
    empowered, without further action by the Board, to cause the
    Company to pay the ordinary administrative expenses of the Audit
    Committee that are necessary or appropriate in carrying out its
    duties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;<I><U>Annual Self-Evaluation</U>.</I>&#160;&#160;At
    least annually, the Audit Committee shall evaluate its own
    performance.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    A-4
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='120'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">ANNEX&#160;B</FONT></U></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTRO-OPTICAL
    SCIENCES, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">COMPENSATION
    COMMITTEE CHARTER</FONT></U></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">A.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Purpose</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purpose of the Compensation Committee of the Board of
    Directors (the &#147;Board&#148;) of the Electro-Optical
    Sciences, Inc. (the &#147;Company&#148;) is to assist the Board
    in the discharge of its responsibilities relating to
    compensation of the Company&#146;s executive officers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">B.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Structure
    and Membership</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Number</U>.</I>&#160;&#160;The Compensation
    Committee shall consist of at least three members of the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Independence</U>.</I>&#160;&#160;Except as
    otherwise permitted by the applicable NASDAQ rules, each member
    of the Compensation Committee shall be an &#147;independent
    director&#148; as defined by the applicable NASDAQ rules.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Chair</U>.</I>&#160;&#160;Unless the Board elects
    a Chair of the Compensation Committee, the Compensation
    Committee shall elect a Chair by majority vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Compensation</U>.</I>&#160;&#160;The compensation
    of Compensation Committee members shall be as determined by the
    Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Selection and Removal</U>.</I>&#160;&#160;Members
    of the Compensation Committee shall be appointed by the Board,
    upon the recommendation of the Nominating and Corporate
    Governance Committee. The Board may remove members of the
    Compensation Committee from such committee, with or without
    cause.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">C.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Authority
    and Responsibilities</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">General</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee shall discharge its responsibilities,
    and shall assess the information provided by the Company&#146;s
    management, in accordance with its business judgment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Compensation
    Matters</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Executive Officer
    Compensation</U>.</I>&#160;&#160;The Compensation Committee, or
    a majority of the independent directors of the Board, shall
    review and approve, or recommend for approval by the Board, the
    compensation of the Company&#146;s Chief Executive Officer (the
    &#147;CEO&#148;) and the Company&#146;s other executive
    officers, including salary, bonus and incentive compensation
    levels; deferred compensation; executive perquisites; equity
    compensation (including awards to induce employment); severance
    arrangements;
    <FONT style="white-space: nowrap">change-in-control</FONT>
    benefits and other forms of executive officer compensation. The
    Compensation Committee or the independent directors of the
    Board, as the case may be, shall meet without the presence of
    executive officers when approving or deliberating on CEO
    compensation but may, in its or their discretion, invite the CEO
    to be present during the approval of, or deliberations with
    respect to, other executive officer compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Evaluation of Senior
    Executives</U>.</I>&#160;&#160;The Compensation Committee shall
    be responsible for overseeing the evaluation of the
    Company&#146;s senior executives. In conjunction with the Audit
    Committee in the case of the evaluation of the senior financial
    management, the Compensation Committee shall determine the
    nature and frequency of the evaluation and the persons subject
    to the evaluation, supervise the conduct of the evaluation and
    prepare assessments of the performance of the Company&#146;s
    senior executives, to be discussed periodically with the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Plan Recommendations and
    Approvals</U>.</I>&#160;&#160;The Compensation Committee shall
    periodically review and make recommendations to the Board with
    respect to incentive-compensation plans and equity-based plans.
    In addition, in the case of any tax-qualified,
    non-discriminatory employee benefit plans (and any parallel
    nonqualified plans) for which stockholder approval is not sought
    and pursuant to which options or stock may
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    B-1
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    be acquired by officers, directors, employees or consultants of
    the Company, the Compensation Committee, or a majority of the
    independent directors of the Board, shall approve such plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Administration of Plans</U>.</I>&#160;&#160;The
    Compensation Committee shall exercise all rights, authority and
    functions of the Board under all of the Company&#146;s stock
    option, stock incentive, employee stock purchase and other
    equity-based plans, including without limitation, the authority
    to interpret the terms thereof, to grant options thereunder and
    to make stock awards thereunder; provided, however, that, except
    as otherwise expressly authorized to do so by this charter or a
    plan or resolution of the Board, the Compensation Committee
    shall not be authorized to amend any such plan. To the extent
    permitted by applicable law and the provisions of a given
    equity-based plan, and consistent with the requirements of
    applicable law and such equity-based plan, the Compensation
    Committee may delegate to one or more executive officers of the
    Company the power to grant options or other stock awards
    pursuant to such equity-based plan to employees of the Company
    or any subsidiary of the Company who are not directors or
    executive officers of the Company. The Compensation Committee,
    or a majority of the independent directors of the Board, shall
    approve any inducement awards granted in reliance on the
    exemption from shareholder approval contained in NASDAQ
    Rule&#160;4350(i)(1)(A)(iv).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Director Compensation</U>.</I>&#160;&#160;The
    Compensation Committee shall periodically review and make
    recommendations to the Board with respect to director
    compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Compensation Committee Report on Executive
    Compensation</U>.</I>&#160;&#160;The Compensation Committee
    shall prepare for inclusion where necessary in a proxy or
    information statement of the Company relating to an annual
    meeting of security holders at which directors are to be elected
    (or special meeting or written consents in lieu of such
    meeting), the report described in Item&#160;402(k) of
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;<I><U>Compensation Committee Report on Repricing of
    Options/ SARs</U>.</I>&#160;&#160; If during the last fiscal
    year of the Company (while the Company was a reporting company
    pursuant to Section&#160;13(a) or 15(d) of the Securities
    Exchange Act of 1934, as amended, and the rules and regulations
    thereunder (the &#147;Exchange Act&#148;)) any adjustment or
    amendment was made to the exercise price of any stock option or
    stock appreciation right previously awarded to a &#147;named
    executive officer&#148; (as such term is defined from time to
    time in Item&#160;402(a)(3) of
    <FONT style="white-space: nowrap">Regulation&#160;S-K),</FONT>
    the Compensation Committee shall furnish the report required by
    Item&#160;402(i) of
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;<I><U>Additional Powers</U>.</I>&#160;&#160;The
    Compensation Committee shall have such other duties as may be
    delegated from time to time by the Board.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">D.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Procedures
    and Administration</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Meetings</U>.</I>&#160;&#160;The Compensation
    Committee shall meet as often as it deems necessary in order to
    perform its responsibilities. The Compensation Committee may
    also act by unanimous written consent in lieu of a meeting. The
    Compensation Committee shall keep such records of its meetings
    as it shall deem appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Subcommittees</U>.</I>&#160;&#160;The Compensation
    Committee may form and delegate authority to one or more
    subcommittees as it deems appropriate from time to time under
    the circumstances (including (a)&#160;a subcommittee consisting
    of a single member and (b)&#160;a subcommittee consisting of at
    least two members, each of whom qualifies as a
    &#147;non-employee director,&#148; as such term is defined from
    time to time in
    <FONT style="white-space: nowrap">Rule&#160;16b-3</FONT>
    promulgated under the Exchange Act, and an &#147;outside
    director,&#148; as such term is defined from time to time in
    Section&#160;162(m) of the Internal Revenue Code of 1986, as
    amended, and the rules and regulations thereunder).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Reports to Board</U>.</I>&#160;&#160;The
    Compensation Committee shall report regularly to the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Charter</U>.</I>&#160;&#160;The Compensation
    Committee shall periodically review and reassess the adequacy of
    this Charter and recommend any proposed changes to the Board for
    approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Consulting Arrangements</U>.</I>&#160;&#160;The
    Compensation Committee shall have the sole authority to retain
    and terminate any compensation consultant to be used to assist
    in the evaluation of executive officer compensation and shall
    have sole authority to approve the consultant&#146;s fees and
    other retention terms. The Compensation
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    B-2
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Committee shall also have authority to commission compensation
    surveys or studies as the need arises. The Compensation
    Committee is empowered, without further action by the Board, to
    cause the Company to pay the compensation of such consultants as
    established by the Compensation Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Independent Advisors</U>.</I>&#160;&#160;The
    Compensation Committee shall have the authority, without further
    action by the Board, to engage such independent legal,
    accounting and other advisors as it deems necessary or
    appropriate to carry out its responsibilities. Such independent
    advisors may be the regular advisors to the Company. The
    Compensation Committee is empowered, without further action by
    the Board, to cause the Company to pay the compensation of such
    advisors as established by the Compensation Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;<I><U>Investigations</U>.</I>&#160;&#160;The
    Compensation Committee shall have the authority to conduct or
    authorize investigations into any matters within the scope of
    its responsibilities as it shall deem appropriate, including the
    authority to request any officer, employee or advisor of the
    Company to meet with the Compensation Committee or any advisors
    engaged by the Compensation Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;<I><U>Annual Self-Evaluation</U>.</I>&#160;&#160;At
    least annually, the Compensation Committee shall evaluate its
    own performance.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    B-3
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='121'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">ANNEX&#160;C</FONT></U></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTRO-OPTICAL
    SCIENCES, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">NOMINATING
    AND CORPORATE GOVERNANCE COMMITTEE CHARTER</FONT></U></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">A.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Purpose</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purpose of the Nominating and Corporate Governance Committee
    of the Board of Directors (the &#147;Board&#148;) of
    Electro-Optical Sciences, Inc. (the &#147;Company&#148;) is to:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend to the Board the persons to be nominated for election
    as directors at any meeting of stockholders;
</TD>
</TR>

<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    develop and recommend to the Board a set of corporate governance
    guidelines applicable to the Company;&#160;and
</TD>
</TR>

<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversee the evaluation of the Board.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">B.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Structure
    and Membership</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Number</U>.</I>&#160;&#160;The Nominating and
    Corporate Governance Committee shall consist of such number of
    directors as the Board shall from time to time determine.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Independence</U>.</I>&#160;&#160;Except as
    otherwise permitted by the applicable rules of NASDAQ, each
    member of the Nominating and Corporate Governance Committee
    shall be &#147;independent&#148; as defined by such rules.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Chair</U>.</I>&#160;&#160;Unless the Board elects
    a Chair of the Nominating and Corporate Governance Committee,
    the Committee shall elect a Chair by majority vote.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Compensation</U>.</I>&#160;&#160;The compensation
    of Nominating and Corporate Governance Committee members shall
    be as determined by the Board.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Selection and Removal</U>.</I>&#160;&#160;Members
    of the Nominating and Corporate Governance Committee shall be
    appointed by the Board, upon the recommendation of the
    Committee. The Board may remove members of the Nominating and
    Corporate Governance Committee from such Committee, with or
    without cause.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">C.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Authority
    and Responsibilities</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">General</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating and Corporate Governance Committee shall
    discharge its responsibilities, and shall assess the information
    provided by the Company&#146;s management, in accordance with
    its business judgment.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Board
    and Committee Membership</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Selection of Director
    Nominees</U>.</I>&#160;&#160;Except where the Company is legally
    required by contract, bylaw or otherwise to provide third
    parties with the right to nominate directors, the Nominating and
    Corporate Governance Committee shall be responsible for
    recommending to the Board the nominees for election as directors
    at any meeting of stockholders and the persons to be elected by
    the Board to fill any vacancies on the Board. In making such
    recommendations, the Committee shall consider candidates
    proposed by stockholders. The Committee shall review and
    evaluate information available to it regarding candidates
    proposed by stockholders and shall apply the same criteria, and
    shall follow substantially the same process in considering them,
    as it does in considering other candidates.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Criteria for Selecting
    Directors</U>.</I>&#160;&#160;The Board&#146;s criteria for
    selecting directors are as set forth in the Company&#146;s
    Corporate Governance Guidelines. The Nominating and Corporate
    Governance Committee shall use such criteria and the principles
    set forth in such Guidelines to guide its director selection
    process. The Committee shall be responsible for reviewing with
    the Board, on an annual basis, the requisite skills and criteria
    for new Board members as well as the composition of the Board as
    a whole. The Committee may adopt, and periodically review and
    revise as it deems appropriate, procedures regarding director
    candidates proposed by stockholders.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    C-1
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Search Firms</U>.</I>&#160;&#160;The Nominating
    and Corporate Governance Committee shall have the authority to
    retain and terminate any search firm to be used to identify
    director nominees, including authority to approve the search
    firm&#146;s fees and other retention terms. The Committee is
    empowered, without further action by the Board, to cause the
    Company to pay the compensation of any search firm engaged by
    the Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Selection of Committee
    Members</U>.</I>&#160;&#160;The Nominating and Corporate
    Governance Committee shall be responsible for recommending to
    the Board the directors to be appointed to each committee of the
    Board.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Corporate
    Governance</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Corporate Governance
    Guidelines</U>.</I>&#160;&#160;The Nominating and Corporate
    Governance Committee shall develop and recommend to the Board a
    set of Corporate Governance Guidelines applicable to the
    Company. The Committee shall, from time to time as it deems
    appropriate, review and reassess the adequacy of such Corporate
    Governance Guidelines and recommend any proposed changes to the
    Board for approval.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><U><FONT style="font-family: 'Times New Roman', Times">Evaluation
    of the Board; Succession Planning</FONT></U></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Evaluation of the Board</U>.</I>&#160;&#160;The
    Nominating and Corporate Governance Committee shall be
    responsible for overseeing an annual self-evaluation of the
    Board to determine whether it and its committees are functioning
    effectively. The Committee shall determine the nature of the
    evaluation, supervise the conduct of the evaluation and prepare
    an assessment of the Board&#146;s performance, to be discussed
    with the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;<I><U>Succession of Senior
    Executives</U>.</I>&#160;&#160;The Nominating and Corporate
    Governance Committee shall oversee an annual review by the Board
    on succession planning, which shall include transitional
    leadership in the event of an unplanned vacancy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;<I><U>Additional Powers</U>.</I>&#160;&#160;The
    Nominating and Corporate Governance Committee shall have such
    other duties as may be delegated from time to time by the Board.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">D.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Procedures
    and Administration</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;<I><U>Meetings</U>.</I>&#160;&#160;The Nominating and
    Corporate Governance Committee shall meet as often as it deems
    necessary in order to perform its responsibilities. The
    Committee may also act by unanimous written consent in lieu of a
    meeting. The Committee shall keep such records of its meetings
    as it shall deem appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;<I><U>Subcommittees</U>.</I>&#160;&#160;The Nominating
    and Corporate Governance Committee may form and delegate
    authority to one or more subcommittees (including a subcommittee
    consisting of a single member), as it deems appropriate from
    time to time under the circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;<I><U>Reports to the Board</U>.</I>&#160;&#160;The
    Nominating and Corporate Governance Committee shall report
    regularly to the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;<I><U>Charter</U>.</I>&#160;&#160;The Nominating and
    Corporate Governance Committee shall, from time to time as it
    deems appropriate, review and reassess the adequacy of this
    Charter and recommend any proposed changes to the Board for
    approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;<I><U>Independent Advisors</U>.</I>&#160;&#160;The
    Nominating and Corporate Governance Committee shall have the
    authority to engage such independent legal and other advisors as
    it deems necessary or appropriate to carry out its
    responsibilities. Such independent advisors may be the regular
    advisors to the Company. The Committee is empowered, without
    further action by the Board, to cause the Company to pay the
    compensation of such advisors as established by the Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;<I><U>Investigations</U>.</I>&#160;&#160;The Nominating
    and Corporate Governance Committee shall have the authority to
    conduct or authorize investigations into any matters within the
    scope of its responsibilities as it shall deem appropriate,
    including the authority to request any officer, employee or
    advisor of the Company to meet with the Committee or any
    advisors engaged by the Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;<I><U>Annual Self-Evaluation</U>.</I>&#160;&#160;At
    least annually, the Nominating and Corporate Governance
    Committee shall evaluate its own performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Adopted on May&#160;13, 2005 by the Board of Directors of
    Electro-Optical Sciences, Inc.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    C-2
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='122'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">ANNEX&#160;D</FONT></U></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECOND
    AMENDMENT<BR>
    TO<BR>
    ELECTRO-OPTICAL SCIENCES, INC.<BR>
    2003 STOCK INCENTIVE PLAN</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This Second Amendment dated this 17th&#160;day of April 2007
    (the &#147;Amendment&#148;) amends the 2003 Stock Incentive Plan
    of Electro-Optical Sciences, Inc., as amended pursuant to the
    First Amendment thereto dated the 10th&#160;day of
    February&#160;2004 (the &#147;Existing 2003 Plan&#148;).
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RECITALS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Compensation Committee of the Board of Directors
    (the &#147;Compensation Committee&#148;) of Electro-Optical
    Sciences, Inc. (the &#147;Company&#148;) has recommended that
    this Amendment be adopted and approved by the Board of Directors
    of the Company;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Board of Directors of the Company has accepted the
    recommendation of the Compensation Committee and has determined
    that it is in the best interests of the Company and stockholders
    of the Company to adopt and approve this Amendment;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Board of Directors has recommended that the
    stockholders of the Company adopt and approve this Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    NOW, THEREFORE, the Existing 2003 Plan is hereby amended as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;The first sentence of Section&#160;4 of the Existing
    2003 Plan is hereby deleted in its entirety and replaced with
    the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;4. Share Limitations. Subject to the adjustment pursuant
    to Section&#160;9 below, the maximum number of shares of Common
    Stock that may be issued under the Plan is 1,250,000; provided
    however, that upon the vesting in full of the stock option
    granted to Joseph V. Gulfo pursuant to that certain Stock Option
    Agreement dated February&#160;2, 2004, the maximum number of
    shares of Common Stock that may be issued under the Plan shall
    automatically be reduced to that number of shares of Common
    Stock subject to all outstanding options granted pursuant to the
    Plan, including Dr.&#160;Gulfo&#146;s options, that have not
    expired or been forfeited or cancelled as of such date.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned, in his capacity as Secretary of the Company,
    hereby certifies that this Amendment was adopted by the Board of
    Directors of the Company by a Unanimous Written Consent in Lieu
    of a Meeting dated April&#160;17, 2007.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Richard
    I. Steinhart</FONT></DIV>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;Richard I. Steinhart
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="8%"></TD>
    <TD width="43%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Secretary
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Date: April&#160;17, 2007
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    D-1
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='123'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><U><FONT style="font-family: 'Times New Roman', Times">ANNEX&#160;E</FONT></U></B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">AMENDMENT<BR>
    TO<BR>
    ELECTRO-OPTICAL SCIENCES, INC.<BR>
    2005 STOCK INCENTIVE PLAN</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This Amendment dated this 17th&#160;day of April 2007 (the
    &#147;Amendment&#148;) amends the 2005 Stock Incentive Plan of
    Electro-Optical Sciences, Inc. (the &#147;Existing 2005
    Plan&#148;).
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RECITALS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Compensation Committee of the Board of Directors
    (the &#147;Compensation Committee&#148;) of Electro-Optical
    Sciences, Inc. (the &#147;Company&#148;) has recommended that
    this Amendment be adopted and approved by the Board of Directors
    of the Company;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Board of Directors of the Company has accepted the
    recommendation of the Compensation Committee and has determined
    that it is in the best interests of the Company and stockholders
    of the Company to adopt and approve this Amendment;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    WHEREAS, the Board of Directors has recommended that the
    stockholders of the Company adopt and approve this Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    NOW, THEREFORE, the Existing 2005 Plan is hereby amended as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;The first sentence of Section&#160;4 of the Existing
    2005 Plan is hereby deleted in its entirety and replaced with
    the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;4. Share Limitations. Subject to the adjustment pursuant
    to Section&#160;9 below, the maximum number of shares of Common
    Stock that may be issued under the Plan is 1,724,028.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;The last sentence of Section&#160;4 of the Existing 2005
    Plan is hereby deleted in its entirety.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned, in his capacity as Secretary of the Company,
    hereby certifies that this Amendment was adopted by the Board of
    Directors of the Company by a Unanimous Written Consent in Lieu
    of a Meeting dated April&#160;17, 2007.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Richard
    I. Steinhart</DIV>
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;Richard I. Steinhart
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="8%"></TD>
    <TD width="43%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Secretary
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Date: April&#160;17, 2007
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    E-1
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="y33491y3349103.gif" alt="(PROXY CARD FRONT)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">TO VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE ELECTRO-OPTICAL SCIENCES, INC. PROXY SOLICITED
BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 21, 2007 The
undersigned hereby appoints Breaux Castleman, Joseph V. Gulfo, M.D., and Richard I. P Steinhart,
and each of them (with full power to act alone), as attorneys and proxies of the undersigned, with
full power of substitution, to vote all shares of stock of Electro-Optical R Sciences, Inc. which
the undersigned may be entitled to vote at the Annual Meeting of Stockholders of Electro-Optical
Sciences, Inc. to be held at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, New
York 10591, on Monday, May&nbsp;21, 2007 at 9:00 a.m., O local time, and at any and all postponements,
continuations and adjournments thereof, with all powers that the undersigned would possess if
personally present, upon and in respect of the X following matters and in accordance with the
following instructions, with discretionary authority as to any and all other matters that may
properly come before the meeting. Y UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE
VOTED FOR ALL NOMINEES LISTED FOR PROPOSAL 1 AND FOR PROPOSALS 2, 3 AND 4, AS MORE SPECIFICALLY
DESCRIBED IN THE PROXY STATEMENT. IF SPECIFIC INSTRUCTIONS ARE INDICATED, THIS PROXY WILL BE VOTED
IN ACCORDANCE THEREWITH. CONTINUED AND TO BE SIGNED ON REVERSE SIDE SEE REVERSE SIDE</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="y33491y3349104.gif" alt="(PROXY CARD END)">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">ELECTRO-OPTICAL SCIENCES, INC. OFFERS STOCKHOLDERS OF RECORD THREE WAYS TO VOTE YOUR PROXY Your
telephone or Internet vote authorizes the named proxies to vote your shares in the same manner as
if you had returned your proxy card. We encourage you to use these cost effective and convenient
ways of voting, 24 hours a day, 7&nbsp;days a week. TELEPHONE VOTING INTERNET VOTING VOTING BY MAIL
This method of voting is Visit the Internet voting website Simply sign and date your available for
residents of the at http://proxy.georgeson.com. proxy card and return it in U.S. and Canada. On a
touch Enter the COMPANY NUMBER the postage-paid envelope tone telephone, call TOLL FREE and
CONTROL NUMBER shown to Georgeson Inc., Wall Street 1-877-450-9556, 24 hours a day, below and
follow the instructions Station, P.O. Box 1100, New 7&nbsp;days a week. You will be asked on your
screen. You will incur York, NY 10269-0646. If you to enter ONLY the CONTROL only your usual
Internet charges. are voting by telephone or the NUMBER shown below. Have Available until 11:59 PM,
EST, Internet, please do not mail your voting instruction card May&nbsp;20, 2007. your proxy card.
ready, then follow the prerecorded instructions. Your vote will be confirmed and cast as you
direct. Available until 11:59 PM, EST, May&nbsp;20, 2007. COMPANY NUMBER CONTROL NUMBER t DETACH BELOW
AND RETURN USING THE ENVELOPE PROVIDED ONLY IF YOU ARE VOTING BY MAIL t X Please mark votes as in
this example. THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE NOMINEES FOR DIRECTOR LISTED BELOW.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSALS 2, 3 AND 4 BELOW. Proposal 1. To elect
directors to serve for the ensuing year and until their Proposal 2. To ratify selection of Eisner
FOR AGAINST ABSTAIN successors are elected. LLP as the Company&#146;s independent registered Nominees:
Joseph V. Gulfo, M.D., Breaux Castleman, Sidney Braginsky, public accounting firm for George C.
Chryssis, Martin D. Cleary, Dan W. Lufkin and the fiscal year ending Gerald Wagner, Ph.D. December
31, 2007. FOR AGAINST ABSTAIN FOR ALL NOMINEES WITHHOLD LISTED ABOVE (EXCEPT AUTHORITY TO VOTE Proposal 3. To approve the amendment AS MARKED TO
THE FOR ALL NOMINEES to our 2003 Stock Incentive CONTRARY BELOW) LISTED ABOVE Plan. FOR AGAINST
ABSTAIN Proposal 4. To ratify the amendment to To withhold authority to vote for any nominee(s),
write such nominee(s)&#146; name(s) our 2005 Stock Incentive above. Plan. Date&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2007 Signature(s)
Signature(s) Please sign exactly as your name appears hereon. If the stock is registered in the
names of two or more persons, each should sign. Executors, administrators, trustees, guardians and
attorneys-in-fact should add their titles. If signer is a corporation, please give full corporate
name and have a duly authorized officer sign, stating title. If signer is a partnership, please
sign in partnership name by authorized person. Please vote, date and promptly return this proxy in
the enclosed return envelope which is postage prepaid if mailed in the United States.</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y33491y3349101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y33491y3349101.gif
M1TE&.#EA^@`^`,00`,#`P$!`0("`@/#P\.#@X!`0$"`@(%!04-#0T'!P<#`P
M,+"PL)"0D*"@H&!@8````/___P``````````````````````````````````
M`````````````````````````"'Y!`$``!``+`````#Z`#X```7_("2.9&F>
M:*JN;.N^<"S/=&W?>(X/XC`0NJ!P2"P:<P0`H"%H'@R'@.&A"%@#T:O6:E`4
MK(>F8`%`',_HM%JG7`BBBD,5*V@H`03>S-=V9Q55!PQF:X6&AT0(;@Y3!0<)
M=GJ((@T)"@8.#9.;G)TB20P!!0\!#DI`GBD$!XZHJ:^P.PP)`0]A9)*Q*@0)
MCKFZP,$E``)=`0D`PC$+!@&_RM"=`*RV"]%[<=?:B`,)#[;)VS,$#PGB)`AB
M8^<W!`X/!@*N[#&.VP/3HU5*M9KT,KT*"'CVCP6!6N&4#0A5H$""!81$("!5
M\$6#*0<(5CRA2`"M@0H7>,.4L$2#!PXV_[)X5Z"D2@@#$"AAXB!`%0$N@0TH
M!F^!1A'>(KXL@4`!E9_"""A%P$3,NRF`$@@8)$[`J``Y34Q4,)3CJ)23",AL
M`X!!TRVBOFF1.I7!G8KN&IIRP<I:5Q(G'PB@X0,"`3)*S*H3L,5H0WA7'`RV
M`[A,GKLE!CCX.F^%-[N0(0#XMI<$OCL,U-&R^>W;'#HUV3)PBQ-I9A@+#3@2
MRF*!7C6N=7RV;=J*%T!7I$*ZDR3W:QL$&&AD!J\RBY,!T,1^X'S&6&)-$AAH
M9F44%7G'8VU&:0*`T0.87>RT=8:`@&\.:*OGY_L*3B6T#1L/OX;55<]/9<6"
M-QD9L=,H!:1G$/\3M3BTFGPHY.4/?YZL8DTM!XS0P"@%QC#`%`H&@<`!IDVX
M`@"T1.%6=09!16$J"Z'RG@%^U:(`A"P`T%"(.2Q0RP,M&?0&%53=D!>++ZZ!
M0&6C6'+;#`Q0@:,-#?Q8#I*?D&@``T),`5:2DS"080G>?(,E"K$YM)\+[GE'
M2FX?/L"C#>/-"28:'IE``(+?"1C9-%-@)42;I6WI0I31#1%E`7<>8F%YWV3H
MWCM4/#*8$]]`P:40(WYSF'(O3%3`FBT,,,JFC8XSY0D`"%H"2SDID9T33=@!
M`*DN+&"8DP><>4*4-P:Q60&KIHJ".P$42P(O)DC6W!$+@:'"=-SII6S_"LP4
M8*(-M22J&P-VTL,`%#`PX,`OIKY9Q`!5EG:`@`B4"4\!AN[PG@+@V3"%.4(0
M^-(`)&Z[2Q-:35%:INBA()-Z/IHF`(Z=%AK?$.X9%<^U)W`VQ%,J9>OK")O-
M@P`#1I730$03/>#2`#^B:E(3:0$)JE9N&%S.K=(M\`05R'RLV3=^RN".E!N]
MTV$+/KJ"@,W:GE`+E_CH"F3,OA5JQ7T-EG)`%C9'&NX92]""6`(,(#D>&R3J
MA2MVN!*1K<`J0$*"-P64S&.ZQU@\AAY)-%;&"6X,M@`#WCTLG@`.E(Q)'4KP
M,%[;GRS!R'>X(O!C@BQ`SL+()#K@,P0+.("9_XXHI0PW3,&!Q,93"6B.6V"T
M&+P=9XR_I=42;Y`&I,$YC1PNI>^J0`R)09Z0Q&2]YM@`\1/7&`"2DAV-P"@#
M&>6R&@T;<+HV?Y6\=<P'AS^U8JW]K+)G91;OV2RE-2!)3,34!`_9M1A`1N#%
M&+SU-S-'WH3B9#/!`K8W#05-@4NUX-<:QD6*KVV#-PDIRX^.<0KA?2,B[RD'
M1L02.BGP3"16*@T8D)&+*@''"LA`@"16T36U4#!HJG!`D48`+("I*PWND4WS
M2G"0JZWH&G4R%[VF@C,7'*E&0$H&`BAEBUJY)`EW<-V?[H"'&P"@7B5H4I0,
M\+D:++$A"9C'WY:%N_^KJ"X8XZ&"^_AR'L*50XK*Z`6$R*&7AL`Q1S8R496\
MHX#^+:L7*.EB&D)GL.V%JF3!.HXH!)3&!UQO"-.HAA[BM2\[6&5^.*D,`1J!
M,33H3`&0N*"Q:$`,)&60/4:X2"`E0K@"9,($H?&@^$I#K`J)0G7?,.0H:Y`^
M0;K`/+8P0SJ,@A5?09&*1?3$1+A(`@SMD@C>T>4,KF@M,7FM*YMIW:O*\<PA
MF(9B(23%0R!##@,\8S/>ZF8.C-*9(!#`*`K(A"^U<9(OD6!8G53G"OXR3WU"
MX!VG`YH_!\H)$@DHEP1-Z"&F<-`G*?2A:+@,"M[33HA:E`CU1,'9+LI1(0Q/
M0)20>D!'1ZJ#D\#MH]0AJ4KU-:IF?>..*^6HOTSPTIC:%#8,I>GY;LK3V@")
DAS7MJ5"Q131*4&2H2#V!*O%%()@F]:&5D$H^GTK5JHXR!``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y33491y3349102.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y33491y3349102.gif
M1TE&.#EA'0(``=4[`("`@,#`P$!`0````,O+R^7EY;"PL/#P\!`0$"`@(&!@
M8.#@X*"@H-#0T#`P,%!04'!P<)"0D/___S\_/W]_?[^_OQ\?'U]?7Y^?GR\O
M+^_O[P\/#\_/S]_?WZ6EI65E96]O;T]/3R4E)8^/CW-S<T5%1;BXN*ZNKJ^O
MK[6UM9N;F]75U;.SLRPL+%A86&IJ:L7%Q1(2$@D)"<'!P3@X.#DY.8F)B<S,
MS-S<W)R<G!D9&?___P```````````````"'Y!`$``#L`+``````=`@`!``;_
MP)UP2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>$PNF\_HM'K-;KO?S`-$
ML!`>(H#ZC@$("!<`$0=PA(6&AXB)BHN&!PB/"(,)DY$1`PX##0>4#XR>GZ"A
MHJ.D8P$#!H$'#0(!IP$."CL)$`8#"PP#@Z6\O;Z_P,%IC@D*NT(`N@,`.P("
MR3NOPM/4U=;7PJP#"'JY##O+S<\#T0-^17P`ZNOL[>[O\/'R\_3U]O?X^?K[
M_/W^_P`#"LRG!YNH!@$`.&!VZML.!,P$/+!4KH&15JXR:MS(L:/'CR!#BAQ)
MLJ3)DRA3JES)LJ7+ES!/*CAG$%0N!0H0,'"T,,^#_P2V(C18]@#!$0$UDRI=
MJJ8/4T\0$`R`L,/2@*L!&B08@'0'A&T&CCX=2[:L%:=F$27,TC6MV[=PT<*M
MUG:NW;LUY>(%5G>OW[^]]`(NU7>PX<.)!",&57BQX\=I%$-6U'BRY<M<)&,N
M5'FSY\]/-(-NTWFTZ=/(:*)V4WJU:\RB7Y=I+;OVXMBVP]#.S=LO[MY==@,?
M_O8W<;;'D_M6K=R+\.;0#1J/+N4Y]>O"IF-W8GV[]U+:OROI+KZ\I_#F+Z9?
M_PL]>R'DW\MOX_Y]_/GXT=1G?S^__S'[K=???P1Z$6!Z`Q:H8!8'FI?@@A!2
MT6!Y#T9H86C,65CAA1PJ,?^A>!MV*&(1'WX7XH@HENC=B2B*J.)V++;(X8O8
MQ2BCA31>9^.-$.9(W8X\*NAC=$`&N40#87TW)'1%&HF$5ADXM-V2DZ5"Q`$T
M9611-%NJY^096G&@093>4?F8`%<Y,(0"Y.RPP%5<-7,5,UY^24:8$D@P9I+7
MF;G8*1%`\,`""R0@E1!!9?4*-'7:&88<&W"0)P<;\$F=GXB]^0"=#?#19C(/
M&`.--$4T^64`;`XPB9B83'4,=)@BQH!4`NS":$X`(#!..1D*4,"OP`8K[+#$
M%FOLL<@FJ^RRS#;K[+/01EL`#A%L-4`)'A20@@XUI`!#"]L`(.VXY)9KKKDD
M9-C_'*H)1(!,FT,D,ZHY%Q%@[[WXYJOOOOSVZ^^_``<L\,`$%VSPP0>K0(,,
MJMHP`[XFG'"O!YC$\`+"&&>L\<8<W_N!NL<9@``>[;XK1`*=_+0HO$28.N(!
M#+3Z`,A&,+!5*\D=X("[U.F<IJUMY@+6#JW26:JC5RR0DZIY2)'K`(,.I_,(
M9%['@"Q#+$"3UL=DA83+%C*`)M262B''51"\*IO.&.A9=70'%&0%V`HN$-4V
M$,AMQ0(/A*OV:A!0D*>>&W09(=W_&3"V`%)R$0":"32.&BR1YGD!UA<B/A\@
M6R&0]Q@V7T+S9:%[/@$'EXNH.7L!]'W)3F<\3<=G!SS=_^X@.F/.X>KEW=&Y
M`H:?4?M5QERFM%0.2![K<+Q[A^I5D?^=AM)^/];Z53,?L3QPS?<<^@`S'?*X
MJI+_%?,V"NA-Q/:]==]<`TO?OH@!6R4P>EJ^5^_A_02Z3QS,,N,?(2)`J^"Y
MQ6Y2B9P3V,<;__4&@4Q3GR>&!SX)/@5^5\$9AD;D0-N(+8-E(P7U("*]I"B.
M>!;<'P=;!$'/I9`4X],)4V#6N:9-@8&YZ2!J#.`ZQF$C`/438"]JET#850&'
MMM$A:#B'OA<*8U9<$:(HJ,>5\MU0BOA1XF:N][H27H.(%13&^,"'Q24@L39:
MG$S^$`"\M%`1`%[\1.D^EYDRRO\GC8YYGJH$,1=MC(P4M:L?'+]P1MG@T3`T
M))X=DP)$584P$<=[G1@*^9I#_@5^">3C8$*GP43HL9-AH*1K+(D_2P$0>X_\
M"QC3=X@/AK$,HEP-*<NB,PM\`X()L"%D#I"J0;IAC;XT0RQ1,\NQL&U,K1)`
M*A^S`#1!A`V`*"(:M(:J"`0@CO\IYE*TY@`,:$!,&7"`$R$#"_*A`8-<6:9N
M*,!."ES`:!I*#D+4(8!6704#%-A`!RY@Q<]P<I%1&&,;UR"`/&&@`Q6`Y^%L
M@Z54*$``4H'3)9[1!UA8``0;Z"=HP!BU+Y1.EVI8@`/T9($+)+1#V@2%UO#@
M#(EN0R+_`&!``/06``ML@`(:V(`N:G,V5VT!C/(3`S73\5`!6.LJ$J``!B:`
M`85"**7B2\4<C@H]`4`@IGTP()R$$``06$`#20T'$:@Y3L?P+5Q8H*(/LS!4
M=125JBZUE@+4X8`Q2:`"%G#J@J"Z!JWQX0$0=:DS(+K6(9PB3J5R!E<M(#C"
M\2Q><RI"``R`S<&,3X%3X&+VGH"ER:IC#D9UJ40':RV9TB098GU`!MHF@0D\
M-I["J"P3Y@F`>KKT$5>QYC%0JU!`A,JSZ@"L;>&$@@H8-P15?09A08I:-6$F
M=`Z@200R,('J9L"IYV.C^CJ;"@"`UIZB'>PZ#``!!P1O;,Q)_PA:=#:X"NAN
MH<$(0"0XZ]F'PG5.684/5O[@"K$)`">#%:U$$R!>`"A@`NVD0%YK.]SPAA8K
MJMGJ;6A5!P!4H+U&"V0&T_%=`6?0&>O@B!'@Q!R$7-.,"&[G!LHZ'[X>Q:@7
M<$!A`+$.P(9W4S)M)II<@0?O#C:B`M:5,ZX:B(PDH0$6J&YU$W`$:G[6&?=]
M*9PJNJ5TL'B&7P$?!"Z<IPI8U1E`=C!%*WH.&I=/PBWK@VR;[`H%6//$F0/&
M!"HP`0EDX+H)F6I<!PL!:S'XP1X>[%S5D9$UA\$5W16NA^$TUS?73BA5Z&Q&
MKAP&:O*8'8-M\%4NS,X*2+0G9$:',_\D=]C"K".4`!40*<86@514]\(86+2L
MT^2,3:G#`*Z@M"(ZVV-G@#>N@\:U$`%P`0J`H-@LLG0`>DS/P?YZT3(N,%TK
M,"8+H`"%AJVM0GE;A,X:D`S#/$WWO'VEPRZCPZ+=0)WS9`'1$AC$ZC!MJJMA
MXB<[(,QP$C*1<QVO"U_``A(HC:27C6EGSQI.T8:W.MX<``;DN-NNV!*Q0X#/
M#`Q`<E,N`ED-$>ZW:`TYIB#T#KB;*ET]^^!HXK($,#`S.(^FOYD>FV@=D(`*
M=*"D%<BE<%MZ<%49G&D,1Y4Z:J8.O7&;"*460@,0`/"<[I0("F"`KMG0\;0\
MC2I"H(B;;O;_+@18RL31G?<0#F"`N;IB'5&>=;0'36:YB1;KP%D`#Z52VYJ;
MM`,32"Z8B4=F/2HTZ45`\Q#0*UF1CS7>0X``:RG@8B-4O2Q#44!1%L#+JPCA
M)T$9"@"*0@3&7F``(9@`R((',P44H]DRG_6[QRSL;YNQ'="1^%(M1Z^6[7>L
M_"ZWUR3K"B.8V-#='FF>-.!<7SR>+)JG$ZJ^(H1G2H0BI^A2G2]P`01G:;)%
MX0K/92UDJ\;;R$Z*P`:XW('BDR("259RI=HC=M.P*9>0%4(X0$P.4NU@`C=O
M[01.+E$1^+\$'Q"`'C"`*W`N!GB`")B`"B@M-V`!QF5<$\`""SB!_Q18@<:2
M+MLA-C*T`XPR?[MB?Q-P`6WC:2BS#CDP@";0,2JX@BS8@B[X@O=R`N[@`3!8
M@S9X@_GR,=?1.JFP$"9#-+)`"[:`"T^W`Q8`<'DR`>J$-#)R?&.Q`(]@*'K`
M*,F`"9J``(;2"4.``*QU5XW'A*#AA$\X!P6Q%D+`!V6F"D0@7$*FA6#X)6+X
MA.W7#&_(A'%X&5]8AY]QAY:1AWJX&7PX&7[XAY<1B)`QB(0X&89X)HGH)(OH
M&(C8B([QB(L1B9*(&)2(&)9XB8:1B8>QB9P(&)YH&*`8BLNQ0J:8(G-H(JFH
MBJC8BATRBH-1BK`X%[((&+18B\6QBBNBB_\SPHLPXHL7<HM_D8O"6!;$Z!?&
M>(QCD8Q[L8S,R!3.B!?0&(U*,8UW48W6F!?`6"/;6"#8:!?:^(W7$(YS,8[D
M6`WF"!?HF([3L(YOT8[N&`SPZ!;R.(_L]XKXR![UF!;WN(^\T(]F\8\`20H"
M618$69"B<)"\X'I,D)`*"0H,.0I$5#RL,&H<^%_2`Y$1>1[=.!HYD0"QP(':
MQP"V$!5PUS(=:1X3*0I?1GD[H#*#H`!JTF=BL9+BT9*A8`L#P$>M@@`729(W
MB9-E\I$O-PE(T6J;(%Q">1$&\)10&952.9546956>958F95:N95<V95>^95@
M&99B.99D699F>9;_7ND"1NE/K'`*M5,'SD"37L%DC4*4?;*6G@%1[\837^%P
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M&Q%:21-:B!4Z2A=J&?[)%QO*H`KZH9V8H;(DHH_1H8?03&G#53'U-28ZB21J
M&*?P"$@Q%)CP6H/WHK<1HX.A$#'U#38IEXNIHZ?(.GL$'TC!*$=#I",J'_1S
M">+0E*4R$%1:I59ZI5B:I5JZI5S:I?@`2N81-P!@"ZV3I$9Q$3&1IB@1=FK:
MIB$1`3/AIG+J$7`ZIW:Z$6YVIWJ**CP*&#GQ`%^Q`)9`/VZHDOHI1GI5"F8(
M#,F(HH5P`'TC0P<`.1*TB9:XJ+^`J<;7IQ+"J:(H1%.W:],0JHAP`,"W"*8J
M#*3*I*S:JJ[ZJK`:J[(ZJ[1:J[9Z').Z)8KS`/];DCY*\PS(H)%"D#X-`%A)
M`EHNDZMG*!$6`:G1\`"\.@2!8@>=L*M;PF=G\*M)HI3:9EAMH90/Q2G0ZI!A
M4*S1N@.^^E!)8JW#N@#%JDR((JR1`:SMJJW!6CS.RJX[H#B*:091QU7&FG64
MU:U<]:V4%:Y*-Z['44Y^`(4/X`!JX@C-0`L7EPOT(PL2"[&3!P[O1@8,6PXT
MR60\Y`CUQ&3#TQ4\Y+`06PXR!IEB8%1]4P?FE0Q]N0>'(@3FA9*HX`@/2Y?"
M@P`].W)&`;.WH+(1:Q0:RPVG4)B1\9?,(+%$*W=_214I"[0KN[1L9`9G];2Z
M$K-$TP`T>W$V"R\YZSG_.VNU/@L<;$0ON4!VMZ`X'.@'RT`1$K&O=+"S%Z=Y
MY+H%:^L':P$-5P4S")21,B8$5]6V0SBHJSH%N&8+FD`.G7(`/0E$?6,'Y$`+
M0)@+;K*W7J"Y[FJW^SI9F8"X;WNWE'5Q#[4##;"X4Z!8`""R2-&XF2"7-GFX
MNC"$J;NZ9F!5X0`(6F,.DJNZ.S&Y*-,FP8NYL>"YG+L:6$(O\Z)>TIH).G-O
M%D%H]+(,/`D^9-"\-+&4S7`.L_(-@Z!8W_N\62:V8%(,T=`6$)NJC/(XX!`1
MXW!O&@4&52A#0Z>ZZON\UBNW=8>%R\L%.6$`F,"!G**^KDL.K?"\1@7`9C`(
M_V)U>48!OSCK`.[;)O#K@?=;O[(A#0P,OF)+0`3<"1AQO0``MG>0"1Y;>],+
MP5F3$[M`ON3PO`;@+IPG/)8`O8CR3$TY=!K<DVS"NE&0#'!Z"QJ4P@E1?^90
MPOX+402<MF7@,UOQO7:0PPD,#D+Y"DY,<V@0P3E1O48C,G1"A<SPPT4LQ),A
M#:3[)DJ'OE=,#F]RNB;Y#?9W:+7WL(,`OV#+*TBZOGMPN[=@35(Z!F\9OS@C
MR.3+*#B#O%&GQ,FIN:]`#H6\#&L,QWA[-4G*,E'L!Z^+Q9-L8#5I/TBQQJFK
MI&4@5@1TK7Z`R%VAR'[`R)!<>\,A#9H"L;!P,D+&!_]>)V.W/`L.,'DTR\4K
M[`>Y$&W>50X/.U]1>LRUK"80E2OO]2@(\,OFL%,0]15CW"8[E1-?05E6J\P/
M_,T$++34/%-08\O.)9*3A[6:DPM1T0='6\[N[#G,?,YJPLY=S`QO\FY#,;YF
MF\WR-Y-FZ\W)?*J@P0JZRJPUK+J9]@V)278\\ZY)DIAH/%L"8!'(^@SGH*]>
M015HP:Z\]`P&7042K31V@+#+ZB98$]+B>J[G-*X+K;H!:[>\&M,2':_]&CO`
M:M,S_=`?S:PX/=)5X$/^Y0QE=]+TN@=(8=(CA]+F&L"W&M52/=547=56?=58
MG=5:O=5<W=5>_=5@'=9B/=;_9%W69GW6:)W6:KW6;-W6;OW6<!W7<CW7=%W7
M=GW7>)W7>KW7?-W7?OW7@!W8@CW8A%W8AGW8B)W8BKW8C-W8COW8D!W9DCW9
ME%W9EIT4JQ=SFKW9G-W9GOW9H!W:HCW:I%W:IGW:J)W:JKW:K-W:KOW:L!W;
MLCW;M&W:\'?9B9B_N/V'NKW;==C;8E#4%\T*1"#<%@$_(GV1@R4.(*9T#S50
M8S<'#Y`D@\6KRNT,Q*VZX;H+CQ/1C<%#(HTHAPD?G9)I#<`*U"W>:Y5I5('<
MK(0.5$&O$-"L<_#>;2`V==``6#>IF!,!&,G<+NW?-`'>*YIX#@$!4B('$I$A
MQ"TH_V?X#=5]W`W].#.)HV6`WO"Q)K7BW/]5!T5M--T=W1+Q=0+`,ZF;T4K=
MW,U`WQUN!_\U>`:$K-3-9W@P!#.#X"-7WQYNWE7QWV<8WW0RW\I=/,8-IR,'
M2L#=!,5ZJ@I1:*>P/FRZ"B,#"[6R;.8@M]8D,@RP='V0*UVB,S,3ON!@3::'
M)3GL"I`[Y86+KL+\Y!IW<;`@"[/RE,]D#DWN"EB"A?)GLW1>QF]F$;3`+HZ'
M%-L`E]<4"Z@"SE1PW58%!=#LQWN`"1X.%%H^Y@FAS"*)->';.@EP#/2:U`]E
MY32EP/CKYY?.O?QF52(CU&NB:_)%EVWR)LES,A`@Z$U.P/]T$K)V\,L-]T=<
M-<U"J\!QRLG1A>O@<.@S`<.1?@ORURLS,2M8'G$BT\:3"D>(#L-W?DTV0^=2
M4EO@P`W?^PIERH%1[@CDU1=)?B0.,`(6[.AL6@Y0;F0X\0<.X>;'CK,&YH;S
M?H9GN@=,1B]N'O#DL.^X,'*9X'7P7@2:1RB`7N]RFQ#O_C@^=+D.;^DS]1"\
MBB6#'K^RT`HV(ZVLSE6-E2?6X5U*VQ4[`ZA5H1.K4`>UIT`BT\^S("68U0QT
MDM0/&Q8NQU4*W,D^?`Z1(^XG!H5`<04U%<U+(/'?T":"$@'.!;2:P,E=\?&2
MNW1A\?%GZ+./T^EE)^P1EY%9?^S_6%\5@Y#R6"?+@Y?KLC"Y%X_P#OX,8R\(
MV;[R.Z&[P<KQX1[KMS#W^RJ%))*H3Y(`DH(![;Y`W9?PR'#X26U8\#)1--=,
M1N/M=\_SX#!7:R[P-H\.-=D)]KX^"106:'_LN;+<CP-$6!SZ$^5#3\K#ZT/H
MCM!,"7$B`3#R`>?H;@6_;T)V1E%Y7&$1M0>L"D`5.W/O\&$TGVXTV@`^:O/D
MK<`X/U_\IS!8O0K%"H_G&I?J-T=Y7\][6=(*_WXRIVL1J\\,DO_D,>,5G2#Y
MB/\X"*X`MC"Q0P;V\&[G?9'[TT[\:7;WJ0^D00@$AIT``!#LD$@`0M#<'12#
M@:"1-.X&_P?$0A`(#)*#P+)Y1"8422L@^9"^X7".A$Z)W]_5:_*KWB,?()`6
MJG;ZD`8B(A"J'M*0%!X8FA02DA@0L!0`&`Z0#OL"!ZL<B*(.#M5VJAH>,A&$
M5A>PQLP^CP08P&"1&F;%U*H6``8*K8[``!2Z(AR28E55$?#B*.CHJ.\R=XJT
M)G<@$HH&#`YF#1P>:)$$(@X&-@6<$1AV9A,BDHC8V08/#C#E4].G2P!Q;(`-
MB9"J%Q.!T89(":"*V````2Y(P*#@RY1H;_C@TK7#@$4`"00)(]9@3X!,I91E
MB6#I'Z:0!BJ]&])/B1F7M)H]`W>0W#I5^[BI2]BPP38B09$(^?_SY%RZ8UBX
M+?,"!A%+6T@B"&!$D>>8(F?1%H&040*'@VGA"IS*<*H!1@<>^.2Z;M$!NQ-=
M&EC@I6F^!0X$+?W$M8_=!GBIF#RY<.^EL8O`.3`GCM;<(P;!0-"\@//2!0/J
M-2CFZRH8+0D"+*#'#8$Y8]$,P$VKP-JUM[K/UN/&YN01!)N,.-*\XX%2P`,6
MS#Q;3/2"!PYJ)UGV+T&GB6B>X"/$!TR7(:6?#ZZ\P\'%+1!W,"@R:V"1``(Z
MT+%@5KB?(B$-20",O(I08`O45BGF"KP44.TL\1!8*`'.;MDA`:5V\N,(!FF1
MK9XEM$!.`.>BV8>T>A2ST(%'B/"0M@/_IE)@N>9:>P(!V`XYB9NO9!O#&?_@
M"Y*!"]RZ+4@KX+@HR8JD8&.1*0I)):$1XQ.P.U4:<&``!`0QBKS%P)J&"@AL
M`<"!CII,`H)I8'L"`BD4\$0,)BVZCQW7WH1'3CBJW#(?I';$BAM@0$M`JJ^.
MA"B`"2AHE`)$$_U/"P'L\L00Z-R8XA<IKFQ/'T'6'$#+APX0`,Y+5]$2GD#!
M-.\+A#BM!\TI=-QAF42#Q.B:C7`%,*)W)K+1``8$C'!0*1XX@$PKG,ERRPDM
MM5,!%"-Z8XPWDEVG4`,J7>R=-VPQ=<LNXP"K&'X"',#08YO$2PH!Z`N4*V*V
MDL(!/9(4X!$*OY7@J5<D,#'RWX$)+MC@@Q%.^$@#'E*X8%2\(,SAB2$:C^*+
M#WX@@PDXGB`+C"^&!N2122ZY7Y-13EGEE:,)EN6788Y9YIEIKGGE_VS.6>>=
M>>[9YY^!#IIFG(4NVNBCD4Y:Z:69CH;HIJ&.6NJIJ:Y::F4BSEKKK;GNVNNO
MP0Y;[+')+MOLL]%.6^VUV6[;[;?ACEONN>FN>VSD@,M;[[WY[MOOOP$/7/#!
7"2_<\,,13USQQ1EOW/''(8\<KB```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>y33491y3349103.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y33491y3349103.gif
M1TE&.#EA_0+>`_<``````#DY.5)24FMK:WM[>XR,C)R<G*6EI;6UM<;&QL[.
MSM;6UN?GY^_O[_?W]___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````_0+>`P`(_@`?"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#A
MPX@3*U[,N+'CQY`C2YY,N;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7K
MU[!CRYY-N[;MV[ASZ][-N[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KU
MZ]BS:]_.O;OW[^##_HL?3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^O?S[^_
M__\`!BC@@`06:."!"":HX((,-NC@@Q!&*.&$%%9HX8489JCAAAQVZ.&'((8H
MXH@DEFCBB2BFJ.**++;HXHLPQBCCC#36:..-..:HXXX\]NCCCT`&*>201!9I
MY)%()JGDDDPVZ>234$8IY9145FGEE5AFJ>667';IY9=@ABGFF&26:>:9:*:I
MYIILMNGFFW#&*>><=-9IYYUXYJGGGGSVZ>>?@`8JZ*"$%FKHH8@FJNBBC#;J
MZ*.01BKII)16:NFEF&:JZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJK_K#&
M*NNLM-9JZZVXYJKKKKSVZNNOP`8K[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16
M:^VUV&:K[;;<=NOMM^"&*^ZXY)9K[KGHIJONNNRVZ^Z[\,8K[[STUFOOO?CF
MJ^^^_/;K[[\`!RSPP`07;/#!"">L\,(,-^SPPQ!'+/'$%%=L\<489ZSQQAQW
M[/''((<L\L@DEVSRR2BGK/+*++?L\LLPQRSSS#37;//-..>L\\X\]^SSST`'
M+?301!=M]-%()ZWTTDPW[?334$<M]=145VWUU5AGK?767'?M]==@ARWVV&27
M;?;9:*>M]MILM^WVVW#'+??<=-=M]]UXYZWW_MY\]^WWWX`'+OC@A!=N^.&(
M)Z[XXHPW[OCCD$<N^>245V[YY9AGKOGFG'?N^>>@AR[ZZ*27;OKIJ*>N^NJL
MM^[ZZ[#'+OOLM-=N^^VXYZ[[[KSW[OOOP`<O_/#$%V_\\<@GK_SRS#?O_//0
M1R_]]-17;_WUV&>O_?;<=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__ST
MUV___?CGK__^_/?O__\`#*``!TC``AKP@`A,H`(7R,`&.O"!$(R@!"=(P0I:
M\((8S*`&-\C!#GKP@R`,H0A'2,(2FO"$*$RA"E?(PA:Z\(4PC*$,9TC#&MKP
MACC,H0YWR,,>^O"'_D`,HA"'2,0B&O&(2$RB$I?(Q"8Z\8E0C*(4ITC%*EKQ
MBM<K``"VR$6!)"````A``@H"@`,,)`$`>$`#"+!%`2C@`5KDXA;1*$<S#D2.
M`##``P)`@($L```+\",`"D`0,`YD``!P@!?3B,:%X'&,"$@C0?`8`($X```#
M.*,`MD@`!CR`D@2AXQ;U^(!(RC&.<GS`)3/I1T0"H).7'*-`(AE*.0X@D'B\
MI1K9"``W"D0``AB(`,#X1H$0H)($00`8`V!'56)R(*9LHR=M*<LS2O(!C13E
M%@^@30%,4X[(?)8#&/#'`S#`DY%,P`+0B`""&""8QNPD'Q?`@'0V@)QE_CQG
M),E)3D7>T9P+B.0"%`#(7Q+2FN%DP!8%TH`YSC*-M%1(/A=@```T(*+_Y*<G
ML;G%!CQ`H0@@YP#Z.-%S)A,`Y$R```BY3WHN8)SE-"D=/?K1`!2`G,=L:#L?
M>E)R+D``F2PI4!DPSWH"8(Q_A&0`U@C//P82FD<=:`!(:4J:MI0!`PCF1`\`
M@&+RE*=7?>E5L_I)@)IT6@#8J4ZAZL\'_'&C1RT`/`7"57^F]:L'N:M`COH`
M`@0SDFTMY1:?RE5)*I,`?12L8B6ZTUAB=*\[)0AB[XI&?RX@J)$M"$8):M2\
M1G:R.RU`)A7I@``0-+*/Q2@M]2I8N1*DK@\X_D``%#I&HK9SI`19JQ>1"5J\
MKO:SK/0M1*\IW$]FEEIZ12--/\K7@02@G<IE9FX+:ER\&D2O"I@M<V5[7#06
MX*`VE>1*(^E16C[6LY8\ZGE9*Q#:^E6-`7@N::M[$(PZEKAWW*E[X?G<ZZ*6
MN*I-(VLC*=V!-#20#MCD`/P9265N=)&!;>]1W[M8Q0X8P-<T+WX#3%]KZ76]
MF17M`PQ`TN/J]<-X7.XGZS@0KL[5FG]T:UK3J%`%@%2QY[TN0"O:V4FRF+QH
M].1%$=G)%7.QF14V;C0["MF'-B#(';XC'C'L4Z"6M<H5-?%.N5K-!VP2R4F&
MZI-1*M@JEQBJ)\6C_F#E>%&4+N"G)&4Q6G>JW('0MI:E;6>!)?Q4%//SJ1D-
M*)F;K-DTFM8`!:!E1>D9@$QJV)%RA"1^2^K1K#*`H*1L+QL;:E85V[>K8<VO
M0"R-Z;*Z$XUFY6J:MZC+7.X1R0H-9`/BNU0T%X2@RUT``1Q`ZCRNF8MC''`X
MRTQ/58=ZR7RE-'+5>F$5?Y+'<'PQ;.F;8U$3.LJ+''$!Q-A(,++YT8PM-!DS
MVU!P_G&^1V7O2:WI@&K?5:'@[&MP&WI:6UN7T`IE@&M;G,B^"F#6F<[Q)5&[
M5%!B5+8=QJV]P6UOA*M[SE!5)SL-HD56$I4`]$RGM<,:V(GNT]JUE#$C_@'9
M50D?0,-_CBV@L1WJDC)@VFA<0%&YJE"S/IC8V66IF_O99)@#4J$&>/-[+[SN
M<=\Q`;/&N%''".6/AYFN8I3J`7PN:$%>F:+4+2[',1ICER.WR\H,8Y>M&=DU
MMC$!;6TNLI&,Q\PVER`QWB,A_[AO@6P[FW@LYR3'CNP_@G.JA;PI+UL=;VMN
ML<#:+.->QPAXY\[=E45^^V,;2<9J`IX!O!0`VI_M3V!F^R"R#:,9&R\0FU)>
MC5VUY<HY:DV.UO'T]`:ERB(,Q['3OC2W%QJ8L<C[WOL^AU,6L/"#3_Q4+K3X
MR#_^\)./_!4;F?E3=C[TB2_]Z4=?^=8W_O*S_B_\YW._^MQ7/OC#/_[O8Y_\
MYS?_]K-??O:GW_W=#W\7WV_]]M>?_M.W?_[Q#WW]]U_\\@>``>A_S$>`R6>`
MS<=_U/=[#-B`#OB`$!B!$CB!%%B!%GB!&)B!&KB!'-B!'OB!(!B"(CB")%B"
M)GB"*)B"*KB"+-B"+OB":(-\B<5%JR<0?D=\F?5RF]1+!O!@R#9E;T9\`M"#
M!D%1WB8`!^!L"[$`J%0`JW>#<D0`".!14!A\[42#!6&$K#:%!S%X1=A%#Y$`
MV]9+!;!Y!=$`!["#0WAS6.A]>)18O'1<O%2$!N!M`\"%-HA\D26&D!=T#]&&
M<5@0<YB%=;B%2A@J_C*X5X-U$%78=F?D;8_T4,@7A,57:_PV96+D$!4U99DF
M<L$W``W0B([8AG05?-I%$/"V13?GB0[!:\&W:\D$B9$F9=25B'UU>"HVB)=(
M21LEBES43@[`2U-V4`P!B+@H60OU6J:XBHC(:HCUC`1@1Z0(=UP$C<^X4P1U
M>(@%B8&4`,_H2J_TC)0(2&\64-Y&C(752]O(15Z5$.DX4N#83#=8CF&75ICW
MC%PT4HAUA8M8BFTT6<<(54>6A6#($(4U`.I4CY&5C6&TCOW8AOEHC=%H3%Q$
MC+=(7.DH```91E18C1+93H4E``@P4*'W<'G5C\)HD;H86URDD<)HB:,R_HUD
MU(\$F8P'45JC1%,.L(FC)4@VF8<_Z7K(=(.1Y0!Q%`"Y!Y3-Y0"B]%0W2!#9
MN&`^EG6*2%U$:6>NA&3@V$LUB5\)X6UMY7?PA)-YI),\695]1I,&(8Q9IXM7
MV5Y9R8H(`9;4R)7%B))R!&AN^8M8N4VE(I-368-R65]M%%ADJ6)/69?XE9AQ
M9)%JM(/'51!Q9`"!M8D'E9BT.)-4:61/U9@U.5?P-@"NM'*8"6F#-DL(L%.F
M)`"&Z6T>!9%J*8AR-%>ZZ)EU&4REJ9FKF)J1>9+4Q9:T:9.VZ9,OUHR;&9B,
M6)`4MT61Z5.(J9R#*1#9F%C>UH[^Z)@%X6U/_GAX2JF9FKEZ;:B=1?AFEYB:
MHZ28#B&,!C!V=L><!N&<G(F6"<%+<;13NBB>64B>N8F,H\2>#6&,@^2>%^E<
ML>E6Y$DJOUB.Y6A7!>J)"EJ.O]2@R1F4I=D`KM1.J3BAQ3E=05F5'?F3?A=<
M\HF<Y>:5![&#^!1&Z-D01`5.9;A<.RB8R&ED(_F@_L1+.%EK@UBB2TB##_I4
M+<I%IG>("`&@.>I1.PJ=JC*)(]J5P=>D/4JAR'>92AJ=7>F;@32/;_9%`DJ+
MX+F(^VD0V0A/.^A588H0#%"(X+13@/F=51E\3S6'ID1(@WBF/KF`'Z6F0MJ;
M6$J1PS5(`VJE2UI\_FEYG)[XI'LDH5\HI<5G`!Z5H8O:5`_*7!UJ9!_ZB<XF
MDU@(J0JQB7946,1HIPFA`'I:<OB9$+!)?'&:C*,YB)R*$+[8H6DJB]99I'@I
M2:V:C*^Z*FT*I7<ZGUW:8HC%`&$)G5JZI9#IJVLV@VIF9*N8F*(HDK2GJ0]9
MH,\(7\SY9M%D657J$`K@2ID4B`5Q`,-Z2=5JJ'X*E!IIDX!YK:)J$`D`KO]Y
MJ^JJB^V*6'^IJ&UJIZM9$.9ZFE::FR':GH!*$`DFH-$'1^?I3EM$I95Z7;'9
MAI-9$'043(D7B8)JJ_C%H_UJL%ST3;6HJ+JXB04YL;7$E78*G?\ZK[]I_I,D
M*YP+:W@;^BF]&I^+:J*6Y&V.:DEQE%B_NJ)3J91%N8E(J1`W6$W1Y)3=ZJ8S
M^I:/Z9ZH](K=V1`7RJ'!1)8[JTH].Z(UJXMD:9-.VP#):J=5:V=MQ+*K>DU?
M>TUAFZP(ZHP2697Z"(WC*)$3^0`,R4?']+%7"K0$>DT9Z9`EMQ`D"X]<E&GO
MZJND&+C"R)JIJ&*/ZXEV>Q"BM)X!Y;9Y*[AP=:YS"XWI*I`_R;@MJ4@W:+=F
MQ)"6BP!CVZT`NFH8V9(;R9K*FBD'Z(9Y&:NO](B8:(8_V[L#P4O+E8[@Y)\'
M\;*'Z[>H&K%J*;PMB4Z<9!!5B[L(\8,Q6TJR_GAX9IBJ"[B2#P".XQI\WJ24
M4OMK>$1*9]JZ!.&]RCAEX3N[F%*[DXB[/OM1:=A&1'BS?<NP;^=6:HJ$#9"4
M1=B$V_FP3.NEA&B'>.A*[&E*F22]"(&&@^>'9UB_/,B&Y[J]C.J56HA)>'BH
M4^:S+Q?!@':^](J\_(O`*E:S8@/`53$`PU8_[6:2\J-W^3-.,'C#.)S#.KS#
M/-S#/OS#0!S$3?+!Q82)-Y5,KN2$`[&)-.5WJIN[EK1)V*D`8T@`O%M*23S"
M'>IWH93$7C58OCB24EN%(JFQ+>FH!^NS!VN1U$N./PFFXSN5AW=3;47%6V@0
MY=:)C7C$;GB'"H$`_EE\IWFIF8>7M2N6I>Q[`*0;Q_':L,74QD]EQQPLQW/L
M@VQD4S(:*'"[@\&&2?CX3'XJ1XVU28F%2(24C8_,D86&2:Z4:6PIH%Q<D[\[
M96SJQE8HBGV$RR>ICTF,MUN4RC!)OK?[Q@6ERS.IC\L$NM6XROT&E,\(1JQ$
M?-@9RGSIP<I+20R*R.%(`'%IS*]\5Y`LS%"\8G/+:@*QB7[E4(="DUP55%GG
M=\Z;B6UFE;],8#?*E;/V<)M$9TQ&8&,TS]J\J`\ESTQ\R#ZFQ28:RS&\OXH(
M:*9$D<&4SWP:RT!YT")WET`*QVFE2&&763OX=A0-;]_T5`VPB0LL=FID_DH!
M+5'4E5V^9M`4+5B5%--01=!,5M$^B0`<#4:UC-#GI(JE.+.:_,[*MW*+"$:\
M6U'HV$L\;;9I55&R.Y.H%5*)FM2`2M,77=5M50!6;-!2AM`3RK#SV]`#05#P
M5&X(`-6Y%],QK=$8G5X6I;"=B$8)-4KCW-8%I99:--9:O<173<!DO4B2Y-8^
MF=79>51;W=4XW9YSK:)>W=!^!Z2IB2@T&4GN[-!<"6^!1=<#<;#C/-"_7+S5
M>`#%I-FU---;O%"F?9)&3=3;C%@K+9T=.DJ\&5^879T)P=:J*G+66(.TC0!L
M1$K$Q*$;I=3PUL0VR=F/[<OXM=J+A-HX^]4&_K:(A*U*%65&?M?;SAW6!-J.
MY3;24$6F]HMTB;+)[@F^GD33,5V?_NIM?,U0S.M-V2C+6,W%6"W=^&W-Q0RB
ML\V^U93/GRW0@CS(HNC;4T9X7_I42'VP.]6(IZB6ZLVHUAR9:DG=^TW+XNNC
M@&W8RVW0Z*UIPTO9N53+!I":H==.?K?9CNV)P;QF1&I)`=68V\W9]:W:6Q18
M_+3<-'G?,4U0+_S8!':R+\[A>!W;R?M41@FHPSW=9$9'BN1B0,F;I!S8LOW"
M,ZZBV7V-$`MHY@K>3IR:4\[A$M;,[45/A=W=Q+UB)8X`)XZ*"5"(/RXH#5K9
M=HG4#'M0:PQ&CGG?_A^%KP)9U7<NYEEMY\)T5Q7NVMQ]S@5KT?G-YV>^V#"]
MX8_-Q5K4V,@4M7Q+T>7VFE2IU`9!Z(H^=QM.D\I=W9LNZ(!>Z)&UWB_]W%0>
M2<$TK*J$>NCZ)W..Z#*-=@M-6&'$E*']Z&?8I9:=ZPZPZX(>R_Y<[`5]Z&`M
MX&O&GC0ITL">Z!Q>W4=>TR*GT]9[5^9Z<F"N>$7NU0M]TF)4["J-ZHPN<R]M
M[=9>T[I>T)#NQ#M]8HANRC2UW8-RZUQNDUOIER*W>9=<K-%=L>D\N/VN>/I-
MB8<T9;+$[`/^O,9\S)\\OXX>[\2LS6\(L;PLH,P+RK!^4M"=OGD=?)1Y_A`'
M;T<5;[M%&^G$A4@8'X6CQO!U^;VN1N7F6E,-&9?K;*@./TM>S%!A3JFA"MA,
MN$DKM7*`[,@/;\M(W+"`UO/ZG<MX5,:^F8\=C.[`'NX13XM6#Y5QY,<QCV3E
MI@`QS4;\:$M\ZO-*#^E5'T:&;.UF'_70%,@S?VM?[W94N8AIBDA\1+STP\)"
M'/B"/_B$7_@28H5G!*YX#TZ*S,QYI_5Q7!#PUHD-:]&5+]WA[M=QS?80B_#^
MF$:ZC,N0',LQ&]-//%5#GO2#A-!Y9Q#`'49*',9S[_19>/>/GHUZE/EN-8:8
M/.U]O.I2BXF-/TN7K,24@O@*BT?$"+<ZK\S#_DQ<&IWQA'GCM/C%(S^X+,_H
MI>?O6%^5+_;1<B_ZJDKZ_4C1_=[BL^R("5\0Z,S)LG^1HNS\!1O++6J^%R_8
M&(O5TISAS\O\_@X0!@``("!@8(('"14N9-C0X4.($25.I%C1XD6,&35NY-C1
MXT>0(46&'+B@(0(``1`^0!```(*$)16B#/!PP<"%-P$LE*FSHL&#"@<"$.`@
M)@"30XL>->E3*%*%"90J=`IQ*``&"77BK)H3I\VO6K\.'2!V)\N4)AL,`%#`
M(4V$#5!"[=JPP<"L#PX0Y0EU9LJX<YL.1&!T+D*?#%P:H!KV0<^!!K(V$$C7
M,=.$E(/6Q9R0YH.[_E@3[A4PTO1IU*E5KV;=VO5KV)T7NH3YM^9COP\XF_5Z
M%O/NA@PB$WSJ\@#F@<9_.Y:9L`"`RB9U7VXXT"!CO0#8[MP-?+KO[T=IAW_@
M<J5N`@0<FC>:4*!;[]^E,T!06W9Y``G:/WC_X#EVSPB`22?%VNJM+Y.>4V\A
M`@SDK#GGB-L-0I]TFJ^^V#+4<$,.._3P0Q`?@C`AX0#8#S2\<)/.@?X<ZFJK
MJRPC*+WTI&/HO1(;.&JNK&0B+$7(P&LN-`;^XRVB@?:ZS:"YOJ.Q1B>?M/'%
ML5Y*R8'$!M)1HA)/E*JF^!X`2@`#$MCR*1N[7.A+_!0`2SLM>XL1*O,8_OKL
MP=P>4("K@9XD("F_6#103.O*/#-$1!-5=%%&&WUM3O7P!#3&`0X]L+$Y98S1
MQMGR<X!)IO8JRT>D1%61O,Y0*HU-5$5$RB4%A!.@PDP'FW-*QYPJ22`#:#U+
MKOH0R`M3AGR]RCZ%&&AP*)40)/;`$>7L4]JK`.4T/$D/A'&H2:^J-+-EDSO/
M47++-?=<=!$=:``:CU-3(2)Q,Z"^`\9S,5?F9)QH3Q.S*TW%3ZV$JJ2`!6NU
M.;:."PTQZA@J:2\#]CK`UWO!*Q;?LPBF#2<U8;SVW838U.E)9!>2RP"7;I,-
MY`?8A'4A!A;(2J<!YK*O*YE>7FA/,*D;D>=6_I^:%X%Z7X(Y`9132G=IIIMV
M^FF,HL4/V<].]8ROBB]=SF*'GINS1ZAX)M4DL:%Z-]YM!X*O802%"\"@F/GD
M.FBMR9.)IJ_J)%%JO=USD.V$TALV-!M'[)L_`XU4J#^=C&HP@"UQADI!AAI<
MF^L1&6\80E4?$/P!HPB'>G322S=]4:GA\LQ>"MFF4DA](W(@R6`-.JXYKP?V
M*W?I%KOZ-E&#K0Q+P#$#:@#BN6O8N]<[`^HLFDQR8-EKT5+)`0<,CH^M`K8$
M>42XL->>,,,V^ZK`L@Z643+0HJ.[N>S-G[OUG;CW?J`33]=_?_[[_TAJST$*
M30J9W=Q:)3E;Q6A!_G_YU^^LU@"7Z$XZ$&S.7(Z5$/8HA#9IR].I;(:M3$4J
MA,\Z4G.VHI#MD*6#"4GA4(Y#-YBEC`#;>>%]'M#")"ED+S$R@%&J\D$$7FU.
M*^$@!Z'CPQ%"J(`/*%``9IA#_T51BE.DX@`=DH#M#$`_5K3AD;QX*@XND(4`
MJ"&*`,`O&QF,<Q!20!97PJ\3"60`17085$*C(V-=180"_**N<N,U`B+`(`*H
MSPH]LYT"N.F+#F&``=CBQ'%9;2$(0*0B%:(`K]6,A`'$2A"U4H"4%0!7MYJ3
M)LVB0$F>JI&/)$`DJ_A*6,92EK.D98;R5TM<YE*7N^1E+WWY2V`&4YC#_B1F
M,8UY3&0F4YG+9&8SG?E,:$93FM.D9C6M>4UL9E.;V^1F-[WY37"&4YSC)&<Y
MS7E.=*:S?Q;<U"'55KVC7(5,>!QA'3E%JCEU,48!,("E=I9)9*G-674TVMXR
M%Z<&&&2!`7-+L1I$R(889")%<DDB/QF``!2``>UIHW96$JZAE$R=(R4I--E9
M+4Y>L#K:20\BOX-*>SHK4QE;8:8"<$NTP!0W9^3B4P:5TSQ%\(7\4B1-+#6R
MR$RR>-\9`%#,M!B!W+1E*2F:FT!*F))F5:O/[(KJY"*U-2K/@`-%CB'!ZA<%
M^.YB+S$,ZZS3GK/B+W#<BLI4YEH:"HKT.0.*_A,"<B>1O?I-`!`#76#9@A"4
MI*\Q#=UJ8QU;S*YDT&^,Y>*>2A.F5([-(6>UD52XIKB0*0TWRDFE>/*#(J#8
MZ#]#(HQ`EE)'N$(%I!*1JY-..U7UQ&F)"QF`5!_[6^#VLBHL8U5?AM:2`-C*
M3]6;J>[81:/:<!9>T=)99H`D,+`Q%SH&DLH.)X@7T.*-IPU9@'1NHC(8YL1&
M>_&:>4L2%@A)1:3!I6]]JUB5NN`I1@)@V*U66JN=JE2Z/2WMV$QU5J`)I$32
MZ5QQ'1!!,3+27HN$B*"08L+W^@9"`O"M?3W\8?\-M[:A1:]L[K34S$IPLS7-
M30&'A<'Q6E<T!&,2_F>?D];2((R,9CS/7/RIU()N$B)I38F;,'QA#?OE)@`"
M<9.=/+K(WG:R*[TG4C`[(LU26<LD;@AHIWH;F91-NPN02L)4F2G&QB>JU</L
M#OLYUY6@)+?]"HT.I?QD/.?Y7%T%C/@&S$2\7#E/68YIH1>@UMX4AB5NE0[O
MJ%Q`GLHD>/49'H5M\V(2EC=_<[$D6K!CV-.6&86&U'.I3?VANN!PQRM][K+V
MJ-.>XC-&\;R@37&Z0V]9D8(L3I!H<^8I#1;4.RX1@)1(2-V4^(F"!H@J$@-0
MM,*-]=33IK9K.$-)M76Z+]Y"`#WY2-93S936(0UP2M[\$$RN*Z"Y,5A,_J6"
MG9+`<2%RM/1+4>K%$1F1B:#,J(TZJL5DH;C:`R=XP4,R.TQ7V.`+9WC#,T0F
MG#I<XA.GN&JT77&,9USC&^=XQSW^<9"'7.0C)WG)37YRE*=<Y2MG><M=_G*8
MQUSF,Z=YS6U^<YSG7.<[YWG/??YSH`==Z$,G>M&-?G2D)UWI2W_(28=RE_FV
M)L@904EJJK[9J&MDZHG:.D,4`$^K7"6C$8?-`@C@$E-B)`%YN7JB!,*:KGM]
MZP)HH$,H8Q`G@OTO"9G>JC$B9X:4J"&528XH8=-V@I)E)7&_&DCB_G9TTB<!
M<IX\0A@/]ZSO*\(B03Q/,A^USW.HE4@*/4]:_HF`!+#70WLY/>5`WWA%05XU
ME^>[$[V2=<4\>_*'C<C5Y:OWWH\X.UP32.4%>>?5=%XHI]^];"^^]__-5_;J
MA([G-T3[#BD_)J6O"/8=Y7V>,/DY';I)&:7B2MK61OL>FCYJO/^<,^WEQRP4
MP)D<\!RR7WW]%/E@L(EOL0:9/]-8O^J;+B9K.FFSB,=+0'$JP)@P@,>YF<<Y
M-SOQC:M[B0CDNZ31HH(JFCF*B=1+K@9XG`(H'PUT"0)X.T%*`(4:%@^<()3)
MJ/83"@A,"?MX01"L%Y/`P<<H@`G4D0%0K)NXN+NCJJLYO@]$"R2<DD<Z-Z/!
M0!NT-]``)8\2$28K_H@<3"Z]0#OSRB+I"+*70`E%4K"N*3'^&!`O!)>4*$$8
M00NM^$&6$``%,(@YJI=GTT"\>Z$5;,&+@#P6X4(2H4*`&PU`?(P:Y*<M@8X,
MO!?[$`#%(B_D:Z2DL`^CJ;IP*8P#&*0R@@B4*`#%DHKQNQ&+N0GN`QT#R$//
MX"\^U(TFG,$'=)C;@8D_U`X&RX]57(#M(("-$B0&8)>680O^6L"2<D#<*(`$
M>([!,,:6V#PWA#VU.4;9TKVB@8F"0#UD?`P.TZBFFCS;N[JSJX]E00M"6L;`
M(21H-(G>`D>V><9KK,9SQ,:,4A9SO,8^X4;U0(F\J)<R1#V!<!.:0+T&_C&)
M?TR`@)R.5JJ7!7G"MCA'!P!%-VDJ=4RXQV"^XHN);)1':T2*NS@]NML^H:#&
M`&"`/=E$#:(LF"&(R>O(&^*O96P`AW3#FU#&;B0*U,,H+>I'_P@`2N,I5:D/
MV[,(R#N[`R!(J(!(!&B0K'!'>D1)<BS&=UR/!1&.K-L+B?1(CZRZ!7B.!#`[
MZ$``@6#&"KR)+?%$Y6N_V3G`B`"EG?1'FB3'FSB]<-PL`&F`O9A$S]')HX2*
MGB1'X>#(TD"NFGE+;A1&DB)&XO!(`G`+HQ".ZFF["UR@EQC"ND*`F]@HY\@M
MWSHB/6$,K(PQMD`+Z=B+Z;!,__@3SS2@PWP,_LH4#:/PP<>0JLH$G=)\C+(P
MBCU9@-EY(7YR"$TRBDK,#5]$"1OQQ1GBJ(&!B=0L*.5DK%Y9L1B)+MADS=)D
M03NS2M5D(B=Z&ZM`RY!I(-$T1-MDC-E1OYU(S,98`'P$':KTR+3[S=!DP'E3
M'DORQ9_JE<IL#]?4#MF\S8G\R(<0"*/8"[*3/7[!*C"$"?U3GO.0"N!SPSN<
MG<G[O^K@SH=H3P3U"]'$PE%SE1A1I,CTS`M]SSBL3I20Q1F235)T"%<T)\.D
M1.2<$Y%RS(QQ490XD3#,%$-<G)0H-H'<"<1300OTT4Q!O.^L#AK%T0)TNIWP
MN^LL@,L2C89H2*\$_A4B%=*%$$TF?4+D=%&KC*IB>[X<S8R],#+L4%(F(AI`
MNDZK1".(^,F=:0HT_0HO_1.KK+HAE5'_9(DI_4WHJP@@O=*=F%.VS*<LW=(\
MA42$*+:($%`2J3PM]<\$18LS@3J)J+I,G*JO&CR+R<V+H#0J#=+'**,B=1CF
M0PEX*Z2W`%4]B5,AA:LR(LR1:E'_A"340[W&5-4#[;P;-;X$L#QD01HG18JJ
M^U$K;3R4X-4(!501.5)D5=-CK=5>#57K8TQ'PJG_6,T+5=8JE5;_?%2K#+(%
M8#:#@"=BS-&">M;*6SOMX,<9S=,=RKJS8XB[T*AU11K?4``#"%:[=%#F_IL\
M^E#5)H6.K>13V(.(2_6;9AR-LPC74Q36_(!6RWM50[7.B#)-,`VM2))*-;W.
M2-75SZLZQC3/LK28/;G8+NO*%,53)AW5\%L(4-H^Q'.`K,!37F'7A"U4%85/
M<))5Q$2>S)B5D_"-!K'.#UW0EV!,'7*+@F+!]H"ZSK0DB<)3I!T-43K-9?W(
MJ=4+I:V-K#T`I?U$OQ@`M121%QI/T$2A>P1.]3C1T+++`[7*WMS8E@VX6-R;
M]2J`MH.\54O1OJQ+=&-2X<S;G6#!+3';<RU/Q6*`6<%3CUPU2F5<B`#0P.F9
M^52/N#W:W/!:VJRK?95;AH"8?HD(NCN1!D'._A=*6>A1T+]HT*MC%YZ44`+B
M,+*KCK(E6#?4T#&R0J7:OIM8D1U3V1KZT\`10EBE/B9[V[[<O;I;+&AL5\0D
MHQ`TFF_TRM,JJ.3U*ZQH7;P,1\:=WHJ<WK@T4O_TWNJU#_*U/*8,`,6:BXBC
MNY1LBW_52:+L4?DM2,%$R,;ETHET$[6T5XEDRN;3D2`[WW>C7IZ:7E#I+2"L
MO_]DRN=PBSV9E\J(%0>>,0)@2T`[O:9*V+8S&O<]/HWJWN45BX,<%/"='/E5
ML.E)X>I-W_1YVX<HD8925`G3/4K"*)"LCT^%O0:1X,/$W0ITH&;4T.)#O:HJ
M1R1VB`\VB!`&U9NH_AFB1$TF0PD!AHETO&$=P=,/]AH%:#O!;`G"!.)RXEDU
MY<JQ:SH4O$`N=0`/+%'0*!K^\DT)7!<%B!^^X[<"$-YF9&-BVZ)93$'4Y%*Z
M[&,YAA<XWB+HX#<*G!V3A!E@]-]CI<,XL\4JU(HF3,2)5=,=,D6T0[]RHT7K
M'&2BV"([%*6,8J*'8L%"4B3%`$N6R*(;Q"A3AH]E&<1-OCHS+D$.UC"8Z,51
M5C#&E2B'F$-S*]P-A,%.YKM#]LU\Q2@GU-\*'2^L<0@VQCN-$A!4'F6(BE3U
MU,3V$.:@M:XR/0MA)KPU)$UA!N?`>V1@5M5<7E%BO`E?;1\4M$RI;<)#_L-;
M\,!%FB1,=:XY]&201X2:K)6=/MW=69K=1LD?LDNHV`@RA3X7AX8-Q9V(B.Z0
MBV8ZX4BD<`4VJ)&+(*2ZN=F_)QO$1RG%<S%IUU!IIILB+%H73UX:6:G*X$O5
M:LMHD0"_=,'I@VMIG_YIH`YJH1YJHBYJHSYJI$YJDFH`*D3$1DT_3M39X(CI
MD"#ICM!I=',)G%H[BD6-HYP(HV&`\P`_(HLX-784L5Z-6.%IK(X(;-X0K@X9
MFGZ:MN8(J^Z(LKZBO*CK<(*@<:R7]+'J"X[JC;AKCS!LK4/IAH"D'U-.Q<8(
MX9CKP$$L7J8(QD;`KDX4Q-Z(NN9K%^FPAX;F_M/Q[(Q0`%?^""=2-/'UW)*2
MO\;`8+N6ZB!./MF^"-+.[#R];8JH5HOHX-*CO;-NE,U.[-<#B0$@2=>`8?W1
M;77).L=V+($X%,J\1$($Y>N$0IV\&A8DB+S@9^O.CZ(A-]E)FL%*Q>W614LV
MMQ7=0NOV[B2<Q214Q"A\"/A.(*YI0_G.[C<LYCA,`&=6%B-\")W4T(U6"$]4
M3>K.[_G";RX-[@I<0JJX9,_Y%^'`CN\TXS?C15^L''+C2H+0.^_611^ZY#9T
MD32\SFHFBAK"[EBV;D&BB!"WYT&*Z1CWF*OH9A47BA`DQ45$CV(N684XT>,[
M8Q-?ER_,2_V&;_E*_E4(C\->)`"ZU,2K&4,`R-3J3L+M)G*[.&8I7"N<4'"J
M@$-C:BZ"Z#:,."^\-9-/R@^34,KC=,IKW$O;NUZ5)(J,@L:M!"R\Q$DY%R&X
M9!LW7X"-3,E_.6%`,<9K=`BAG-^&;`LB?$EVM`R93%O^BJIYN3%&RMXJSZGV
MR.[(U,I#?\J%:'2+>EL'5ZKZM8R#G,DLQAI?C$E[7#3U%:FL9/,G1CVV@"<Z
M?]+3<R*7=/1,]\OG]>&$7,AVG$?+D.PO[LCR$_63]$M25X!?MZ@>IMZ$O,A(
M3\98/V446<TR:<K`8\HZ-_9H',II3-54%TB;S$MBGUR1)-A`7S*?!,M%_@_(
M:+<+2"=W;0=W8B+SY)!L\@(I\A2+K&C-W$).R`Q1A6T9[\P8J;+CB;#0L\V.
M">>MN8E-@Z?.A9=,%D+X0_6*R@6=RU/.A/<<Q00T]*QR9O[XOY!9H_'$TSJT
M0N[@DL<ZHLU6UI[X&UI;G]43C7QYMG"`NT`(\UQ,AY5%FZYXA:!A.VEXSZE-
MAL<>QM-XBE=->>;<_N1=Z73-NS!9AB=1E></>'KQA=]8H[GZMGU-N"KYHD=Y
M1JU1*@[/*W+ZK+?Z&%ORH!W.M.4KHU6+[%R0SBSXTJ3BA,#7>PEYL[W:NI?>
MDR]H8?+W?\\(F25*V#93;^585:4/KQT+`#%L_F!I6)QWPY4=:1S5?$#2/N5&
MZ+(?^>CBTCNM;-SV1O50"?5EB5.]6=&V/K/'^;C;5IQ-C_+P;P60"@&&T1HE
M;&XM^X;HXLU?4N2^//1L?IC==.O*Y!O-IYQGB,F3?@IRQ`.(..9/4U.G_FX/
MT]W_Y)<8>I/'3J*8)YM@U9L_?I8O6(H_?L*O_L*_$F/-E.YW_W`&B`<"#P`0
M"`"!P(0*#QI$V/`!@(@2&2JL:/$BQHP:-W+LZ+'B1`0+1BXP,-'`1XH"&P!`
MB:#@@Y<)$,Q,D``B0I4,7R;DR0#``)HF'PKDN9%!@`$'1.Z$&;,@@`,*"5Z4
M29-F@I]!$PPU*M`!_@.<"54J]/J`JEB,%'4B#$"@)LT%7ME6A?GRIX,"`!H0
M6/!PKL.T%M<&;DJTHEFJ41<BO`L@[X$"`P2ZO3J3@5F+1A<G1%O1I`&A4*4F
M;-!`<$6MHAMF9LC6:LV;J"^"7OV@`0(#!``0H-W2-MW6.0L3?^`6;@*_!`C\
M]/O`0>[=O2VJY@KSM=/#9;-3-2I<H$D`SGG"QOH\.N^Z4Z\''NR0[G'+SC_2
MKV__OOV)\XM*#/!Q@`"GK;284<UU5H!8P3E%GE-#"9:9>@,VMF!!!`B@T`#9
M)63@0`5X-=0"XGVU&%T6A:A`0@-,1Q9([Q5'P``.K"2`7$Z56%$"CSWP_I.%
M3^DVUH1`"GG16J2%&.1L_,VGX@,P)I2C7RSUB,```3CDY(PU:F14CPD),!U(
MI#TP%)9GZ<AB3PVR%Z)L3_G%%H=G(>@``&VJ)>9003UG)I%XLB<DFVF^6=Q#
M,,IX&XT/*-"2?S$)<*AGVR7D(%N!"I1C>X*FV)M1EKKYP)$`GN:3B!TF$.!`
M&@ITXJ;:M7@80X9FB1^MM=IZGWX5T2E16!V%*,!5`@00EDS*66G=3:X5YQ5/
MBX86'HHJ%?O`EQ<YBP`"`@!0`&84@@H43;NI*A`!5N969X[/1H1BE=A6>=J-
M%96+[6[.H3D6`=$6Q^-,`#XU9)+?.I<A2B$"_H#B7W4."O"K39JK+9+WOG1L
MO=^^=8!;*;;T+0`,R,@OE1="N%UR(6Z5X7Y>"C"37@?G6$`"!*$$4;X7I7ON
MP6+MINZ*+YIKTDTA>MRE10*LC$#+"A00P`$S95STT4G3C#!O*.Y\;L\`,P2R
MOY1Q)N5,U5IT+;2"Q1I5S`%(#`#%(GIUM4F].9`Q4IS"-.^Y6?$6-ICRFEMQ
MP`;53!?7%]YZ..*)CR51RA`Q_A$#2P,@@`&]-@#Q<QA/GH",R@K)+$P8!U#`
M`J,+Q@#FDV.D^0#6=9OFJKN-[J!%#FB^LHRBDVYZ`P:HS5SGA-;N.U#SW9LJ
M5(0N('L!,@+&L$+`_O*'<`"&/X2ZYZX.R<!N*TN_6:;\G0I4FPMD&(`!`CY%
MO?6@,N_\N*5AOGQ$?6'$P/D&E(Z@`N>+25#\=+<_L=A.6P(XP*'HTH#;<2XF
MC=+6_?*WOP5J"WWJ4PC^V*8_TP$0>9DS(`)AI;SW=68O"3$?VYJWN@",;H!T
ML9W:@K*V\;6./PDIX.1"6*Y>8<HH,-R<C%`XND-9I'<Q-%[X2IB\(=%OB(I[
M(A1Q]3B%["HBO>H($:-XN.5IL8M>_&)%#C`9,-YJ9&2T51;/B)\!S`QU:GQC
MD_H&1TG-L8YVO..M<K6=B#0*CXH3P!7]*$@X-F!8@]R(&0^I2/S\I%<U_ESD
MX13P$H3Y,9&0O"0F%1<2DB@@/!&962;M<\%0DK)6")`C)BU9RE42(#!I7*5'
M]"*F2L8/EK:\)4@FHLO^C!*7OOPE,(,IS&$2LYC&7.4N=VG(8S*SF<Y\)C2C
M*<UI"C*9$FEE+ZFIS6URLYO>_"8X+ZG'<)*SG.8\)SK3J4Z#3!&/Q^N(*FD5
M3XX42#;S?,YN9OFJ=Y)2`6I[97WX61$%V,LA!-V(`CP6N%HQP$Y13"A`ZP,^
M^@CTC?[4D4>R@JLD?N2B`/7D1/Y5'XC6JG<&K!Q'&FK#@')4G>.\8T4SH@!4
M(NZ>&IGI2N^)J<8)*::7/$XV*=I2]Y"+:D--_LM;H&A3_/@4D7]*R5'?"%2H
M;K164[4(T"QSDZ5JCSY(,1<"6!C(".&4I>LD4CMA&M4Z<M6I*Z5G+1_2U$7.
M-2--19-`ZRK1N!Y.KQ&:JU^U6%>_!K:KX!E76PM++51]Q6ANI95BM?E2>7HK
M6^-CSE>(USJ*L,Y>:5O`^)SH0^(1H"O>X\T5.[L2W\V.KTTRW$]FUIT*201;
M==(69B\BKH.`3JX<?4FVBG="<=FO2[%-5>PT."I`,NDB1A2NP2*"$;ZD$'ZP
M@T@!9)>^2U6P>=%-WG?-QA2)I$6(V\6)[-:Z6X30CS<\W9%*G/3<`?@EO&<Y
M8D9,RC;23/0BD8NA_FQ:DM[,JNV`!OGL?86[(Q)BI+WVLZ]%0NO=D.+0P`16
M,&=SYES-UC>DOHE0$\]KW@:$-UOX(P`%<]C@.B%&1`)6;I-J.UK\WH9X%HXL
M-2>+G]Z^!%AAG4ZYFJ8YA%B()GIYD[!@]IL?BQ1OXGJ*CY]6Y`0<^0'M.J5T
MG3HJU5G9;J#22W)ZC*VGF0C,6EII]C3#MG")R&0T0=E+MFPX)H4(9DP.:U(X
M&N0$U,L!+Z-D10`T9B^C>6],#E%H?@R=;>EKT070%Y`<#>D07>QI$8%9E3>R
M`#.[.0$HPXC86$)DIO%9/'YF]&N-7"J++$TT*.JO102-Y;!<FLHB:O6Y_J*5
M9.X!R]9^`9#3:/JMDYGZSQ=!]*`E'6.>D>MO+D;(TARJD#WWV=B^08Y?>%+G
M8%LLV`TP-IZ#`K?T6(0@HZ235.K'[4TKC$O.]DNKK0/IL^8R(N_=*^Q>XARJ
ML.I2!Q':H;(+D0#`3T"=_%>_K5P0?2,7X`+);L(SQ!%1/T`RCV')5NVB\7W7
MTCO>2M!O5\TDHE&+.0RQN`,PWJ0YP;=&"`%HQ.7VSHTIRB4?!\J>%E4C@\^,
M,$0ID<^=)".=TPQZ&.%2^\2FYM/DB,0:[O)S&.+PB@M;3\$3Z?&V-:DW@8DA
M>I(KP;\5%AD)O"5#!Z6\DB[SD//\(9Z"4L1S_A*9`-P[YE%O*4@C$B0"(&A5
MXA'Z`T[E`#HY!+C?:A.4L#JNC>%\Z&[3^+<HJ2>K@YS>7^1Q93'*FF1"I(T%
MIMR617I8T3-HEXEQ;1R-DX``**#I(O7X=2/4V\I'"+F<0>YR5,]ZUR?3MA$5
M/9\6:I+JV6_VM\<)4B8'^I^[2(3,A\@LTQS3S<PR4@JA>.Y/G[!=9@1;!L`<
MK#_#MB\954B8R4WJ9O82[@__2^\]/EJ.EWRCG;<IZA/UR-C&MJ`"/_YX1RQ4
MF-[Q#<E+%%QI'`1(F4D:L42Z11^2,(A_>5_JK)7E45:^95Z+E(=-"`9TZ$9Z
M0."D+%SF(<=,<`?J_CD&9$A&3D'>6ZG96TW4\6@?_(D@7A1`9(Q19<#%ZW2?
M"1K6I1A``6C+F6&=`YZ'!V9-6OC<\R5($<8+#QI$]=42C&#<HJU'PI`@1NB%
M`22'82Q427S?LP$)4B@%%PZ'^&B50'12$*[:0D2A#W:@="1,!F8'6$`$C9!;
M[07?.]&.I,2'32#`3\R2::0%[#$&9LP$BGB*O[U)$<*>68#%&#;-D2Q4!9:1
M4^P&Z17$VQU$G$1&6IR*@,Q6Y'F)",).)Y+.TTG<Q/&&R+3+"KY@Q[%@C/G6
MT8E<;Y!<M?!(*UH)N8P1H@SAL:4B$D;8HTC(VUR'+T()*")7$C8?]/F=_C/&
M2C*&H0_2$2X*FZ(<A([8G5B<XIU("-9Q%.5)GVU]!<51Q"DNX]WIEMH9ECKZ
MW^$)2H@X![J)A4RLF.0-H^*I1YF@SO+X(D%<G4AY"L-!#1%=CN'@W"*^GB:6
M"KIYQ4^8825&T;:U3":2"]H,F<-X'XNAHZ%5BU%<V9/-'MX`S49B&4PHW440
M#,<HE,>%V<>!V+;8VI_$X)J56H<1V\!LC,$H5.$`GVZU34'=CZ'I!0-49):I
M6UA-!LB(3=4D8<W@#>9,C5A06MH,(T6H9(N5#+AX&AM:A-KTW4D"3M4XP+P@
M"Z@=C;9P2_@I1+R9!*T11[J$S;9$9$*49)V`_HQ1!J-.&E93KDA4_D;<",25
MO4M:5,E8W:50^F!6Q<:__.2BP(S,",ZK7:)@XF%JL!"VX%FO*&52B,^9%68`
M?-N2K:5=3F04A15O@*!(_9`,(<0"%5@#J800J9`/+4UK763FR*:,.`!I44K[
MJ!G[7-?E\%9,NF!1_`X,AAP-E0]QS<<D44;[-)%M\I5OTI@7BLL`*(#S*.=U
M`"$+B=CYJ)"9+%%Y+MCF2,]Y4L2(.9\=YM?\/.=&F,1\7*>"G></X4X$;0Y<
MMN4-:5:`%0?KN(Y*Q"80N4]$/-*QR:</UB:D2%>%A5"-_8Y">:2PV2=]&5T(
M<E^G,)A7,HT2B5Z$_OX>`X`AY5Q12^#F>6%/.3X':?4*ZW12Q^`8:F*27$R;
M+]X*%PE36]5HK>PH+J71[_FH1PQI,:F$D7Y$DA+I+_W$HY5$G2QI1P#2,/4H
MD]H'E5ZIEMX2C6ZI-'DE^2B.E(:2E7HI%IDIFH92EZ8IF[:IF[XIG,:IG,XI
MG=:IG=XIGN:IGNXIG_:IG_XIH`:JH+II`TB.!6G$FB8.S:E1_K544QT44+Z1
M8B4J8]Q1F=Z'2HE4IMJ4)66J%Y'4K7CJ_=@3ZDUIQY#1.[V$'/U$J0Y4A5(@
MK9CE`.)I(?D8QN2H1205)"WJ&8U,S:@%K%+$I=J*8NDJ%%$J?0PKOBG*_G04
M(CS%E;)R1)>JDK/6RJ+P:A>E:D1D40?EQY5(VQ/M5)^:VPD]G2UA*Q@E5K`6
M7JL>*ZS"$;)^1+3*JZI4ZV/5(AA-*U_9*WY8R-*@:DNM7WNH3;MJJ!;-ZY6:
MQ`6)Q(1BF$.$V')=5J]@Z'RH5N!UEY1NC&7AUL1R6$<8%\W-EL0^!,4:A`?R
MXHJ1ETQP;'(=*KZB&9:AK*)DR,JPIW8MUXG]5Y@2T&^RQX`-!(W-%Z;8%=*P
MT`%D4(:"2H8(UP#X8L*U6'`E+8*Z;(/=K*.,['KQ1-8ZA<4:46YBQ'HAJ'ME
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M'HSXOM?^BEGJGN^]/458/(W_6MKR7F3U.M9"Z9L)59P,D0L`?XN=N05IUF]3
MP&ZW!6]&6"7&],;^_E:B-4T$Z=A'>^G=*,J(GL0*RS5'0?);*C+%V%%=G*4A
MVB&JS7'<*!)F5-DERJE<"Z_)"Q==-0IKJ5`%WY7K>QE?UQ&9TZKPGK`P0]")
M6.H/3D3<=2RQT.P)Q#W=T*I%UZ&$[13$J910U)$&^O#@DMSB"J\NN8CE//[P
M*S*DV&EQ7Z0BM)IO]`B;71+>:^7Q.DZ=P&'$."+)$WX*GP`R-E)+C%2<"<&Q
M$-NCMXPQ,VJK<4@%G93@').=&C\Q-38%#@/>HK04*#\>:H:P+M6P1S1`0^V&
M)"U>3I@>YJG9+A62\IV7M-K<!=Y'[@7`ZK5>(]]<BS8,)1(Q[/3>RX9C_D\U
M(2QC5/O]JG$J!*40Q_KI4@%6*K`2($Q@1F1D61#.\3'SB3&C%37/7B$Z8N_U
M8"'/8$8X">^Y(21SW_U(8!<6,N;!<S"^Q;E(A?$MR\=ILT4N<$$<P(4T7>GI
MDN-0<S->)(B.B*,V8L%^DRDCM$>0!9V$!ATBKQ_&12S?4+=@(1QBI@U?Y",F
M9EW4X`W^+4Z,M'@A*KO"CA]>QC'#FFL484:/[PD9`!@.BEE$,Y!H("9;,Y$0
M"JELA8,TAP$L\C=314V_UTL#(CFSH#F3H/:ELSM;2\<$LCI#,A;Z5U)(XCR_
M+.9M]46TS$3XQSY_CK=4!T_C:W,<,8-@X5(G_G1OW1X??R-:EW)MD<1(J&9$
M!*=&B,H!'L`\CDBZ,?&A7,X0:IM#1D4Z,I;UV14NV]!@EW%'2,DNMC3,3G8]
M.F'#]%8_)DKM8>)*E\DDRLHO>L4@5_'309!XG>(F.JI0E^+H$6:K;8DM-@E2
M(S;8^J(_/G4<DTK%HJ+DW3$$^W%&,`W*7N/UK)HGUIY=4JLL`O>!8`2=]`U!
M)/930?)=RO:89#=RJDC.2'>'X+;\+(QVVU"9&-YNFVVV/;0WZ5B.\(I'_$JP
M&))HP@M"_.3LW;=9'@O0_*5`:"5(1+9(W7<?_S5/6I%UP:R5F8MA<O9"U$QO
M_>2*85I2%H=5:K!^_CM%_B)O^F9WK/P,B^53VLQ<;&>CNFC8^@WIQ+"97U"X
M?QF:OSRU31>+NW'D3:CN'7-E7V9$>!R*_)9*69ZE2=I,:=;EM-2B33>9B(.K
M(0](*P$SH/AN09#-N@`T?S3*C>=-!G?-4\YSL^P-]-[S5;:@Y>G80;/Q_4C.
MB5X8\)07"<V>?>:6@>JG@QJ$7R\$@<\8:LD(:_/@<*(T0SS7FT-XB,X>=;*X
M=[JGXZIWHHLH@#Y$H;)0`:RU6-1Y`[FF>@<U-@-M"YE.U(FEDFN+@CXZ=3_Z
M[!5GBZJZ#S%0;_:L1JBZV-J/1CBI0J!MB.9G`ZT04,@H`[`H?#[S2NEZ_D1U
MS;1IXW65B&I&N:?O#H)0\FW07*OS9LN29P>!.4PH@`&%LD:T9Z2>%9I/!$E3
M]RH!Z:"6T7R4R27%":".Z;FO2F!,MISJ6'3UT3%EZ;O;BH4D!]"X^QGA1MGF
MN\"G5$N`E@+/Z62AD`DWT^`-?*U@Z+N^T4_@N\-7/(Z,Y[BW:41+!"I;O,=_
M/,B?^\:C:\B7O,F??)V.O$*B/,NWO,M[Z4LMFD0X^<O7O,W??#CIF">)>DH9
MZHK2O&TCI^DF$<+>U#\-QBZAA%Y!*JW,5/T`6D9HU+<'/4;T3X("?='?"A]&
MDD)Y1)G>DQDUE:BZJD#6AP#X(DO8.\FE%-!3_B)',+U]J&JN^I4JD=38Z_F`
M=SO4$Y6/ZMBU<EEE5P]-W*J9>WV]MNK:D-%513BVN3VGTPI!X',^2:M#\-FR
MJIF=[0;-6[XB;7T>O>O7EVK8PVHB*6%]F,2A7*OQ='PA$VVM%-;Z71"K1GP:
M)C(AUA*VDGSL77/?IY7?J6U'D&L0A;=[0XA-)7Z^<A3)ZU5A(1HTJ[G!/BM&
M=&_3^OL=>3ZQ@KY[%_XW`S5<N;[C&SG"@*&1F.OWL_3KTWZ:+#30QNOM0W;>
MMS[OUVBX`S]'*&Q9E/#+>2S@PEB!`$0``@T0`$@@```!!@\>+"``(.$"A@`0
M,%PP`$```P8`6'RH_K'!`P0"&`Q06"``@`$)&+9LZ<!`R@$2%T"$Z+(E``,X
M)U9\<$"F1(L80=:T^<`@T`4P@_)DB))G@`(B*2*<V=!FQX)#,QH(V1!C0@8.
MMCI-Z'*!SXM=0Y;]V10I@H\^P;+U:+<!2I4LG;KDV',N0Z8JA?;%>M3!`80"
M#O0M.))P2X=V>18\*/8N2*J"8^ZEZ'1MY(<0Z5K,BM1`X,Q>>3H`T/@!8P(#
M&!9TT/`C:Y&+68[^//@J:M5O(S]@\+&``Z,W<=L=69)`99T!7&K\;0!A`-C/
M37(G4!8XS:R^2^?<Z5+GW8@/R#,$6ORS8?GSZ=>W?Q]_WZR%T=N\7;\F_JD0
M2."K!0HP2"("M$O@(?$(2``!@39;0*"V`!``@0BCJVF``3&2Z+.:'I3KIIH*
M@%#""`/H<``,25R()P4/8!"`I1(`H``%S!H10KX^(P##!`YT$,6!;LP1*0&D
M.F[!!IV2$"<%J0I@P`8=.%+'K40L$JL1!1!@,Z<X&N``!,8R;<04.V(OR"&1
MPE'(&KODTD0N6\SP(1@-^^O-$]U4$$\Y#;L21QT?,@`!CJ*3CDH:Q3M10Z<*
M<E'".B,M2\8$WBO/N(0@_+*A`Q/@[P%"D83(3SDMA1*G`6ACH$;;V-L0SDAK
MFG%(`Q%DCTH2083SSS;E;+'(!K#$"M(4`UB1_M."8!5*`0!@K0BE##G*<MD.
M5=1VS4RMQ%+747?L<<#T./2PQG`3%!9$3O-[%]YXY=7/)E(90@@B>PV;S":?
MRJI)1X9,8F^`_PXBJ$:I6BI(J`,Z`M(E`:+[$<R6,&)O*M/2^@W'E@RP%V"+
MHW/-W3>S`B`DBFHZ\X$"HIO-8`$<('FB`&X+6>!%<4H/I[\8%KG4^+::K=0'
M#KJRXI^T6E-2?!.ZC>C;#M92VJ)=1DKG'VF36H`&",@8*Q,]UM>O-<_J"><'
M.IR/YIKX,EI0EW[.&>.BGY6NX8?!KFECK`*&F].#6G*X-J9YBN_LN.J^[6Z<
M"+^Q4QVI7+S3C1NX_NWC,-->.W&5J[[M:IUN4V`GFBE_]K&B<=I*8H9@_FSM
MGJBJB*S?J/Y[8-/=.OQDB':"N*76__V\Y8E+GA?YY)4WJUZG#H0(MOL<8(#&
M+-?<G?#7&-6^\(4[XMZ][RL"7VF3L\H0@/\X"D#BO^4VG'#%S3IO9_1[1RIZ
M]'SB&?OO;=J)52V14O]DMQGRM01"!WA>F`:U`(=-+'_=*\C]XJ.X`YJO7^MK
M'WWX5$&*[,X^GRG(5Q[0@`IZSR79ZUVSF+:5WGUP:?\I($[2HD#F@%!_,_S,
M"SD5+0.-;$G2<LT*&9`2`9#I-F7!H?SB,L&3/4"#!!`*XE8H*TG%<%KR_K,6
M0BIB12\N+85F\Y?A=D:_B>R$?(13X@N9N#PWOA&.;CRA"7>RQC#BSR4-0%BB
MJL9`%^8O>^,#9$<$TB,(,6!W"]@(0NQ%P#:BQXPY01^Y$L`2\NE1?D*#7T<4
MT".)0`4G"G.D)O'8$CUR!%$)\!D9N^>2`Y62(7K<BF4&-"!+TF6'^=-C(6UI
MIH8L,FY]Z2`NT>>2Z=%'A&0\82O#]P!>>E(Z*'SF(6>I3$[!JD.JO!XK):G#
MBCQS0/8BV>1:1B7J./,[Y%H((E-S%CN^9"$>G&0M*\D0TA6`D?(#YZB6V#V2
MR>HS!S+`J)*)0@ENLH#]1$T985F^-5+REG&4_NA$*6J?%I'0A(T9'NY>1IOP
MU:Y4H/+CPY(6&^.QR247(QI#&""`O@F,=H_T&]!D>D:SF"EN"B38X-*72;4`
M@*.@(1]')#(WM2V*E"M5FFNBMTJAO@VE2G482!OWDZG(<Z<?A1E+7;JVVRR3
M)\.4)-\$<\'#5<1MWFMDW`:VU1*Z-)K=4VI+^Y96AMR(A1[;IF$01TR"_:<!
M<.5)B_I8$(VXSJ-OO0A=U+@FL@:M,?*LJ@(/5M;Q^<2M@7WI%9_RI8SE,I8%
M9>;M:$I*_40R/<"[5W3*,MFK'J^BL97M\FH2I)$$8"&625"CG!2M$SFLCH[5
MGENHELT/*>Y<-.H(_JQ&U"(&5DN;>G()H'PUPYWQ*)R*HRY'6'(D3?$L(3JJ
M('6=Y)0'0N@AV\E(E005WLWX]KL[^1*$GJ>`?AZ*O=V%$W##M%V#,/$S\.7O
MEA#@7.AR9"&J[9D8NSF`7CGX*ZW;D:%TPD>=O8^W<F(NA)P;U\ULN,!@PM1K
M-)62P%68(T"EBK@.1P#Q^A7$'>:)P\Y90H@$C,`&7M"E=N7@#$$8P!7Q;P)`
M?*!XNGA.(69@7(TRQ8K,%S(%0&0+J>RZ#$\1R;J='T.3>UPM`TJ;$57P;,E<
MYG@Q0"\",`",`GL=N!B-*.IMB9&)Z]C12+&`DY$*G_2<'`8"!ZIY[$QP_FJ*
M0=\IK@'O$4`"_J.`./-4?"\9--GL>>>_6<8J;W,8&!_@Z(S`IB1=H5`!%%K@
MC.#9GH\.4V*,R.@@I_K3DD'.;1HP:+X@1)@,EEVM4Z*0_URH+YLNE6(N=``9
MON\R*Y%U1OSLX7_->M7OZ1!8WR*541N'B^:]"5:;(Y5CHX5G]^II9OR<Z.RP
MIJ5N%LM7_9KH5M]L-,I6FIV9G41N,E.DB@OUHA%<9X.&!]+8IG:X;=J<]0B<
M=HIV]6=P;6:'/QSB$9?XQ.FC4(I//+`7U_C&.=YQ_'S;X^]J:<A)7G*3G[RB
M%D<Y1>6]<I>_'.8QEVC+95YSF]]<XBK'^;Q`_KYSG_\<Z!WO>=")7G2C'QWI
M25?ZTIG>=*<_'>I1E_K4J5YUJU\=ZUG7^M:YWG6O?QWL81?[V,E>=J?D!2_T
MS*[1%N.^>R76A#4^XQ(_0SW\I-@FP:$V,^/5.YK'2Z$FY*'R%$!IB5[HV#JO
MCV7RN*+Z['VPI5F+9AI"KH`!W"602WGB!`CY^WC^/@6Y<*?N+3V]^-HET;)/
ML@LS>=TX`"52^4HGU7X?!;`,)YZF?.[;+AFBZ,;L,7<`E--SHY/1*E6DXDBC
M;RR96'$SRZ47DT%JB9!X'D\!HW^7IVIYW'E9O$</@6;R0`_'0QLT>4J2(8(?
M#UN6.HPN((:2TYCC_F-3ZVD!#:?H!$E(>O>W7WDFZ-B$;5[L3_TD0__DXT80
MQ<$8A_N@A+J@Y(6&[JR<`KXX`FR<+_DZ)4VT+_A0;H1N`RAX(@%PJV621@`R
M$&X"!CL29R26S,/J@T]82GO*;UX(CHZ01_%F<'EL4(Y2XM*D#S]@)6-@)8+X
MROW:XRFHP][TZ+_`32@<0&&60PB3Q[``R<3([_\6CS2J@SGBQ8="BR6HL#X&
MQL98`BJ:T&VDIH]:HH@"33ZH+7>4IO].,'BF(@VIH@X_\.0(@`"N1`'V\+'4
MS&-*"K+NY0`>XC\(0*,,`B$4`C#ZQ3W>K&P82MT80X(6[1%AY#*\;<O0_J,Q
M,*\NUJTN-((']X1I0D/O2LQM@,)5G"]:$(/8,!&E.N4\`FDX^.H`@$QS<B,D
M@`=6;I&;'$8B6N1F?N\KDB(`:L(G',;MC&,!F/$.30FH5B;Q#`=BE$.1JG#8
M%F,[-!$SI",FJH,CU`(9(Y&<.@TC%NT2&R-:_D:II*,`$NM(UF0P,/$53</M
M=N<S&B`:3U$__"H%W1"HH@5&8"70!D`%?0\B%((,=R9Z0J;A")$AL",VP`96
MGI'7BJTR%FU9UNPCCI`/W4@@4@(B`FT@9PB'7A%U$">W+B1#)!`!U(5-!L1-
M%LPEC%!QJH6/K(<J*(56$"52#H=^$DU.O$7#_K@/5`AL-&1P34S(2RKF0H)(
M24BMCX#"5"@,411%#W^2;E`E3@PO+IBK>U:%M5#&*X_J[+[D9[8$*)"J*K,(
M)>`PAZP+A@YD2>"&A!)0\?"+*R<E)CW0603%($/$4]YR(H!%51(B)@.J5Z[%
MF3+&A(Z'8="R9:9M":T%J)QE$N<C#-'//L+PA&"H+B>QYT#L2[(R*N@'KVJQ
M@ERH-,#JP%3L??BM*Q#@0)YQ))6'-!P`[4AHA+J)[YH)<K"I(2IF;N)'M%;&
M:K2/NZJO:F#'KZHI;[JRTR(I,4]&1S:'M9*&<!3L8CAH302GF9#"9FJ&UKCG
ML-KF">%F`2;S,M/'_H0L*6O<+YE88FCVID;@<Q[ELSUIZ/S<2C3/$W]00BRY
MK2=0*2;!A+E\DP"'\ZD0Z/FJ,YHD['6$;&LZ34XZ!T.=KR)B1W&FBBHH<"NT
M(V@@9$U`E"*8BB$.RS`*0@453S)D4G_XD2Y,IR-YRKKT2D?2K3Q>,]*$,Z5B
M:IE"<*%V=#=Y,VG@LT4S$$AYPH>N1@JE)4-&B\'6Z'X6+"OTKB(0*5&RK9I0
MJ`&,2,WV$&O()3T<R;YLZ'L&R2G=$`'8M.".U`Z94W&",[2$+#H"H`0["2T1
M-""M;,H,[4?VM$]OQ$R?8MS(9X?H)R,R(E&%=#3-I/54S/A.3>YT#D]M_JR8
M('0S;".+0*N;L(I1NW2+ZNZ_OD8^MD(Q]+(L".)+`PI,[)0GCH/@/#78<.37
M8K-39TA$^V)-%ZBF&B`L<&29GG12:_54R\,M`'4D2:=8&5&Z[$/""N@=(X9^
M+!(G)I.<#B018<3?[G2;("JL[HTBBHA,"*J+.&W5$N4A/)#@H(*`%%2;&BI^
MYH-/L&E`Q&J&GL4`"D9V0"B98`7V%,BCG+4"C6-%"&>:?&DP"W8>Y6,&2Q7`
M7(KS;FH::?#VCBT^&*"38"^Q8)"S:K3*HNF?>DI498=4\^=<%U9=74<A@BF:
MGD55MP)=RT0:_15@>8)"".U]ZL,!%,35[@4C_H$*436V)10FUU*)7T%C5#(2
M)R@2BL`D)2,')V[V97_6FY(TU%Y(5^\N``I$4$X1GS*V5:RO<%@E7$7+M<HU
M(,$#/L.T>RJK?(CR9[D3EOX"/+F13]RB:4]((=/1,-_F9Z!2Q'QL:^.0+FXD
M);(*VR2"N0XW':=/@.AQ0Z?S/Q.VG+RGB/13<F"#14&S+^R**C9KB<H"GU)2
M:R2T7;I)J9@1;N,C6L9Q55/T(7S2+9@T<-UE3!=2=(7)!%VIQIS%KFX$1DCW
M<)I*UW#B1O[C5^<,!?%P>-N0F;)(:U]M)"G$:_-N6N4#76,RL?)1`\-2VVI,
M\.AB;==57,",N]SV_J86\%-P9%#]#37AU8R"D[SD!,KJ*[F:TJ10T9Y0K/D`
M50!S`LG\,G$P8B>,XDRXK5I+LV5N(L:21H$/`_?<=TX0$WL=K'N%5/[^$$91
MQ*/@+P$X^'K_-T8$^"Q_5W/R17;<DD9?^`$I`GZC#$92`C8>V*`,JWMF-T,0
M0LK@9MP<A_IZ1+IV1X>#!KM"XH.M+##_PUF&;G\'&,FNEEGXJQ;KQ$T^^-M\
MV(:!IUG]"GC&S.N**"L$P@]/9@`BE6?/L4E)L/>$RHP0`CA+MNZRC=4N9&@K
M$6.E+;KD5G.(HMD8ROE88B.#(]0TXMKZK(,,D8^KK0"N#5!=(P.%+3&\_E&&
M"B)@V$=2]\>1VZC-R"V3:9.3)=9P7"\9_8H#D1`MW+@3@4_:2(4?/_F2B\W>
M6-@M\BT^4#EQUP)#/L./V8\.)^*37Y5_UB28A8B2^\(W;,)]9KE6>P?'W!CV
MEJ4`2.A>G2*1/T9A'C0G52TVF$8!XK@4@2^%9()TI*7APKB;)I(;K:Y83P@F
MLD(DDU2B*!`T/'!YJJJB',*>9>WH_!"@WXB?Y\6?A<_E1B[L+C5S2P7O+/.?
M-XXD)(IZ7`6?W6BB(YHD+CKF[(LV8^."YX4@Q#?]0CJB+88NM^YY+O8E3-('
M3UJV9H:B+Z2#[QFFV=CFO-68")JFW8BC[?FG_JTN*U(:BFQ"GV$:J9-:J9>:
MJ4/+)FI:B(&MJ:>:JJO:JL/N(4?W-*Z:J[O:J[\:Z;):J(X"K,O:K,\:K4,.
M5FPB4IU([E[TG2N.E>Q.9"G.!PNOY!2O+%X:/_`ZYNCZX3:VKL&P@;>PS/BZ
MFV3TX@2;/@1;L>4E:,T*`#M-*!Z[E1`;ZK)"-\.G(;EP>7"H+++/XWP0L\E,
MKY?WC4I[XBQ;CGQ"M'L0LX@:XDH[P(YZM`W;M"H*K\32,*HXMT,/M;MNI?5Y
M2KM0KC^;E5C[L'';L!_NM)&4-YM[XY0[N@]/NLV,MJ_[XDA[C&2+NA.6M?=:
MNY^.H>GRH7&ZE?@%_M7*.21@(COD;+KZ1;P?8B8BI#CTS)S;&"*X=#@\C1W+
MP[UC3:P=VHB^\3(4XEH1:UL[@Q8I8CA<#R!#P]?$>W6JHCC,C2/O*CN2@PQU
MPA<Y`RY&XL#U))8CL;[A`K]3.3#:HQ,'&33<6+TK&QP=\C1F:<9A!*L"W$0[
MW!PIP\'7BZ7TXN]&D;^!'-;^&R=T/'K\NS6?K2&=++%)8F!^G)PH(O8.(-0(
MK<3C(C#(T&OJ#=R.`M/",<4G@A7+W.#P3`ECI&*"L9D\1\P=,1Q;N2''@L+#
MCOY*8Y[_QSZ*"UV()%)X$C)!2%WVNL*49-$B9%9K)8"N5BFE4C$=I#'+_D/0
M@<I8"@4G*MUZ@#(R\S33'U/%P-)-F/(+:3`JPZ1(U\M1V$.%L4(H!:)V3N4!
M%P4IBPHFAQ)(;')##YU]4&31DP6I(EU=:N+5CYK`*D4E_OPGGQA&<??68W@G
M03T0C\4P'T2#17U87"1/<O+1$W,#1632/UTSMW.&UQ4KC.MR$SM;QB?2^R1.
M%D2D<IU\L=U&,/U.AE(PFGW9;871X5(JO(O?T3T:185L@G-2OA(!8GW3`]/1
M3_W.P6ZM;0*-FQGQ^IRD(J:CBN9@5-3<*_RR,\9AON([]9-LR+-N.=1QI7%(
MA1.L.+YTFTE$K<AB_`KE]Y9YO9/34KTP3()T_F_$<NSI/!`G0WT(;Y.S(ZSQ
M*28&Y"USY)T/1.HS3/"4='I[9P]&P81'4)2SNXU^:UW>IW9J=#84ZCNF(OG#
MY)43ZE]WF5S>K:1Q:$JJ=;`J=;YJ[+.F=`B'.4%G8J`^D\YCZNNG<*I3537&
M/*%F*AS0(>!^A0V#/S'"-_^KKP*_/!<&YU%]O*&N!+=WOWD;A=*H39T"0EJP
MX[7VSOUM\$8W3H5U92&X-F)U?ZYI64?J#.OF:F-_]764>5/_)AZ>[^`/HB?3
MC+]$-Q"'97O5H:K,B4XCMUUHA5[M5<DTOT$Q>>\H?0_*H+@M]K^>8K$JBMQN
M>G1_>5-6IFR_^`W(_DWE?HA)596KB8)4.3ZBR%Z6WW].9GR"?H4\?[`%R%`#
MP$]3YO4!XL$#!``$#BQH4*`"!`<*`"A(4"``!`DK6KR(,:/&C1P[>L3(8,##
MD20+./AX\`&``PD/%%R9L$$#AP80+)B8LF+$G#ASI@Q`(`&"!$(9@`0P8*@!
MA#U54H1IL*E`F@EN4G1:D4&``0>JXMR9DP`!!@`69-W:U2I6B4]9&G19<6G-
M!$MY7C4(]H'+O%@=(#!````!MA+=LLT+%VQ$@D(;)UBKN"!0QPB,-OV*\(%?
MP((S0A4H\[->B)EW]EQ<FNE=G%35KL4I&O;JJPL,&!!0-B'9I'151VV;_E#J
M@]:P#6.-*!KN98IYEZ^%3+KQT,?.G],M@-ML\*N1'TR>7GGM]\8WC2?.C)$@
M60<%&@X@#!TO^@=RE9*&CS*__OW\\]/%_1!7#)R$4D0$")"0`(,1\)Y`+CD`
M%83,S9>3:=RE]@"#!C$@@'86@577<SAI*)!K4;G50$_"[>1`BA/*IQ``!@3P
M(4(MRO9;A@@:)%)%G]5EH4ZY"30``3<])A!!"R0@0`,.^J92@P\D4-9-"O`X
M6'=D>=A0?$D61.(#')KEW$Y,.CE:1F$^>&""66(87W<JN:465"["-Z*45)(Y
MVP-):?:<3R$Z%Z:)A8&6IT%J&;BC0`K.62)F_MOE6%U$6[Y5@(A7X<0D@7=.
MZI.!4HZY%H.>=MBF08_R95&*;2(P0`";SOHEC,$9!B24_>W*:Z^^[A?13;R)
M9)8"`!20@$L&/""``$+A5@`#K#*V0)"A%D164+#N^&A"5-:T%`!7.G>3M@$(
MU^RSQUI&P)4&?:MNM')Z)UJ,!L1+5I_"#A78?.DBX)"XULHG:P*!F148N)UE
M^^Q@*K6KDF!";240`;(B</"U%5^\%'47PLCPMOAA5I6K#3OJL$'&(JOL`_LF
M0*S&#U^)FJT6(X``;A3]"RV[XU)4;K)`C4Q1`04O9=2[,O[UT,\Y!HW`N7<Y
MZFS.ZT(M=4HOQWRS_M4OYDA8I0AUW;&F$K4;LD-)1P6QEA*+O%;(`R"X=6Y@
M=5N12,O>!,"`K[4-IZI5![R0KK\>CGCBO.ZT0+]&OBM2`&Z%!("S2+/:@,[6
MRMDX``&8)%&C;P7P^0*?F^VR2`(0-+68JO=FE$OS'7#N`+#/ZQ*:%=&.%.S5
M=?YYB!M&;H#I!0S\)9.]"^3``;@)<`"!"T0.^F@O&6!T``:@Z<",2&DG9_/G
M.GO2:7`"7[US'.(TO>?IBZY0Y(9U+ACX<,J>DIP-!.;LZJE7#COKK:5]VD.3
M<[I7.R2UA'0%,![JVK<ZX5#.<GW[7P2_1K_'B8E_3/H:T5#'(MZ1#W7X_J/?
M`!1`H+<\1&;H(U!36E@BQ]DO*O#[DKL"T*B>X&]>`J&<]HR'/,4)<8A$5%P*
MBZBHE"$14(D3RQ*96"`*[:HI1WQBXAIGQ5Y5,8N_VF*-N`C&,,;0BEX4HQG/
MB$;$"6!M:=1/X=S5QB\>3CAQY,\:ZXA',S:.1GGLXW[NZ,=`"G*0B2LC(0WB
M$./TD553;-TA->(`0SYRDA^Q6`(D2<D\8C*3G.RD)S\)RE"*<I2D+*4I3XG*
M5*IRE:QLI2M?"<M8RG*6M*RE+6^)RUSJ<I>\[*4O?PG,8.I2`7YC)$@46!%B
MEL^12Z3C1XS9*VC^RIG./.1.%'"N3:8QB'YD_@`R0TG':N;1FRAQ0&`4^0!E
M!DJ8OC3?,Z7X&F8B49P<48`2$2=-7U%3GH2TIT"`@@!MHI&;BX1G)^D8E$?F
MLR)4LHE%5,1/=N+2G1XQ)D3#2,\S+I17^Q1E1NM(T#QN])$?%>1(:W61BTK4
MC*S#S0`\1,#MZ:B',GJ2@VH'OC46B0%&6UY"^+9"QN!F+"42B6`&U"^I`/5Z
M@9%5$CTG4R'!*&?*(ZIFO&<['>)4(D);$FX^=Q(6>8\`0.K?46,(5>[-*'CS
M2159,C65]S0`JS-$*4X0V+MP<J:`S*-K#WMJ.X$H#ZQHY>M,$BC8KU8O(4HB
MR4/W&E6];%4E71UL_O5B:D",>>XJW?NJ6RPT`"E924A6>VF2=#H8WIEV@^Z3
M7E-E2M6A&B6I$76.C%[+/>=5[K-FM6I%VO<]MC25LUAMZ$.9TULVGC8DJ9TL
M3Q&K$LBB"7A1Q6R&1N)(Z]+VIXZ][6:?RM>5*HX@!<M8T&CW)B<19$=%TM%0
M'&*6J&UE6S@+#!L;0*4"T*QR.!M:R)KE,H=4)2$.R.^XCI4`^+H,P5&[I\;6
MVU^'6:PKO*/(@=Z;F\I][EL1#LO%^G60U35XP<@:L9\^O$+&`D"]#R&04R=L
M,+O!:422$UHXWS:T#-4X8W.K;]]N4I,1WZ3$0^NQ9AD`Y`X+J<#'@F-4_G`L
MX=4E.,,"V/#2A"PQ]$H$P0HV&LZ6LM_#5%"R-2JOW4B7E`L#+#=SF]A@ANSF
M$'=X`0+V4$K[]!!S27AI2WF3B'.LF[<!.&+(4C",*WQ<.9N8L6C&F(@5;&3[
M1DS/)(XSUMY<Y]]F>6AT!L"`#<)D_1)ZRF:!\Z+%>S@E82E#`R"0L19PIP*(
MY$9>\=MPWD01",&5/G:&CZK3E#,5HC31#\L1`3)UDDNI>*I#@LMH!3N1F]BZ
M`(/Q7%A7K)!E!4M</"*-=N!R;$55B=M$FD^L1?(8TSG@V7YZDZVB3>XIA?,]
M)WDUN]M[+(,4CR!H4L"RPIWLLN1;(/O&=CJ7_B75=4J$WND<][2K'8!K]_O?
MK8X1F5*&DS\1QD(0<HOV:N2A]K)NP6NC=G3K_6]DBZDLOX:+3SR#9X;;V]-*
MJU:S*<0D81>;+>PVKH\F]&T*C5S:B*SVKHL7)4"].MR1:AS#S_1R@VBHWC+&
MB(HP;F&5*QO5OT+,2XPSHL$$(`$!4`"5&D`0D@05``1:"@XA1FPY+:0A*;8H
MK<*F]A5AJ#L$.>)$TJ[VZ/9P?`*`[7WT??B4Y/WOZ'%Y0IPX=HK]Y>7G>3?.
MV`ZJ6VW'Z_3QG(*NI)7*%=Y)BV?:VT%/^,A:/J5@OWS>!2^FU).^]2#\B\[L
M,ARZC7G9PN[[05[O_G8%D2GOE[?50FW;>GX;Q$4\W!!#`D8TWX-M4LT_R+6!
M[WFXQP;P)"$(.J-^J!S9_8.EYWJJ&_]UZO>-[>V1]4&D0Y27U^8V0P)5=^K3
MFV'__(/C&4JO^;YW\\%X\.<QH/87@>%N>9$K,#(>1<%Y0K(>#K$_\85^,L-X
M^^<CR5>!+F,;V:$9!]@9_3=@\^>!FX&`<D1-&DB`SV&"G;%]9D,<7X,36V(`
M%9=P-K43C#$4TY%MV%$6(FASQF=0TU<<FR>`Q:=_-,4;@S(;?!%.'C0M"*&#
MCE$B'9AAK=>`E2$:,@%^D")^\*126`&$[!1Z#U%#S#(2`Z`[&O%K[<9J_C7W
M`*Z"(+#B5#?!)9D"%G^R3'&'(3\BA6!X=UAA*J#1(3<8&!IS)$JCA7>X%E`'
M;`7!;KBA,6$R)O=&(7)X$(`1*7`D<IEQB$Z1B-#F2$A1<_<V&'KH%(X(;C:8
M.=,S&ZHH=(83%7I2%EO7)3T!BV\(;7Q"*2@B*6LQ`%YV$6W8B31UAXXH(8,8
MAQTB)\=')[!!BPL0B@<1A$DH*+H";PKD<^IG*[QGBYF"BM!8<\HX)FN">8P4
M)GO2A?%D;*Q8B.S$?:W#?<J5$>3%+[EQ7H"F-PLV9C?3&X\!%EX60#X".##R
M+X3S?KTV,V8C-S4$9]`G)^=D8Q;&,337$__E_FXGYF.)9REO,S<;<X]2M(]\
M`T==8UY<EF(CLA(3^5`XUB`FF1L"B308N7+:\I$RV3<TF7#4Y)*:X8]E<Y&"
M]F:;YC#.P3/KLCDM-HR;%6,4*'45F0!I\V,>.8=P0BW,XF`ZAC.WEV<3\Y)\
MUAG59RP*PVV$LI*(MG_5!Q9D0W,X:1D]"34?N3+)4E,)J6E!H67K*!A.0Q@-
M*5Y)%0"Z0Q;8]4[*$UA%E5;R<4.-(CX`=&V@5EP7L4,8XD/%<SKKXTCX\SM-
MM5B,)A@U@U*-F10XT0`B=$G/04"@PR+94P`+B%(P%(=C)3PJMI@$YE=)<BX$
M$"2B.7(^@CVD$U5X_K5:<P5=J>E:K16;Q4D]6T10,I(]P6F:>XB8A/4_X:4^
MKW,Y4*)KZ>%I+H4D8-&8(V1"2`)#^L.59[@_`.0_S@F<N?4\T2,SN\-`#G1`
MJM6;W&B-X!F=5P5=[!E>L`DSGF,8F&D1UK6.FMDG+L.9`H5+#7`N#[%K224E
M'7%2>,2@J%0MCS>AI41%G]2A8H1)=LB=<81%'O&AMG2BYC=)W'<E5#(2],B&
M0ZBB5O16"E`;GG:A)!51DU129X1?H56/,FI%@-01/>I*1CJC>9143?*@2+J.
M29I%`>I3J.2D?E2E7$061"I':72A5YI*7@JE/MJD32H`.1JF9XJF::JF_FN:
M1=PW$@K)IG$JIW-*IW6*$DGU$-]GIWO*IWWJIS.Z5)CWIX-*J(5JJ+B$IUZ*
M38**@CNJ$6"Z*^2D$+:F4?-1H6`$J5V'$)*:3^ITJ0J132.J<!\!J4XJJ;RB
M3IG:2`JA'4B*(XECH];81Z?JI3/X35#JI@\!HQP!4&444AV14&$$%JH:3?/A
M3X)$K*CJ,#DHHQ25'Y.QAKP'IL'*'W#W3OIT%=0:1MH7B$5J8;?:*SUQK(,T
MK(Z*$0GUJ;_D`$U*$AMJHA'UJ^2:&<FZ*^EZ1O3J*\RZ$<Z*$O04KWYDKQB(
M1V'HK42$KTA4KHLCI"L5,`+:?2BQ5/P97+C7_CSO.5,KMVON]Q7)A9C.(AP3
M$1@O%343"URF15N.I:")F3/,]5Q3VE>>=5I5E30(Q%92%5MG]5M&-18G(9S:
M09P3^[.KM;)%$K3&A5?0(US?-9W5A5N/MR-OA4BC>5T/<7DRRUTC\7ZR55BJ
M%[$]:U>YIEM(ZU8#-QSOL;%6*[%D=80#P;%L"T!3"QM=]3O$TP`1VQ,&"K)*
MV[*':1%CF[%F:Q/=M5>.))S&-8.`A21>2UFT(XVX%;&,(T,QJ[7_<U1^H5--
M(W4;6K*M.AO;Y5U.I1EA:QB>QKAY2[5`NHGB92PC\1A&Y3G1JA'XU60ZUA49
M$R0)PS2ZB6UIYV)/_C$A?S:4YO*Q2U-E58-#<2AH=%-G!E9I(R9?21%INS<<
M%;E?P$LD*&:II&&]@:8M@P:3"&-FX%N[9S9?AY8U7L8T!U9H^`AES0MH!\%B
M@GHQD%AG$'9JLBMJ]LMI#/:^^'LE,&:[OH&[?:9\O/M/OJMH.0:3:ZN_0]D5
M\-5I`Z9AT4(N4.:_6)&/18F29A&],%K`2ND=ONL7LPNAI%81YHLC':R5FD4F
M588L_$L`%[QMPR)CUOM?<]AHIX.\4W/#1!/!P[>^"`.61>G"^?+#ZG%3XK6N
M(^$P2Y65CPHT\5:,H$AST&9<LD9SZG8<-_>&5-<Z`Y<[-I5S-N43/0%P_BMG
M<[E&MDC'(WW2<I`HQ=E+C62,%XWB;%(<N%=R$DEAB@<1Q7!D7!J'%9U!&%,W
M)4W"=`OF(?E2MED<<?HZQVF"@6^<(;LFHI/2QQ8RC51RQ>CF,A&WQ4&W8)S(
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M07(KM;I42V!C"KLP1WD=C82_H1[LMV(:1-+(X<X?^S&ULAOV,6P]`81Y08+U
M-QQ+LR@!R-$V&S@$MS3YEQ<.("WH(=B<!\F_H15<X14(+-,QX:#:0A3A(1\1
M>-9.62%][6L8DH7*1=+D[!1.>'F4/8$;I]>(EY9P@G:<D9&HX]".S8XO^#M6
M"*<'(=IHO=,)FH2O_EK7U>C4X@'9_A<?1:TQ^.>:%3,6=KUR2XB-'K0<H!W5
MF4&#-BA,2QP@%N&B>2;.H[QJFES%U(B)!*&)I`TC87*?F0W0?AW7V>J.O!V.
M4Q,A:0W'I,S7`>V%G:?(S+,2E]QQF8P0UHR$-\+8@B@E;&*#I+(A@E&5X0W)
MU>>LHK(A[_@T4IR1V2@?L(;@F3C+W1&)I0PCJ%AY(_.,%C;@F'=1Z9AA?=+>
M1_$JMU7/@:A4W6VX%-'>^@T39KS>\8',6*DQ?OAR8\E'O&??7IC71!BX"J1J
M98(>P0BZ[-2PR%TQ#UNP*QS`A3S$Y;8WF"O>M6(L>)DU\`PC8\DTW':5_GNY
M8#99E8AT--)[E/(")_X(8LO6?`>)N;&",['B)'1.AT[RO3XAD14&+U9#P7TR
MERT3ES4TDEC.K%7!X`7IUE1);'M^NU7N)S5%DAN-4GC^YI:>$D;3%<[K:;P(
MDE[3<"PCU!##/D3Y06YYL0EQZ/%V=7RY3GV>-:R1YD:!YW8>-XZ^D#,\%#'3
M'7(N,/-Q+N@$YN'ROQ=S>V/>)P-,R$C^:2YJIFS:$XJ[FZ)+(`11FYI^3<]C
M+%_<UCE!.Z5SF;>'/RE+6.`9F;J!G7T3/K(IQ\U7F0[TLSN;G)4KL4*;&;R)
M$ZKE.PFJ`/(#7IUI0__4*#N1.1=HC9-I*[`)_BK4[AL5NUO73F['J^TVPIHG
M#=^A^U4R1:!-P0`<Y#]3`O!/\A*T0;<?5+B.$HO9#A\(.GW,8Y\XDO+U3N\O
MM*`DGQ,95%<I$>^?PQ=A;!'AWD"7"?(*S95]`O'0XT)]0J#(NVN'6D<9VG29
M%.W\4?50/T127S'NFDH<DJ9.=$A;A_5M1!;%PR1G./9I?Q3Z=:.GV4I\FZ1O
M1$C>%%I7K_:($Z"?LZMWS_>"951PSTIVKTN)%/:5L_=]C_B)K_B+S_B-[_B/
M#_F1+_F33_F5;_F7C_F9K_EJKTZ<U*,-74\['T:G>JJ^PJD+VT/@FDH!.T_F
MRCSG]"NTZOI%=/J;_H_U!_M$GQ_@',&O8%1]]6K1%(KZHL3Z162D#37;^B'5
M`W743VS[?8K[S>3ZH+^OWRZLF*VPLBJJKE3\!CO[W0_DT9\?X/_\NM19`@H:
MB*MI6)OTWW?^DB.Y9X6ZVOU3?\^YPZ4RKT-'FQLVA"NZ`/%@`0""`!X@`)!`
M```"#!X()``@@($&#Q,>"+#@X4,$`A($F,@@8H`##QT8"`!`0,F(!!&T!(``
MHD2*!P4P&$#`ILH$&S?"1(!0(4.'`@<0'*`1J,\',0N`/(`30%*3*%66'#!@
MXT`%3`$8&%FS:0*,"TZFI'HPYL*T,R=6[(B3`$(%`+H^)*"5Z8*C;ZNB_M5H
M\V/(D24?8IP:V&N!L!7=U@3JX,#"E1LO9ES0F.G2KR-E'@;,U.++Q`A"/W:<
MF69%H`A'>_[+T(!!T;5MW\:=6_=NWKU]_P8>7/APXL4?/@TZN^L``4$C%GW8
M(`&``ETC&D`P6R=3Y-GMJFUN6B?"HAB9-F"8H*,`B]03%`"@<>!<TS&9,DB_
M?G33SSZO>R?``82J`R^H`'0:J`#U#K1(@``*@`Z\!&:;"`'XNNI.N07@2V"!
M#1/RT#WQ#@)I``0&.N"]^/;B<`&$PF,0/P+4$X"]#SOTRCWX2%*(O0<RM(L\
MT$0C:,81FW(00@)XC$@CA`)`(($F!1*10=,"_C#1M0=-LL^G^1;<;LD4IWQQ
M0IHL_(Z`YE14S++\&$P03(%:_$^[!A^<3L$CMVJQ*1U75#-*^-IL#SL'/3+-
MQBH17'1.$%WS4\%!'UC2.8*,PS1333?EM%-//]7-1,MDHFXC`PCEC\J>'IJ.
M4%'W0RBP`PQR``##)F*JHXUFM6B[5//:JLN-%-J5-ON$?6B@51]H-56U9#6(
M@`*"U4@B!T1#J(%KOQKU@5=3A50MO*9--CZ$9!(0`&T?.!5;VF(]S"!BX^6(
M-J]\Y58RVKZ-J=9;#2!2JVOKJC:`:[G:**=G$]9)V@>NQ<]%^])]8-9K$;K6
MOP$R5J@!A!]26,BF_@`>;2`&,F8LX(<?(-CA<ITT2-EA5[26TFDA7M&G<!D:
MU>254UXL7L=X=9G*S,@U6ERE>2[Y.Y#M!35JJ:>FNFJK<5//@(5DHE```N[R
M2J9L-T*OOV&SVUIII0M0-,*'&$#@`/B,[>]8P_;;*^ZY]T-6+<<>*-O9<%TK
MJ'!22<[57F'M@QMM^P8WMG"7,(XN)0$&."!CG=^U%U*XY;Y4;9\6_PS2!I)+
MFVTJW6[J[E2Y%9W7<"LV2/+)`<C8-?1Z*MHRU^OU27;%ZP[*=J@M<CTFX\4V
M:.SHCB5Y^<2['0TAVXDLO?/:;;=><N:!=Y:_V6>[NGSSST<__=O@PVZ@_L\6
M,$#KG$?_GG[NOCKQ<>W?CL^`C>^;2I3(%SZ[V<\G^#&1F?AF-M&]+GL;T9*1
M$J`>A_0-?`1$``.PE"+WJ0U2!U+/!#,XN].!A6F;NZ!K$"A`SM6&=,#3(.;R
M)Y.(^4]SOK-?EV8GO.`9!(11BI+$($@;`C1D?C@DV^F@QD.\B2\A0)P@D9(G
MGA!24%RS<^!#?AA"0NV,>$*!XK*H![D';)&"!PHCS,!'NO$=3WUOA&,<Y1@<
M6W%))J+:%@-3);-Z$:J.#]/?$!.&''>9BF[=`E:Y&!BN`1Z+@7Q<F`[WE\@'
M,$``U=*CVMA(&P<$CHR4TDLE+QDN/-*ND!YL_IZ]!HC%)DI2;8'S%B%5QBJ:
MO<]IWAK/_!26EXPU8)3[8]E7`E`;2EKL8[C4)/$BMBND62:4K>+EVRXI+DC"
MJTO1!-PT4=C*#,Y/;MA+8;1":<G,A-*7:EP:\8ZYD#FVTYWO?&>-:$0=!B#'
M3*QCB'7P9R>FR+,C]/PDLPARPX?4!3NS^<X+OU0?!D[GH`3IBB-%4R>FY1.5
ME<P/<YJX30PZ=)X0$@K,.B0C]6@T7$])T9Z&V"$R&M0[WPEIV,9H$)?^$T("
MQ9T+WZ07856*-#"#DI161%($F!289?PC4^JBH%F1S*=D&AXBH>0=,;;'2%BB
MDI$TJC2*;J=+1-WJ_N9P]$*?SJ:J@ML?6-FCUGJQ])#[&<!46X(7'\'3KG>]
MJP,60A`!$#1>!4%5;:3BD=DPH`%6&<!9:4>KR5S%KX.]9T#1T\S@@:0`"]C2
M"XVBDG.)!B,/PNRT),H4R5`F<W^]J%L*D#$+)K-;B$EL82UI'U_:1S4/NIB]
M2KL:T<RV>(*LF&5#*\J^:192L+VG`VI%6<L8X"E^"=]9$M-6MBSKMJM-+>W^
MQI0$].5NTDV+%[O5`,1XQ*]?>:Y8KIL[3C9V):SMSWI[F[87DM=R"3CO`\$G
M7P?(E[B_Q2#@GEN``;(3KP=&L!SK4A`]XJ<@B,N-7S]%4`EO9)D)QG"&_G]S
M87":Q#>L#$X1-3SBJYWH)Z$D<8I5S"F8!&"[E"J(P51\NJRLV,8:9D!W_^?"
M3.X&Q+Y1`%UN/.1,J:E#9JTPD96\Y.<]V$N&6S%^;L)D*LM1RJRC'G!^W!OX
M_*[*7[8->'L,9C*3>%:`W<A>55)F-K?9S6^&<YSEG&('I`0I]4+SG/6\9S[W
MV<]_!O3,"I*`!MBY5(%&=*(5O6A&-UI]+4:H1%[L:$I7VM*7QG2C'<R]3'?:
MTY\&=:B7?.;"]574IT9UJE6]:JO567)@8W6L93UK6M<:ST6R=:YUO6M>.[IP
M@>UUL(4];&(3^=?%1G:RE;UL>!Z;V<^&=K2E_LTI9T_;VM?&=K;=1!!@:]O;
MWP9WKJL=;G*7V]RH'O>YU;UN=B\ZW>V&=[SE/6]ZU]O>]\9WOO6];W[WV]__
M%O5`H,9M*B7$3?()W9-MMQT%/"4]FB,-:'.#T$ECZRC4@?5!+OXM@<?W4MV3
MG,`+1Y(;.AC"MGM0/6MV')7X5>1\]7CD1G[:EQ?$5Q\*8+F6)W"?=!<I9B,(
MXGBNT\`T/"4SJC#!!;XLI4NN.<&"FL\Q#D#8U9S!5N>9[;YU&ZS'9.@Z+_A&
MC/YPVS@=`:R5',GYE!*)/X3B.F>[YN!C:I\<Y3,.7A9"DA(Z@N>HVSJ/,82V
M9;S:'`7""S%,PW\^_D3C=;T],1:+3KT'P8M?%NJE/FVPO^XGA*^Y/9T7#=9U
M,IVI7)QD"%43012[$3M[>3.<9KGDR"5P%X,=Y+]&2A$O[KKN:2[W142*!O\H
M\(P#OG#;&?KO=U]PR6WG]J7J>O[L-;?"(2W/FQ_=BDB?E:"7?44"KVO3%PYV
MO,#^U@<SGM>-IY/T,W<OZ9>^PL..4^[#CDA3`?ZAE4\0PY!><JNJK>TX"@A)
M"<,@/L]B&M)#FMF(/\Z[O[\KN")JB6'RD^MQ%PK$*`!PB.=SOO1SO`H<N:2#
M/9A@,)V3P.73O(1S0)%;%?$+/15,LRXAO09PL/+PO-KPO[JJC2?IB<,B_@BX
MD(A582CFFST5W+R^4PL,?``U8[KY$3BX^4%O.:'WXR3KZ8GDFY\GF3\J/#NU
M,+B#@[IZ"0`A3(G/*`B]P#XP3!N<JCCQ^T(7?!@KG#\>!)RW>P@F]+LP?,#H
M0*C5VT/R`[NA6\,9)#J=&SS%T$*!,P"'\,&<(;XGR2UUD4)?\8D%<[N"<(R%
M\!B^.Z+/RXVO<[!JZ43!(HBB>)&"Z\(AU$-/_$,%2`D(RSY4H4,E^CX5U,(4
M'+A:E(C:@T/YN[_^"`H&$+C`:)SU^0HD%(V4P*^-8(R>*,/-&2;:^X[-.T(G
M3#B3.R%D)+B%4)!2M(W-LQ,L5`R>2\,?L;^#_IB+6-3#9QPB"B2(9RQ'!W0)
M",J@0J0]7M1%GPC'T%%&N9L1_CE&2G1`0%1'9IQ"W$!":KP4+`3&>OQ#>;1&
M@X`/@8P(I)D5!Q$6;B0]+$,/#5Q"E6"<J9@_9&1%KDNXCJP(DK0-Q'L:@&&?
MGI,(7RS)@L0I[T.5?C2D:5%(-\JU:NR\SNI%J)/`(M((A'H0!/B;O1(``R"T
MV^A(E8-%J),P![NAI^RXEMO)@CR)0V,7>HK"@00/N$NJ%X0:2Q3'JH"^(AE*
MC4B)XLM#L*-*GWA*/X'$>"2X2".``W!+3[Q*4LE'L5O(2XE+VY@-"/G*DA2X
MH20`46P32]R-A$R__I@)':,L`*2\C;Z+R[[;RFE1QL3!0+W"-:@KP-NP.P2"
M#ZVH"YDXR[<TR9BPE.C!/PGLL8L$'(A"*EB;2X+\O2(RP_GIR,`BR<&DI6A,
MN*UT/5OSR8*K,Q<+2N-#,WV)L541B9%;O5.<#B6422I\0)X[B@/(RFTKG`'X
MFWY<0^.9LO);N=K(2BR4'/%DOF-32=8D1QB$2/CY"KM<$>@LB//,0X%;SM_<
MPK";3YYDO80`3:"+R)`#RP!%R`2]GJ'3SR#TOIQH":_2NI3LQ,V;&P::P"1K
MJNDX`.MA@%FIB-6DR6\T'JJ0'E)4EULD2<C,Q<E;T/@</^P;4!G%177D_KES
M:4X&]0D'(`NV.Z`)$=+"JZ..5"SAK*0%8``EM4K!=`DC5,&@"PK$^(P%NQ;:
M]!/LB!MVS$`_#-"Z(,[(X5(K]=';/"`FI4F><U)OY#97LQZ;W(C^0A.NU-&/
M4YZ_+*B89-.!2E.'P%+:T4$8+43`Q,[+C$CYVSP@18Q#?;QW%`LJ[5+[:$NE
MBDG`JST+4SVL40GE<+`#J+&1',7XE$D'@`_1&L65=`K8J52R\4;=3%4DK!6/
MO#\*S<L,O*'K1,6@6`B!W+7!G$N>6\X>34.1\)59S8R&,`D`I3K9JPU7$Z.T
M\=(DG+]9L;/L1,)3-$?;J:`LO,$%)4M]3,O(_D'$-2O'E\S)->5'9''1%7D2
M^OP\8]T<GG3!8=73KM3)=8U6^Z"^PH$.0GU(?.4-@`U$P10Q+HG5A"U7]IC(
MUR,7T'0XRB)5-UD(Y;*<+C%1,,2-K)Q8IIB-B[L+=!U.;%78F7%4<$4J,2K,
M+43)87M%,20__P,][3R/><35`70,)8V7+'DI">-!Y7H[.B01VPH=T)327!S'
M2YG5$.75.B)8E)5).331`55/EXA$,0)8H57%OE,SFYQ58!3)/1PZF=U"J0V=
MG]U*=>E(IOVGNWE:C4T7@_.8OWM:JNW(N_/3@-58`0TZ1D0H:#$8TH.UCH4Q
MSZ.^U.!$5"'<S=-"_L(%S'>$NE2<UN3\0\PZQQ,50_R*VYF=25Y[/ENRE[WJ
MO)`3/2_,"?ZK)+;+"]1-1@,MT!Z[N,)9%A(,S:];,*BA7$!*)1ULW/F95<RE
MPN8C/UD-S/%;K,(Q@!LB6-K-1D<L"#DE/:_9*[?L1=%]3YL#Q-@=M+!LQ[TM
MW?1+WC/UWJ.=P]QC7;TMR=_UPO_3N64<"=]+U7DE&>M!&O:$LA55N!.<Q_3#
M#3N#,%([0YI]U,(9X'<4P<#27M;=O*.`0%I3@(VSKH0CO=']M=)E&8?[QX<Y
MK+[(8.[*VTM$L5RIO"Z"X(S14/+=6\[K3KF$*&V<GXZMN:<;WB/B-@N^_N#%
MDT\5E+K$@E_%V)M"W1#*L#Q[E&`WA+E5U#B"&.(5=E6G@5'AU;J8:]"DQ=WB
M%3L,]D,:I6%'=+BV"T!-Y<K%W=2"BV"9NU_SNSR;6T;^O0V$RC@5R3D!!D$"
MGF/H*E2+4V*PV;R(&+-[2[(D`SA0<\5`)N1"-F3AT*`^/N1%9F1";M)&AN1(
MEN1)IN1*MN1+QN1,UN1-YN1.]N1/_C([]-%X;%_O[>(A9C[HZ!Z^'.,57+\Y
M?EZ.&`E41F)`C#C+BSY8+M[]C+PTOKY3IN+JPZ?FNPN4NRG*4^)@ACG-V1"V
MH^6Q0SH6/D=2%M=N$^4MU<,HECPH8Y6-0]"9_B.H&.Y"JWNO89F;K5LX6"LJ
M'(:@62:4:X[/6PXLU9!AW'C@.*X-4>ZX;!ZY7NXM>!6-:T9'B:!EP(,.D5.,
M'?[F&*.Y5R:VUJME\=6Y\,L9_Y-=P.L/ZF/E&S1B[&5CU-NKJDK#H0-IU<ME
M_L4Z&5,X!;7H[8W`(D*+6BVBD/836[TS].3FQ%S=0VOI,;:>^H.PWHOHWDJ)
M;H/H;0L,^ZV^^Y/1?E5B-Z%0%!3*G<Y7AM`]UN5`J)[I,79JKBSI+]2B\T79
MKQ;I(NF^V[C.MK6-HRZX3%5J`R9-@&8*MNY*AJ#IE;X;4@N,KK:^V%P^&PZV
M'(QH:F;!C5[$.G3#_E"B8S=LP7M-X2:S01T<Y4O)32V=297\NH^XW)'N6\36
MTQIDS5G1"AC=0`FE1<[U3T7TVVV4P</$0X(,/:N(7\'>-C1,7#YLY<Y-0C+L
MDFR]U%5,;5OD4ZL=VMY4#-'>;8YX1M`65$'[5I*L[&\U1]4\3-$X"H=P,!S<
MS\LK0G(MJ)?=P5CF5+YJXL@.WKJ*7:#B;>/N7FKN-?;I.\XF4+C#1XUH6/\8
MUY2HB.G8JXT&"0SE7.`=QK<)"CDNV)PIQA3&;!V&P32\[Y\85\PE5!=F2]>]
MQ*J.Q0<O/U1MR*+`QIN3Z_6-7_A^88D@6N\V2(%4R6EM5RJ6XQHF7Y$5_BAW
M3%06'VX$+W"6^]O'?L)K.1T&RMN)#8IKJ17)UO'X?L=IO&U:XDG\.#/=(/&D
MQLP<%TV/E#*"LW$:=W'WWK6G1%?YWM@H]<L*KZI$##K[F(TG=V7E&?.7ED!1
MM-5T_,A.;4H#GS^E9,H7<^$XIVZH85;83EG/W$)=94V]`\M35%)=!<6!ZDQH
MK&N&T$MQ-4Q)E&C@K4T-%-DH-9B,=<S';E./U,R5E4FJ_#KC1-/R/O3$^.!+
M=P@\KW-6S_11W"O,<4L/*9>3E<OU6$9IADJ=>Y'^6O)+)Q2]ZJL0AW7[<_5)
M$[A9*0F$.#,F7?6Y#/5Q5<P&EC7KO%0P;\W__B0XDAS0I5K"C+AM__SOCNYV
MV&L`$AQ#.Q^Z=*?.$Y4>[$-&JVMS146Y8:;0O?)+IW,(&RU>"7QJ;U=:`%:)
MHB!/C#5VW0Y+0N>\V3B58&?0&J7/<V_/%]/IEJAJ&7U1FHE-?4]#@IO.Z*P7
M]F!XE73W_<0R@9C6,'O'L\)V"N1.6\E8DIP54<R-ER<;=2]K#11)^`C%C^?X
MBK]>QY6U%4;2R9[OL./1%6E50PV[HK[/<<=3ZPGPQQY2J\!.;7\;(OWM&1W%
M17U5$Y3-4W?ZCFM:7]7F+:U2>%QU17>ZFFCZ/?U,%YF;:2&]+/4\+H=:HQ_C
M-RU#B!?3'+'5DOCT_FXMTY6/X9HP^W_:CKB7]O:DH6@/^QS#^J<IB:.'VDHR
M$SME/$5V=*;@>X/KTSQ-W["G$L,P]M`7(\HOTC!<""GCO,)7^TGM<V7;M*76
M^JJE%9`@.`V',0S_6+LX2V'E?<?6[2(JBDZ:=_KD.>1?5B2D\'`U63OW_8ID
MV>J&6M_VD4:_\#.M?GHZ6#S;5LGI]X1'V=LO"'(AN'=%\>X'WBPO26T=ZJ]K
M61DG]/B$?^?W<6Y#_Z<&5X`@0(#!@P<.%```4'#A`P,``BQ@*'&AP(4)(RYD
MD'!CP@(/%B0L>.!AR`<7%R9X*!$!QXT()A;4V!*`1X$8'\B\^3'DR`$`_@Z8
M!!`Q`("7"UD&*'BR($L!.Q7"C"IU*M6J5J]BS:I5:D\$7AT"<``2*L.Q4\T^
M2'ERK`&"#<!&-(LPH=B2:TNJ%?H4YE*&/@LTB$FW;$G""O\&QCE8J5Z+C0TO
M7$#4@$2TAML^>'N7;%"=G?D^1HLT@0,'+/5:ONP6KH.$1A^P'-`@X0&O"`3\
MW%NU[\*N7P<OQ6VWL>F$"23R9OKP.&RB1ONFUEVY\.>Q"!PT+\K8L_(`S!$X
M?X!8<%C?",!B3SX>-H`!*Q\2++L`NU^]LP$D%MG>-GJT#H1#M91D`%!6EFVG
M(3#?`IZ9A]Y?],E$7T%FR00`02>-QE1XGTT8_E)T6X$8HH@CDG@54:0MY-Q8
M+2TXTV/2"8?1:2TQAQ91'J&UV4(Q/M42`4'-A!-1`1#@4VZ&L4CAD$72QA!O
M+BJT(D>R3<?942[62)U/GB6WW4*MD64D1T!)]]Y,WR4D``'"*=`40TCUR!%W
M'#)THH3A";@18S,9(*&7$Q$PTX]_&D1=F9%IV=A(+;E'J$2!^AC3DD8"96>*
MVKF(``-+LBD146H*1$!$R:44P&T$>@H`B@6I6-A<`<X4@)\3E12=I:P6-2"1
ME%99$&Y.<0@I1X/2"6:<&Q%;HK++,MML07/YZ=``4F[4XDPZ6:;630L4,&0!
MVY;DT'$YHE:8ML<F_O0CE#$9X!.1S"$I)UH,M/L0`?`ZNBZU`AB0'Z)61M;M
M0]_^RU"@KSGJF$Y](6!D`0H4'!6WWF);P*\$^T1F0?<I0&V7=#Z[6$'2TEG`
M<%,BK'!4"1@YP*H@\_9AF0<OI(#)^SGYHD0L)^2RA/2Z>V]:(C?4'I`<O43O
MQ9YYK%>7"O@T0,IJ1=M>:C?OF5``_5)5*W70,D3R6T'CVR%4(Y'9%\_MO?RD
M4$TGZZS<<]-=M]T2S7HW3'F'R+?>?P,>N."#$QZ5WWL77FA\B6NE0%):';Y5
MY(Q37KGEEV.>N>:;<]ZYYW;S.WGFFZ;\N>FGHYZZZJNSWKKKKT\%\>H,_BP.
MN^VWXYZ[[KOSWKOOOP,?O/##$U^\\<<CG[SRRS/?O///0Q^]]--37[WUUV.?
M/?(V$W4O?8+*OBY*#LM>G8O6!MQSZ3(5F'#)#TEHL@!Y[_L:W,\*[#U#:S_L
M&$<!%"`^F]D(OQ*CKY844"J;@5>7FH:IT)RL)5%!X'6RIK4#2&AB`[L)6!(S
MEB'%#P#SBPH"`@7`N$#)*!U$EVONMZ+%S<B">K).P6;$(HE%T"51X1X`]'<T
M$5;PAWJ:T,VD%K%,T8E;ZIO*23J2,XSP4'\VE%.L`IBOQ_!/=@Y,$'4:UA%P
M:<=L1S$AP;0W-[4,P$@%ZIE`A',<\3U`6#HT_M^U1#,3C[QI(Q+J4E\:0!0R
MC:5\\4*6V2*%1C529";/:4^H>N:EL322)C+TD(MD-<%RB5!E55)D$G,X1%HQ
M$E)X9".3CI07CC"G`;@9U%\V=:1`1@4L:S+.%G&5FRVZ<(X/N!FL@O1!#X9D
MBM7"82^1!I-#)F2-H72B$$LB3#R2JR4O6<HS%>BTA)3O),A$E3`O0DI(-<IM
M&)&C:UB8J\*0,XR_%&/1>NA&,\H--T912V#ZTA.07<D[F5FACGIE'>R<!E\`
M8J#.0'::P/@D;A$KCJH.Y:LPTI,]^M0,?CII(3JB9#C<R=9D+HE"X[COB2)E
MY\=`B9&QI.<Q<&++_FKR!(`VP8\]%4UH5&02GY$`RU%YR2FA9+:B1AW-?2N"
M)G5DUBM\PD2>!8FH2U.Z4=<`%*3DXLYF*AA0CP)IA)]1ZM`JRLZ>)N1"+\+0
M<O:9$']!QYEE;<!I/BK)O=SGIIF$9[/*R11-612I#[C5+H763\B8K'VP(8#]
MDME#38YT1S112^T@LQ"'_$AF=H4-7OE:`+^.]9H?S2BP&D@=M6#U@P&H9T$3
MFU>]FE1E:56(R>(6*#P^`*<;>@!N"L!88C(`.VQ%&&\"*\Z(58DH@4F)<(2J
MM9>6R:B.+6G.7N,5L=ZDB04-[)L(JQL^ZH6Z8RR=EXZ;MFLZ%Z]?A9EF_D5J
M6:$AUD:JDI!#<'1<B)EE++G-C%?HVBRP]/``V52IT;YIW0B%UE![(8H@)])>
MF1BPH,GYX)%@DIJY/"54-FDG`!&0&`"#YB9NHJ-M!!```892("])S7WF5-4'
MS@FQS1S.`"3,70X!>"D.:.]>&YK'QQE$.,EBL,:2VC/]IG9C8=4N6'LHX8\Z
MY"4.611C6ARJ$;M&A'7AC'*/6%J)@*7"^5E*C$-L70(3TWTG`?-5I'L:Z+8S
MOP5.#</F*DX,6Q.,B@G+_E1B'2FC13@#`+)]F^6`11%0K$X6SC0YJ=P!ZM`L
MS*TQ:;B*7>Y`RI)A+EC3(O+G_XU+P/[CB`!`_NQ6`J((B='YV&8<$(#1+MIM
M+IKDBTF9KDE2:<'4N5G*(ATY!LBQTXEU4ZD26^FG(,0C'HZF,<V2L=14F:21
MVAN@RQH4)[^ZF85.,;&C+=T49[@S]SS)I3F].#;/1-?D15_7(!@E0\4W),<N
M20-RW=@^DT@L"+B91V9B1*3"&2<+0#,DGSQ@Y&9DWTL=#$[%7-#[E.VH(4N*
M<AV0@`,,:<Y^8H#`D^D5B(?QK[U&:FK`]&Z,LJ2M3,RLG%&+G/]Q+2@&N'AX
MR%PSE11RM`R12<)APH`$@`6V=,I89D!:9`>'A"@@,<!4)T*A*%-9TT?]9H\G
MXG",/ZXE6TLP=URN_F^"D,O)!/CN4``>$X%G^R+_*4I?Y$UOX*J<Y1DG>;XI
M7KO52KS.#`^)3$XS<YPS$]XCPG6R[$[JTIZ((4K]:\&(7#0\\I(C:#ZYB:\\
M7AI_B.]?&K.-'SKM*W46DR+U+&<VGEJSF)HHCA^WE;%M6L2ZJ;6/>NO8!:9S
MD\=Q(`4Y"'6X["+8PMWH(9'62XM^U)&(WK%GT2A5)#_[:V=;(H:'//$9OTM4
M/?:MJ3T)0D2_[XI<B2S@UO!<71Y74U>>MF'\.:/#)DFT`#\D`HD/[0&F=ZW<
MQ[G]+>W'1E,:?FK>GU"5Z7'N4QNOX`90/%KR31K_.53\D4=4><?]G=5I_OV5
M37%<80R(8(D46N2%Z?V6LIF>BJ47)1%(2RD*_*B%("W:>L3&2#7(8N1>K[S*
ME!D75(Q=496$6,R)[TD%`L;=WSU544150]F@ROR3`89=8_#2?$S6"8Y7[IG,
M`!#$C,&<_3FA5Y$?%(J<?P"(>-!$8B#A^XF(6JA)I_Q=D!2$F&P$<Q`>.S5;
M,D453\$)$B$1[-T/"_W(:;18DXSAF1"*L=!1)`W*`=F;OU1@8?!(G/F:)RF=
M#DX>5'13EJQ7',542&4$IV#32/'5AJQ6I*B7>Q431TC'JSB63S7?5-`AI'`=
M:(AA&A((=OS@GZ!BGV#54OB1-J7)+'G=]B6B_J3@X1W2B/-]%1G:H65XHBL1
M2:=PX8APR]*$%!S!AL-$5_X)G\TLT1WV&,>X(2?!(07]R[)%4=EX$4TTX\*4
MU[ZDG!\24,IE6[:D&LE9F1@&&2_^B0:=T,:L4D;DW:+AA`$@HTB!3?2%D[EA
M8KCXH"&>&V=@3<2`(JQL(/YT#T$U'CM"(\YH8#L^Y+V](G\UQC&*4!DEH3KB
MA,#0A`+X23=J9`=RADB6S]64A-)D9$(68TL*CNBX9$QN#DS*9$W:Y$WB9$[J
MY$[R9$_ZY$\"95`*Y5`295$:Y5$B95(JY5(R95,ZY5-"951*Y512955:I5&N
M4"$1$`;)X?1)'QT1_E!A=1[Y2`3[*,?YW(^]O5CV7<MO,0P9-62:!%&L<"41
M44ST>16#2=KS:=4=&H5,R(Z;G*%#G=Q&`-!\Q>%"^(1@!2#^1*-,M>6J_=#4
M`1VLM(]R9>6;D*5F=D2!=2-%"E$`<*4X`F)F!H7.J<UFKM@F21.R"22Z",!H
MN@B3_.4DLH=37$0MK>!55H[H:4R_E1)0)*9JV298#LM7I1/"S$@/UM%LKMCK
MF4ED@N.H-(8LO=/)0=M;D1*O=-4N9L8\8F$`_9'9%-A(#(I:J!"J#&:RD5+$
M=>6-T>-%"=.@=)-0B$\ET<_)G)32U5B#%41R)I(T+43BU6,H\4K3[&5__O;8
M1NS7.%FC,IH3%R7=)LY0N@C$@<ZF>0Y<&#D$9>1F"IT6;U+.3J'=2O$G<4K9
M(\W@5=G11&7F0`D?8<(B6-2<PI'>2<25?O#4.P('?\W=!YK516(34O0@0AV6
M1$!8.PT*;KR1,Z)=\N4$8<Y<6"F'4P0A>(Q?F2#B`S@.]"V7(TDIB>93_ZU0
MAE!48&1(=BP2]_TH2G346<[5GF@56;EH`]HC27[I#L+GAR2I+#U4DTYG(;J?
MB`J.;PGIA$KIYI%$*:8&9.G&>3$'^QSI>$G6BZ@>5=@B<7[4?.U6.R*?&%UJ
M(L&6;(U?;=V61.3HKRA$CJ[GB7((F`1&LHD?_IDLYO,)EN=I*?UAD8"12W@8
ME:'>!*0R6OP(S6Q)U,^E!F@5!+`ZQGA^AK#>*?E%I(VF&\!XG/CA1L]=5`9*
M*Z$23EQIEV4XH7!::*A0%7A1*>%!V-'162S1!(*A'7!.&&\DZ?!Q!I24E_BU
M!Y\%69=AA!-Z1.#!Y^SIF&$XZT3XA*:TA\DL`$)DWF;9*&BL7`E!G[R*RD04
M',?4F"#EZ$9JG77128DM'=G)BLR`:\4237SR3;ZQ*G$P'V>([,FV#])!5[[E
MS,>NY26*H7]!&5F,:X0=&18J[``PK,->$3A*IK<2#J_!7-,8Q:\YWT5LFY-6
M:Z(.*U<EU_F`C*R"_IO6PJ*[@5)V]N$?XA-*9JDC/B+&$DA*U$91C(0R06R,
MFN*4?-HPE>59P0D^[>8;<JL&=JC,,.WC&-7@"IAT,4JL&@I9.87G2>W\D=O<
MZE([.A"%:H?3:N4PO2W;AMS;'FW.)*W2"@[/(=Q3=-B1RNJUC5T5?HV=T1W1
MN!V7$ER<NJ;[T2O,V:MI?6I,X-U76A!EIAT"8-Q+6!WLXMB*R%Q\UNC0\,M+
M:40!^(09.NEX)9\#F(PF6H4\:9?5=6RN-MY-7&N>@I_=(6QNC&[;[9OYT@[1
MM.S$!F^97*OH^IS8R=-%H"_L"6J>ZEY1`*#I:IK#.H0"-._S=BZ>@J[@_E0(
M1UBOD%74Z997]1'>R^**0&D'@5)IUM+NB]`8IM:>.I[$^LU>O7(@H:3>I/XG
MZ]76C;@C:.!&:02`<'B:0[&GN5DM/]JFX>%JIKHCKD8D4@C8`6^$1X"?!`MO
M^"F5L>9MFUGI9ZF$#S,3]9&$7@BLY=DO`4^K\-T'X@YJFH2%J;GP`'=K`>M-
M"H:%+3(P=6)$$4H'BZK5`D9A`_A?Z0*2#%[PO[+H?!3@C>J%"1I-"N,I2P4I
M1@"?PQ4G[$$*L-Q,3K7JH*(>ZRHR0[Q*\>X?EB(,#H_4!.;OGURA1(BQ`I)&
M&TM4)Y>ILTDRLDI@1VTRAZ`Q%.(?2X;H=144_ADK72$O:YJH&+>BQ8+0)!B'
M2"6>$V=LR7LJ*D;$(B8MFV7X8D-M6'=0JG-"B2N6%"4CGS#28H'I5=FI52Z.
M!8J8T!Z-WFD4B#<#(5IJ[<U>:#D-9YTD$T.@(E!MY,[&2GXB9"%-!"\;Q3'#
MBST'Z''FH0<>[K!>RN5EAO7I(BI-DB+O9K55J"\3LSZ#LTS-+$>27[3J,HCL
MX\A8#770S#E_1ILM-!"5*#-*(T-H[.Q&BEJ&\$8&*I?AXTH2(.Y>I,#$XW=.
MJDS@WNAEL]DP)`M9RPUY[D;<FT9;M-<M51&53M=*T&2:(_[.LI54=-$`E4AZ
M!E2O1,NT#<F1)NRV_JM%NP=':QA(%S0A+C/E#J3!5*YS/@4CYG0MR_`43[11
MML;'M77TY+)0SG5<@W'HV'5>Z_5>)P\U\_5?`W9@"_9@$W9A&_9A(W9B*_9B
M,W9C._9C0W9D2_9D4W9E6_9E8W9F:_9F<W9G>_9G@W9HB_9HDW9IF_9IHW9J
MJ_9JLW9KN_9KPW9LR_9LTW9MV_9MXW9NZ_9N\W9O^_9O`W=P"_=P$W=Q&[=D
M*Q%$!LQ=XK3"X-)PH&:^JJB@"!%H&E@#.D9T4R?*P$1]RHA7YV\Y)A@[.G+^
MK`IT$/6_B.57U\]4K`UHIK/TPJ9L"DJM*M8!Y%)+6)%"]M!Y?V[-F/?W_G2T
M`(CELATW4E;3AGKG6"#RVZ10-#4HZ:7E[4F%;WINA$,)='HWVAI3_D;2*/UW
M5Z51?%.3O9G-\2(T/^OS1%!P31^JAY?S+<UFWLX9Q3DG<!)%H]`A(JWFSO0,
MCR,:(0'S@1?EE4I5,H&@6T%OH"I;BFZT.E:J,--H=Q.0Y\YIOE)4C::&F8J<
MPBFK/7(54V&259GS#U?Q0EW5>^B3FNY)HWS(EC/R1$#@;1*F94!@F-OIZ(G?
M/.4YQ#)4IC4RD0^EX9702X1J"6OBJ9$6D[NRL^8N1K7C\RF4K?:%=W67I9)P
MC/)5!@L?<4&B8X07FE5O=9$K2<!7***=HZ:*_G+"W''U["53FJ8U)A92QD$J
M:JC;[Q'BU0,?EJP*.E`.[Z5P(R.''.DIVYD]>:!:K!D[LH#)+*BGJW1C=0'F
MFPZ3+@!^6).YV'4/C(6I3+";35.XX+-M^X,9"LM&.Y&^>6'\[++'5B:-=+E.
M&#H^3I85@+=KN[]AF=;<^Y8YZ;K*^\7^.E&6E*P-9.B)+`$W[E9+>Y`_^H<$
MKL),+;,_*7!%Q[HC4*A9(T-TF]8L.8<LP('LQ;I1[JL_Z8=<V]_RZAO^&H+E
M[:]Y3+9G1K.M^1MR/,U__.SJ],`3I=6][O!6WUZ$G"UK5.H^^F""3-!+!/S:
MF/R2G;0K/:S'74;A_AAP;5RT/IU[4EY@<B*[BB_G-7O53[T"0U?XKKS^GLJ@
M&!7VHJS[6<?^)DO6M[J>S][#:?V_QSG/(^7R2=*A.Z+UAA[1Q[,#0['7Y6B4
MF]_K,;%VZ@7A4[Q%0^=X1?'A27VR3X7Q%4IY$;H'ZD?P12!G</H_#RR=GOU"
M7+&4\A[`V;H"-\`"8%_F/[[-O3Z8,'NCGI^KZGU/&GE``BE%0>P%WB\J#],2
M-J%#"*ZFR5B:]\9^_`:=+04:)[_/53X5@CUY+%Y4X*"_DJXJ!I\5#E'U"^&-
M?8<E-D8FQRC28[7MKOYV@$EM.O_H97^/QJT:!WKN]V0KTL<B?M4@1G1C_@PS
M0"QXP"```(,'$SQXL.!@0P(/&C8TX$!AQ8()*"HLB``B`($/&A3TV#$B@(D5
M42XTF')`R0,I%3($0("FP8<D(\)$8'```8,O.W[<V3"````JCRI4<%!AR94R
M(]Z$Z3-J18,?H<*4B;*E0*@.+1HT4/'KP8=;*W9],+3GSZ9.=?*D"O0JTJIV
MP<+4NY=O7[]_`0<6/)AP8<.'$2=6O)AQ8\>)%13@R1'E@@(%`Q3XB+1B@KI6
M1\9<&;3BT(\,+ALLH"!C69LX)\-<"B"C0@,`!I!6:!HV;LI[T:)$T!+`:N`1
M!1AH\+:DWL@%"21\N]FR:M1'@S^0G-0I=N2__O4F(#X`(^C-V[6.5NB3H^N9
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M;8HO!PPH2(`#*"K)_K7-8!N`@=X\*T`A!@`P*B*!(I+U`50#"$"YWF`%5MCE
M5HJ*@59WY2O44J&-MM!G%9)L``.,LM4FF@B0B=MN41++@)8>VI8FA@+8S21S
MP1677.UF:DG;F;B%53("Y.VH(YI$FI5=6%.B5MJ!"=938(,H:D"`W.[3=Z_1
M&DCV4[5\RNXMA2(^:K2%'=9K8X8UOO2V<@4.N."34<Y38)\".&#6B\,]^%(`
MTFUX)U9I[A@TJ]+U:8#-&D;)9Z!#KBCBFDL.-^6EF8938`<.$,E7Y&`3(&``
M$$!`LI>HQE6`I>8]R.J.LM[ZUU1Q\[>AL2L"-FU][Y-8[+Z2;MKNN[D4_KB!
M615H"60#`.?:I,"O;F@^<0T`RBB?#A\\<>8.4H"!Y1CPN2/`'Z]H\H$LE[CM
MG!$'ZF&\22_=2X$+RLCSF)U-RFN=;3N(69A&\SKUBX/6B#;<BU;H@.)@=];T
MX8FO4N#?D\OWWW]9UWW?>I&ZB7GU"D)^7."9]SW7Z^=]WJ@`U/X68*6++]_\
M)4M&X'M6>YO-\.8?:`G7B.9[8"/(#6H\+0`84)]F]DM2O]VL;W;*8M;[1G<^
M!2Y02'6#DH?^XD`&3I""+9)@F"Y800UN4$20\N`'01A"$>:$@R4TX0E1F$(5
MKI"%+73A"V$80QG.D(8UM.$-<9A#'>Z0ASWT9N$/@1A$(0Z1B$4TXA&1F$0E
M+I&)373B$Z$812E.D8I5M.(5L9A%+6Z1BUWTXA?!&$8QCI&,933C&=&81C6N
JD8UM=.,;X1A'.<Z1CG6TXQWQF$<][I&/??3C'P$92$$.DI"%%%-````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>y33491y3349104.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y33491y3349104.gif
M1TE&.#EA_0+>`_<``````"DI*3DY.4)"0E)24EI:6FMK:WM[>X2$A(R,C)24
ME)R<G*6EI:VMK;6UM<;&QL[.SM;6UN?GY^_O[_?W]___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````_0+>`P`(_@`K"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#A
MPX@3*U[,N+'CQY`C2YY,N;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7K
MU[!CRYY-N[;MV[ASZ][-N[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KU
MZ]BS:]_.O;OW[^##_HL?3[Z\^?/HTZM?S[X]>@(`XLM_4`%^A(+PY<>G7V$"
M`_@$,$!!!0?H)Y\$$1@8($$0'""```?PAU"##T8X4(+R$;#`!!(8&-\!]0%P
M7P44_`=`@`,.]$!\(U:0(`$+.6"```8T0%")``HHD'TA&D@??`X,!)\$`OF7
M8XH8&CA@!`<00$`"+1[$(WP,#-0AC`(U"(``"4B08D(40BAADO)!Z:&9'E)`
MYHE5"L2DDU`>].:3]W7H(8@DFH@B00\4R*67.XJ8Y7XAMLACGD>Z>:)!^<57
MHY`>_J@?A$0*)".--AZ$(YM(GHG?I`=4VNA\1>JI8ZF)!BH?I2Y.VJ5[_A=Y
M"$"0\4%0D*Q!3C`J``9,8("L$D#@J`'Y+2`0`QZV:1"R!K8I+*^_`A"JK`94
M4&M_N_8Z4($`)##0LPKY&:VW)&8[@;4`V(HKN@*<BRZ1%)A;P;-*KGAB?K8B
M=*U\(]IYK(=1+IOLH`8F0&^9!\M'@;T&$!N?L0[$Y^2U?$J,KYT&5JNK@BDR
MJ]^(UV(8)+KYDHPMQQ78:Q"U`JTK<<,";#F@N/&1>^.N!`QHKWXVMWPBS#*C
M:V"N\L:+,KH$`"W`PK(&#"M$M4Y``07N4CQ0U%.[FP"O$:A))=448#UO?`-%
M+,#8LU(=<;H&V>N`VM>J7(&=$TAM+]@F;VU`_M<14%GDED&G3#9"=@Y(=P4(
M<.TU`%7NFZ[45/LLK<_G)K[WXE4^"W;D0/Y;K;YLKSK@!&0_^T#=B6-YT+-O
M3["VK7=#+C@`F\^^^;G@6KIEB",C^SFDO?/:'P6:2UV!WEU+\*NWIJ.^*,DB
M7\VVS[8B3X'RW:*]\N-,STHRY%5/3[J(A<\=G[L#69[\\FC7?JOX+'Z?M4#6
M]\WX\8IC3R[%XT=0//:_>UI$K":]DE&O(&$#0*5<Q("1F8Q@*A)>@8PU$`5,
MKB`3)(@%092[!W;P>_%98`0:J+L$_(H_'RR(R"(P@0=`0&HAO!`)'6=`R0GJ
M?.,3(0E3&"*#14`"_@]P6@'9E3U_95`@)3J508XHD`UJCT&#^U84I0B`"%8+
M/CZ<``0"AL4M:K%%'4R@".-#`28F<4#Q898#Y9?`%\904;23&T&LYD0"'I!$
MYUMA"U]XHS>V*HY3W%Z^Q/C`@1#230T\Y!_1.+T$MC"*AQ/@``&GL$+Z+&8*
M2]#9$F(U>R4@`0XB@)=B9D!A;9(@I(3BV7*'(7?)$7J[0PA\(-``X<U.(=&*
MCP"JI$G0J8N29$17Q&"4QU@:)&'96YM\0L7)T*4K9@_P5RH=,LU!K7)8#=,B
M-GN%3.;5#)2I5*:C`B9.KE'Q0L842,PB4,WWD4IZ'MIB.BNP3AY:S91$_JRD
MHQ"0`+]5()=;4I:B3JE.$3VK8=E\GP'XB<5+ZD=-\QQH0=:)KH7V\WX?I*@D
MH?8SA)[+CB_S:"]OA+Y[#HR>TQ/(BLYV`(2R,Z6"NV;!SEG`D1KR7)J\WOF>
MB)!-R6<!-D7B1YV9-(^B:P*)6]L$@DHBW&W367[2)?K>]TO7;0E<[30>0MJY
M4K0]=&<*8QA",S>I+8U(2YA<6D'0JLL4=9"IZ\QJBN3S*P$L4)<&DB=!4>J_
M0!:RJR%-*%XQ.2*?/HP@<#5HFMZ'R33ZK*C99"K5$GN?P<;O@_';Z$,H]B60
M-O)O"BR;+?\ZN%82"``4;.+D&L4DU&IP<@<U_L`!,@7!`MII@1&KUM9H%"VR
M5A$AGP14B;:40]%6BX9(E%[='A0S#ODQM[=,K@3XB4Y!'<1QY]HMV9A8W(,P
ML0).3*%XH^C6*"Y@<I_L5V;I%R?S6;>#W?WC!+@;0\?"YW=6J]5MJ_O(W\XQ
MI<@"$6>'"%[TMG>X!(UO*U\I2#@.=9"@Q2VO]NO@!X8WBN.;JF87@K7(L?'!
MX*-?_CIW1YY2E'5P@ZE*X].ZUT7WF%.\EO4D`"0*-!9P,"K>U#`HK135LEKJ
MNU[G:!CBHU9`F=D=L?=T3+7QY8MN$7C`EPZXTPDT%FVGF\#68+2P@*'8JFQC
M\'AI%^*W[JY`Y(JD_D#0+)!(OG+&[+-7EK=\0`RU*;]L@W/VF$P]J9GNPW?L
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M@)$5:(U;`ZJG""*!!?S*``I8H)%.Y,`I#6Q(<*S4S$M>70,1J4].BM"`9OFI
M^^#\7ZI#ZZM:I3H&=7SC3%?A\WJN'P1-W<8`.%?+@T[Q-B^`Z]YN.J(XQ2<_
M+;WB`GDYVM%.\E.M*7NC>I2J_LWVYL[-Y;R*^4%V[O:I2\FZ!0Y2P]M$\C6V
M_4LC;RZ9_K3P[9!.X9IJO.0G/Q`!+&#*E,^\YI.[^<Y[_O.@#[WH1T_ZTIO^
M]*A/O5BXY?.0*PI&:UK0'Y7T=MI!JM39&Q2>[,0?RUV(HI>2.T%87W65/EU"
MV[K?BK%T^#4#J^'(Q]`"V3ROXT/*4(**O4#A_BBQ#<U>8@+5.'^,1D$)D-*/
MU%>]9@%ZH`Z"*[;%FEV]9/6EE$O.71;DCZD_9W[OG19$-)-[`\%^,>0Q$4<0
MLN9\QL)N)S(@!*A`ZS)\MJ14%6"`CE5(<3,L\5<QT/(A:-,P&VB!RO<L1#)H
MI_4Y%*A^F@4V8N-^I1-%9M,^949&1;9BU8(Q(P,?YX)U=G=D,F,O2Q5,:C8\
M3F8\7^9B5A)#_8,_EY-HD",VCF80_7<Z,1,D1XA<!]1!,<AJ;78^<A2#5S@]
M>F,V6@=-5N9_*IAI)D5FQ/."_K4BU<)@SY:$M&,VBT(Z>"(L"Z5\/>0W>N1"
M&E9BW^5$!/$K0=)5_HJ$(9VE;BIF$&9S7E@RB).#9[`317!8$')4*QUTB9*(
M)UAG-8_H=VFH69TD*U7T+)_D(&Q3:[4F<B*R-6O35_ER<L*B.DFB.@"U2[Y4
M>3"%3P@H0:Y%60263\'$*/Q24*6T.Y2(-JDH`*(T9:SDA=^DBK;23KZ(-G@"
M*>LUBJ284@F#20@7,P)P'['5,+Z%4`:P?1;$``^20`F@`)N486?8(EN34C/W
M4_O&BP;452P70O$CC"466-IB$!AB,UREC(Q8B:K&:CP3CF:%4OMH3*FF5M75
M,]RX4:7H7^]G7K!%7K5%(C`6,P#8??\"+3%C,QT47*424874B0;Q*WX2_F'\
M-8P#UDPEXY+5=&*EY6L1!"VS]9'G-9*I56!XLFT"6&(7B9'>&$4;Z5^51H/S
MPV0:ED#>HTPC`A]I%3AR-&CN8FA4U9,M9D<5B(\"@6CL0Y/<XV'Y.&QAR3:#
MYB5KXV[^I5'A%FY/F39@9BL;PP`88D!BF92PDI'G!%^[@TQ9!U;RH6'10B08
M@B4YQ8LH%$4OQ2OWUF`#46Y\V(_K!7$-&&KP1'=KR6PGA3$'V$']QH$PYE_9
M)IJJ!HDB1I'(!IBP<BA1]WJU22**!RRU!WFUI#I5J%I#&6"VB6T*\')Z]W=>
M9GT(\2MBUWRNB'T+671KI9QMIHH&X$"N!VUH_CB<86=(/=@G%<(?&%)8\)%:
MM"F;Z)F>ZKF>[-F>[OF>\!F?\CF?]%F?]GF?+W%R*Y:-'"&*"0$?+.%74>&?
M"D&@%&&@*'$]'8&@4\&@%0&@#@&A:@&A$!`S&^&@A@1Y*Z&@6D%O5!,S&OH0
M!X``^B)V_]EJ*"&@!&*1%3&B$@%*&0&CUF*B"K$`V_>B\4:C*1$QR(<1"G"C
M"R&C&.&B`:JC%\$`0XD0+BJA:8&D@=)U%8&ANM.C"T&D&\&C6[&.$<.B4*.C
M4AHB`8JB5V.D`T2FLB2F$P&A7[H1:FJF(S$@/(IY*<&D%K&F'F&G"PHC=+H6
M>,IA;@JG`"!EF^6F_@\!J(*:%>.S4_!H>2V#)?>B(5GWF4<FDF@$(PY`J?4!
M(=TR=*CUD`X`("/#*P4B2A70`)A*$`T`JO4!J5-%-J)Z(J0YJ3UF+7L()P]9
M@2=)E:T&'P/BC.#U(,;2*!-@JK-*$%H6,WL#H0"2F%NR9422JC2WJN=%.@1P
M,"!RJ;.*/<7:(UG7K+!:JJ>Z(T_RD!20`,A:64XB`'WRK;BZJ07&*X$Z1PWC
MKKR2.-#V(`IP6O+D+8N"K80V-]'RKW-W+HN:I+Q*3S!2L#;4K@GP)=2*F]6B
ML#/:J$XRK8@%()7%);!ZK.94KU7$CINJK0(;*+0ZJ@I'<)TZCL>2JRP7_K!4
M8ZX=FZ[K2JK$.K(M(ULT]R!Z";/).JXJ:ZLJR[#Q0@`6-%4@6ZTN@K&NZ&\#
M&*D%0@&?&JT3.[4MH[&D>K2VLG_Q*J])A:DH2[(>"[0C`K(-^ZXGQ!7,4B7G
MM0#K.+7WLB4CNU(0$#$V2B,S2K?L>$7=8G]8A"P$L"('X``%0A_QH0!!B;=V
M&T&!.[A8:;.N"@"&*RURB[C'!;=]NRCGQ0#(8C!711#((D](BEKK6*&!6DMU
M&T!CV4"\HJS/%*\/LT&`*[B!VKAA(TH-`+*J>[JG]0"FJR+0A"YL*RV4ZXH)
MX+>I"UUI5#,6%+&,L[D1$R'P<:CHH@#VITL'_F!!P<L`5N8D!4=SJ)6WN]N[
M*O6[V-NV`_&Y"1*ZV3LV`@`!Z[BY$@A$LU*^]_,\;PLA4T8`ZNHDP+M!R**Z
ME0LA[]LM@RN^8`NY05DQ[7NY,)*Y\)M\O/N]C(.\C*.\O&*ZX/M?D5O!9_._
MN<7`/62\#MPMM"M:"W"I9Z._#\"_D,*^)1,Q#M`A$2*\@^NV3?>ZPHM:*/R\
M*QRH4X97WVNW<LNZ[-(DW2+"S=LM/!R]<EH5"=2KF_0@-JR#*Z.GUO:V^K$Q
MZI3"OW5?MD<ZQ^6H$Y/%33LZJQNI[V/#$[LKX\.I!ZP?5-N%[ZA`4DQ/7,RM
M/#DW/S1,1*RFF_0S_E]\QE6#)5OC+6SL)TD3)7Y,L=;6PF"Z5!(@:XO2IO[V
M(5D'M5O;J%N,+E"\R?8",F.<F(B\-TMKQYN<A'-L?E'\Q\1D(%#$`%MC9:L\
MQ6CLBDZB+JP,R9)L>W>R)8F\M/8K=I/<Q57D(1+HC'N#()&\*,/,R&0\IIH,
MH+K\MB1+Q!Y"Q3?R0Z0;(K=<RGX7-H&;+K]BQF&LR5?#RFH2+")YR5CZ7YSY
M459\P&X,IKTL->V\%8-3QU(<S'LZL;\2`5%F(X`,T+P+IJ;,NN.,1^4\H_\<
MT(5H>V'C,(NFQHO2T`7]/$3\(`0MT"8Z(_RKSW=LT;2E.R="S6!*R0P-_M%G
M#,T!YH`BXM`1\(YZX\UB+-*E#*!K`R!K_%N+HM$!72#GLB+2&TO[C"4@/3NA
MFC0O7=`Q3;V8!J%'78C.""-1W=/CZ-"H!!\@<M3\+*9`!,O**,8YS<Q&?=6\
MRR1.'4``&LRW$L]@ZM,%?2$RS2MC34QN/=!8#<T[[8,E/3'53,QVO-%[^@`Q
MDQ_5ES@$A=+)I[__I-(+[7?!3-@E+2V1*M0_#",VO=?TC"49;=8-`-2"([U9
M,3AKB[TA`M9^O3("X``K4KQV>R*M#;Y89-JL&[N#6[N-&MN)JSN+.[MHZJIB
M;"VKK=L+3<3(4K?\NMH%L39!0K_!.L%'O-L%_A7!!#!!IG;:N#VCMNW;8VHO
M#>0`6RK;ZEI+_/DUD1W=:@W8T-2;FKTHQ\V."4"W$7"VTA.\QO(\I8U:YC>O
M1`+;Z)VI$5S>C$,!SET0M>0]!2[<#O#>7%(0S)*UHNM:5+)E>VI!K.VKP;S>
M9/TOR&WASPO,P3U'JVW<0=PS*DS>&F[7!NW?KHVZ;`V@*=['@,W@%_62LR+9
M`.ZKCBR*SP(Q-.S#$P[9-7WC58A:\YW)FDS<52N[P5O,G#WC)2[?](W/_K4`
M^.HF)\F]:,HLLOJO_8JI6CVK1!RU/*?&_HIY9"YXO^WDFLSE9SZU1"RT8XFB
M&=9$P&HIS56S:"Z2_@]"8]+R*RG37&R=Y@8]HZ8F'UUN.-S"3+[;K<']YHX,
MH)+=<>V-)61+-=P"39VEJ64[=58N`/GZ*U:GXF\N`8NN<))-L'=>$)$DL7,N
MY]YV2I^>KRZ2Y:E](SR+KKG-YV<S=9=>KA^B<&L=XN<K,8`-Z]49[)->U"MN
MJ>%JSLV\[,X(V'%^Z7MJ/PYS/2^GR#QMHB!J*:I:ZR1\PV*,[;R:Z3X\1U@"
MZ<SBYRW%Y@8-H9=^:8`CVH71SX'1Q%N!('/3UE*QKDD*&_JN$!*PO`./$?P>
MHB>1\(N![^S1IT"QO($H'"M"JOAY\1B?\1J_\0K!H6F\NXH2\'_A\#3A_N<M
M9*%=&A(>GQ(0CQ(F?Z"$FA"S_M#^SA(K_Q")RF*:HO`O0?*H<<_)1R3(^B]"
M9!5""A(PZO,D<?1*.N`D%J1X\J,A`?0G(?4-P?0F42!*=/51#Z0.$6"_TB9K
M4_,K0?4-,5\'8,146JI(+A-*3QJ&BN:!FB0E&/-0\?86`:!X'Q)*K]@,AZ8<
M$?<ZL?<<0?@DBQ&^BMN?2/8)ZH/V#A%/8A#G$J<U8?A/H?AV*['6O(?J_BO!
M2K19!ZT\5R#R-*H0BZHB"2^Y3JN)DVI3CDX*4/&02T]5`ND#H><E^ZTU6RDS
M/\6LRK%[HV4KC>R_<BY/^ZN,JL8#*_H4Q];V_D,`]V'[>)RR8\NRSQ_]SPZN
MTL+[5YZT)V(_>6SMLB+GNR^L;]NKSKZM*WLBZH*SI*JU/0JR_\K\J[I;]H/^
MB5[_#_GE8NZSX`\0`"94J"!`0`4'`!(0%&"@`@,!``A`,""PP@$`%"(0D!B!
MX,<%!A54X`C`(D&.%`H2J*#`X`*2)@5*K`#``$8"$EK:Y/C19X4%#2I,`'"@
M0H*&`'X"$)!`HLX&'`DXB(E2J4T$`BL65?D1HD0(/Q68K/C@8<2)%0=B[/H3
MX<F/8VT">#`!J<T(:B\"D+#U0-NA=PUX9'CP@4*&#K\F4-D@XM^J#`!0=5O9
M\F7,F35OYDP0HX3#_@[&+AC+H&I5DP*,?C2Y`*,#CJH3'G"`\8$$`01T4_@<
M^N/A`Y)92F:0T&%JDP<><'P`N`(%FV,3`H@@L`&`!1`=?DR8O6%-``H6%`4N
M'"CVTC59JH_]E[CQT7+/,Y"\D.!U!Q**GB<-P#1-]3Z"(*('9JN-+I\`I(D`
M`9:;"COM?'J`0(X2,&\\^A!CT,'N(ORMJ`O1\X^D!G4;$,&X_*OOQ`<.$P""
MTNHK#RP"U9,,@NJ*@_`[[K!SP"#PQ"OJ.N68:ZL^R90KZL#E%!+NQAP[_*Y"
M\R22TB$J:41QIPB<$JBZ`GTT**'\]MM0-Y_B\X]%GZ#T;[S^&&"3)I.$_CS@
M.@M-PFP"CB#0[P&,EA)12=ILZPDUI@ZP[3J8".KNQX-Z+)*N1\><3+_5*E/M
MI]F:?.`]F_##=%'LVO3/N!2[-&D",&-4Z,J8)*.L,UIKM?76RB#PSZD)@"SH
MH$-[,LDYFJ`S@*.!*E*)*(<.HZX"71G@]2-E*XC`+`DBD"`AEH;%:`(*$C++
MK8H(&(PL+&5:]:.29")J/8FJO?;7P@)D[Z1LMY7(UXK`4_<CZ&@#("Q?@51P
M/:LJJ);9!.%E2:J)VEV77:6"O4K=BB6*&..!")+7K(*!U3BL0UG#^#0Z,?X8
MY9P4&DL"B>'22((3[97HVW"WI+>"!RC*:"B>_I2*2;\$7HZ93Z&%U8UCBT\C
M*%J#5#QHYA,#3HCDD7T*V6F"B'YYZT/I=+C:?BUCD0(##.!-:-8BC?=G9IL>
M=J_<!@-8VYH_PEE<5FF.R.J!+3ML7+T%RODV;;D%'`*,ZB:LZ\0!A-:_J.D[
M"&.)F#8)85P[]_QS33DR"NRDK^*<(*90/U;H:HWEV23*<MN/VI\+?"OS;EGZ
M]O7FW)*L5)F:JRB":X6BG?@'A#JX6MNW/KCDZ:3B5RF#D#?>LWWKI?=@GWIJ
MW::&4<_I4Z>2LOZGGIJNOGC0I&5J^.)]8IZJK1G/2N2?UD^>Y5^MGY]_`^2&
M)?#;WV_0HJ>#[6YP_FWQ5?*^M[J$!1!-!!2*W,Q%G?@UK62%F<SFJ#*AS"D%
M)P=I7_FT%BD@;=!C`MQ9"H4F-O&1C6T_J8X`)$`!HIR,-6/[F;$L2)`('$`!
M3MD.0@XX0P52ZHA[8=!EQG-#GR0Q>9NCR0BM)40B^B1ZDOM5!ZW4O^)1,"88
M,0WHS'C&6_TN+&J""4;Z8SJWM"8KL!$:<)B$F[3QY2$F"<M'B"09AQ#H.KE[
MRP+R@B`]"<@D9L%([9S$(T<]\C@.FPT@=](?F'#$?4O[B"`EXI2BZ4DRWK$/
M09S5*#;&RBF<TZ2!;-,63:YR/`Z8$`$.8R%(6H4!31LE1$))R]S<TD/W_@$1
M^%*YH=S$ZD@[6DC8AL/,2H)/D]!AR70^*$GY30:$-GN0(<N2)B>19TF&*MWM
MKHG+="5,(L*<4CFG^1$O42`V*JD(,)6BJU))IY;@Q"37(CF92XY&F3"T45'D
M`QZM&90T"XU(H\0G/CO:QHWR`=`L9T,[>VH1.X=\0#VWB4^8)#*;SND.1SW)
M$I#NQ`$7[21=!NF3>,YSCZ1D9SHYHA.1HE&G._6)?B(%%)%T373]XB+JDI))
MMM%Q*@KC2W58XE.W_*@H.@'A`0S&DK4QA2[0F2%7=5(?/SZ&I&+EIA&G2I"0
M"&`DUHI(`G13LJH:9&T'.-1BG!,1G1#$)0)H_E0$VHHF`UI'*K,"XE\)0`'!
M>$2JD-%B1!)9U[92@`((B(C=%CO6LP)5K5VKB-U`V#&"V)5_9U%(8QY#U8B\
M"V@6"1=9/[*1H%%3?%DE$&#L&J[!GJ8G.1Q(:[FB6SA>%K@\2^V'')(>:W%D
M=2K!:V`J^SBT!M6?J^W87ALE5=4>#+%!0QW;<B@3A`4J?`%2*E5@>P"BKF>[
MF4UN;#\R@482"`+*34E!])A3ALR0(+158E$*ID>[)">OIGR,KYYFS!&%MJT#
M$6Y/G(I0GD98IX`JU>>*2BL*.[1SVJK`@"7\X31-94)%K(P$QJ(V$*=8Q0!;
M\8>SU>$6Q_@G)K:)_G-D'%4",&#$]SG=C6_U8@]_A,8HA@VM@%SB$]O8QTMF
M<F5.#-K.7;@S3VYRE2^3U0,$^2>'R8F5O?QE,(>Y<US6<I4#G-D#0%G,N"*S
M9\K,YJ>L6<YSIG.=[7QG/.=9SWOF<Y_]_&=`!UK0@R9TH0U]:$0G6M&+9G2C
M'?UH2$=:TI.F=*4M?6E,9UK3F^9TISW]:5"'6M2C)G6I37UJ5*=:U:MF=:M=
M_6I8QUK6LZ9UK6U]:USG6M>[YG6O??UK8`=;V,,F=K&-?6QD)UO9RV9VLYW]
M;&A'6]K3IG:UK7UM;&=;V]OF=K>]_6UPAUO<XR9WN<U];G2G6]V=;B3&_K*%
MN8P\V"?5P9Q&U$6`!0Q$WM:2'`5V*1$&=$630J8)O3$&&.9X97:,,XARL(>Y
M=S_5)(31#\+\/5@EFYHC'N'(K&YJ<'4=`.0RL?>]RZB?9W6XX/!&.<8RM9<R
MODZ]_\ZQ2EH>\IAP'*!6R>L$:.Z`C*N:C!^:N50"KG+,&67C,?&X'H?R<R5+
M#-^L,LF`,5)*I,,E>@37V=*7WNVMN!N?!W?63\:N+@HX*X_[P:<BA29/C!W6
M7Q37T]E)#LY,=7R/&#--V-5%,SVA?#LHWV_,2)QJ/H)'`!VK^G?590!GD1U=
M)8&)X+M6=Y;#F\0OQ1Y,D'9O"MQ<)L<)7&H8_J]'N#]>UIS?B^=C=EC1DP4\
M83%]=W62^M%79G.K0PQ&MC,=*+<\YNU.$?A,1OO`=1N'7(4`N":7$7#A\/EF
M'U;T!])VI$^@[`<6&A$C$/J*+$0F`E@6YJ$O6373V^:K<A;0)S"=YDN6C\YO
M^W>I0OBCX"7T>E]UXF6RFG4!%V=9/GQ:/NG#OK<X"/M#NN<SP-Z:@`)T/J[3
MB1SR".\#/\3`H0A4"?]+CNX:B*P8C/W;N5=#.0J<N/P3P;[(0`BL/@XL/0\$
M#Q#4/Y@AP>,SI=3I%;K00<+*NO5PO/V*B.+J+N3KHV]+/.YS"P1,0NIC&S[:
MP+;SJM<:%N18",);_D)-V2I4<2.\N\$DS"&Y(CPI!"(=8[4.1,&)F3XF]`D$
M/`R'0+DP-#^SP2^,>IVIJ;HI_!DU)$)_>995R:$!BX`RA#6T`2@7>0X\!**Y
MV</9ZT./^,-$M)9!3)#D(Y)(XJL+(XJH4:P0.C`#R(J8ZT`C]#8D?!V,60@L
MM#O$P#YZTSYX4XH:RA_JX","N4+,P3J]0HQZLJ]1U)6?*L6RRZ&$2(`<XK=(
MR8NT>3E4ZT!ND<$/81M51$632(`$L*K`0;EA+,9H=#O+V,)2B<6$(HPE9,:4
MH;IC3)N;D#5OA`EP;"EQS"ER[)8O21UK04=E5#QU`:UV@2Z"R*'Q6(B*_O@=
M['$`74$840RW4L0G=#0`TTA%=$F;AKS%YQL_/6G'_&K%A'@1\UO(F)M"&UJ7
MB!C%0^3#+]03YJA(>JPA.C2U#IR`.4I#!%1(=(Q(BA0`CRC&D[RGAV1(;BRQ
MJD-!B[2O=YRAEGS)>3Q&K=*O5C-!H*1'=US#1EP5HS1'172L.,(*MS(^?D,,
MMT"Y&M)$>J,N'22,@P0W8!2IKG!(MDE+=+F3-:R_2&S%=2D?.=PORW@,X^/"
M%,F4LU2*8E1)OXS+E2RUENR5J`&M[=M#MF2;\3`*P@-,Q63#P62JQNE'P3R)
MQ(Q*@3#,U#+!/)RUBJC,U0K$B<G,PC2(SKS,_JOL(ZYZG%+T"9R<BP4@O-])
MF[;BP]?LMH1TP0/D35-T0$9\RT2ZP!44/XO00?,#3K?PDIUK/QR"/R^<OF+<
MB^&DP:TP0QAD,'?IR0:TOCV,Q>DDO@V4/JC\B=^IL`H(P>\K3N[43.V<2^N<
M3%4[3X=23PPLI7',SMNQ".*\3D'I(Z^,SI[2D^F@CMAT+"%\P2+T3F[K2XZ)
M/)E(`%44B,P4SK=[O1?L&(.;R'QTB\@#+;E0EX[LR]6RS$3Z/(K$3N3KF))`
M3)&:4%?TKAP\49G@T.TTQ<MHN<?!O<UI"]/4SYBPB!I4EXB8-1T%&`Q]1DI<
M4:L0TI@I4D$QEZW@_IS<--'58HD*9`H&0B08/#AN^[JM=+>14X@Q;:H+V[=]
MNSB`$SBGVR.6*%,MHX#',#NK4@W"L8K'>;"*ZQ&+^[?!4(`>T[AGN2E%;%,T
M9;DT3:U]:T8X5<1`I9W34=.:FS<N\CJGH[>>\],(`%1:*Y>?D-2CFT)6&M1+
M342?4ZY-[3&IF\WN2;D9`Q"GN#^)@!-343I2]=)UX[.@R]7-V%5"\U5>#59A
M'59B+59C/59D359E759F;59G?59HC59IG59JK59KO59LS59MW59N[59O_59P
M13<U>[0W"U=S)=8R-8KD2Y!1E+'#8(UVY8QU_9P=DS`4>=</F]=SW5=D_M,(
MXMDH;8&..]6K<DVQA&"-@977A,45_X"B"-NJ#ELK"3.D01O7GE(QB_V<@NV,
MC*6SC176COTU&PR/SLHK!(&O1/E8LYL*@V"`0[*;>L2+G?`_!2C9_;*NCD&L
MW!`78/U4G#6X>\0,EP")]>BH-07:UX$66U*NO-HN`Q@+6PD<E%4-E=6I\0`,
MNJJ)>$W:FEC8MS@P7#E8P5%*T-&96Q%;7;FQM-6,M,57,'.`BFB*KG#;6]%7
MAMU:=R7;RUC;RJ!;8AO9!D%&U#$+`A"YCCH\S3`.062*!\B+IU*K"'@B"9",
M[ZN)P$T;SYB(Y5@-NH(`3[&5SMU<>V.`JE5$_L+(L<DQI`E)LQRA*J7@,AS!
MW(L8C.F(6L(U7-F-,3`A.*I0@#(SL<%5,GSUV\X0V[[56\^!V#$3&N#-V\T`
M7N)M,HAP@&L!K.9E6*^M%=^ULNB]C.[E6F,;V3+"UZV2VPZ['LXX#,:CC(.M
M1KU!`/!-L'<E"L*H#JJK7^7E#/I5Q('(7\X0`-/0#YU0E/W2E?[MG7<]C+PZ
MV/W-/]N54\8X7Q\KW![IW["@(P.X)J05"YF``#(9D]?BB'SKQGMB60'HW0Z.
M69@=&(R8KR8Q@+R"K7S;8/0II:>%ELXRB_'@HW>=+TB9%<<X8;LEX)WH&`;8
M#HB8B$B"#?.5@,;)_K+7V>'`>5E^;#$`)CB/Z&$3=MG.(LL%*)=QH0OTBHM'
M_0WEH@P4^>'`68X?U@R[>"Z>,>%9:1(A0EXS-BBA.:03GMGD@X@KQHPQUJOU
M\!G(0QTC+#W&L>-'&]EQ$5L$`2&*K16WO5?J40#B$43#<,)&UDEVY=NNE62B
MI+WLO0Q.+;*N;8O2VV3P[6&V^=[+>.2&JN(5DXRN(&*ZJ`[JE0Q7'%TMFUSJ
M2#N\T&5^(TA\LXSK>)W!T&5?7D_(?2++I0W8%5Q<GJ\9;MC*@(C+BX!H65P_
MH5Q@1N;%'8C!@:V$/6:FH@P#$(H%L*6$R&*PV%R2$#F*:!:!\&;<L&1G_KXQ
M<PE$E4C@8&9<Q^TNE[V1KDV(COECR\#E</[D<4XX-UQH0(:\(&*)AQ;FPQAH
M^9P<C`Y,EVUGG_OEL_!<OL(,@V:(B,1H44;89^Y!2F/D?GXAP@FB!"M>37[I
M/JQ1XX585F97NO5?M@WE4ZX5^^7)3X;7H'Y7X]WI2++=UQJZ&_L3E>L=NC@,
MPL@/1^X=#ZTCIPL<:E1$)3M8!39DKD6`3#D`^)V=A%A@I>AJ?N-`K'Y5Q3J(
M`R@E]QW>U]WJL#B`!5`),'$._?@^FS`*HL"AE.OJ=E9$W$``FQ,*?R8(LGY?
M'QN[PNTCL#Z)G7-DNCZ.N@`H^\6,PZ#L&T(0_B%2Q.8(:ZW-#$M>:M,.G$^$
M)T5N;8)PBHBU3+,06^CH(UT).N@P+XLP:WA25ZS>JMG)-$9>ZE..9.--7TU>
MZJ7JFFM2Z:]M8/O]:]*N%>KFMP.^%0)X&<_(%/4MZLK^$)4C#/&BE:U";D66
ML'1,B*Y`D!`$.JXUVQ[!094&X$MV58WZVL'5;[ZZ9&QNSE:F'I?]UT?T6GEJ
MHY'8DO#^VDDV"Q0ABH25)^H58NTSBNKP[TQ.D)Z)B-1F<*'I;^+!9A^;@`98
M@*Q\[IP>%_(EG(-U;Z,X8LU8)=)U:X&E;?TN:I(.(`)=;@57Y!Z_V9(P"WR]
M\/N6Y=]^B.WX\2U!_B26KC27CF]&DNA`IFF$M>D):8#JC<C*U6FA"5T*O@A;
MFB^?U@PO!\"W[@SSP$'5W92:(-VD=5NQ39L(J-U:$6TI1]P5NP[>@-_][K`?
M.:RK%EZA27&N4I>M77"&?B',`>\`O^E4SCB(@(X"GUNE$%NDKFF(%5@;<XT&
M2`#]<``Y,<5_Z>D^DFG3N/3NTB$98]6/H*PWKVDHI_1/MM_FSHQM"<A/SO1'
MAO7+@,@PB=_F4%Y7#NJDE:=T[FN[QAB\Y=_F%O:K".Y@'^5(&]D^6O'GH"RJ
MK16^3;[A+9<R@CO:J_:WP]G]0HH'6?;+F("T&N'3MI5/9T-O[XJQ,(K&_@;;
MY_`]J*USLYBLABM=G2**JT'8R+5,SX5I$J;O_:[U!K!81-\J?*WU;3GJ1J_U
M_,#QKL2.2/'MV*9WK09VA5DK75G8ZJ"-FB#BZNB*B*=JQ.[P\'[X68EX?9;8
MLWAUZ,9L>-)LYAJ/D+46AY*,4[[AR2GMY?;>DVAXLX!M!\8,I)?MM:UQL=6/
MMJAXS,#$CM'XHP#NZAYS?HTQ";B>=1XTT1Q<_>AHOG!D-U?"7R;T'VE<3JT,
MHW^=[[OR+&?T^5[[5$6=LZ^,BFB4B^9FN,\98`?F%C$2W=,CIU88PR4`H>`6
MSZ5@]&K<,3Y878E[`<#RY>C(%M.5!6C<'Z$*_J.W:?#`:`<?ER1Q8X`=8P01
ME\\E],M0:*G2ERK?9H'$#-E'2>H=NLFG)XEV*\TH_0-#:849#$^I\:UGLK$'
MC3T6M,/0L"D&8PI8V\:L#*2!@&VG;-')V&-N\.?HD[3S]C[GV[6EHS3+Q:`E
MIL<AY'$!][9UPCX*8G&Q#*M2"<D8L#?^8UUAX@BN?RA.6W#O?H`#B`H"!Q(L
M:/`@0H00#@@`8,"!0`@`*CR8*!``!($5+RXX`(#`@XLA*T@`,#*AP`@&``A(
M(*&"28$.!`AP$%/B0(PH*S"@>0""``4X+V:D2,"A`HLH'QPUD%3@`@$$'"`0
M0&'"T8P3H@(X\')G_LF3%%<:&"EA)4B0,,7N;.OV+=RX<N?2K6OW+MZ\;55^
MA*CW+^#`@@<3?NO@:P0`$0HS;GPW9L**$_`>ID!2L>/,=2M:UNSY,^C0HD>3
M+FWZM.,#!B)(.$``-6R])CL7I*`R05[5K%W'!CWA=N_@PH>7GASZ*_'DR@=3
MJ-H2^?+H1!%.<`B];G.:"(Q+#TS!>O?P;W$./5B>H,ZY#P08&)T>?5&X&P&O
M;Y_09L[XXO?S[^__/X`!BB>!`A0I9=!\!4$F%P`,2$#;9PLLIB!;;>$'6(,/
M1J;4@M)=A])5`X4H((DEFH@:=XQ]>&)A?-4D$`&X">14!1`<-95&$\WG_J)?
M-CE`0$N=S59!!$<MD*)!B0'05044*$#3D41YA!)&4_)$$P,"3>"1`%Y-1T$"
M4MGT@&5\K7:1`V2]M,"2&+7&DI<[04!62$HRB5!22V8$@`)J#M03`?J=EN!`
M);VF(`"3E72@6XD5Y2B+D4J:%Z&`G4=7I1AFE*E![TT:5W4,1&#38CUIJ5BH
MHV*V$7ZIDFI@H$P=(!*1`#A@XP(H_99A!:Y!(.M%7?J%$)P0]?2K`+D2<$`$
M#QA@7TRN/6!C3!$D&T%2+['T@$KM2<"`8A0L&\&<]FTH*K@0[.I@0M^&"Y,`
MW#XKD`*!O@K;A00MVFFBES':5IB=507AIP4;_HP0IY3^*U?">4EH8%L/'_P6
M@:>&5-)B,Y%48`75A83?1A5W'-.]B6D;4@(R)D9PIV16-V%BD]U)Y:Q-IB<1
M!0(@8)D$#8B4&,PQ)5!SKPC`E&4%%\X7))'#(G2`C!4,+1++!"788(XV3YCR
M:$SU50&;>A)4G:WL14`V2P8TM&21&)$U84'5R?B=2UWU5!:,BADPJ[,.C00N
M;HFMYE!*,_-$P%1'\1PFC@))X)Q+%)3T$P%9,E63XB0Q/FQKB"O0V9Q^YVTF
MW(5Z5/E`H>-]V0%W-POD=J95]"/33-GX^9/)3F;32Q(DJ]I`]>[D]9E$KO0B
M3`OI>-0!3X$8ID.+_C%%_%=>-[\P?%.27D&>&+VG4Y48I04>E1"$[6FG>Z9)
M_L0&.7G4D`3DVGQ*"<`?TD;SO;\D_@?&-)L`1!4!H.TD)H0"G].(Y1>@#1!H
M0`%``DYBD@.2Z5H#-!5DYC.?!R9`4`=9T(4Z=)!\008_#(R`J4+C*E2!*P(0
M6M2S6)*TAC#@`>"JR:*ZXA'%).902</,#UFSI&6Q#28L\1M+H'>QAFP)`!*8
M`!.Y9ZL_)7%MDFN(:Z:XJ`/L<`(Y;)"2&+*D*W;E*'ZA80(@:*"6-"0D2^K2
MC0JRQ97PK8HQ610!5F+'J'7M([]:%D5HHH`(^`I8%3```2:`2`K8Q#@!_D2)
M1$3%)@F41%2O*E9%T+6DG:B&6[RI2*"Z92!-8B\GPO+=("?I+A<NZ'_"`B4$
M1$FE!ZRR:CEQ8[QDV3Z"B,L`#4C,WZR"F9DH@%NSR=]$>OG+8_IO3VYLD]AF
M";'\K*4M)81F-".01@)89H+^>R8VUV*9^>2+2-NT)=6R)LZE<(A,$*M(.(_#
M,8_]T"!DF\`]C3B!JVS2B'X!UT_Z>4ASS6M1DVD`DY;DE9PYL58"$`A`IRBU
M*1X%.0UYB9*<-,7O/#2-2`,<V1A@&8]`)*-)@0A'1S;,"C8T,0_EGTI3Y-&\
M0;&E,ER491J2$9?*#H@F&]-E@J8HJ6#F.R7M_E="#F`T@1R`EO/\7\T,L-2)
M[D1B(&MH/:4ZD#06L&8(()I2ISDD<=Z)=S(I):T:=LOO(*V<NZR11;[CSNI$
M12#(H^=5X2H0N0:Q<"<3U[`.4\"+^;1?8TW(D$I"F\-(K"3.)&"MR-0XDD#D
MFNIL+/H*$E:!3*V:*"'A2/"C6,<ET#/:O-\TQ];/)<FL7_O29^&XR2W'230Q
M$#$4;5^*F>H\U*[]JFEOX>H5AW2&MP-IB+@:Y("9.+&BM$VD0"_JV^0R8+G2
M1<"2'L+/X#)Q25]A+4&<6R@9^M:+JW6M0$=33HQP1J_4_&&N!/)5GIB+6!7:
MWVPD"D*T1D1MF\S7_D;V6\`S2NB"#YU/*]WHEP2I59P-KF8&^?LIVQ(2:S,"
M0'R[1*Z56&XB)K15A3L<*T!6<R8.B,`"?(C8D4C+1C43X0=/\BQNV:]7H31K
MM$9L0`'\DBE9&M(&PR4M5:UH()E$87H.:YYW`=DB>WN=ST+3@&2=F)GV/&]K
M%87EYQ8D*9UADV6J<RC<@K<DW$5J&B7*4)L@;61G9NC:V%91GGV$;,=U8DX!
M`&=H3F@"/:DS>2O07:2"=R!S[M@3`\W$UY8YO:(Y(`0N=!Z=8(5PA<-*:2G4
MF:LH$YB>'6N#>U),A*8VP.Y,K7TO@DT/6V2L^0VM4AI,,@F_>IP2_E14_J8R
ML+/"K"D."-A&AI)KJEAE=D!*@)!"R[PBHV<D3H*2<6#<LH%L!8LO`5-#5A<3
M;$\E@VA!6GKTEY4)0&]UD*33>Q-2Z3T593[DQM)HD,=7MZI4U5GVEZK_V14*
MS#9G,H*BC`Q:`83.JM#>=6A$CF@5SA[QB;$4-&8RZI%V.P!,%@;<:WLU18F'
MN^(*0';'+GIPGAH\41-X>!I1BMR1R]#.L-T7N9"DF8H$30+N+NQDP#6[XR9%
MY@6AD5UO%==:'W*J7$5)O,Y:ZHEHE>&#M<QD)0`1!(_$TTTV,G\-2&LWPOJM
M7A<-.K].%PV'+DL2<:&^MLP\6BHTAUQDFT1T_@1$FI\*3D4LM$W8>$<FKB2^
M\'Q-W,$&)RNZ5#5JW.(.*2G0N(M1SX5?"6[8])"DO*8B>G]FM!,%3W]E$3>6
M5R*^7[[):(+&)B.>5;X*"<A*_O`K`+40B,,D`0I[Y,<C.3*X^*OA]3@Q7_B)
M))*S'MJ:O,[LX7K6ZUZM].6OF`)G#SO1'RSVZ5,_-FU[2,#6G?9#.==K6?JS
MDAS@D3/UL%?F`AYMR[8Z\=8(W1J_+4TF\QVLE1]LB(-GF4[7YM9HYT&X-3+B
MV(2>$8G^#<3ZR$_UN)]X553]O0GJ:(3[_9]SX=91E(YG&!O3E,>SZ8Z-=08B
M%4Z%C%!3?,633$68_E1'?!"/\R1$VS154)3'4*B@\!G9M^U55IS%1TR/9\%@
MUFE%5I1/\JA3]0TA$;9/H2&$+67<7S2$!3H``TR&<=T%!(B*S0278X2=6V#A
MS-W:>"!5$7XA&(:A&!+&$8**H]T%`\1104A>`W`87DC$5-3>&+*37MB&`?#1
M'.:A'LZASXTA^\5%_>E%&A5/0:1)ET097CS`^"'B'EH-%^[$=Q@`LS4B)<J&
MT]#;XV0;(P[&I1A$)CK$)LJ&!\5%WSA$IM''(T)2*E8B*[:B*[YB3EPBHT!1
M4R'9*>J%6EG+3R`9'N:%M+T%=@D0X#"&]+5%,<9&'\+%),+BIR2C:2PC_C,2
MH40QWUG11AJ.QXU`A(U0CT8PSPH>1(P0A%GQ")KXB?&PA%]D1[>1";9%CUO0
MW4!8W?I((DJ0(YZTB59$15#8VGL13\:4#?*$A@!"TRW^XEM`1F;%Q2?ZTM@@
MP(VX1,(13?K]4)LP3:WPD43H!T:T$$$PA"U9&C5-8ST9$82X'#8USD"VR7)A
MD[F!QM6,XJ.M(F%T8B=Z1DVRHDBZ546<Q&^XQ0HUBQ^)$NZ=83QBE9:X4"6I
MRF)LBR@EY:NH7K24!2&I6$+LC4&H!D?)2WW)$1C=BSVUT$@%BHNEEM9)DA-5
MQ&J`BS,6!D(UT``EHY(QB#L9Y%YT";<,(Y&P_@>W&*+TE&'N!=$`K<=2B1%M
M6!YMQ`3BI$Y"JEJ;09@LYILXKE:!H=@P\5`#34!;-E`:0>-@@!:^R.1@B(PC
MDL8QCF%.SN(.=0E,>N)3/8!99971E1*].4YK'HW2B8S'0!8P48!5W9J%$02X
MV.9('@1N&N2%O,RE>>9F]<H#5,1WK29CS*:MJ(F=U`R@%$7X'$1UPD2?L,]U
MHD0X&F!#`1)M?!)+-"9-L!IP/I3'3*/I1<ULE`1*D1BQ5.!:G6:PJ!B0M)K3
M3!&]E9-1A4;W[$EWTB-$205T.B+M@%S'Z./G=*,I"I[8V&.-,$]P'FB@$,L"
MH,5)>$WC:)`W/N)W_AK%3"!/>!X2QXSHA6Q@E,#$AN9@/!K)6A8,?B8)`]B/
M2-8CCIH$@$V$@"'$;.Y5O?`/7TT3?C7G-T'@VKC%;U*19ZG5D=I2D,''U9")
M"'FFE"T,4S[+NKQ$O40:9A3+070IO&@EO=@+$"6)47:,"T%640)E"L%5<);3
MG#Z40V(=I'A6S_7$))H$(D6;@D7F17!DK5SH-#KGP/T+@-(E8?@9D^72O'`/
MFEH@POB1(:G>K%"86M:24V(&\/VE_4%`6WX0&*7+95C2JDS$IQ+E0:28J*9J
M6O9+"F%,J([J?&`J8R)91L@GKE!?C0Z$Q'"6%=Y'4!@3DF+=.J%:04@$_G2$
M!58\A-6YTT9TFC<U&P7TQ`*LI%M8I6:UQ]4A81XM4P@NWZ2!Z2TE*P7P6SMI
MH6"D)'A96`BQ(Q!QC>'$6#<AS;3.:R]2HZ!VRDK24Z\T%:LUD&!6@/S`U81L
MA/UTDSOU$J.:A._(2'X]YEH`70*41:MA4\VX:Z)DY@`QQ(P.QM7@:S+IJUN4
MC!/1:JU,0$44A6#-1W&&Q').R7=LS;ZJ$6=Y2VWB1]-155O4+&?AQFOJ!*UJ
M#-!*C=!.!'*N+$Q$S<56``*HS`"*';<RU58>[)\,*T+<%8_&&M/%9D+DS%2U
MWE#(59'^WM`94]"$1-(-)SN5SFY:ED*DK91:_L32QLQ0A`4%`)V@:2NM9*E;
M3DB$T<H)8=`M_JUE%:[6\JMX?I`#;`3P.`I^I&204%ABR`A^Y$R!+$AB2*1]
M.=__!&KCKH5-\)-KMMIDKD>!D(I;4B0TQ9=`MI/2*>X[?E.Y3E3E:$B"1.F"
MD!KMNB7#CNYIP92IC>Y.T&Z50MW\%`CRJFHS>58]!5`#I:G7540"#!";N%/K
MP-4"["7R;._6,DO9)0C:DI(J[B*X9`GM8<W5K6^60&4%,0OOO03X(D0P7A#.
M?JMV@I@<SBW:M=CJ@=%*?$SL"0#+KFOLVJM8D0D\01/T?NXZ(5,\&02SIIW:
M%@30;(3)/`G$T%N:_D$3/R+L8>5HC,F7`.AMC9J$QY0N@CF-J?SG@2!J:"3O
M.ZU:[5+I\U*6&XJ;+T5K9UQ5./%9LK)*L>ZFJ76&]#5PFY!E,`&M$F]2L#TO
MJ/DH-B5HP3A+MDE0S2Q$M@U+O1+$]?V:`/`@A#H%?Q$239C;L`U,N%G$&EO%
MNW7;3JU=4,"$YR*('CU$/Z+5&]N2]E4;!\X0CV5HTC1%7Z;;9TAGUU73RI!6
MLJ::9XG6U$H=$NI,9+X$?3+5:UQ(C#P2JS!*@-(6`0]$%HD%";>,93AL2%2M
M^=%*G]!("Q,$!\.PILVP[-;3:%%6[=:<RL8,BCGIE-H,F?3LE.0R)7>*_M.V
M!]>.<L\>'5A,\M0A,%WU5B/K\D;<K6$EL\$.2P.$;#1^L]BQ[F5&<*NQRY,Q
MA<\\++M\ZSD30"AB'?I:F+5`*Q8?,D7NCGI&)G?L;7LD2$V=&DP<[M_6"C-=
M+V7.)9DHB3UC&,'6L3B_):F%ET`3!LTQ;`BW\SL;A.G]4<T`\*S0U<?V<[BX
MKYQ2II/)KSN3JB:QK?CNL/.:[[:BM,]@Z2%AV$!@]$CBJA&M]`QQB_"`,U"'
M(<=65KNY,9.\VR,]<*LF5%%K29@D-0LRA%Z.#8[&R%>4[9W@A%NQ<NL12LNB
MQT1WB$VTFW^96WHDIEA!TSZZKDIN]1UG1G*Q_ILZ(75CLM."%I<^MJB+0&1<
M<X^8G&`AVXW=/G5=YT1'P"B1^!JP680,O@5=)]RY\IJ(.`?2E&WNM"B&G<Y)
M-`#S>'-0?S9H3PR[AC;#@*8R(F**P06C`LAJD[9KOS9LPV)ISD4E38"/J#9`
MLTA<@J%G*V1L_S9PS^%LSP5?3!:36O%_+&81MK9<;@B#(/=G@(^@<*REH;&&
MB:?GVL1;IQ\TM8<>#1%$&NRJ90G\0%-A!S=ZI[=ZDV%NRT9[(VM<,+=GA*YF
MK9I-YQXTC01VP:Y\V320KEJN#!$B*92_8),QK=JXKK>"M\N"XT5O>^+T;>>U
M-L5(3"?Y;`\8MXEU_L+;-+4-9K^H6G"G.89.Y8S35-#$L/0$5"-A[H#<N[DC
M6>4VIYE1B,!3Q6T%2TS&4;#%CB<$FR#;/FF9U\H=-^U3C7\$IXV(=-SD^CS'
M8AU/Y%R$1)Z=?1^`NYK;!#CD1X1WD.;$E/-GOXZ1:K%:1<:)?;.UZ+3%3?+'
M;#=YE(O'*=<%?9KJJ60:>2R,F_^P:0_T6]D&KS#$B;')GD!J>UB+A&3+V"0&
MNQS+>N2*)-\*UBZ))@VZF5;$(*U''<5JSHUQHZ.$ZK5')TTEK4C;_,'-4;19
MJ<\?=*AZ0IA10:#E0!"<%-UQ4FQW='`*H#>+VFP-\2FB``CNH3K>`#$T_FMX
MK#:UE%Z.RJZ[+:D.2RR/[I+(XL`.D(U`RV0.$&`.T&;"7HF49IB<F*]S9F_$
M.5UP<-X03<R,D-P91$^`.UH/M[5.WVR@("D77%M-1&<5#2I_1U'@C,(N52/C
MK-1X*\D&+-;9-E9A!+W#51+ZU`$XR83$J]FJZ227H9[P5(8O[EX)./))48Q<
M+$N\Q'?C8TU7<==D8SF2C_5\8XY\1;IVB8&4#F_`Q%$8QWH%UH$$*'F2\B9G
M7<TO7PI+17@UA-L::FDM:@*]29>\Q.R@N):DH>AP$;T,8,R8A&:+QH".Q4>(
M%(*L:=6.J)]1N)1X&(JGAXHC31,M?7^EN=4C_K:"5)8B(C8@[XR:-U1)K(1Q
M,$"F'L^"K7M!0#7&G$]&6LF(7LDC;:?8:=UH#JX%H9#65HME9O!$2.^P+^5)
MX(=E=0A[M=,)N>FR+LR<+"F$A2!"^5#@41MKR7IDVKJ=M,ED<`E!JEH>/0L]
M<ORSB'M@_&29"F6IGN'>O-!B<#4!F40>"6%`&Z\P>WZMJ,I@%;]846R#%-:<
M*H4BO=C1Y[P(C4NY_)"F]THN)86YUG2IO$:T8XL7>D8M282$8/I5/KR^C$2*
MG>YB,(1/@\\KF43;A`2C)XO!RN^\`,0#``PB,```H0(```XB*``PH4)$B0L3
M+FSXL,(!`A`>$#`@_A%DR`D4'PB(0#'C`PD#(S@`$*&"P`HN0U;P*$%B!`H2
M#.H$(."`@PH*-KJ$R4``1P$+)IQD@+-F5*E3J5:U>A4K@`<Q`8"4J94"UXH*
MR=8$*Y"L0@@TTZI-^""L6+!RX4Y<VS6B5I=M$4:5*1$B4@4/&N`%.S=D`@`+
M<BJ,6\$@@8P#0QZ@+-7EQY`"M$84**#"20!QXXHFC14U:@D*(H[<>IFF`002
M%9ME(/4R2(I:3PJE.5%H1*,1B!\0,.%WR(7)<3_H/=-P<.&&'QA@72&!`9E[
MT\(<2Y9Q8>+%CV].$+8E5Z@'5_;->&"E3P.WYR>\G==]:OTU_QXX$)$"_@@P
M`DF`^YH:KP(*7HHH@03:D\B_A/[+Z+J3'ABI+P$I$`"!L"1H(*,$:/LOMX/,
M$JI$".*+*((#'IM*-NPZ!$"R"HY;K;7.:/H+)`$5(H`!B,22$,`%L4L`PX@T
M?.O%_9Q\$LJI.GLPH@@[@\XFZ220;J*M3GK,`0ED(D"Z,!,2D<&/KJ0I0L\>
MXE&KE<"$JJ:3O!-P`@&VPO*M/FLBX,J(.&.*@KVVXNQ""B8("]%%%TULL9!6
M`D""L$;J2B`"%*5`4:XT7;33**&,(`%`#]OSJSWYU.T^VT[LTR`Q\<JKS+8B
M90XX7,W:*M:_4)HNKP=<4E2OKH8C#Z?%QHL`_B+NP../LP3Z@O,!'L4B,P(!
M'#A@))@"#534U'X#UT16IRO+3N*0$M"KKE"ZTK5TB7L)@FCW#)0M5<&EU<^W
MK,4**1NWLHPX-"D@2J&M9/JWM086L$R`L,8-3EZDY+6SWW`UWCBKIS+2-H(%
M3)QK80$:B*"C5B?RV`#M2)5L.ST;JE$A@@QZK2Z9!%P`9:!6I:AEYTJM4N6(
M#-BH(Q&!ZIE2)A$#3*%*)4(KK06(;8N`2].J42)`5743-!85PL[6KA2SE6-Q
M!1C,0B;IBHMA`R:4"`'0Y`X)X[E:9NY7Y@22`&.0[-15N;KVC@ZD<2\LEH+M
M9DUP-RZ!G;KI.A73_C0YK:R5Z>$&'-23NKB>3ILJ7^O"+Z2[$\?45G8I]W,N
M!85MG<7+98?;W=-'3PA%W6<'2<BJ!!(0)Y<28"A!CTX^BW5)KXMH):%,/S<M
MJLE":'?2M>=8Y/\F8`!0[5`?LCH:BXZH^PHF6(`S^(9T`%!N\WJ8QGNGQ0L"
M`\P/R_6$$#JX?>N9FT0H4+>E0"0"\2L):T:6'[&%37`0.T"&;+4`ZRF$,5"K
MG$1<,K>32$9_;?E/"-,RP.U)15M%@LN:NA(C!CUN.G3*$V.,`A*-!$ML@-)-
MK0I'`0*8\(:$T\V>/H@7U55),YU10,M8XSB0*`A%DEM5L%[$,^@=A%I4_GI/
M:``0%`E-Z%M?.V%-?M,FK@0OAC;LBIR@YX`D58E$AKN.@%0R&@Y*P(H5:,\!
M9L.@.';I56%<407P9!4%M4QL75027F2'I7^M1(8D"9T>[:C',%5R)LD2XQ@Y
MV4E/`M*3$'C>)TE9RNTM+7^4(5E7!&2SL=7$."?+GP"@D@"00<`XWD',7G;(
M01B2*30",`!#JF,2Z"Q+)ST\EYL20!R1U04LHH&)XY9EG&3Q;%E3S%)E-M(2
M2F5N8"`365^B-IE[^:Y)H7Q)XY15$A,RR&0H,XX1#X`R`H#(.`P9IY]<4BU`
M"25H+\M(-UTB*U=B#YW*Z9WH`$J`!T"``")B_L"$)AH5_;6*,_?I38LHX\3*
MQ!.7Y1&(3U0E-WLV@`(!'9I]Z&1*E[[42=G3G@%:"E.;WM0J"03`,&VIH/MY
M)GP.B0H%P$>C!;34`?H3@(-$EQ_]]7)R$E&=!$I%(P=1CRS>L0M(GNH9`W!&
M?.,C0(T<EQ8#Z!)MN#IB:VRYTZWTKS-$#9^JC!.16(W/?R^=`*`0DDH@I5,X
M^B.``E;"5@$4"$!%#2N^#MM/];&OBSBA0%O#FLK%NJ=<O<RLB29[6`6$Q3)5
M@J%=C50!D=%)`0(@DRTGP*[^$;"H2Q62#P\2J`G8$K$)2FUDT:=(G/X6N%L-
M[G")6USC'A>YR55N_I@\5%KD[E6YT97N=*E;7>M>%[O9U6YJ#G!6"=PPN@C0
MZG;)6U[SGA>]Z57O>G];P,,B`(WLE2]Y[^H7RP"IMVUQED(T$Y5LA8V$"H&)
M9:7((OV%=4-IH4];8/)=U7YV*DC9Z7CU.,I%&C>S\]7PACG<80]_N"8^DDJF
MJLJ8`"MDOY'R+W^Y*,R6&0`Y_'5+2'P4P@'3Z,416(F+6]9:A737MS5!BG.,
M\YB]CI9AO]T7B-E;TT[&=S].1B^402)E)E\YO?!C<50`9:F?J(]3$[#,5APE
M(!BO&%`TS`TE:0F==_*5B_]Q"$3B4AB528`SP4%D5'+[1NSH,"0"<4!C_ENC
M6/NYB9`;&:R8?^(^P2E5BNXE$U@Z.V&;H&F+,$UR5#)<RG]1P#(%)B0K1[N?
MSFR:*ITN7:E1\Y?75C>I/SE/5#F-*E8_J2UAY:!2F7H5K(G:20?8Y`0!`[$R
MM0^P9NDO7K&L'Q)F\$\+.LD`1<:E/&DJ*GA6P,TJ<-$&P00!E[F42+X,.=!D
M-`%[\G8S(2/@!2B`PB`A;)&FY=#19J8@&#&.<QR"4$279&T)K&?^EKT2@M30
MADCS6D9<%D0[NL:FJ"Z<IF$H(&9AIGFB.O6MIY+'JP@1*W_!T7610LRQ(EI*
M=1GYQI15G`W6C2$AC3>GL1DRYSZI4."*,5W/_BJ0K?0S`FN5TIJ7W&S4C%DJ
MHODQG01D0OW-',__(9B"%,(9K7`&*A\DMQT_,RFKGX<L5B_?3\1N%=:JSR0,
M^QM^M&BEG+%N3[+5(X@D,G*(-\8[%J)`'FF2I$)2''Y+?0Q2-D)%N;HUTPY!
MSX`,:^F.=&2G4('\`80J$9&YI7QA71C^#CRP"<W9KOU5>E`6$KZL'SC>!X$H
MY&FJ/@GB\7H=@6B_M[J^PR+I\ECD_/YB0B9"Z_'U+\TM)6V.>4!ABRS_<77G
M@W7?37):.E!TTWC!6Y5?\2Y!AH8.3O`,[9`4)F%QX4Y=NA41!$@=32>ALG(`
MI=6Y(`6Q;0(]9):-_F6LAX4!+VX`1`W0@%`3D#/0J##0A.!D(^H8I2M(A0$D
MYB=>R<WRKV7PB4;F23O2;2?4(@$6L`(*XZL6HUEVBBJ"SI@RXC;4;E8TYW%2
M!5@$0DCJ15EJ8GU,Y71&;8B\RNJJ1$0:Y*9<0N$^KR@6I#/RR>;NPF@6!'PJ
MH^%@AD8@(.@^0B!<Z7&^9YU:*=\08D=([:!^0W_TC.X2Q"EDI9L0*5MXQB%J
MJEC"\"-^"&5:AB?6">#@+8P&ZJ%NHB?8:=3@S9VXXJP,`B+4D.!>ZB9R8B?J
MT."\B0D'`B=TAB4,`GLL8OY2+?I00N@"!Q(I!R>$<)^.9@*.)MEVXN[4_F<"
M5H*(*FG0;"0XRL_ZJB-K<&A=2F(!"J,(N=#HV$RJR&+0*HDSXL(@O"]/!L0@
M,"C<K*[J0H7-'%!_QJXS;LO%!H)3)H)2@F?'<O&*((B,``!)A,,D\BV9?*E+
M-B=WPL*C<L(R5,:'^J]M7J=+B&HI'.`W2B)/',B41DIL)``5=3!.,LL_XN.0
MZ*-HX&T%*R<V^HAL`@TO#@#3$D#YC*4K#')$]'&GO`>3J&CML`0A(40@@V4B
M:4+PYHY\K@0Q[C'O7.0O9,*,6+"@4$?N/N2E?&0"?ZK"<@1GP'$A#Y)$6D75
MS*+F+&,]SN?Z<$.$*,D](@3/VL\J=F>57B<._E,1S]!$*]Z(>-;I(=4G(J],
M(-Z)DA[.,=".\=K-^T`B.UKF^#3"2!SB;#Z0:P"DN[CO)RX%(C*%*(?"&BVC
M+\@2,T8PO[JC7;JD[?ZHW8;$M+R#.5SG=NK.2-I&3R9G)-@'I_CF$,<C8%`P
M+[%%6[CEY@BI`Q42*54%5Z;G'^F"&R73)2;@`=Y)1V9%)I;",:F1=WA$9^P%
MY88%AS`2R?`B7W2#(TY0809EYCYI2Q2@JGQC5EXF_%BH7VHS-E-M:S"+)X%M
M(FIN@5[K+URB*YMC5Z(J541G!ILC0#J#-UYB/%X"--_$*D',(:;SA2)J4*;#
MA#AC-PGHF3:0OSCC_C@<0K5^(MY$YH?<@CY#Z"YV2CZ;(C[7TC=K(N#&XT5,
M$)`PT41:IB4XPR^[B\B6;:/&D9OF$"R6IB0J1S'0Y`#.QY.L1??:PE]2L"LZ
MYW,81C`((^/>!N6XT6W$8O->E',.P'.BAP'@<>.0$FV&*#EXA%1H).=:]"-_
M!S#XY#KM`IS$<<U(Z:B\$C2B<VV<@SO?3D:_D8JL3]0FL3)?12+6A423!P2+
M,CO=YDLBH@'.[12W=.(JH&Y$,<5$*2B::2%N=!8G`QZ[-'RD`^D:XRQA!"`%
MJTE-BP#D+BK`9VGPM(L`$U"APJ^8@DBJS%;&"T%QZ/#"2@(.[`H)"+<<_LWR
M5,L!ZN9%E''2$$*GA&UM%DF7QI.3Y)&+`*>2MN0M]C+.4,2,).(P'<DT6T@@
M:R,O,V)7_R-3^6A$9O6+:LT.$0V8VJAP6+-$O:,]1A(WQ::.[N1-\((DYX8%
MJ67O`)/C3FBP0")@_B*%(&>%]H1-?K5?BDZA1LRYJJ\2)2*U_"Q";J8G:ZTZ
MB<^/?%5LUF^(PJ(<[W%.IHU65;5.C8X!F)/#2E%)+.R3>)`C?LAHZJDC0"0(
MQ:E<RFE/"41BL2XY:((*?Y$@%^F@Q,)C%_%BFX9";6-+9F5'XBEE"J=C%Y*@
M*&6D@M1H>LYK4LJA($I$:K9D>28/DQ1"6Z3^_CY)("RH0:5GG3#THEA*+#YV
M9-"I0Z6$2RK*_&XIEXA&2ISS5/?M(@[Q-DXRU<84,33"FQ3&(B`6,E0U4$0#
MH%QFI3!V20NV3G&)7S>L*?#+:*R,DP0D\&9-?7#K/N)*^ZHD;.I+<!1H;?K'
M=5BO\M#1,A&/!EW'LNCJ<#=(WKJ(<:U5L'@2`C8W02AK*VCK<V=E$^O'H4+7
ML_R5KRBW<_DG6MT+*/BV;RDP.$A7IW@J8APB(96$^?(*=8*,2T4K<7A-:AZ5
MT])B;?Q5^S0B+H[&^G#4/1AM7`L%V8B7.GWI?W;+T>JJW6B7;L/7PU;"1<3W
MO)+-?*5+E-*WROJ4_GW?%W[C5W[GEY1:#W[9C7[S5W_WEW_[UW__%RN4+JNF
MXM6BZR:!QV<($V%-#7L:6#GN-%PD3BH*&(`KV((OF&XIH)K.C%VM2UW;I:3<
M-USF;4K7E'0DV"^Z%8-7F(5;6+[JQ<DFK_(@BD:$(J(@!%CS-,2.3W+DSX[4
M#S(.JU6"SM*8I!RE`M3*HZ"^9Z[&QUI\6$CRKT].Y44`8(GJITN%N"8J[:R`
M:J>4=I&"@_#<0X95V(6?I"=L*&+&R$04,=4@>+K2&$+6^(U3P^?:94,&Z#FF
M0@+.$O)2%_A^PE%UZWIGXOB>SY"Q6'TDK(NK['F(F`#:<W4\0YC.>$.D_@AJ
MNV(D#NXE8#->+((/(963QTL+C5`R6G$I@HD,FZ8I-7$J\D0!\N0VO);VKL1:
M2ED62WA?:J8*@U@ING)H;VBC^)`FG`)]'*J&,OF,O95K!`2.-6;>8K3C)%FZ
M3FZ1GODXKP(MZ&3S0I@JOFM6_-80;:+GELIPF1!B@8[V:,PB7`(A;(D)%2-X
MCJPUEN81IP(660I]_U=A4V=7U^@Z7.-!\,3BA.-X7U(JO\9.]K';%K!<-*0B
MJV0VM*)N[E8/)4-6CY(PY0,BPX**1\<::0/&'CHB_1%+"CJ36)!#BL0[=-"%
M!G(E7[?W!FU<I>*&X2@F9'JS&CBT1DR'"7DC_@\BM(BXD8,XM[3"^0*8(GS(
M>]AG>?WR@!/OAQ\B1R5.]1S*]+RXBWG$M12-83LI>I*GJ5>W]V:/TCS"*GBP
MO\I(B3$W)$QE5LS(/X`82P:)5&RB580NT]Z#$N$C+JKJF"'DH#%N]**BN^"U
M1BK7B<UXPVJZ!B='.(-P-G20;(8IG2([.T&3,N=E65X"-=4%-&AD;@U[0:`S
M=V@M2[(E-$<3ATKXL8_).SF;QB[SA2P;.@`EZV+[,363L=-&0/#09P1B#[?R
M^["R6MK)9^*PT41MF/5-X=0$*,(DX$[+EUVQ(ACBGJE"9+ZGS33B87LWFXN[
M"(]",IA'FV!V"9N0_BL(XK1Z%%,\BYJW9\Z0XA)[,";@NY5747@H1<7^`I9E
MF2HF8`+RV10YR"2@K13/5(\NKE]2BT"EXTQ+$7#0:/7P@@"80L?VV9<T&!&C
M(C0%Y3:@UM_\LMG^3IE(-DKUSAV3HNX&#=L,G&WV10'B-%O8Y8)J"VUDS:VC
M(I]-VVW^Q41ME)S*=3#3T4UN/#]2E,"10[78J50T(\6J]*5*\B'$-JK];C3:
M9#M=`SL5A&"=V:#MVD5\Z_PLTJ<624%L$IL!PR.FI#"K'#>3S2'KHSY*D\1W
M)2-G$D*.^W7N&*;^=2OL&L[/J:*U62&M,%>AURJHQ47KF346H,T3!J]K_O%>
MN0+226A/\`QE#&.>(B^M)VF+*0*(A35?-=KH(%TJ7KHVJC<9%R-L["[#QI7+
M!:>+!I:+YB19+>DM]JIHJS%'@I(O#0)O:KU86QMGE.,@SPJ3S,16S16@?[V8
M*8*-=%W5>YMCR.4V04DJA-4>9["V].4U$/9RGF([N?2S"\(D8MM.DO(JIJU%
M_8?1D5BSRZ^J.6XAF#5C_/(*+9J3W)W$=4]T`,5#/;P@C^.)U31DK]0OW0DB
M1.:SB.HA#$*?'".;$.-HK9A30GEJQV5!-I%@S90ZIJ+,I;@X3_N\F>REV1D*
M;63@FI9LT*00Q5906GYNY5;=X!9F7!:_.N,Y_JS6UPV7WQ;TK&[1+%"V1(@<
MI$T6(52J3S$4ZV*>9O%BN[M-8N]IO?/-VEG.VXE0X?WB.%@<VX>TD:IB2R[*
M6B#"(VT%R<4>-5#BM0X"G-`WR$%'(E>TUMS[114%WT&.E-S^<>#^!)=JQU,8
M0*+[<?A^D@7EV%S/9+JTDLY<PB@ODM.BP,VT0!X?B[*Q#LT9M0F^ZX=]KX+#
MXJT4A1M[X'MOIX0J=QV@I[A"JR`Y.U>_]=48_RH'@'@KI\TG-K>[IW\^^YI8
MCS!UM+P7<1L(>)LSJ1\K@/!&<5D#]LM=K`-7B[7Z<4N)RD4S6E_9U7':3>ZN
M;60*>IXG5HP$3^8B_M>W9-HSB=U]+3@$W<>N")'%QHNZ"(Q^SN[Q/%>[[7FT
MA4>$O?0!HH+`@00+&CQH$(`#@1(`1!`8`<"$!P`&`G@P@8`!A`4=5(0(P,!'
M@1XY%J0X\,"!E"L-')!`$()$A@XCK!1X((%!E2PI3J`900&`H41MWJS@0(!)
MDA\OFA0@]&>%`P@&)ECIM`*#D4N[>OT*-JS8L4B5DCV+-JU:L!36NGT;5N:"
M"`\$K"PI\&);C@D`Z*P@EZ[="@8,T"6@-RO"AG-M&J!@@`"$!P1T9DWJX#`#
MP@8>1$A`H(+>O`\H,#AJ4F%*R917-F00063IU`!@'LCJ%"5>A!=WEZ28_CF!
M@`F,(WBLB!(N6=4X61.X.])IQ(6G.287N)7K[J779<+>.AD`A`CD85;0^`!"
MY`H3!"2(L/5A0>_PQ7-.OYY@\HBPZS;0BEI'3<V&T%9'T0<>9\8)P)5R#CX(
MUP01$+`9A!9>B&&&&G:E'@`4MB6311!PY]!`'7Y8@00B$4#9`Z*Y:%)L`+@'
M$P7"0=668@^L6"$%"C#XDF@CYC7B;5XQ5X&/`@BP@%1)"="`9$L=8-96YN56
M48@<B:<E8!\Y@)AA`E$&P`$H7;?A04@JR>1/76:U@$1&(M2E0"(1M)U):)+)
M8@5"$>4A0U2Z)Y6,4A[$)XP3W!BD?B/QN=!4_@WBV=20BRE6P8XAP:AB2'FF
M":J&#1VP5ZBFGHIJJG`EI6JKKKX*ZV*AQ7IAJ;#Z1&NNNN[*:Z^\2C!AA;X.
M2VRQ![UG;+)=41#;7\JJ*A6&YCU;4+347JO6J+9BRVVWWGX+X00A30MNAI@^
M^"E9IB&&8HI#R=?0K(C)%U%M*?FE9Z5K.2`2C:5JZJE%&Q$D'J!$806H>Z4V
MT&\"$K25;KD23TQQQ19?_.!H%J)Y%@6(`4I`6PV%1%-3]N%$,E)#66L07N>.
M164#=!D@P,,5]`5;?7\-):QHF9$'0&,/!TV>8#<)E]D#5#X4,<;>LNP6N4[S
M"G6H4E=<]=1BU5MF_I(,A`ECC(@U"1B+84H0YU!#,B#`H>+-B5!?AE'0J4XC
MJS9R7B>GR"!&#$:*4-H%*T!EG]BU;2E"%)E'`06#420?2"YZ6")I%@'N,T%;
M95IY<RHKN[>W''^N^*1KO8RHZ5ICB%OB8HW>%>ICJKZEZZUBN?I8S`+`@&T"
M9!:G[00UY``$!"R@LF2Q&2!!?&TI()E'#\UX`.;5#C5MO70/M>3V)B?N$9.!
MFC2!\T,!/Q/T$$AODDNV`DM8@%,]=E%D4FF,9.8#_1A_01$91[M=R8Y:HVL:
M[-2BL7SE#E2CF0M:#I@:`AD$@KP)VZMPMT"QZ$5<EN()1Q#PEXA08'%,_N&<
M0"A0N0181G[^FU%!&!0!<2G$+S+4F^L^UCGK-$58XA&7?%28FIX13(A:J<A%
M).`>R^4%<T0CCW]$0T2%-`U4)V)`6RCSI$A=Y``#\].L!E(9EF1*))TADH@H
M8SP%Q&0D(9K`;>P"D[W99U$,$M.G2F*\+/J)*".2D9C02``%&(],S(/(V"1T
ML`F&B6D*.9M`C.>AA0SR>!-8P)(:<#*V":!";J3>U4)EHSH^!)!JU"01+;F_
MT+"I25S#RH@40D;&R4TH$VRDPL[C+`]6H)6&#-I/KL,VMRU@13`"`.':IBA+
MXBA39AM7+\EFD`Z544APV^7!/`(F9^[RD!DL_@@&9_>4G/WO.F?ZR/_(PS;]
M<20B9AD(#&N(&(I\KX7XZHK+PG:1<\*GG6HB8EZ(N#F]R&1R!,J?P;H&Q80X
M8(H;DHD"C,8YPVSE)[V9204V*:"VB.L!%/F.?133FR4Y<"#DK,AS(J">C8#4
M15STS`%"4T#DA*0^Q'$>$A\:)PD\:2X445YAK%D\2O)':AV-0$Y[.IZ?O@:`
M@H&*320#21>Q;3),.L\!9M9%5+7TJ9E:TD.G6A?D$>1_`J'05)Q#JJ&^2#0"
M\,Q/YP?`27D$K2K3J,9VUSN@&@]Y>%F`9#`Y/=[5YY4*,>I,7CJ9YW#.IQN9
MSEYKZ=%7V@5SB.P=_E*7I]?C=9-@+MI3``^ZOD=5!"_R!-1:33*R[*TL;^P<
MB@T3$CH=DF8O%358^P*$`*6X9"<JA5%N&X)/)@).)C#9[5@=PE`-Z=(G'KG2
M*S&BFHBPK"$CD@D%J&(5K!24HR_;#4IN:9P7T;8T(_V-7&7J7!-6``%'R0E%
M8-3<$@+1FCF2($YRR5WSE$0":F1/15W4$'I=A(./!(#C$""R_ZCJH25\KW^'
M9-T7;J8A$@@P2"@ZF\14J"0^%$A?:BG@"MLGPIQMRWQ%B!(4_M`RSDJ`2GD(
M`0M;<P+Q_=R)#5R0G&17-"P4+PEM'$(<;W:MU!4C1P@`N`9,1+3J;<A>_G0J
MWJ7(+0)T$XE.:B@IUXJFAXV[7VP1<D^+/,#)#+&>@*;5'K[F,"*E&8W'9$-;
MX988<@1Y*>E4A2GQ7,<I3F&O5K*:DJH`43$E6:E'MJ7>ST&`00D8TDH%PC`&
MR;1EHXV.B_#"I**Q#5>)_JXX2_2R<WG7G*`9R@,.[:6!H-`S-0$:2ADTTE:I
M1])UM6;1R$H0OU8@2JD6T6GY#".4=&ET:'**CA-0%6_":)-%<PA*])E.0AL1
MG]PE6'A(6A%FNUK9`RFTF2TWZHM^.G+=Y)WOT">\@32@K4&!Z4CPZ)"VN.0P
M_QG@0#)BL)"YZR,R-)G!<O3E@\B$ROA;R+PI_J-@CL0,I30S#\[064_%U"NX
M!,,<D@62V\Q`8&DJNS65395`\>PF,2Z2[L4G.!P!/'<O*,'?J4U7TH%\QD.K
M'B]D#,``"&`RT=V>M.62<]"+,!F<H(URB4\X0B8G10&LKG:ODU1;0`W))KQK
M%=N8OO/DE):/+9P`SI\NI"B3_(I9>O>DBCVBNK3'=J,!K7EMJ[&6;Q?MX2[Z
MT4THNV^VW&#IUEJ<5E(^L-D3,0?X)1LKXK$YWJA"]E;UUSQD19I\<:YE/6A;
MYN65Q,O$4O:A0&XQNI1U>6@!Y`*8`0"'*8]0_'($,2Y2&F:SXP"*W!M:KD3V
M3-"VB*]JXD+E5))]_C/M2@YVP*S(2*F;%3939"\EN://??R1DZ?(`3$'I_0=
M$$<+VJF_%UTHDW]WPHH"I<!C%C)2T":?Y&*HK0W^")E)<K7CV4O&TOTU04LH
MXVHR)<2-"QH_Q5Q62;9D[O)D"U%/-]-;8D9_M\=DUR<UV.5AVH5HT(=MYP$X
MV#=D&:B!QD(1/#48(]=F,&(@?%%/"&(?A7$8XF<0O1=79S4>S86"9,)JF9$4
MM1%3B88E5.8?FG$=OC%:[`8]_R0UV/09P]&#V795'<(`UQ$9Z?$W]_$9H;%5
M7`0@J&(7@E$;NU$8G@$:![$57X18K2&$XC4:R8&"QU%+=.5A!SA$,+%N_IX1
MA&9X50BW91Z5>Y;S4NFA6#Y8%G#X128B6`F2=[W#ATGAAQN(B(FX*U4$(M'Q
M7#2A?8X2.=+$*<3$(G6B'X278L*Q*2EBB5*U)`>P:()T7CCH(IHW0CR2:%VB
M)=E4>`(A%/*337]T>-OD*<+1):'$(DY124!2(XQB&P%T(1-2)G5!BO=F267R
M2<2C:C_2)@+Q=V%W,LEQ72%!2_-A2PGP+SDT$-&(%(1G>`)!1Z`7-+=A.')T
MBLY(-JSX)>"(*&143)$(C67"CB3ACHJ(C_FH+,O'$:RBCZB"?2+#C?^X&`FG
M:V#AC\K1>`3)D`WID`C!+`8`?-42+`^9)EQ$_A[Y89$&\1H24!??=A#`8E8.
MDD`;:9(G29`H5$@A6283B))O,8X.\Y)CM2(@R9*DDC%]-Y.N@E`%MD24HC<L
M<QN$110G)WM$88`)HXUC$7#FHI/69B%YDC\[2955:957J29(`G28XS)5=V^F
M)AJ-85B,Y'$4)99UT6,1="H+J40/LG,5AY5O\4EQ"2M9DRT/:9=823E.TA1<
MV11+HCE]@T)REB[YLSGD\T9!8DR%HRB/5T8>)!1M(5U8M"0V:1$*0$PRQTWB
M)7J/>1.1.6->(94+X7FBA$L#80#]%4Q/F2%]07L<4G:UDQ"LB1:M$W9+(0%_
M*(ZZ"1)%.2;L(H\$_@,HT[0R.=:4`F(PD<(O,Z*-7`,H:9DA4\268:%^)H&)
M#$2;M1F<:?%1V5DQ%Z$1X*1.I,,[>[-)?`8X)/26WH0Y_&,2)Y526X8^/T$E
M<"AR'R$2#_$U$4532\$S@^4N0256QO8[AA5:=E(B^RF:#:(:4Q@:Z>1?#^%7
M.C>0:8)"@Q$6_,5SW,:A$-)`T[.=@M(@$J!_]E@T;IA/0J&3341U<>25X@B6
M70%8M_83;),T!$``$@(T0N.2T?E9]K46%.050GHATWD6)>D6#F2D%)-/JN$R
M?DD:'N01&X5"!G,31UF<+%H7_D00A)(B]09C18835Q5O(;$97U=CQYD7_BVV
M$2`$$O4EIE/Q$F7Z=5^WH`>U$`SV.1;&*BKF8<YB*IB1/NVD:W0T4R:4')!T
M<L:4F5%F2O[)>:^TG,S#2Q\%I`2!0YA*%/<"C1-Y'L+B>FH".(/)5OS$-DAZ
M$.D">NX2.5-Y*GC43)2:2%J!.$1B)+"D3;0J)7^BIA8Q3!X"7^:TF8H:*80$
M.*NY%'2$9*-!B=89J^;!B+Q$)TBV)+!!1@]AJ&(BC9>Z.DYA)5L)E"^"*[O%
M9V<)%1UW:WIC,*\Y'[`F'ROE6188`;]3>"6">_X9-B6A;61U$?&*9//J`/7*
MKJG::D`3*;.F98$T%6H$;?\'*L=#JKAF5@YJ_D(<)ECL\Y^""(I4)585!(`S
MXE8&4%G9=UH(,0$3L)Y)HE,C41V$P0`2<C]AXYZ\,:JJ49Z6<IXAJFZFHQ'9
M4RJN&J@RQ5@CZT6A-3V3Q58A"XO1XQ#E$V]'$HCV@1+$\UA+)3W3T9_JPSX*
MYQQ8$EDZQ%B<\U!H2;1@-E-;P6[K0;%KM:03,QJ%\:3AJA>9!FIMACGI5)BC
M2H5=076;X7+QN@`'T``.TU8?@7L]:G1[)W7BRA4H$;B#BT1$VG/L2:M8]Q%L
MXZ=;IV6F0E9=*&[N`A-Z:EXFI*'^-3EL^B($YB4]ZG(HM&$#4E\U1R*U=!!+
MPCTC,I*$\5EB>1O9_B>E$H&JE&8PAC<4%&(M0!LJYJ5?L.NG-[-"%O&Z4+=B
M&YH:J%L2R/:FI;M1%#$DV-=ASLL1"\A2P'<5_6@OGV-[&-:CG,8<)5%>L!N\
M6I-\E&,GJ+&WWNH>LX*>!,$_>>LH2_&^)7M$>\,3$5$]/':EEN:?J"M]2O8B
M<5K`96*`NF1/#+H0[$<ZO6<6(E1FJ"(<$">AH<%K)$$SKC6ZNU1J)#>Y37IK
M%=J6P":>N'%_2_$IHW-=I!F96X$^GP4RCL9=/T&N.@MI!1LY*!NX,_*SEKDA
MS3=TTM%JT89ZP581#7MGL9.OD[:O)1*%8(D`D/<P5%PZ)29MLD5T%F2I_B8!
M@N*)L`-2LN5&(&C(.>]A6!E6&C*D16UFKFITM45#49C#P0K7&8YA=`2*;GH3
MC%(L9HB;L4YAB.V&AP4:/(8L*3!R`%PZN7!YA75QOB+1L0='``D'*OU&%#HA
M779:&$LXNKH!%4V7N-.&I<?9NF4(NV3(K?\K(*%G'Z=Z`$&X)=\VMW-1MXA;
M0@51NC2!>DJL(2>L7GJAN=.6R(AZ4-2[)0123ELF=4O'RM,G$DL8S73"%<#&
M<K03<R&W<F0<92AQ=0_PEF,W9*%S)V-2PM-TF[=!6T3)/0H`,7@ZGL!%/L!X
MFVO5F6%#)=AQOGOVE.4(K.IVCTX1T"E1)>?;_I-F2[G$:";GVG&J]GF6C"&<
M5D27)Q0PP6FCJZ^14G,'Z&(/;'X8Z+'6-,-AQK9"7,.3,B%/5A/M!:@*I2:@
MZ+ELF;(T@69(@KR@HLQ`5W)"!F4NAW]&O1"2NZ96L1$EX8#@9[I&-1!6HM3A
M6SEL=ETMEI;AEKYM3&D`^#D8'&9M2Y=G33&A.AU%-"M86X,K:T)7J(1U6!^3
M8W"![+D($8/Q)+M`EU?LK$`GP;(KX3AFHAZAT1[O$1^IX<MU?#ZSU;)F6Y;7
M5:!*(P!)C!W0>2'*[#)YY<GU1FUD5[_TQCE4%MF\$;6=]8.'*-?;S(*.`1ES
M^,D<<5U=J]I?&\8E_A08:#F&N7W.2(B%V2>[:$W<"Q2G=K(1S'@X=C&*(1(B
MQ'AZPH%"1WR.(Z(DRD@^GWB;R1&-W=D5Q#82<^)&2Y(`A;(B!^W+0T+/9E2B
ME)*<7H,8-`*7D@*0SZ<ET3B.C(=/0Y(<^7U"B+%QPHC0AI,<KO@3T.T`TBTC
M\AU*JPJ1PK&L,-*LYJPEC`B+$2W8OF9"%&V,TNB=Q0WB&"/,(0X6&8$A)KY9
M*#[-),[B+>[B)HDL%Q+CW33C%33B+][B>9DJ<RD6.H[C/X[CO0KD)&[0#\+4
M8HT6(_?AV#GD3>[D3RXQUQ%K<%',7Q&_7R'E`\N30@SE7>[E+QY&8\H>_HY9
M3/Q=*>UM$+[G1?#=B;SZ2L]ECF&S;K\CY.`T2=IDK+PT29%L1LQTJ&X>=@W]
M(G%>XLJ$8!#1+P=K-DT"X:IWX\HA$P&2-V312<_HYX;#$:>JK0U^Z)=.R5;Z
MY3-9YZ'N%JBV45,!A&>\S$C+MY4SL:D.`4[[<7Q66%'!.9X13U@NM$G56(5E
M)6JU4VP&@$654\WSM(1LH/(9%!;5%6$8GE9KKU[U5(EEUOM2G%6]N6*A$8*A
M$S)!@\>Y:39QV6>EAROA[0#41T7#O:2.DM7.[CT^8A+!07O!$[*<%YHM8:`+
MP="1R"]J'P>P`))YY?_[8_"6?D,S&PXVR..;_A*JK8`$C!4PYA7T1RK:R\A.
M(;Z/#A<4X>"V^TCLLA!A+J?'Q9<C+^8(`7H<M(!NU%X!8J?OWNQ=%(2"/HU9
M(AD*"XA@<DNDU-#QA42!*_.ZR29+>>F2M.C*ZN@PCR''IA/Q>AE]&19!""8\
M5\V6\VA9<>H+VFD?(3<.,%Y,\?6SU5V6YO34YA77R1Y^!9;\6&Q<[B`>`:%>
MLCGB`AO28^J80M4DH112O6L.VXWR@4+C(60^Q/?KAB?#H?3?;5$859_+_HB(
M*NV.0E=UX52-KZ*$D:.100%3*A`.[H*4D=P7ZVS2[NSNGOA#FG+5U;C3)MI@
MO12EO!EU4O6T;'-N_C;P%1ANXI@4^F;OLV7U!$(!X4@:96]SBD\0/Y$1!B`S
MS/P1=7+[1@Z\E&PF%6'QY:?Z6=,>:J0CPNAAE[T=0A<VU^$XR)SXXK(0TK7O
MOWWKE!9BJN<N'>0:;5,B$<OLK`H1%=]?&^7^&7_ZX>)_`%&A@@0`$`16.'"@
M`H`'`AD`$,B0PD&*%2D26`!`PL""!Q-6<``Q8D.&!TL:4"`00DF++4-6>"`2
M)D0)*2M,Z,CRY4B!$22B/"C`P4R3#P@:%/B1Y<*&+2OZC*`2P(25`BF4W$DP
M:@6?39U^!1M6X,L#!K@6W!DA`0$`)0\@J)`@@=,'`@Y,8#J1*%@)!@1$_HU)
MD:%$@8''"M`K5O%BQHT=/X8<N7$"A0S,&BX,42?$F'@K8EX((>;$J@<-AUQP
M$$%ELQ1!'U3+EF'(B:"72L:=6_=NWKW%)@`P-ZF`!Q$4=#1@(((#`2)O*WY(
MP"-QXQU71I@HD7#>F`\>L'V0&&Q@S"\),EBN<2&#C9B31_B.%8`#M0+:`\#.
M%*'0"!D-;M\N+`,(>``"`N;RB;X#`&!@+X0(-#!`W\:#R*>:!""*.06*DZBN
M"01`BJ()#A`JJ`8.:@##KT)*8*.S],(I`@%.%"C%@PZ<,$<==^31*9\F(.#$
MTC++*T.97#L2+9&&)(H"MEH["\BAD!2Q@A07_J"/(<.8E+!'+[\$\\OK#J*`
M@2>;Z@L``W9Z3BR"IJR@S#.M8NL_.TU"*D6AVJ2+,YE*B\````B<*".%,)M`
M4`()'.M)%YW,J2$YU6RJHXA"#&N"!`008`'/%A"```<00`PS"C85U=(PQQ+I
M0`$:#*S$.$O""=26##C`Q:04VG7%ORC2JJ>I/NJ5(Z]613;99`4X#J^C/%*(
MI8<<1'(K"PW#*<2/'HH)3F:G>@H_J3Z<\JH'LA+WK&.59;===RMB[MW<''`1
M*GGOQ3>RT]K"ZR6[(H!`T`;C"LZBE2"((.'[T'O((`9XI8C9A!.>Z``"1"-`
MH948MG0E"1([8.!\_D<F^:"'(":QN.,,>H\Y/UT:%&.%=MI/Y8)\:C`D%T^^
M%4(<_PV80<PL+A"\,B$N.6FE%9L@`@)$7AJLLB*0P.*HK\ZWM*MXK<II-1W8
MM+9T*<JHK;:D@XDM1A$ZDB.SVXKJ5$X3T,L!M;UJH&T`D,:Z;R\)\FH",RD5
M*,TU7[:H6P($H+N"(2<UH"&+]1I0V'4%TI133[EZ$FP099([58,6]+MTI0DZ
M0#S3,=]4``0\6SUVI>.%3"\)T)8]]])'Z^TUW%9277?AAR>^>./Q;?KIW!+8
MZGCGVZ4@4+AZ;SNRZ`V8_GGMM[\7=N[_WA[UX+\GOV2<#-!U-]]K5S/]_O+?
M+U[5'C&3G]T1Y_NJH_57I1]3^/\'8``%.,#M\2E'-#/@JJ[CO8J49']AHM_E
M"#A!"E;0@A=<C($,E))`J6DKF?,@ZT(5D@>4Y2`*P!UORI83!0@*?28+%5*^
MPQQ9[>8X;3'(!$#%++UT:$F*8D#%>'6<B?S(AF;[3PO;!\.+8=")3X1B%(]7
M%XE)0&(9V4A9BF.U!V%L-N"JP*LF)#C\9(<ZR1$("B$0$L!X\"$,E(P$'I(?
MBT'`0+R2C^,`H`#XV,5*(A%45,S$&S+F!P!G;(T:V2A%1C;2D8^\5W<$LAJ/
MP&4!6S%/NKJ"DZ$8<4(('%A@KK(5N8!$/:&A_A[F-`DN!T*$6#.9@%:N8H`&
MT3*5$0DE1$8ID%)"TI>_!&8P<4,;@4@L80Q0D0/\TA9JE822EM%1!%EUEHDA
MTT$)?,Q.N/2?\`3F-@5Q$GV$<I>QZ4::IJ3F,54D3':VTYW"I-_;F)D<!IP+
M(EQJR(]$I2,$AH<H,9'G-?VIOB4EB9OH#%!'%G"`!K2(.-4;IDP(0QYY0O2=
M%\5H1@F(F7T6S@$K\4PFK4683H%Q0N?,I.V&<L[=["1&PL)+*Q$"L<Z<Y0!#
MV1O?<H-2F@!`I1H%:E"%2C[,U*4!\'E:@I;3G(_5,3Y-X5E2H+;3,A;),+A"
MZHGZ.3[(#.UBW\%C_C?O"8!+U@5B;<DB-A\3$T/Z\ZH'R.I0Y3I7NL8.-`\`
MHD,X=0`(,"M.J")AX9:RM]Y`ZDY[R9P8]8BG6\9)`9KSC/Y^.*@@3F<B#W%?
M;@R+2L2V;JIU!6UH1>L\WA4F-:-%;6I5N]H!7B][%7@A:V4[6]K6=G6SS*QM
M=;M;WO;6M[\%;G"%NULX/B:WPT5N<I7KO/KESW^?L6C^)-@8ECS0-W.D"(FX
MNESN=M>[%E%K4?AB$\9TR3&$J4F8"("[@WW7O>]M)%D552D(D*X"R&QB:.R+
MWQ#%1SF8&USD+D6ZT)'PLIP268'-:YI[+FJ):?N:3]H2K?IJ)D0=T>'<_IIF
MMD--]FFU$16GIE2U0^:*,6^*4\9NLD,%B.T@5=$@`<@+7QK7F'AMX=A_[#(4
M18JKQ#R^V"(WUA_UI*PZ.K[I@XI6$F2*IE-)\1DV*7JQ0)E%J9C%V49^K!^>
M$,U`!M@P>XBR$CZ:=2;*>6,%,@8P-"Z&`AD1G'VZ"%8'D8=3?+1QGO4<NX+Q
MTBR$G14IYP+H7<9E+F_QR`.R!:V%\"I8ZEJT'BGPZ*YLEZ(N>LF80/(QP@"Z
M2$RA=.JLZDJ:3D5GEPIC`IQ%(S<30%`-H;2I94+1Z>[9UK?.UU)>@K]T1L":
MO(:*.KG\XB-Y<TJVX=#$H()LL+RDJ"(!SIIZ_E@I.`W6.Q#=S+!#(\VZ!*?6
M7_$)KVPC&IDXVZ2X1G>ZW[4=;S8E)`'=#+P'2@&J%%LS3<'GN]]FQR0-M"6!
MH1FBF$.`[/C3VM.FV4U&XN*$KE&B7E'+H+;K%%YO,^`02;BZ-;YQ,/4Y+G_V
M)T%^BEZ?>A2VY!7*LWI%\I$:I>1CD4"LOVUN!@_$)HMF"8":TI5'@Y3+9"GU
M!"+XYJVHO+PC7F6]388XCC?=Z3G"L:]+LA2L?N=$5(>KU4U)GTWAA43T\0^7
M*>!4M@PE.<59"Y27[._$,3V3Z#DU@[3LE?<\E0(#*IIPY#YFLO9Q9@]7<GJR
M^%F*PXGL"B'()=]-_JVG-][QD"'K@M:VE,0.C/*>/8C=0ABG`%?**PHV"`4>
MN[='`;:Y5,(,H.9;*,(N)4V+DE3K6IQ&PFX)B*0!O-P(U^C%\-JQD"T,6PY`
MT<<7W_B]__;QE;]\YA=EXLV'?O2=?GKI5]_ZU\=^]K5?X^)N_+C;!S^NP]O[
M.YV>^CVZWT>C*YGSKW7]77U_^.5?XP4_YI+ZX=/X)[3`_D`]^8VQ+OB;OP%<
M+AP1"*`(F@^3,$#CKY8@EF9QB#_C)G,)GCV:+QA2K'][D@]B,1"C(1Y#HJHH
M"-)A",GS-03K"1?Z(--C.ZO8E!":(1$S#>$[#KK8P!0\I&/KG`JXH?8C_L`?
MI"UKN@G\(#._"[.-Z+'FR3Q`XC4#N#J2@,*6B+J&N2\0J8O3@B[TP"(ENZ,S
MD[I8FB,*\*8=6X@9Z2"XFB,KXJ,M]#+P<,#(B0"KB0DT`Y>8X!B(&C(L.H_T
M2)CY^,)">CX@%$35"I9X>:6:DHA"ZR5@*2,U40B<*#@*-"^/2P`PZYB7RR[A
M0`A%2[I30Z5]X3U<RHQIHZ2D0`"9"QX\0Z>8<!'DR![@<$!-'+[T&L)K0PIZ
M$</X&\1=1"T90XB4^*:#"K83;`E1D9&0$+JPPC\)TC7\P(^)*2>>H(AMDJ:=
M,#;Q0J>1,*83Q">G")CFP#C`:T8IO!S1DXV&_D``ROH8QN/%=EPM9-JEAN..
MBFJ)A6JH-V$`I-".\)C$@>J.BGJN[:`WBP,\PV@WYQ.HBBJ(?@L>9-J0O!$H
M"B02\)JW"7`2)^P*CQ(8=G3'CA2M6E&10V2E?'HY"8`3B@@WG'JEJ8M"\-+$
M2O2)Q*`7BP"*8J*7I!LZ@[RW:9NFD0B2@S!)F6L)XI@F:<*>@X!%FD0Y];,*
MAN@_AV`ZCY1*T1*4TXJ)LO*C]=B(JOM)*2PR!G&^?:Q`!I$ZEH'#M&L[KA,`
MK_.9OQ.OG=@UKYBHAV,.^OB.!B$[\_J7;C/)AZ.`(7L(B.J6^I``I5H0!JB5
MA#$AM@K$J73,=UHD_I6X/=I[1,QS"A*!2EW)B<-JH(4:E*;(,-)S"LW[K]_K
M%+P8DI(H#1&42QF2*(/`*\IRP1$Z/:\9/F9)31EZDAIT"4=)HQ'JN@YBG(W8
MK,<TSN/\GL9$SN5DSN9TSN>$SNB4SNFDSNILQ^ZKH.^SSNU4KM+P00J!#.!0
MPO+B3/!ZK@`TI]?D2.YD3]XRC/N+C(Q3C*O(2L=0@+F3KK;S$LRX/_1LS_\T
M'N$<L06Q"^TTH31"FP2LK-2+O_@X`-[<S/U"P>`+H1Y\KF;;$\\PP)/[J^8H
MS4BA`-W[4"5:&YIIP+!0E4B1O(:PT$_410"%T=S!";@3ES4+&"B!&<\0_J,B
M-+-G"PO`9";\(\,FN\*9T$*-D*.J8@R,N(HI$<*7TJ(X1!N61`@XY*(IE"R!
M6("+R9OQI$CQ:@OZ:)8D;:M<C-$S?1Y:Q(F&<)V)D`!6:XDFC9*98K`)N#@!
M>47GX$=>N0JD`)X#D,6&\$^4%!>T+$05444VX<?P@$\V>4FS>`E%U$2*&RCM
M$)DLY0GY1---S1US;(OPZ"MO^PW6D,9+*8_W&T?\FY)AA(HVT52PV)1C2A=?
M?-#,6R8]Y3*\`L=2I;EA%,+\Y`EKRT;]&%1.-=:DN<BC6HJ((SBPT*<I:;@[
M!0MVTU-S815Y6HF*7$^GN`IY$@YX3!=ZLJ>%_I,(9,(21=4+X@.HMT'12EU4
MGLS)%SW6><T:D:!`^#0ZI_@6SQ!)I8-*/$5*7"4YF>R+I=S6?S.IAW!3LE*1
MFLI&*B7*AWU4=!(YDYO6G:/2A:M&>:77CG47PP3+.A*\L(BJF<!*Q.N[Q0,+
M(*U6JCM+Z1C,3;F/_'@8`4&:!#E`LA(6^G"9N:/`O62JA2!+;MD+KH336U$.
MN].YF6BK@_78IY474!$54J&W%Q2PL`"<:9Q,"!N^!MU-YS@HS`$5T00)WTRQ
MCK`OI\A7V&J-+L5`OO*KS>2<O:D+8/3,M<$6R^2+^6*4%)64.B%6CH7:P=T=
M3+0*W5!.'DE<PF7<_N%RK<:%7!C%K<BEW,JUW,O%W,S57.4"$HNXG9980%Z+
MC[6AB+PQ&\81FTDEF`N]UK<9"@D@%34YD=#E,*]DH`5A7;%`ILV3FS;E"P+=
M')!H#E&[B=91M;.0)R_=W.4-$Q*K".>U"&6:&+S(&YOQ'S9*F+J`"X!*#)Q(
MH"Y5MEBR"X1Y"`>(GCZ\)*H92ZCQWO]K"63:(L3@0A7["E?KH[GHCD#AE<.+
M$V4K"^QDW@#.$=DX$@+V")%8@!E3,Y'!E8J`2!B:B8@5WOJ33V)RB!3R/2GD
M%(K8W?`0T3B$$A2J",7JTUCK/D\BB^GY$1-VC;44X!?^DDE+.!F6B9J%_BWZ
MT$RO>"QX.9)I00T#H)SCJ+4'1A)%LPHES&#PHL)B(MHH)1HPRD`M7<<^C4E5
M4EZ;RSP,D951JN(A;!X*J"$8%N,=\9WUX92V`+,%/@A!X>&)T=Z9((B-L!`*
MKJ@)N)]#>AKO2>(&*B%>04:):-2IP!]/:HFN8[8X/8@/`4:Y'%=LM))U&N-(
M/JGJ\9VQ&PH@F8OR);*VT;=#:IR7L*4%`+FO`-^)@0T&\$SYC8B3I,B::F"6
M:(!;C0M2!5V_:"/!:,'/L(N8<E=DTXLPEN1@UHT*?C_#V-T'3:%AI1+F()=/
MB][JH47!JC96YF,POB0?"P]Z@@"(?%:8:1%A_H&1:*2(L9N1H)B2&.GBE](C
M`!;F=EZ,,JX>I]$+&XE#CU!=316EX"BY[X7F4QK":;[8*D1++7FYG2@I.$H1
M)51G0J9)$[-GF&)A'DQF=Z9H`*3D&E8(,,XZ,0)C!)"Z\<1GD5B0L#J:9U:V
M"+#(KX,/[3())]4IB?!>:.40G@W:DHV8]*68^=W?J3J8B=F(D*`/^N7?`WPM
M&Z[HH_X*>#[@PI$\..F@_**(D)8*?1R=ZNGD,.4\MAA.P9B2M&4LMN%)9!I?
MO\K:<$G>#F6<R.*;'CR;P]@;&#'>Q(ABKT;JNNZ;SQVCB=87PX4,"%!@NP;L
M"F*>'!ELS9(>W8BM_L!6;.&:W,5V[,>&[,B6[,FF[,JV[,O&[,S6[,WF[,[V
M[,\&[=`6[=$F[=(V[=-&[=16[=5F[=9V[=>&[=B6[=FF[=JV[=O&[=S6[=WF
M[=[V[=\&[N`6[N$F[N(V[N-&[N16[N5F[N9V[N>&[NB6[NFF[NJV[NO&[NS6
M[NWF[N[V[N\&[_`6[_$F[_(V[_-&[_16[_5F[_9V[_>&[_B6[_FF[_JV[_O&
M[_S6[_WF[_[V[_\&\``7\`$G\`(W\`-'\`17\`5G\`9W\`>'\`B7\`FG\`JW
M\`O'\`S7\`WG<'=6R`\'\1`7\1$G\1(W\1-'\117<1,?H!5W\1>'\1B7_O$9
MAW'.%EP;N_$;<[P<MVL>AR\?UQT@=R\AKV@B]RXC7QTDYRXE%V8F5RXG[QLH
M1RXI'V,J%RXK7QHL!RXM%V`N]RTO)QDPYRTQWUPQ[S;%NN/\.B2*$$^A-9NF
M$)3$\#B?J$][$98+@X]^*T,VQX]U/:0V>IO`-)O2_!(RQQ<R3Q/2<],%4?2%
MT$2?``YY\G,"<)'X$,W]\0D\1S9(CQ@_.=VHD"<,D2="]Q)#SUPP)R&`Z10K
M@JLWG3I_;@Z28`\BBZ5/-8ETB0E-V]`(GC8B7@B<@G6&R)O"K!KI&':JP0ZY
MHQI7"Q-3EQ<Q_Y!3C,.UC/;"[#JAW8K1*$RY_NM+8J^<;BE,$K%3BXH)51;V
M)'&`D%@G@@A'8K<:98\YK5QV'.T19[]<+Y?3PF"<%%)8'--W[2@78;>+L^*4
MB2`+Z;!@5E$>IO!U_/%WF(AU(GZ)C/.]5X6Z%E^52DQD$$%+@<"10Y)?!)H2
MFJ$-L+R1!'C5F%CX<^=J@-J*P!S676/EB@=S>[=<+R^MH(`:K=@;%4&`C"")
M@/^.!,B;R'KCP)A18,[UD6QXE?1YH'_@L3,+7__U)6QVC`\38`XCJ/FUHY>H
MD2^WP?`>9'K5D/`YEF_IF.@EQ@E'JU"*F8<3BY\0FZ]<+Y?/))Z/O`?U2E-V
M+"H(%&.*3-^)Z-!/_J5X@*;_=1_K"M-]<U-ZFQDM3*?!PE+'^HZCY@R.2\'_
M>E:)_(RA>J`F=U)C>'1GHPK)>\<W&TX+='F7_*O?;"_WN9XX3!%QQA)2@+["
MO[=Y@..@&@%H#8E8"Y%_9HY8?'1GB@?%_7,G]C<Z]L)T<S1>%;IG%S$W>2VM
M"ZX7]?`(_LU'_4]%1@[>DSXA?K1?Y5CQZP0`.(V@&A."]YAZ&WJO=QL'DWP7
MWHZ_+Y_2$L999/H/(WGB98"H,$$``0`5#@)P<'!AA0<&*R@H^,#AA(,2`$"H
M`&"B@`0*-#YH\!"A`P<C25H$(($ARY8N7[X\"7,FS9HV;^+4F'-GRP,&_A9.
MP)B``$,""4`*)#@RX4&3"QD(H`"`0=$$3ETZ/!AQ(\64$)PN2"!@HL&K%9PR
M99CVXDJ>;F6ZC2MW+MVZ=N_BS:MW+TRX?"M`?1`!@@`&`P]$D"#R`4BI`"(@
M35LA`L:45#<>=+A4(<NL%2@(V'@X\0$!%3<ZAKQ1I(3$#`!,8)TX@E3.2/^R
M](M[-T[=?"\NB!#A`-&!"%J+/<VX(8#-34=29NZ@=6D))ENW9G@5M&@!B"64
MGI"5LL&LUTG_G(I]I63,O!&^CR]_/OWZ]GG[W@L50.&#$PXT1\`#%&@$F5@(
MJ;9<!0@0M="!CRT$X$+N,11=9A!*8$!S!K0%_N&!!6K6W%C,-=?<:PH*\%%\
M^=WW'HMZ1:`A``>T!5YS-"(8X5++F1541@X4-.-*(38'V4$6,@=9AANN9&%'
MDY57(@`$2.!8B0+<5D&*\KW8HI=?@AFFF#MU.:9]!.*$)DMJAEFFF76Y^2:;
MN\TY4YUOZH2GGGORV>=?<?H9J)B`"EH3H84B6M^AB3+:J*-\+?JHI'A%*FFE
MDV(JUZ69<MKII)MZ&FI?HMH$*JFGPH>JJJL^:BJKGKJ*:*RO9CHKK;?B"F>N
MN[ID:Z"^\BIKL,,2BY^4QR*;K+++,MNLL\]"&ZVTTU)++:_58INMMMMRVZVW
M4A8;KKCCDENNN>>B_INNNNNRVZZ[[\(;K[SSTENOO??BFZ^^^_+;K[__`ARP
MP`,37+#!!R.<L,(+,]RPPP]#'+'$$U-<L<478YRQQAMSW+'''X,<LL@CDURR
MR2>CG++**[/<LLLOPQRSS#/37+/--^.<L\X[\]RSSS\#';300Q-=M-%'(YVT
MTDLSW;333T,=M=134UVUU5=CG;766W/=M==?@QVVV&.37;;99Z.=MMIKL]VV
MVV_#';?<<]-=M]UWXYVWWGOSW;???P,>N."#$UZXX8<CGKCBBS/>N../0QZY
MY)-37KGEEV.>N>:;<]ZYYY^#'KK>04ZYW+$+(#N!24=9!&!_&C584%%2_G)(
M^HRPLQ1!002H]A-E1U%&%4,)I#7E0:A70+J`N95(9?)2`GAL4+$;9#N'J&>D
MT0)J42^0ZS@:;WP%R$^FH0%&(B2]^++;?H!:4BZ@0&7:$X`EE*C#+SM#-@I)
M`>D<:@1^"_D?>YK7%MU-"3*H,Q)!V%>B\Z6O1`OX'_I:=Z,J80\AVQ.?0[:W
M(`@][WDERAYEW`<8S""0=PCI'DN(QQDI.:]]`[0?9;:70L@$!5E$$1_Y8L0?
MVT1P2A#HX$$0`,(`<D9#'ES=A';8H,(1#UD%&"``%H"`T&2$/_%;@`/B%YKX
M42!Z!)*``#JBH<NP\"`%*0GQAE)%!2R@`;A;_@AE"##!QTC()%@R204=\Q,D
M0J1Z5;SB_!`B``>\YB<%V6(#O/A&J71OC0X@W@'DUZ`J<D^-!C%`81*)N^8H
M1'Y0LF/]VC(^!7Q1`9#4Y/,8J18!;+&+XGLCA%X#`2W"$4@G&0@`$D`\TZSQ
M->[#)1>IB,C;_="3=;SC8*8")08XT(JA40TL<[E(0J*/C+W\Y00LJ<$Y/J\U
MMV/E(N&(/@!%8'JC9.8<];<0/QKRF(I\8QP7LL`30F"9!:$-''$9/J:(DC)F
ME(Q&#OD:+!5$G"9,G_LN@LD*B'&%X'10LJ9X-UX>2T'ZNTAZGDA%__`',_++
MGD_:>1)WSLB=$M51_D4N<H#72,"(L#$B2VX9FM/PAP*BW"@`_KA2![8$I9%<
MBAU-I+U,AG!*%2G))W,J2@`U:7FS:R(Y=2.^XQFUBC5\WBH_:L_Y=5!_$KKJ
M5"%JD/49!$`MG=$J%PA4*!V%K/K[W5>SUT'Y.1.35RVAADSY5I9PU(@946L%
M7&K2FH;T-$-UR58+$D;8%':<<_QG5)ZJDH,88*%SE!!?+SNAYE!`,]N[2&A,
MY\268%1*"K*;2*2$@+)J"4L_+(F1]&<2A[A/0RW!96AF]X!C/D"2#E"-1PDR
M0\H$%T`/\`Y+E,N4GM(RA`<I8R9!,\^2#)>5/Q5D2CPR(]@\=+LGG)%I_C6B
M1%$:5P(3J:!T"^K(YV&W@K,=+NK4BDF"&':^"&2(;B=D`-GY3[:'I.U'`XP[
MZVKIB?4SZP06_->>%C2^*/5I?Q%B`/G9=X,>C=X"U.1`[#*$`O@SH7'5*-LT
M'L2Y"C$>@H5;0?S>KL3)L]]D=WA>@U!7/`[(GB%_"\L4-Z?#W,,(@S!YVW&&
MSZ,+:6V)7JLW&0%@`!7QZHP#.$+M:N@_`*!`A;.#K-E="8$E6G%Q%1R5[Q)&
M0T`,R@&"DI[X0;>]"_[LE6W'&:%654H2D!^;PWO8PNY'P]J3GVZ-BU</4OG+
M=G[?"%'7Y^T9$76,.18$5%IA\RZ:TE0<LY6;_I,1&2^X@[T,X80[C9%28_8D
M/>7S=P6]$(=..<_-65-SV@+J$VOW(%)I,X0UO6B*2CK!,Z3J)^%<:"R11]52
M(F%S8HT0L8CE-=O+,H`(E.270%G*>Y-``)HCQ[*R>:*LS.&81VKB/VO7S2J=
M*&$-*R,M>_9">JXB1J4;[@F-Q0$"F&=01T+=V#[OMZ]A`/)>X^=_4[>2GY%=
M^!90[W;[N;UH;6]N/%KP(),(LG(]20:9<T<"BUN3(.>/CW\"\8;6F;MPG>A<
M1ZT5L$;7X*XF]D?7#=N3`SSG\BX1:4M.<8:$J"(X7VG#'^[92XOOWR$?9)&J
MZ%!.7]LEW/9VWPC=_F]'9K&:]0SAP'\[HX$(``%G1#=\'8#A<B[@,EH7SI38
M>="S\*>Y&SFFM.$N2*PC54)H%YX[ZPN@[:&TD@;QGY\Q_'>SIGW?Q;;[.A?)
M$CR3FI[",R0CD4?X[>70A,1L`-H3$QI?\J?!,MD\E5?*V;;O,]5;CKPT+[OY
M:X;&E-H$O6E$>7GWFE/<?^TW'5$/(;_[6;ET%Y_>)<^0S!_)]^B;Y0ZW9Q*#
M"#0!T7OE,9](5@TZ1+9IGXK7A[G#M;/$ZGXK@"DW7;H@CI-]-*ZVC5XW<?.S
MU78[7/9D=F<DNI8PQ.,$C>,C'Z#5SM%KB%[SY!H%1%$"$(@[_1?YW!*B_@G$
M`1+(!(C%URV>=/G0`2@<;$V<_#':C8A2!30@D+T0]"P:_]`(X3%/B2S4NHF/
M`-9?`BV$29B0`P6(D1P+<30/>YG@2GQ@"&K:]>W>XYW$#>D:!`+%_BE%@P@@
M!S($@-@&$1);PVF7#Q'`:W0@!*V46CC<CU71G)G5*FD:2Y"?Z-R)Z+A$&9IA
M&JKA&K)A&[KA&\)A',KA'-)A'=KA'>)A'NHAG4%+`)F:M/AAM@3BM@QBM12B
MM<R:("8BMASBM#0B("ZBMCQBM$QB'T8B(IX5(UZB(VXB)&:B)'8B)8:B)7XB
M)OZA*)8B)Z:B)YZB*K;BLU0B+(ZB+*XB*KZB_K-,XA[JXB[R8B_ZXB\"8S`*
MXS`28S$:XS$B8S(JXS(R8S,ZXS-"8S1*XS128S5:XS5B8S:.R[>42$PT!UGL
MQBUI8]QP(RXZ2CE:E31YQE^LXSBV#3HR2ZN48TP@TEB41QDY`)?1V]B9A`%,
MV2W5#R=%P'Y<A@$LAFFX(]O`X[+((S=Z(_>=%0-`Q7#8TE0,DRU=B%0XQ`,<
MP`.(4D]E'P`FY-DLI+(T9*6`2Z\$!W-T&I?U5K!=&=R!Q&HH!4@\'WN-9.(<
MRTG.14KN%F=D14(X@`%LY*E984*H$$MNQ%*6Q%EYG0$X64XNSDZ>8S=JBE7^
MY(4T1&@X0(,Y%C_V_M0_.B5&$-I90<`MW9*S2>7A4&6C^.1XQ9OJ$8":O.5:
M^F);,DI=!HEF/5]<UB5-0$#Y\40AV67DX&6BU.7390_A$52GY02%N$4Z%>;D
M'*:L8.53!,AS0%@*^D450A/<&>24/-8!Z./DO08!3,`$C!U"#!%_L,YD,DYE
M%LI?BM!TA$9<!I%+2-\!',4A8017/,9O,L!"'<!M.<1P3HC7F05L*HYL"@IM
M.E1'@%*O7.9"+)>`:.12>IVGR8^"[`=C=&=R%B5SQB9M/F=UQB#M/*1?.-1*
M",!B;$1:$D"E62%";&1PU:=&.,!XDF=SFN>OH.="W.81<>9+_%LB<1EJ_@*(
M/Z[F^.!C:4[(62YE?_IG@)[GK+G$+97(:Q8HA>ZA<P(HAK)$:DWG;EFHA\XA
MB/H);4;1OHF(6CIFADJ`.(*@KQ`FB@*.BO;)7_;E`SR=3_%A3'B=KN&D74`F
MCOZ-CO))76(4Z_0E$,4H2YB$@$Q)`H@CZOBCKJF93V"@:NJ5AI3&,!%$4#R`
MEI$FDO:-DNY)7<I(5"P$E#D;;6JD21R9EBP`8AS$+4&%0PG'2SEEG2[E+9$%
M9?`8FN:-FNK)6_9EH?YH!PII468%8;39SB4/4;BD4XZG=LY=3!KJH?[GBF+E
MTSF@9CI3;O;*?FIJ\IB$76W$^7A:IJ)J4)Y(_GS"!N_,:*?B#:+BR:<:BH7^
MEZ!.:")-F3X.Y0&(G5>:);`6U%RBQH).`(WB:MWHZIOP*DU4*Z2(9+3NS;2:
MR;7VQ8GN1G9I:Y)ZZZ[.X[C"(;>."3JB:[J6*[6>:[NVH;H.2KS*ZQK2:YO8
MZ[VF8;[RJ[SZZ[^B:\`*K+82;,'BZL$BK*$J[,(B:<,Z+(I";,12Z,12+'E:
M[,5J[,9R;,=Z[,>";,B*[&"69,F:[,FB;,JJ[,JR;,NZ[,O";,S*[,RJ+*D`
MR\A.I<WB[!O>;(OT[,ZRI<X"+1O^K'T4+9BDSL2=#OP!T`ZBB0MIT@-)@/*(
M)!0>R_*)R`O-7X"L_H0,M1]5D%LW6JT!%=;WE!\,%9`$38;K3-[8)I%>I842
MF1J<90_<_I`%>8=@.@2'5MG]O*`*):T`1:VG_:T-DFU*'`N>+>W+U:T-1<\)
MH@Z-?9'L=)S=!IG7NH[#P5]&.*WU^%7SE!?:SNW:\@?8?MG8<BU22926P5+8
M)LLP/5`%>:X,71\10AC^E>JK'"U][*Z7.!(8*:W6V88DM='L<9-`;(C(35)*
M#1(658CRX=X"F)(6:<BD?9\\M1(<-0#8B=U4Z%3DQH\^04@R01@G2>1FQI,G
M$5-7EE$"C)WXJL;M.-0&R2_&K2_J7-(&P5+U5H#Y>E(3@A9#R`]DV!+\_OZN
M*JTO%6T1VY'2^!H4^DX`G%63X@KO5^6O\88>7D$&>=S1^,R2_L82VLF1^1+/
MY'4>+]&>Z+&19,%>983/`Z>'\(*=^WIO/U43_$;8_V8A[I#P5!RP"+N73*$/
M\?82$),5_.91W/'1K?0NE]P*Y#&<DN7:C'0<$=D49`D53P$ISEW?ZO;::44>
M0W1<29D>9.57]RC560"1TEK<_)04%X.6:%E9:-EO&^>5H+D9["S5FH74:C76
ME@T=Y`DA`*^5]^4:L2FN%'OP'9N;QQW:>'4P_ES&S/U<&C<`CZE4%7<A47D5
M1WT2&K<Q2?D4\9DQ,J$8625915RR=K%@@]S2_FL&7BL3<F3Y:4PU&TTQL="^
M"DI54V_I%Q4)7*NJFLDQI71=A!L)*(T)V[G-UH`@,JZQF.*YV*4AU:T=F.(9
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M/_5N44]1X[17_]U`RP^=)L0F>_"C/?6OB?4WPE__#O-/?^ZP_=.545I5KY0^
MTQ_-S=%?NX?^9)KU^93M"("832=9W=JN882+0NFJT+2+/#$G)Y4BZX^;-7('
M$0E0S]W`G;9D,1@MA]R!?7%!^9Q*-;(7DG(AV[:^F=SVH""^^1Q9==R"<;$5
M-=T&(7=P4O+%Z96E0IC"!3?R2@D0!5UL&Y;$F?9)<'&^*=XV:_=L.S?=7@B<
MD9M"(S0DLYQ,*-R]45QJ;W(PF_!#A-L+#W<HGUL9\S;)^;;JXDY[I]]#_LCR
MRJ5;3PTXD/'VNT6/8(*V+K,*%)^5UGU;V6$8!IN&\+GV4N`@WO5>`Q-7K^PO
M9D1=\6V18911]TZ>^.`P*2,>5(!T@XR5A,_P^T)O%67?4=EXW.F5A%L>.8<X
M8_R=BV,F`W3?\=U(\GGX%$MXZ:TXC,/%^WW2DF/5PCG=YW&3*($I_1A$C^\X
M(^V=61%<[JH4"G-3X"DP*KDP&,<X(\UX[JIXC3OY*RVP\0!(F/.=@!N?%A'2
MYY;$V>7YVN'PV^E1!4@?K80V?HPV(J?B"D+/&#VN!-P;_RD@`5!M2UBM(E])
M/G[R02QA47^MZEXZI\.&!(;&I!*;`-Y@V98N_AW9GP8-A')KSZOC./3TH-T>
M$H%0`"&9>M]^(0`_8:M/,?247N&NE`L:-2>G^LOE*2;M8"#!W8I%\D/X(`D6
MM0%J$6Q94/],NOE)5=2ANK!_.LV%^@G%&J6QV"\AFF3+=>R"V8TP9F9J&A3B
MKOO8W*D<^F[<>ZB@(>7L.^7D^Y\,+=$Z>,"+SK]#"L&KH<'OA<*'BDE*U.+F
M=$^MA-,>!-1&?.V`KJ4#^]72V2$]/-EB[JJ[+O1M/-FV'X[PH?,L[7"L^I&4
M_-O2+\S/;2/;.F>TG^8"G<L-V_VP?/\$KMH.;F6@[I24'P%UFO,0>Z<U[:-3
M@$Z5>EOL+<U1P'Y4_F&(+2B#`\:^,;C%\Y`@_9]+2`C33JVPUVZKW^ZH!0_`
M,'Q>K'VG_#"R5[#R%J^5AQYU_Q$1;S@A%>J*:]WT_GB48Z\(<^\9?2\N\3WV
M^B_ZYG"OR7#[TGB2'_G\!A#*=7DNX>\W42]F]/#D`=GJ+<0`GY"^;5,&+T`J
M247<9V]P'+X.PY<P+;[OU/@#TPC=FX:T_6]$@9.T-4"=4Y20=\944#JM;>9T
M[E3SWJAFS,X*NY$K';'R)?$>$2B_M/U=3'^GJ#M5=;'$'8`F;\\55T06/X0G
MLY1L9[_QY''4[=X8C[*3[S<H[_&Q3Y3Z8S<RQ;']UO]SBW%6X?$7JW*A_@8%
M0`@`\*!"P0H1`"RH0"`A``@%'R0LR-`@``(&,5(T>`#`A`H2`!RH8'$B@(PF
M*W`<>7&A28X>08HD6<%`PX<5(B[@&`%G@PH3``@DN'*CPX(.;E80@*!"`I08
M%YB,BK$"A*`=1P:EH,"D1I`&,$X0(/!DQ0,:*[(L^/)C2`8`)"``T%$N5;MW
M\>;5NY=O7[]_`3\%/)AP88R"#2=6O)CQ7HT,%RB(>C&H`\L\2SYP\/9!S<-@
M.49TT+(@R`1HQV(4H):`@)$"+#^@D':B:Y(D*0@`R]"R@PB>[\Y<;;`UT=Q@
MWX8<2OOXZ]Z_$2ME;9LA!`205SJ\+K'RY:@O_KFS+)X\`6:##@:&I+HZ)O""
M`,"2?@_[,G$`O:43IUZAN7W^Q7'3+;_:C&O-O9$,0`B^T2I`+R*1B"I(00$6
M,.^@"28@(#Z[(B``PJ)$0S`AKN13RC6#$C"@+OLTXXRW^F8J:+C:$'K`PX$$
M^+"Q'7GL<;#H?`R2+R"%+-)(Q1Z;2TG*E#2J)"4%@.XSH`X`:K<FX4*K.(-F
M7,BV)0\3;S\L'V)(20?<D\`\X:;+2LF;(F!`((4J:O(A,M/DJ4L`$Q"@S[<4
M`J#//[FS,RHJPR/PH^26HZDCCF9#L:'.!(.OI#K?M$_)`;UT<ZZD6CK34Z/V
M_/+,`RV5P($Y'9T`_M(("Z+@`8X&PDB"UB3`2R``S*,@)"M'B@R^KI[:\B"X
M2-1TKBC-G&NT&#EMS5>.(-#MOB.QS38Q(K4MDMMNP04W2=J@]>\G^+BZ*:>(
MFKQUH,T`8$`C*C%B*R98P^3/TML$T$Q`M"I(5]$([54O*']!4X@"@`]>%2QH
MH[JIN()E6D`N7KFS>"Z$`E6K@JF2ZUA?T!0X]T.0FF00(B4GB'AE.M$J]]*B
M8#*X7X=/JN\UA%/"ZM[N>!(8IX08@)`AH%*&M6@)U2N-O;L6&`TH.AO$$J0%
MQ)I+/GH+X@K,F:T$&%^*'7UTKES#35OM]]8^\MNVX=YQW/<HHU`RGTJR_HRK
M`R00*`&G!'#UW;?D?2HDR!00"%2$"%B`(9YD?FV!F@BZC265$%^``;&6JHD!
MVHYM_'&"72):0-!5"BJR!1K@/,5X0W><UV`CLBW0!6H/5O*[IUJ8.PHI[YF!
MJ#XOB'#-FBX(:9&R_CLHCTI4_6YSF19]]IE4HI[NM4QB7';(/6X>\`D:$%1.
M`XY'3R:[HP[)`:>*=S1JGPY(P"`#8'M+Y=#@!;1J8B.C.(.H:E9.:HG>#C<B
MS>VN0MX;W5M<@Q[7)$!'<;,@C]YV0<)D4(,=],O<B(*E#S4K)+.1`*WXQK7<
M$``M!F#ADAHE(880`#.1@Y(#9F,YXW6$A!<Y_F%0X@>K#EFDABQY"X;Z]*M\
M5>"((OP(1P00OR'2\#U8HY#N$B*6VXWJ`,FR2J"6A4/^R.6*^BE*I+C'H!^&
M1`*1BEF31HB8*19QA]`KT?:8B)4YXG&`*$2;G$IH+$B1R0$,B:)!?-4D6%'@
M`&.)W[1BM1J)D*99!(AAUP1#P@/X#DQD.L@,,8,0^R%$)&+SX"D#@TK&<%"5
MK=06&ET92UG.TH*P+)+%:)E+7:YREWYA92^!&4QA#I.8O62`+8N9S%S^4I?,
M5.8SH1E-:4Z3FM4,IC-IB25M;I.;W?3F-\$93G&.DYSE-.<YT9E.=:Z3G>UT
MYSOA&4]YSI.>];3G_CWQ24]K[I.?_?3G/P$:4($.E*`%->A!$9I0A2Z4H0UU
MZ$,A&E&)3I2B%;7H13&:48UNE*,=]>A'01I2D8Z4I"4UZ305Y"QOH<T@%C((
MNY140;S`92\3".)AU,1*"MS4+\?4EE-<>A>?TK1("#DE4?EBT[:`!"-#9:E=
MD)K,)E$Q2$SM"ZV4=$F]*)6F-;'C7Z(JU!P^=3!>95J[L'E28EJE(%;Y*@8M
M)):@5@14>YF=7HP:')[,]2YY_1%??136F4(.L(TIK-KNRI>\1L"O(R%L7@[;
M2Z.TS&,\:JQ5:G67B!3&J'M-JV/MNM?$7%:.:@4H6]]CE9?4A``YK8D!_G+E
M+MBBYV`VFLOG$FLFP!I%`JQ]:F]+R"M&PB>V#('MII3'D)V`Q#0"Z%N4?N+;
M3<E6`LWUVG*4I";C/C4JM8K`6'(5DH,=)'`<@2VFM$O<YK[G;,.ZUG,M--Q-
M(J0FH_$:;L.;TZ](!+C9>\]>!2!?69D)M_Z%`('WJQ!W[:0BN4)(@MT$$K]F
MU[VC@>](8O)9#SK)*LVEKD4L$EO?!NRV_QMEI1@+`&16!274':"@8#,7^Z%U
M603Q*VW[);CS"I<CFP1N:RE<W1$/BVHR)"YR66PKJ<SE`?25B.#F"V/.9E7&
M;BKR7X!R$<S:SU>400@#$.*[`Z24IQBI"044_I0`,9/YS`AY<&*AB5JWLO$`
M3)$70D9#P85\CH*U>H``-PMGT,[T(?5CHL>ZR$BN1,!B6RDEG\<LF"Y6+<6B
M[&T#T)22DDTNKP2`M*4[\MW#\(0`/D'`R4+M&@-8Q@#3DH`"["<96#MZU`LQ
M=:03P-+K86VS!L#TACZ&``HD0`$U>O,$ONLKPKIY("!Q5<G>@A%B-V5XPB:V
M40+-MTAA&V,/</:DT;,FS];(V9W%6*VSV.M?.Y:-*][E9!UG:4\WA2,*D5=*
M[">O<@>X(\SUZP28XJNWKFPBD&ZIH)SM;Y/PRJA+8X#]WD.0/S=:`3)AM+4K
MKA`%/(RPAK[W?9R=_I%/"P:U3-LWN3LR:P14".&%V:Q2BMWM\DU9Q0*(>8I5
MG)[[I,?-(]'J81P2$:M$I.>U^E1$(N*4GZ\U:=?CB:]>[FP5'RLJ";@)FL@B
M:$$?YDY/Q\I[//)=7D$7*$"9#88:2U2&8PQ#'0$*AB5D5+,?"R$38"0!ZLJK
MN3?V+`01^-MG9]0HD1W%>V<[NAV<\[:K!L#F3DF.0;OVO&(LMH(1-5R@*VJL
M+]REFY_\@_];D7&C9.UT1S'<P^QVSF_]FDM*\01`,AL%Y:KLL_/5"?MU]N\U
MEC^3O@M;#7]PNV_E<48MO=GQ;A"N6%TI/`'\=P%,U,=BS.M`>:SRILYL_HQ@
M=BXT=(DEC_7?S$?IZX1!SWN>Y:!H$P:0(8K`3H6B<X;TC:H#<?>QHHATS->_
MR4#4/Y/O3YA*+O1H"BBBKB.RSR3(QT,.X``:(-!<BO52"^[*[JR:)*7:Z^SZ
M#Z=RJ-*Z!ZW:2%;D+@']JK<\1N\2D"I,$`,E3$96951T+0(,C_><SO2R"U,V
MY@-+XRPBSP/_BZ:LBDL<AXL.P#(XKUZ*,-Q([\$Z4/3:XO/,+>T>B]DHK.>D
M:G$4,`$+$`%ISV=XD$*(KK'ZILS:*@ME[RGRBD*L(L4<*Z_0!S$6$*O:"P//
MA@)DI0>WT/H&[5S.D+0P(J]6<`FQA/<`@UUX_F,D:"MY`*,!XV7G7((C.$.\
M5*QH:"JS\*)\#F#5EF6G."*\'@`3-3$B@D>:!A"T)NW.KJ7B]HS>C`*SWB_:
MM`XSO(TJC.(43_`A'@"H"&`T(D`D!(!^RD/22B;<M,^Q7(4"#&#3$@0EYHV"
MC$\V0B[TFO%#[$_J9'"3[BHJ%&(7#V*3G'`::7`*.>\8B6,TK,/<;L\:P_#<
M'"L9/P8Q]&<AS%$N7O$(16^GV)%7P"VQ!F("%FT)H_#T`F\<L=$*B\F`PF\5
M^PS:+L(6TQ$N5&P-_2HWS$,"8NCEIO'@VD)62J_TAJ;(6M$B>-'BN-$ZW'%R
M>M`6>U#DZ,T/#ZX:_M/COTH2`0CQ+UZ.0A!BZ%[N1^:BWF8NIM+CSZC/_NPO
M+[`J(J"NVZ#N*-.#,P(PF&A0Q$*,E"PB[+:K6H("`LACY\A*[6)H=B9@Q%H*
ME.!BB`3@(63+[M`B+(=%OU!"00@"N&#+=SYBNY@**Z_E?LIRNPP"+WF1R>".
M[NHR*W'JD]0+,6J"N<(/+O\0E)B*J6CK<]`C,=_L/:I+N1`CY.9H*]'CJ3B3
M](2L+0VB?,3+JN`B0R`R"!U%,<W-Z!13JBS$JCZL)ISK(T:,-/D,/@@@&/M2
MD7:2:4J#+TL#)9S"A1(`-<L2)?2P+P7B+-WE+#%LCMCRO!(3+GXLOP+3_LA@
M2S7I$"3\<O+2BX94<S#RBETLKN[(DU?T!\0D+#G<+-IZS",D\#W`S!$)0+[D
M\\OPC/+FLY]J<D>>,J("]"\&M$<2!"<JJP&`S8,*%"\:5)GZ4Y:J12\>U"X"
ML$)-BZ+&,T/_"2NIJB"`BD.U1;!RZ2WJ2D11-$55=$59M$5=]$5A-$9E=$9I
M=)7(RBZ4*B\VM$9Y-+'23E0&PZGZ(CD^]$A^DT>1]*@.ZS^!,TF3U(!^D]L&
M+K3V,"\8X$#1`T,)8T>QQ9P,PTLWJ)Q:-#)1SR2HBRU;2\=RI;L^ATT'<SMA
M[+XP@K;LQS3$Z[P,@BT+<KC.Z\/F@D]C2R`._L1):=2`!M!)H)3`WM$2*0P[
MU!21$JM"T#2\:N)UZG188.O`;@O"`N\L&8!,1S25"H.9THI46]0A^D;9PF\:
M)VUR9JWB]FW?%F;D<BW5(J7LF,LJ*.@X=:)>%$#1>(7B'JTEI4+85''>IH)0
M>S0IHA07RX_;]@W=',#97O5#"-'C*&-:00XNK"+/J&5H4`[@%"(!B@=5`RQ4
MP>I+1?5'UE5%JZ[KCF7NV@YMH.]<'N\!/**1H)$$.X*1<@\CB&_MY,I>*R+L
M!*)>:^_LD,TD"&_NN%197=10*P5(SP-_ON\KIP]AT5`PVJ[Z:M`C(=-BH=`V
MT&;Y3M1;VC5E[6I4_E4616W*6GB"N:9N`B(B!&'J;+J1)4X(R/KP*796-11`
M(A>N72Q02;IS9C?0:E(08@N562OE9!OP`5O,A="-L*P&^\RC7_+P8]FP+1K0
M"#]/*89P@,X'77U)7=-U@UHV0U45L_"51&`#WT[2A482**HK-9T-'$WB(:$G
MS(16'KN1ZW!"%T=2*8#1J+BQ%U=Q*F:1:6%48@47JNH1)NV(:Q-71U*$)^3D
MV0YM)=?.OG8"'\,V'O6%)TH19=-6;5-W;6=J3)L3`FA+)=)2+B^3,,F43*G+
MJD`51'63-Y]S<<@RO:`S+7WG=P>3(BS1<4_U`J>*]3AS5U1F-2M1>.O*_FOZ
M=,BP,SDY@@!L2L9VSC+;PHX:X'7-MB\^RU15]VR5MYJT='W=]R[:-R_0B$GO
M0D'C!GW3UWQ9=G7?MW_]-T,?UBY"%&[PEUWY5WT1^'\5>($9>#$*F'6#8W\3
MN($IN((M&*H@6"\>>()7]H(]^(,;(X!)=,KV8J=&E:QR]$=N-+`R."\V6'\/
M&(1E>(852X,CRR_H-R')DT-*]885XX5AF(.#>(AIN(B-6,E$1,$P\_W,ZVY?
M*U"AB\@D1%!5K(F3V$U>K$_ZBP+Z:^$D`#?=1,!$R;EJPL>6N$M;N'5C>$C2
M^(C=F(*-3ULY-]R$%<_HC2;6;5L]`ED3PEAE_D*.&TN4GDW1#L#>5@\"4M6H
M&HW8!#G1NJB0*Z!\?'A;VAB#U[B#A?B--=F"C<]JT6;LG(\=8T_U>M!A@R*4
M>S"0L4*/!*+R'.M=PV_\T).5U6Z2T3:3V?B2-;B2-[F7U[>3V:V-V"UE6@QC
MJM`8M1"MELWR/M!J*.#Y?N)\C(]YC\69JU1(@#B7<7F7==F7O=E]@5D?AY%7
M+M>.55'O"A*T^/AR4YF9)S`73W+AUI#%$'<>)P\7*6B<;7E4Q92?R<F?Q^F;
M!7J!F6IZY7(OLY(JN;>:*P<[IRA+"'-Z4?/%C(R&4#-UOOAU4=-=Q/,M06DZ
M1WB@17JD%>HI<QB1_HKD0&V$I%FZI5\T@+7%0_?9I6FZIFWZIG$ZIW6ZET%B
M*$ZZP8(D0O=B0\,,(DX$([R&;X(C5\Q*@R$NCU@JI93:A:'D9!7#MOJ%+X0T
M2/9(-6&:JN?BRNQJA3526:,J.=5FJ_M"+L[O+P9XI__P>72XAH/:JG$82#++
M]PSB2MNH`?7JI[6F),R#K89M06GQ)A*G1ZIEW*A4J`OCD%[.0GXZ.!X"]'!X
M+R8[8BTD\!!+M,#*P0*#K'6:E$[L39TX(1@"OR31PL;BZ7J,`DCS9O`:D6^S
MQ,084W/J$%&$*:I457^"*1YS]>9B4H.#MPZV-X=S2B>0Q3RLC`=L4\U4_E!$
M(ED*`GW.0S;HE,0:<0YONU(KM2H03(JABD&.R:CZIBVE&,IRP\*>]K^:*[N[
M&,-66[LWD-D`3$3W"TXM$\1:R[&<32P+@C3K=,2&"+:(>WJ=+!%EEE8L##/1
M:^%0Z+92&[T*_&[[!*?KKO3T%@+<K)/3S21\+=,6F2LD+G"TRB&P=200.<!4
MCN6\U=A(SB0F-*YY./Q*K\XZ%ZK^AHD6#;E#C]"Z!M<&N8NX#1UO)(@0\EQ@
M#R*1C=\(:\1S$B2TU3O!M=G*[Z5$,O$6M]NH5<U6SN&>6L6/!<T0KM_@XA17
MC]>8'/HZ(JNGC5Q%U(Z=41#MS<M(21DC1>"8_JM5=P/2</SCECEIK5;-MWS4
MC(]O/KQKI?'6+`W#36)5YJQG%W/U$N_O&!;`8-F%YUG@3+;YR`L0SRT<IXW&
M4RJG;)P-;>_*4ZLK#++DYG,09]E@&T1D=1"SGLJ`,(0_%.!Q]+4)0?G3EQ"T
M/"_8?X\C?`,!32@?Z_6[D`]4FB1*ZLX.=YWRVB*8PZ_O0@="+D^T1PK4/V]K
M<8Y>`7;:+5L&9U8/!<[I',_I:"K#D]W0CW`@YQH%>U:Y6;K3O(I?)YW=1H_"
M%"D.J4+45#P/%\5:J/D)==!7H0M@[\KZUAW5NW#@>`5];&.PWW+J@)R)R*^:
M8RH)0_W15>I^XL?0_L!P=GZ6W0_>Z:*6Z(@]3S=$"6=0$!7I#0_;>#9>;-<0
M"%?/LTK#A43IZVRNLM3*VP4QXM<.+NRP44J>"440:<&]#760W3TK]@CVO\*9
MYZ4PYD>[F+MBY/:=^D[]&&<R)"=`913NA!BR;46R*F@R%2-MKH?&-1K7>.82
MJ,KN)]E0)>?>L=`C4&30'/?6KRVR0;[*2>3DG@=7N)J(?$!<:^UH54PW2F+/
M*CK,&AUK)L.6^D1W"<M>-8Z)`N*MZ]_Q\V;R(VM>X\U;Q8@NGOF=H;DX)E-D
MAZ9UZ43*G!&][#&&(:%^;@^.`M:0]^.V?E225];QU%M?\-H4Q:Y^W[_1_NMS
M.@BC+7>CN]I3<])KA:,C`"O/\C>3XW.N,Y)?%_L5>F&K/2P$Q>>H(F2@:S*\
M6.Z&+'JM\WI4I9F5*-#@'THBP*HVTWL=@"N.!B``0*B0@$"%@Q4>"`!`8&`%
M!``,$$C0````!A4,`)"P,0(!AA$X'MQ882,#BPD`.``P4L)*A!4D:(P8DJ6$
MCQ]%EI3@$62%"0`BP"QI$8"`F@=32DQP$\`!EAM)1A"X4.74"A0$-(@)8,(#
MED/#BAU+MJS9LVC3JEU[<.I3`A,J*(@85:,`"3NG3M!H`"]"I1-E1L3;U,"$
MO0SQ5M3(TR9+QE'Q7FWZ%&9'J'BE.K8L^6-?_IUL0XL>3;JTZ=.H45,8NYIU
MZK)77X\^(/0T;=FXV;8F.\$@;@@"2!L0^L#W[K0.#%#HG;NY\^<(8T//?1QK
MWX2^IVO?SKV[]^_<08-'Z/#T@_'H)?A]?;)\:(4^0Z<4JAZ]?>_B[YMVL)"`
MA.KZ!2C@@`06:."!"":HX((,-NC@@Q!&*.&$%%9HX8489JCAAAR"MX!%!ZPG
MVTGQA44B`4*1-)IT9`&0`$(GB3C4!!CE!]-4(,I(WD<"G*>B:44)@%%:`G%U
M'E`R!E763.NQ.-J/'5;(P&I0C@712VK9.%UD47;II7X,]$7!`0?D%J90*P%X
M9@5I*DE:;659A-!'_G"&%5N=0T'`$@4)&""60D)-)2AJ1=[D0%H'*)"0BQ7H
M&5:18UWE9ENG3?IEA$I:.I94:SFI75!X7BKJJ-2Y.0$"6#UUP&H]?>:B`!I5
M-J93NP$%YP)X4C`IK@P!L$`%4R70(P4B?0C`>7,=>Y6Q0PYET4`2+!0!!!]=
M5-)317'$D4:_(O3501S%-90!S3KP502S7K<2HTX9=9ZG15+@@$'KOMBN2@@E
M]]`!P3%0IK/EZ115435!H"U=A^YH$0/;XDN9IJ0JF&VOOT[PU'4C653LPC%Y
M)@&U"[.H9`0"(+9J<0MS)"Q"LZXZE4:'/CP51]@>.M5"$>>L\UF>+H``_I^*
M$K`5`K2YF&@%)U7@,]#1@446O`Z$&VP"93+`5%<DZY5U5!.0#*"++S(PUU0#
M?>M48\`&=6RXY#D-,:0'Z1K!T@JLVM7!(?J+](L`'Z2GKA,<O(!73E]U5%<'
M;-5W6V"!"I5'-JO]@,AE2W[5`;]6%.K.!F8:=5<*)$!!W99%,#/6`E!``$94
M%WFNTP0IFH"_"HPY5^7!KK=T`@I,-3E+F%>@N=J#?RL`!-]RKKSR5^&XT5'`
ME@P`JVHCR54%T)/<-$R'#<7B89F:?O?T!)QW0$,'G3_0Y3V*"S!+*"J9',XC
MLR1HXW`Z.E*H<!,;%/1`P8H"Z*0DCJC./2-Q_LBW1D=`R<!.((]9"?_*$QO'
ME016C&L>[-AD`&G9#S/[6UZ"PE>2K/WD@>*K`+\>`+[5=&]^:KM1<+@6/0YZ
MT'W8"]3ATK:3_:G-@0$,H`B'2"JY'<161;$(4*@G*<)`)8DLFU2/9B3%<Y4P
M-N1RFDQ\L\782.!\8@D*N688`3(YX"7U2UL%\P>6J0"(7`@YP'R2^#P%Z&E0
M&4G:HQS"`(,(8`&O"Q3L#&"`JFDDC!3$GZ3X)4@-PL2,$OS@3JBT.2+>AX1J
M2^)Z+!B3\QGP)P\@4P->-Y0_QB^)D(RA99+HR(U04FV"%(D0+4G++H7I/_,A
MP*$@@*K5$:1H&5'4_H<JH,M&H>HOPT%:R1X@HCX)A0'22U$*%_6K8_G/FASY
MBJ[4TQ4'X#`H*ZFFH"B0M#3>+X1^VQ.98G*>?$$/.((J9AG=>$<W?>57WK3,
M^@3P.0K44Y`P.4GDRB2!=B80(>&2H*0BT$<*G%-DZ#J)(X\FP5H.").0`]:_
M]N?&C6B+GRJ<#SE5"2-\N4ZD$MU@,7DY445%<E"&>T#R+$I3#9%H`4=I"HHZ
M-AB1/(RG.X6)L:YSK*$DBZB90=L)A0(<BSB@J59AR;HP@B^$>#13$B!12E:"
ME]Y$IG%-*LH!XC+3@\`'?1WAT4``DQ*_V*HD"<N848;$5LW`1$]^P5=9_NFH
M-+J@C20$4,#!KE=2%ZED,XAA3$WU`YFD]N1XG+G*5'EJ&*T>=BALZPF*+(LE
MA.($*;+DRU<=F+:/+/:TG$MF<;"R%@"E!3BSJ:197`L3VCH'MBJ4[8%L>Q;>
MHI8[OI6-OJ#C6@H8QB._3>ZHFAI4[;1G-`:UT',3HMSJ1F@^Z#D)]*S+W>YZ
M][O@#:]XQTO>\IKWO.A-;X>,%:(L/7"3T"JJ]7"3Q$-5*6T6$9)Z]^N@(#7+
M-%IBBV[Y2^#[W'),&^49"N.HJ*^\2'_TK=Q;\]1&D!;XP@0J5#%/XZFRZ*FJ
M/!3+A\\CF)WJM#%%\1.&5]Q:4Z&J90Y]5;W2_N;5I\!)7T3KUP%`9JV;.09F
MJ:)5L(*CSP32!<00GA>+EXR>>"DY6@#4B'\L-IB2:*1/C'K98&`\9*O6)"Y%
MV93XC.O2X!A`F"K^R7:9S&:Q].QGO,O=^!I#T4D93B^)<QU+CO<MWRT+SKUS
M49(D["O"M>W0;4[TEASB*`,T0%]'6\"914<ZE7#D<XTY%-5"1P$$\(HI<<.(
M&QDGEE-AI2M*`IQ=TQ=712M:@QK+WN$F0`$&.DY%EH)@1BH*PR!*\L[1T\NC
MBF)?TJ83T:Y.MFP@I<VN!%!%)GRV-*\(%H[(6MAW78A#.ARWH[D)EB'&K;(3
M;<2ETC$V?[PCCOY3_D*8$-*0P#O`&:-R0AY*BI4;/*B70]PHI_5QW`"O%!]/
MJ3%74N`KFL2H%^E(4JP\8#7ZXW:TAI1J5#OQ('`,>)L/G,M=(F`RTSN76UQJ
M*8&FK4Q!&2GV(/`21Z[TXRQA9I'W?15F1KQ'!=6XSM=2))+9-P(6([/2)&(S
MNTW;<8>JV\M9I*N!\(?4/XEK5N!T9F4&4RY^FO`$6KUS`M\TIY_5"5OU(EH1
M?26OA^+L5$SK4YN$'2JMSC5IE16DAY>UZW@?]EP95U3!?$:M/23)9=[2M;?G
MJ3^UT<E,/RRG$M,')\9>5-XG7YJ]%%XLKKT-Y3=?H.`".#NF\3SG1U_2_C6?
M!8&D3WV4ZJ/ZUKO^];"/O>QG3_O:V_[VN,^][G?/^][[_O?`#[[PAT_\XAL_
M2LY#N+TLTBVV`,4@'WZ1K@RB-@:X\2-%XQA9-!)C%ZG.*<X+T_3NQY$!'__\
MZ$=M\@00:-]51#0XRDK[XW\LI]9_4$6-DT"^HJ=`EL1'^U=_*1%=Z5>`!KA8
MR6-2*_$`>L06T%1_-D-."_$5")<3`A!4UO0T<T6!SX.!OR,D'&@1#W>`)%B"
MEK0N'V%?Z^(4HD$F%W%8\?:"7X$MY/04F4&`0U$1!V``ZY(Z_B)X#Z"#/%A_
M&H&#)GB$2'@IZ\<K_7=W1`(BOO)^8E5_\'$__@^7@6.!+?6G*Z]SA:%4%!QX
M$B.8A&18AAT2&PB'<N*#0V@A*`+5*^5'(FX(/$X!9KIU$5.!@BUCAWAX6*=C
M?K>7?"A!%+Z"$-S7;BSRARE!=P2@*[`4%<X#%!KS$<TG&T`!`8FR+N'G.`N%
M<+_#=X9AAJ(XBMNQ?NUW+.^7,0-15)VU*`,8%#BU+B,F@%0X$N>Q$JTH&_P$
M*PI0A/_W?PL(%0JA`+$(%E]QB:28C,HH&PFH@L>B1S=#5>=15@AW6<$(*R)8
M?]DX@O)U@8#8@HN8*-8TCC)5?_^G$L%H5G"WC.S8CJ*!@@HH5@>Q$COX?P<'
M.RL!,U)5?Q=#A711_HV$6(/WA1HG42T+^(M)5(U?,6_)@T9&^'I)U%RR$6!A
MH84B""94HB/0P6V]]5_N*"I+2#;'DCQ:^(NM^!5O.#?\=%AB6'\MV4Y%986B
MMQ8S2$!>R(7I6'\+H``]8HR0:'M%,@$+`'JOP2(?QG7(IA\DU!T<:19-^9$<
M@H8@0FU@9GT#HXUM!(G8\COE]XA=J41%065CU1P<X3/3HW`Q!$Y.Y3PXDF:T
M!REX]2J%P1&0%Q-2AA?)@A$S!E%L$Q;),Y<*<Q$-XRI\P4W",I=31#)4AC&$
MV#`.(P"FQV,,0Q=#:2TF$V-`%BUT864N<F5!1IB%&&9/R'"D*9JA49JH_IEO
M:)&:I0F583&3K.6:T!&40YD[OM0ZO_)O<H0T_H$Z@*,MTD%.:>-:^G.;&Z5G
M>?A+R4DUMLDZB?(BQ$@W"98IQ?,8C^:6R"D0@G(YM9,H?@8_&#%,EC:>$L!I
M=>,[4J.:+<)S3\*>I^F>P?=M()-]+YB-$2$NTX=?+\(7EQA)<M(QSD,`\@:#
M5FD1.+(`)`(Q[C9^CU,4$G45?$&(O)*@D`D4YY&@$1"A)\1RVC@[!&.:>1>1
M:_A)ZW9";[5-*^1"E3E-AEB(?\(22\1O-J1*70DNU4.B,704`+1@F@$XLS2/
M'11#K1076T-CTW,]&+6C:_24S@*?;*&>FR(:_E`:1L.7?_>7*3YRBZBV;19Q
MC_T'0<5A-0=05@?``,GS%7_$?NFX*"_AA,.&/,*(D`\0C%\:A.;X+4#!+_D2
M<V!Z$*M#->PG*-_BIET'-SP4HR4*%-:CJ)WD1X#$20D1%XP:%HZ"J$Z32@N7
MJ3!ZI(;S='2T2=-V/]D21XE#2AKD/`;Z09;:;N%#1U@"J:OII+)J%E.ZGFI1
MJ[B7@<?BC;;(A9)750\XIQ`(=T1#+JUX/)WU$4`1,V=Z683:-"`HC%S(A0L)
M=\]XIV#Q%''U+6B4,,5J<NC(IZ-GJ+%AG`"@*+J)KHUX50:D;DX#4G^3<S"1
M/,;I92.5G.>)+_GJ_J?.*1>%*$^KLF]I%!1!9Z\I96]0438)X'+A^3BLFE'S
MI$BX:AFS2B05>Q83:U55"I,.\(,W2(AFTTXN:*8@TJW\$8`,88L5B#U1X0`'
MAX((AQ'/.H].,81R2HB7!8-.T:9@\3=[RB;KR";:IH#<:A%$6:AUHA-S21=W
M89>)(3P<,W:%`WAWYT4>4UA;U2YPX18,T375=K6#TA20U:+:@K#Y=Q"<M1DB
MH5F@Y7:]$GB.I58"(P%>=:L7B[%W&R=YFWNZVH73:DUG]VT@4JUZ4KCQUXK'
M@B5?,1%J:HY`^[-EH87WDR)>N!*%"Z8<^+B2YRTL<;E<.CV!*A`\FZO?_O@=
MB9BQ:@&;9.%YJDLH>VNK%ON>=BM\81D4JF*'(&L1*C:'!YI88!8<SH-Q#>`\
M[!>"#L"6A5.K?>AW(>0XQG6?CM-G67DC>\*?5A4<:6BVJ+MY`QD@+$*1J+6]
MVTNQL_NDKRN;^<(WZ+N^L=N^YEN^YZNQ['L6'CF_]MND\!N_(R&E^JM[W%=C
M5C4]&H$N*5L4O"*2]AF*X;>([82A#:I$3ZI$$8HCC7A$!5P;=@:)GD@41$%^
MMZ9)V.>.4V(@9R44PFD66J*@:C'"W?N^[MN_X[N_^4M\S^)_1.&)]&>G,XAR
M6HJ,MB@H./6S(7NV/*>E_=<F[93#MKBG`\A^_D%L?_XX@*^JI7BTC"HL&CKU
M>#2!&#MUE-PC/\"+JQUFJ*<9**DAONTYP[&JQL$7C='27+H[@<%ZK0A'N;\:
M5ZBXCYS[JQ38NJP(=\W6P!/8MZVAD.%*%-42@B/9.$?"J^R8+:TB(G/9=M?B
M-+[T=%HQ=%7GJ5_6-'XQ)6%YE\#B,:=J57I2,Y3U'ZJ"F3K[43:3.A>CD5'*
MQGA+RWIKR[Y'CY5E@R,1*\<RLF(U66`8I[;X?IU5M/89P\0&=RO8&L`,DP:5
MCQ"(1J+%@3!3@44AD+)LADHB-/L"$\;92B'2&J"F%YQJH*>65<,94.!':@>`
M*O_FS42C%U-DRH7V_BW&R6EQ1G</NP`OLI/2B<OX*[LO7-"W;'R2*SE4\H;5
M^!3E>$\S9'<_J;*P2&2/.\0/2:O3"$%P^HN$Z-!4,H8HJ9,\61(?\B%AF+B,
MK$98J(P$>\X(8:FM%"K`<;Q9^6U,I6U#<7`"4"8+=6HQ2BQKEV`E@5=&ZD(3
M<&V2%#YWMJ,"3;X$O<8N+-7%M[RWZT.7%A1RZ#NH9L@143HJ=)&DME!A^:0F
MS)^2\G!QF$22V!5I4W[K8E^7Z\'B0T=BR8:D^-+4$]/G/-/<<SY'<LX5YQ+'
M=D3*<6HI1!)(<J0?$RQN;<^Q=*2$@V\\1$*[B+,M/-!4#</\^]2CJ+JM_NL@
MH9W70E&O<^*<X2*%=>)+"*%?DE9UT-1T0@L3(*4UP*.NV',H<G05?:)/:012
M<E1,#["P2SUM)TU,12=Z:-S9!EW+S1U\%P.T=/>5]5F(AVC7`G!,.$+<J:J.
M$%@WVG07H^T]^$,B*YB@;1U7U\T0?)*-3P5!_[F^C!'),`&8'V):/X*J;CL<
M7)S3)<)3D.557-P9]RD26:$X)617A1$XAB<2C:5&`(YZ+<*:#/<D%,Y7IWGA
M4'1\@?1'/.E@117B=DH4JVBG/?W8ENNXIHA39]9!#=`OZFL:"7A/4IBEMMB`
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MZLZ>%@B`E,_>.816NM..Z-)^[1GF$!`T+=4RF=RB[>(^[MN^*$B$.VOSV.2^
M[NS>'<PN/T&Z1NT^_N_T[AR&:KOR%DGH5._\WN^D<>_C=+`EM'7^7O`&C[%U
M8A(H<5D[4>8'7WL:ON$2$_'Q_?`6OWO++3']>_$<3WH9/T(;W_$B/WD?CR`E
M/_(HWWHGWSDAG_(N/VXK7R`Q__(T7Z@M[QTS7_.H)8CLPGRB\7S]QBCY67W7
M!WX.NB0,ZGW8%W[<1]?)F/,"`O4Z7U.F:(6I*&!=&KIUS87VYW]$'$8!^*7X
M!X!P"N(9?812KY0W/_7*TXPZON2B,<<1.,?8_,88/(9NMH'U9_<_K/<*.>15
MNO;<D?9L3TOPZ(Q3&1K`O"XJ]!0M28,>*^EB(80]J,W_1_E$^/5E2/CV_L'Y
MA3]$(8FY,?S14?A$[4*!'N0[TTH66AC("OW+PSS2>,_-@K\=GO_YRR.5+.@X
M>.V46GU8.?'[L)0T5WW%)6&5>EC\4X'\/V3\)GC[X`']N#_]Z"7].%_[U)_]
MWV7][H[]VO_]U<7]@^_]X%_^IR7^MD_^E">B9)EO?%*1='3V84$C/:01O4__
MX-L<F5T6(QS3]0L0%00.)%C0X$&$"14N9-C0X4.($25.I%C1XD6,$P%LY-C1
M(\>,(1%^).E1Y$F4*56N!`"APH0%!%1&`&`P0<V#$'!&I%DA@L^=!GOV7#GR
MI\:C`HE:+-DT*$2G)35&_5C4ZE6L6;5NY=K5_NM7L!);"M0I`4`"`1((`#!@
M=BT!"14D&```MX*"C0PJ.-B8`&A!"`>>#M0I4"W;N(;/"N![MD)'LQL%//@K
MD"--N@M>"CY`@6"#OH_I)AA=@8+@MJ(!:#XL.(+9S&OU3J#;&8!@`(T!)'Z\
MD79=W@\'*QS>L/A(C5##+F?>W/ESZ-&E;QT+DP#-!&KU)A"LF8',`WZ_FYT0
M00`%`!/,2ECZ4L"$XH4K$-A^8"!V\NM[`HC0DX%]!OQ2JB::'B!/@00H0$`S
M@=!3;[?<S')@/00I4,"^"-,[0(&]^*,)`IKZJVG#T_!:8((':N*/H)X.0*""
M[\12+CGA:'3HN.ER_M1Q1QY[]/''A3JZCJ8'/:-IMY?26Q$]"0Z8S#/K/`SJ
M`)?BJPD^(W<BD@(+UQ+QL2^Q),"E`2OC3X"?S".H2_Y6=-.\G^`#$TPDP1R*
M0!4G\$D`)/=+ZJ\ETXL(1X,(3<A0@A`M=$8@&W7T44@CE?2BL>Z[$H`LD80/
MOK@VE>L`F018(,4O%>LHITNSM%0@477Z4DJ!#&`@J#LM.Q*D@40E]4TZ(7MS
M-\]@O?/6RP#]<[].!674.(H4M<Q&9B>5=EIJJ[7VN4K+G*\^`#B,<4,8"6!R
M/4Q=;6^@*QT`#"?Z*N!N5;,H(-5/HE)DL$RB^"-`70A>5(P"5WG55]T(_C#\
MB3]P^?JRUK$>N"E-%8\=T5N9!EWVXB"A9<C9:SOV^&.00UYQ(+,,6ZLMM@!(
M2RZZ[`(-@.W8(B"!<Y]-L2"B#DM-,8%N,F#F"=;:C2CX_J1@K9(?8^^M/WV>
M&4FHEU:YRKAVFRME]FHJN>0(F.ZS)KIX"SJ]EH.[$>.S:Y11[9#;=OMMN-\>
M&5((!(B[6;2C3=MBMN_V^V_``X^NSD=G)5/PC?-.O&_&,T;\<<@CEWQRRA=M
M?&^]%3^(X\H[]_QST$-GCF/.T=7\T-.E3;$C^QPJF0$*DN89(=GE<A9VI1GR
MSS.$<*?(=X3HTM,YPA^R2ZG6(7J=]XMJM\CY_H8,.-:^FU&2GN2*15^I[KI^
MHD"OA:"?LZ+O<\>*=+PO7QQSD0]_Z.!2M3VHO9H/A;^A^XVJ:&ZA2K?J3X<\
M('D"N8Y$\G>1^E$$@+HS@$&N(SZ+1*"!!#G``YBG/9-U3RXGB\!O"KBZVY!L
M10ZP6P)9-)QL360H6D&?QAS'-_:!;"Q7.UX%)F-#O9@G,AOA2V:`LA9UZ2QK
M<N$370C2&+]\C2-N60W+@/,8P>P00FFR6V^L5C:",&9/0ESBU3J#+M]@\38[
M@8#0&`";)JY(38JA2Q!/)@$TDL8Q0TM9$&M#@0EPQC,&>$!C].(``661,@+(
M(9^B"!DO,N]ED^G)_M;>2!,@)LJ'-*P:;KX#LY*E3#-Y1,Q+[H@`=2T@+WM)
M``3`9QG<J`N)4,R+;(B()G>I"R\`Z.,`!2?$K:E(,`-I%PEMV(`*+,``!N"0
M+Q5P+Q$F!G8<\6!<NH:88:%+)ZG<(&).<QL*8"8W5MR-%LUSS9UEI(5KBV'F
MUM>VL80G7`-)P`+<`B,&T(N6Y"E03]K%'7OJ190#<1"Y(#:G#.7Q13&ZC00*
MLZ($<"@!IUR1.F,TD`7X90$*N*?!*D`B<)7)1>LL*.\:UB8#I6=![CIE/6M2
MT0])R)\FO:@"2A31";13:2V1P'FZ9A-WU@6>!3WH3S#*(<M0Y@%HPM.V_MQU
M`):B:T(:&JA,5H,B*>UGJ1.HT(5:6B(TT=.FV4/7B5+43PAY%58&:(`#&IC5
M].C0?QU#:5$[VC-G*BE3WB/;1FKXO=L<I45-G0\P$8#4]-Q0FD^]644KE%"6
M^BFBP3PF`BQD2Z:D#CGJ>Z$Y95@EN@[O`6.*8EOD::L[80DH1,*4[=9$T3;]
M4V`A,HV25$M%\P$TLZN:3&G]]!@]K=%8K2U:0<S*IWSUQVZ$"ZUMVV0K.BTL
M3WN"I5KO<A:7U*R,@=D-REZ+VSU!%+I_(2V4RE-4=,$O4+T=5L3`!$LY"<H\
M#7U291(55].@EK5W<E!Z?3HFRYCM;_$:K5L7_E@W!Q#E2$?ASP)^0M&"R$L`
M]KFM@TH;.TC:LB5?$^T$)M!<HG(W8CU!$WK7NCG)@IBRQ`FQM,:B*66A)P$.
MH$\#/VLG/(DV1')UKPU'E5K3KA;%Y#6OC;GJIF0-CU4-2(MQ87RJ,NV8?P<X
M@`,4AI,5B8JKQ<U2<)-;WJ8D;0(,$(#T!J-B%C.@@6K<L$D&,H$&$`"P0.$O
MBFH57CH%F<S]E:U'=%.L3\FD9G/6%8ZQO!&S'&4N3I7`!?\FX^/>]LR@H@RB
MQZO7G=#&,^AY5;+X:U#L*,LRKF)S::':D5K=EC'#A4Q(Q@E#RZ8:=7)S";@>
M*A#7B))@909M4=MJ_M1]_BM@#Z"J>=_D:J=>%T;;A#.P"R)*S504H"YQV*J,
MS3_^X-7*LU+7JO)Y5"NGEF',3L"^*M"OF?[$53(Q$`4+O,TYNXG;TORVDM!<
M$RV&Y\W(11C%YE1>V7J[8(_A]G7&E5:N(I<F\0K8/_V4QZ,5*'80BEQ%R0.:
M\1'PE#@,YC"]=9ZQ*&""K)KU=UNZSGC3K":D212G.:RN\'C;8:$V+[+G0[`O
MBI,J9A;+S)$\*)OCRFTK:N9G:O)5TX8-RD-T)&**OA:"."T!+]NET*L&1S'"
M-VRV$W(%PD9)G*U(B%8?&M-$Z,DG%F]69\G-T*E^0M/BTNP0(CJ!F':8_@(V
MF813<\"+B"T0OE0`Z%_CNM0*2!8^"<`E>$&ZSAYD6G0]'>M\)U?NNCXUGS!M
MQ15XV1\#F?B_*)WQ>**ENQK`O=P\8..(>V9J1(ETXII$9QULF;B+^*?#"/XE
M:^EYZ0]/`0$`TU:,/YEZWJZUFAP-T*.MINPQ>/R#&'HBRJ<(\Q/2@-&;!B+.
M?PCU%0)]\EE$@`6Y'E(98GV56%_\#KDI]Q>8D?(/I(+@1WZDV-]^^%_K88^:
M/UAJ*$&!4`9QWK]/]$_"_PV*/P$<0`(L0`,\0`1,0`5<0`9L0`=\0`A<"0B*
M0`JL0&SA"'4I'@O<P*\P(0[\0!"TBH_JK1`L_D&5**.\T*;4$*(;,@]."B<3
MC$$9+(A*F;`(0$%,TJ09W,&-8;8V49=W,2R_.*8%<"RKXD$D+,$1;!,?+!#R
M2$(H/"(#`"Z<(`_CXC`X29(HW,(*[(@,_(G?.JZ(X\(=9#(G$T,K5)51XR8-
M)$,W/,`40ABY$T/^>4,3C+99H0E9L@]E,Y&7\XG.*#<[',0!C,,0D38HZZ!J
M(T00'+N;X`O!((#<>B/BB[TJT3]&S$0,@C8)<,2RRZ^\TT11'$52C+_W*T54
M3$557$56;$57?$58C$59G$5:K$5;O$5<S$5=W$5>[$5?_$5@#$9A'$9B+$9C
M/$9D3$9E7$9F;$9G_GQ&:(Q&:9Q&:JQ&:[Q&;,Q&;=Q&;NQ&;_Q&<`Q'<1Q'
M<BQ'<SQ'=$Q'=5Q'=FQ'=WQ'>(Q'>9Q'>JQ'>[Q'?,Q'?=Q'?HR,`R@T7]PL
M`K"@H5*7H($+H:DB?EQ('_&/R_/`5YR,NK&AGE@Q!V@=!EA$AMS('*F5F[BD
M!>`+C8S%!$"1##N3,'D/CES)Z0@M!)@Q!ZNZ6*2-`(L86&$`9&))G62.H9B,
M+DNM):)%VN`0/T$3>W*?G4S*#JP)!\"+&VP3+(&E5W0`WID\5BF9!'B`!LB.
MTE)*K_0*?Z0`OB`-$EH`(INX5I1*/M&I@MP@N!BJKXQ+=#0`F91+NWR4_IS+
M2[W<2[[L2[_\2[Z\2\$<3,(L3,,\3,1,3,5<3,9L3,=\3,B,3,F<3,JL3,N\
M3,S,3,W<3,[L3,_\3-`,3=$<3=(L3=,\3=1,3=5<3=9L3==\3=B,3=F<3=JL
M3=N\3=S,3=W<3=[L3=_\3>`,3N$<3N(L3N,\3N1,3N5<3N9L3N>\$<",3NF<
M3NJL3NNLSN=<QU/,3NYLCM7A-4+1M/D!*G<YO^X\SZ)X(`2XL)M0DM4`C>M@
MB[1XCXV@"3Z\L`@Q@.U$3_ZDB`7(O23)$[C(#=RSPDVQFPI2$?002_3H3P==
MB6P*C\C`+249*G>[4"N2$U&JDKI\4`^MB"&1_L2-L*%-Z1X1/="2D1Z7>@\#
M"Y7]_%`8/8C5@8":PHT+JRE1@AF+\PV[21&GLB%TBU$A#0FZ7"L&P$0'0,LA
M7=*(("%,E(A%?%(FG5(JK5(KO5(LS5(MW5(N[5(O_5(P#5,Q'5,R+5,S/5,T
M35,U75,V;5,W?5,XC5,YG5,ZK5,[O5,\S5,]W5,^[5,__5-`#51!'51"+51#
M%<SK3%1%751&;=2\/%1(C=3.>5%)M<WOE!/BZ-#[($^:J53:5$_V](V-,,ON
MD<^:@H\VN4\^F1#]]%39_$]@0E7<&E"J++(2O;"+NAE,P12J_#!7[<P(Y<H\
MJ5`^N54ER=":V%#L_OK5UPQ16:5/^+B.$PVL%(V`%86)FSH/9GW-&:U1'L71
MO-C1P-([G8*W(-U6VBS2WT%2)457UW32BHA2=YU7>JU7>[U7?,U7?=U7SMPA
M=4D+2CV(E2D*W9J<FIH)NQ$E_>+7`BPN\X123<4(6*D<B%2@'F/8!`PN_E`+
M@'6YN=,+C@5(@1`EO4@+$B*`^?2A^T#9)H&=R=BL)H+9`.$AM@`F!C@E"Z6,
M61$LJ[-9!JB;,5&3FC(/LC(,`5@+G>63H4*`U>B.R!M8@>`R6C(/E'T`JFU!
MEGTNS5@P!+#0DJJ+SNN:^721D`68HZ71H^V\K+L)A<38`W18HWR/(BN0_@N[
M,.&RE)HRB[H1$3WDE%P1KIHB`)GPMY9@)/H4$;.RH<.YCETIC^S!/L&+V\*8
M,4P,D;JI*7GA(?1P@**)6Y(YCUT1+G,YC[@]U3;1#%JJVP&Y0;N)VR:*6[LU
M#U*9R*P;0[=M6(Z@C#;!P+2-@-7A(U!3/[8HFD3D%:"XC)N@#/@4PUJ##Q8S
M-Z3+T7N1D/C</3JSMA$!6QW#LXL"6XW=/=[UDA7YW>'YL_HDEN^M&46[70-L
MCPF#.IK2EPA@DBL:'L+56S0)W?$9%R\;)OB@T<)]C2EJ$4*R%+$,K`F@75@C
M)-P#7%YE7@VCB0,6F+*8B_)]X!`QC]'EW_AE_JW[Q9==A=_YK5_)+:H)X9WU
M95\"/-B_':K)`(UAZEH^T0L71M(9MB$)("&ZT"&*'(@:!I<+Z2$#D.%XZZ8.
MJ3K!0(LD59DGY0L]<>'!D\^"/5@U26(^B0M8,ED!X-GN5>*Z8*0OI@P2>F&V
M&.*5^=C/S2X7)J&X&&.AVF*TS2XM,MH>5N$89+\AT5:%"-B]@"R&N$B>U!)?
MM6-B7..58./]1.3E8.'L(N1;A-J,D,HL6EC\:=N)@-J"/0A&#K^%H(`I=&16
M3.&%@,@ZW(N([>21+&7B2`JQM)^*_9^G4&50ML/``UO-$-O@^-C`:Y*"*AAL
MXH^A$C(MYF*N#5E._D*+@\6+F=T-/2IFEE4P+_E<JE7;"F#:LD-:3HJY/4%:
M&%%:JF6R)L+EYYJX:X(+/@FD]N2/NBD/Z>$,D?VVLR5:W;.AFU@`IQVJ,:DI
MLM*C68X_J6(2ST477JNMC[-G$C&`L:3+1*FG']M:X0(749JQO.6/A`HFIG5H
M%S3*N9DQUEUHRQ6`BBY"2V%=S`U=`D5)..DFW@"7H:J>\%HH47H`!?@/S3A"
MTRCA)SUIS@U@V:6ED4*0?H:_V]K=^O3AC0#>>RMJRSC:"P)F/D$F*0G>&>O>
M(B66\P6U1!QI\*JUX[VY6HG$X_J5RT`-(1L9"`83T2.`(1;1?]*6L]8Q_NNE
MN:#&H*&N8(4FH!'..XAFL@8X&H61E40)9@4&$_X%EX?I'OHM&!IFVA&&NMC=
MZ$0+"F&YC<7&7@E^LF6[H@^&-0YIZ5@>X0FSC[T^LQ*FP?OA:<$;D<J>Z^/#
MO2TNM&%NXAEV;5[^QV<J6?:0Y+38V2>%I36N[6Y"XRB*Q*'5NRT6XZ/%Y/EL
M9%@S8ATB[ONPFX.U8E\"V-A&8Y*)Q#@V-PE`@`2YH=I^Y[J9C$WNX95!D_&.
M8U^N(=9V0_"KVW?Y/H/@XT[6"OIN[V:<%?;&;_[N;U0L;YRQ9(2`6DF>Y(=8
M2\<("P!G%0""9/_610]\Y;E19<X5CH<UC@M__I_BH$K?JCH3DN4'1[X%*ZAL
MQCT76>-RSFVDQ6Y^TB,6BUG9@"1J=F,9MUIWSN)`P^>YX6TM9MF?S,F(.P"7
M-1"6]>7.R&+<D`!\1ENRXFW?\F;4Z";!>/&A(MK7S>'C#KP%RTJEM69>A@MY
M)MD0#YTFNI"0ONC'L%HUTPP2<A7N&>BJ^^EN&^&ZL=K:ZNB@ZIJ//H":=@TZ
MV5O6`@K'Y>D?]-M$P<#`#96'/A&$_I7YC=L4L5J`*XCKF*::;A,EWXW5T</$
MGMKJ;2+&C1B63FU)S]LQ_QPR^XB?L-"(MMX".>JJLS/O%63W8O4[277QLK*1
M'54Z9*TZY!^FE?3@_J6W#"Y>@9BEG`1K,F,Y'$LM6S<OL$XNZZ7J4SYUP2ES
M)EML_JC;NAGUFX&DQFZ`Q!!RO6-:`-Y;"0$O;L\P^^00>P;C#]'HHUCW`-9?
M_CAAY&*C(H6Z`^CK?1$\CFY@#;Z2]P`P@+SLVW#WR#Y>7R^0@C])$3E@,/'V
MDPIW2K;VP$D9VR9N6.+M]59OGX09&ZJV]98`&![BWRXAA?1XZ4X+=^8+'_?=
MY!99'I?Y'3YO\UA$!.<.#KF0WW8E'W5Y38=C%N;Q>:9NU.@P(F*NXI[/".#M
M"WOM+F:,X:Z+.$;C.<;XR`'QBK@>",V(/+[OY3L(KP<+]BM[K7\<![\;_D-.
M^\%T^I0`6*]8>X&@#0%WB`*GG;;->X,@\`QW^[=YY5<^B7L7^\TQ3^,]B0J?
M'QSY\+]WWPR?\+\'_+;1\O"P[DYDXEUFV1)G\19?#"J>C+78VA/O72V>VK2E
M#&4F")C=6A\ZV;EI?6M.<N*6Y]0O\:*]63'/%7UNHEPYBYS5.]D(/((0<ULV
M[GQ6^9[0\:1H_;WH7>:G?-)3$=05+\?%0O,(Z>1570I2^#LA7)HX$7F7WX+;
M6Y7FI1'NVV[B6_2GM%_K;%+_Z#-/W-0V]=W;:=ZPIZ?$/3MW:38#"`$2`#B@
M`$""@`@1!#P`4"$"`(@4$D*,4.$B@0@&(5`$_L!18<2+(D>2+&GR),J4*E>R
M;.GR)<R8,F?2K&GS)LZ<.G?R[.GSYTZ(%4(2C;```(`%%9$R;=H0@($))$,N
M?4@0`(&($84.K7@`JU:K%;Y&%>D`;,6N#KN:15LTI%JQ$)L"F$"0P%BH$P0`
MX)LV(M^$#K]FY2IV)%F[%L/&7<H5;H6SA=<RA@ST,N;,FC=S[NSY,^C0HD4+
M#2D``L0'`B9\!&!0@@0#!QA4>(`@X^L&$D0>4%`AP4'79ST.K#@1Y%(*9X5"
MQ'U0)'&MBS^FO1C];X3>M1DZ9`Y@=FT$8P4P<+[;.G:1R<\>'WAVI'FBU`4*
MUWJ\^E`(`ZE[[&AQ_C2``0HX(($%&G@@@@).)(!`%#1$@$`,]/7`7@PQZ(`$
MA$G@`%^T">"`>E]]58$"4`G0`%0&("!09`)`B%!V`"3PH0`5(,0A`+2U98"*
M+":DVHL47'06CPA\E>%!A.E7XT(V)J1A9'7AJ.-%`B54`8L7-?G5C`ZH]N&"
M(JF6(Y823"3!EQ"0:&*30#8X9(H(N+FABUDF>">>>>JY)Y]]^FF3D#,9\%\%
M>U&0P`%_!OJ2`XG^^2BDD4HZ*:656FJ@A`2<=ZE)')K)*:BABCHJJ:6:JI*=
M(S5Y$D+JU=A2JR5N.M*5,Z4J6JLSK8K3K2?)JBJ#LYXZ++'%&GOL9J41_CJ2
M<B9%1$$#71FVDK(G%423`U*-%M$$(.JZ%D[9LF295>0B>RZZZ:J[+I9]@;7`
M0R\NA)`!T?Z&%$(((,6>B,HQ^$!)$`'WZD426AC!G`(8D%2\`BU4KT@"<<C0
M2#@"'.)W%$20U0$3'7!`G0]0(`'''LO)EVWX/OF=!`ME=3&M(K;L6K\65V#P
M`QNG.@&7P4+,``,DOWFOE0\)9BZ[22N]---^EE;0010)EMI(6SED=0*^+0!<
MSGB15*V6=6W<'W($V07C0E1#E]K&\$4``;AC+3"!`1P"K,!7"E2TT$0@+O`5
MO!G!+>UW\.)=$4<E`:#U`0)KG8#@6DV@LT($_H^E-5(1.&``EFGO2KA5<RW;
M-.FEFWZZ9]5JQ51558-$.%UCPOOUU<L>E51EV#4U;5>R(P:6ZV&';35Z:XF>
M5U:P6U05[VPM11=A#MV>%>MKEQN!70YDM/O:WAV/.OCABS^^3*K##9L!#?%.
MO-7@V2:`@P+9*SQD>['&UT?JRW=0;`U-I=K]U%,?Q&2+`':CP-^L5KF)B"R!
M(%%.[2"BG;]Y1P+S&XKA&O<=VHP)@O:#&__*<A'M`"<D(,M6"+75E8%`\'OD
M>R$,8QB^!35(8O^:E^7RTJHCK4Q3.&N`Y5I5JX)-Z$<*`\QNC,B0SY4)9[_K
MDDA(1B8(<`QM6*'8_@.J>*6>-2IJ2#I`RVJ$$!15;6%@G)>&N(BSB<',1B+J
MRVX`N!V*1<PB1S%`0H(EPSWRL8]\7!10,L(WF@#R6X1$"00<A1Z4%'(E!OQ-
M`D[22#]2LI*6O&1.ON0M7.7P)T.[B13!.$E,DK*4ICPE*E.IRE6RLI4JR966
M.KF35#'Q);`\22U+<LN2R`J/0W0E,(,I3`,A+75Q:]Y.+(/,E1`O)<U2R3+1
M(Y1K#;.:UKPFJ_HUMHX)X``KDMDV33:FE"4I8\!ZV9K@U<VDO(QGYAQ)B=2Y
M,'C%:&&J`LO=&/:SH`5I)`Q`&4DX5!@?G84!D80`Y^#)L"NM\RKH!-*2_NK%
M(*9,3EYDB9N-./:5B<X(35FAC=`0XDULDK2DINP-!21Z-\!AD$0@6RG#(M>5
MK%5@`>(1X-NLI!B"-`1-,M+:32^RE^*8+4F8NV=.$:*8S75.:B-!B(/B=A_I
MJ$4B":"2DW:ZF+U%A"-[J5Q#<N:0E$9+:@<PG%0_5-.OO`X`JLG9:J3&,)/2
MM:Y]A`M7CD<5I`S/(M%32U/N:16!2L<[=*F8BZA*U6EYA[#8N\M<,O>[Y`FP
M>%MUB`'K@MC)7/9UK0N+4&Q:KNHQUGB94Q:X(BM92!W6KJY]+68.4$"[N90H
M&60(`MDJD?=$Q'U!E0M2]%/8[FPP/%43+G8F_GA,XEYG/"A$GPIWFU;DG*8J
M'$HH=)!;W>%:Y3ZG(>[FI/*:V"B76;AU8&D^,I#UQJ:8>FHM;.,K7YQ(D394
M9-F5H,*R+.+7KS+ZT)&@Y"HGH:A(#A-C#V=5X!XE,0)(PB.P"!RG"G`DCO\B
M"1=',B?)%&T@(JM8G!XD$!X:C<+_:M5"^((O-M8SA_P%8T*$B+`+S=%3D8+O
M?'.LXV2.#B:CS-./83)(E@3YKH'=,9*33)->D<_#),6QDJ,LY5V*I,@HH3)*
M=L7D6-;T.23YI4NP?$A;$BR7K))E3,PL*2A+N<T[[E;Y,-H5:(U+(PX`FTGP
M7#$KFP3..7$O+L'U_DR61/,E@[X4F]VL:+N.*6BKZ1E"T(E8"TTH*S95F<O<
MZLX97:2$"`G,L_IUSX&)Y"@>HM.+CDA/>2DL6K$BTT7X.SLLR4Q["_6FRMK9
MKVZ>+$?-<6N*90;(=9Z19AFS&<YTMBD6PP_2B6UCGQ*]Z&D_F4+<42[B<@CL
M[57`.5S-=GFE&9:(T%2TE<6K%\FVE.=*36U+0<AYO&T=QGF;80KD2+GU!2]-
M<R>G<\G@5#+HN)I"[FV2H]RNMBU!S&6;M4>F-L1+^I3T299Y&)7=--U2MNL=
MAG"H?;A8().8W+V%=:D=C%[@5)A%0D0RBO4L720[<?\];WD8W:MJD?+7_NEQ
M;SM).9[%'<Z4B!,=F\XY"PE!>Q![?5`P^2'JQA=^K^Z-.SL<1`"&Z/>?^.1/
ML>?KW\G-8QWD6B>#URF*=WP;DJ,3]]\NM2!T!%[<#I[E@_B*C52:+G7@>$?H
M?"TZX(79:'B_$<4?`A?.*D0D%?&P283_#KAX6"&':>A$%Y%QK#M4INLBL7-?
M@FL4:03K*!7).F:T8)Q81&(T8@5&/G>TT1"B7S"2T?0L8[VFU#@A-HHDV2.&
MO.']+N?`$]^54$44(!,)2O@ABB1\?HD@X=<30%=9DBV!C/(7:7V:$$!D"8@D
MI:1=_/&G,E/"THGY,:-)GVR9)UL&LTY"^:E)_HF?_/:_OTR>?__ZX[__Y&L_
M^Q$*`-;$)\6$F`W8*Z$9,/&?_S4@ZHA+G,4$9$#@]/78];V.,VU2E@U?,#&@
M`WY@TUC)/+D*A`",Q3P,4C#("+H3C-4+SKQ+F1#;IT2:6]T,R@B`OK&4LD''
MZ>U3J2V41324RU&(ACP,$*F8V%B4?D6,S+"@.%T(!13AL\60!X*@%;*+5CQ7
MV"Q0Y+#-U4"-!""`X:`,1%040;R&5C#.%E88_#P%U*"0YQ`,P^!-`W#.:5S>
M:KS<O763;Z@&W(A5!9!5YRS$6:U)W+E4OME;UQ0BA\!-3E$AR%VA)#;-RPE/
M5T1/WY7<D94([G36_EX)CU!$3U$`UFKM5?9X38MP5E49UG\H74V)1\[9G/7D
MG,SQQ5&T8M_!4!5.(B\62R6&SD+`30L1%UOT%@?Q1:&L!D>\!40`''!)URAZ
M1`J5G4N-!Y5<QW9QE55HQUN!5UF,EVP<%37BC=IACS+RX7;0W-*]T"[VHCN6
MBI4$X7DT!\5P48U,7H,AB::\"LXP%(S,W@PR28WTS'/X(^]5B;`UA`HMF)Q<
M$9(8GCXNB=$@(9TL$5G(X>G%R#Y:1+(IB>%Q"#M&XCN.9-(4VDQ,$O7A1`,H
M$I'Y1$J:4CN2I$R6R@&ZW_S]A(T!2`&V4DS.I$_^Y).))%`.)5&:5$\6_B52
M)B4I':52-J53RA!3/J543N7I1"557B56KHM59B57=N6P;*57AJ58(II0CJ59
MGF6I@"5:KB5;(HA:&HB*'=AHU&1,P!^OG!]/[`I=+ID%AAZO]"5*#&!FV"5,
MV,DO41EA)HB=:)D$_`JA%8U)#!$`)J:3U-%3*6"5$,J8#`JUO66!A(3VF.1,
MO"3OB"9*O*1+Z)E*H*:XB82?]00U*0X&V@1K:E^@849MGL0$`E+SQ*9,Y*9-
M4*!AP*%+*,<R3:`*"1:@&89E=$LTP<79D,B@R!EP6I-G$@C.&5O'V!J\))ZH
M5<`^A=)7',0.JLI%V:!;!484OE,Z8<D(.A83_N*7-X62Q[`3L(4,J$6`#]):
M`@A-!'B:0-(+$$F:OCC4?789E43:$K5:&C$``^VG",Y5!13H$#JA>J3:",9(
MQW25BZ@)&SDA?#I)O>Q:7_@((<[("`K5KLV30=5&5/1+1-"G#%JHY\&/?L)@
M0MP7`_P:S!C1Z,THE)2(0>'+/VE:SZQGQ\12"=(:`H24RU!,/)5)/8'+.A&,
M``!'`G4G&0H&DOK+RE4)#?:HNUA:PVP*<Q(67*EGS236?V1/(`)1I25%@;;,
MBTR):\4<GN:IGNXI:(3$`FQ/N16<093AQN3;D-@A1_@-6PUB#A5BB=B=4!AJ
M,A(5NR''(>)-4NP%_DQYR4'H3^4,3D0PU1VVE%,1SU*(U2.*F[]I!;QM83"Z
M%3?F$0'@A:BJB5IHH:KB&U#5T4(4588H0$J=Q7P81->4&\A8JE78AN$D@.HT
MXU#@:B*B$'LD@`,D8J*NU>*LE1B2"/A=U5$\@`)("!CV!URI3^(4C[5IRQQ^
M3!]R![S%:!M^!^9(ZM[`#Q"FS598"=0Y*KA0E76\H5T`D"-JA;'ZQ]IPZ+F!
MH5-98E6U1J0RCL%>!$+U!6I@ED90E5REJUWM*<=V+)[V*5)H"BVZG%$@Q>T,
M7:%`EFE93?7,(LI-QE`<F6.]A6WN53.)CO=0AK*<(M69',SU'7/^+,J)_M!C
M@`VYU:![H.(O@@XM#D_U^&M<](XMQISVE<;NU$Y5%6,KTL56999=<.W*VEQK
M/8`!$("*$(!B5-7)=5Q$3)RZBBTNCIQ_48_8'EG1LFSF4,;,ID700D8T:J1T
M?"Q;%$_'-6O/]6WHC%MK0>=-<4C&<99JN>W&>BSE=FR?$HH$75UT"&PW71UO
M?(BFUM;%HH_F\`;#U4<H>N[3>5W$MA2F:L1YZ5;;Y2NH^A5YK`TX*@8++0<Q
M!FW.BATP?M?E;,=`\(A4@,PUID=K9JYQ!6((%85L34!FS8=2<83['&MUI&YX
M"$4V_NT(:>Y6<4BBJ!U'-!!+D:/J?BW<),I;_JC75;#MQHSN.++K=L3'`R&=
M;P"';[FJO8XNV%7.V66'.&;M(KW%,#+O`V"OW^9BR$W'-%8);3CN[&IO`D<L
M`RG'=*ZN<8101IR-;M!5Y8:PGH+&8OZ>IC!D1[:>F*Q&;531D;#1>US>1>9%
MEP2+@#&DB<Y)H`#DE=P7C#F80-*CM>E1W5GFY^E0B>"1XPDD;T1-[(D>E0BQ
MXQ%&`OL&WM2&9F6FB38Q1`I8BQR,E'Y4F:3)S4R(1J):EDQQZU6(B+G>%KM1
MZ_DC0JB)/L*(#Q?O[7GQ]^V%FM00C&A2\(&IG=K>&2F)G0;8?W41(FM*V"SI
ME7R>$.-PR\RP%F^*_3]VCCW"B(8(E&$NL6LR2`Y?F)AD!0%()`Y52!USLIF2
ML@0H7IR\\+_8J5H9I0C7<ED.B/ZU1`(;VDT`9S0UBC-AAFE6#$N.F8$\'Y^A
M)&!F1G5VF_>!WT4$2J%I#`>V)54*9L"@F:?D,D_LY4@`$5Z^$#9[TC*GA/PU
M$EUZLS6O,SO?"3>W,SS'LSS/,SW7LSW?,S[GLS[O,S_WLS__,T`'M$`/-$$7
MM$$?-$(GM$(O-$,WM$,_-$1'M$1/-$57M$5?-$9GM$9O-$=WM$=_-$B'M$B/
K-$F7M$F?-$JGM$JO-$NWM$N_-$S'M$S/-$W7M$W?-$[GM$[O=$\$!```.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
